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Summary
These guidelines for the treatment of persons who have or are at risk for sexually transmitted 
diseases (STDs) were updated by CDC after consultation with a group of professionals 
knowledgeable in the field of STDs who met in Atlanta on April 30–May 2, 2013. The 
information in this report updates the Sexually Transmitted Diseases Treatment Guidelines, 2010 
(MMWR Recomm Rep 2010;59 [No. RR–12]). These updated guidelines discuss 1) alternative 
treatment regimens for Neisseria gonorrhoeae; 2) the use of nucleic acid amplification tests for the 
diagnosis of trichomoniasis; 3) alternative treatment options for genital warts; 4) the role of 
Mycoplasma genitalium in urethritis/cervicitis and treatment-related implications; 5) updated HPV 
vaccine recommendations and counseling messages; 6) the management of persons who are 
transgender; 7) annual testing for hepatitis C in persons with HIV infection; 8) updated 
recommendations for diagnostic evaluation of urethritis; and 9) retesting to detect repeat infection. 
Physicians and other health-care providers can use these guidelines to assist in the prevention and 
treatment of STDs.
Introduction
The term sexually transmitted diseases (STDs) refers to a variety of clinical syndromes and 
infections caused by pathogens that can be acquired and transmitted through sexual activity. 
Physicians and other health-care providers play a critical role in preventing and treating 
STDs. These guidelines for the treatment of STDs are intended to assist with that effort. 
Although these guidelines emphasize treatment, prevention strategies and diagnostic 
recommendations also are discussed.
This document updates CDC’s Sexually Transmitted Diseases Treatment Guidelines, 2010 
(1). These recommendations should be regarded as a source of clinical guidance rather than 
prescriptive standards; health-care providers should always consider the clinical 
circumstances of each person in the context of local disease prevalence. These guidelines are 
applicable to any patient-care setting that serves persons at risk for STDs, including family-
planning clinics, HIV-care clinics, correctional health-care settings, private physicians’ 
offices, Federally Qualified Health Centers (FQHCs), and other primary-care facilities. 
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These guidelines focus on treatment and counseling and do not address other community 
services and interventions that are essential to STD/HIV prevention efforts.
Methods
These guidelines were developed by CDC staff and an independent workgroup for which 
members were selected on the basis of their expertise in the clinical management of STDs. 
Members of the multidisciplinary workgroup included representatives from federal, state, 
and local health departments; public- and private-sector clinical providers; clinical and basic 
science researchers; and numerous professional organizations. All workgroup members 
disclosed potential conflicts of interest; several members of the workgroup acknowledged 
receiving financial support for clinical research from commercial companies. All potential 
conflicts of interest are listed at the end of the workgroup member section.
In 2012, CDC staff and workgroup members were charged with identifying key questions 
regarding treatment and clinical management that were not addressed in the 2010 STD 
Treatment Guidelines (1). To answer these questions and synthesize new information 
available since publication of the 2010 Guidelines, workgroup members collaborated with 
CDC staff to conduct a systematic literature review using an extensive MEDLINE database 
evidence-based approach (e.g., using published abstracts and peer-reviewed journal articles). 
These reviews also focused on four principal outcomes of STD therapy for each individual 
disease or infection: 1) treatment of infection based on microbiologic eradication; 2) 
alleviation of signs and symptoms; 3) prevention of sequelae; 4) prevention of transmission, 
including advantages such as cost-effectiveness and other advantages (e.g., single-dose 
formulations and directly observed therapy) and disadvantages (e.g., side effects) of specific 
regimens. The outcome of the literature review informed development of background 
materials, including tables of evidence from peer-reviewed publications summarizing the 
type of study (e.g., randomized controlled trial or case series), study population and setting, 
treatments or other interventions, outcome measures assessed, reported findings, and 
weaknesses and biases in study design and analysis.
In April 2013, the workgroup’s research was presented at an in-person meeting of the 
multidisciplinary workgroup members. Each key question was discussed, and pertinent 
publications were reviewed in terms of strengths, weaknesses, and relevance. The 
workgroup evaluated the quality of evidence, provided answers to the key questions, and 
rated the recommendations based on the United Services Preventive Services Task Forces 
(USPSTF) modified rating system (http://www.uspreventiveservicestaskforce.org/uspstf/
grades.htm). The discussion culminated in a proposal of recommendations to be adopted for 
consideration by CDC. (More detailed description of the key questions, search terms, and 
systematic search and review process is available at http://www.cdc.gov/std/tg2015/
evidence.htm). Following the April meeting, the literature was searched periodically by 
CDC staff to identify subsequently published articles warranting consideration by the 
workgroup either through e-mail or conference calls.
CDC developed draft recommendations based on the workgroup’s proposal. To ensure 
development of evidence-based recommendations, a second independent panel of public 
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health and clinical experts reviewed the draft recommendations. The recommendations for 
STD screening during pregnancy, cervical cancer screening, and HPV vaccination were 
developed after CDC staff reviewed the published recommendations from other professional 
organizations, including the American College of Obstetricians and Gynecologists (ACOG), 
USPSTF, American Cancer Society (ACS), American Society for Colposcopy and Cervical 
Pathology (ASCCP), and the Advisory Committee on Immunization Practices (ACIP) as 
part of the initial review process. The sections on hepatitis B virus (HBV) and hepatitis A 
virus (HAV) infections are based on previously published recommendations (2–4).
Throughout this report, the evidence used as the basis for specific recommendations is 
discussed briefly. More comprehensive, annotated discussions of such evidence will appear 
in background papers that will be available in a supplement issue of the journal Clinical 
Infectious Diseases after publication of these treatment guidelines. When more than one 
therapeutic regimen is recommended, the recommendations are listed alphabetically unless 
prioritized based on efficacy, tolerance, or costs. For infections with more than one 
recommended regimen, listed regimens have similar efficacy and similar rates of intolerance 
or toxicity unless otherwise specified. Recommended regimens should be used primarily; 
alternative regimens can be considered in instances of notable drug allergy or other medical 
contraindications to the recommended regimens.
Clinical Prevention Guidance
The prevention and control of STDs are based on the following five major strategies (5):
• accurate risk assessment and education and counseling of persons at risk on ways 
to avoid STDs through changes in sexual behaviors and use of recommended 
prevention services;
• pre-exposure vaccination of persons at risk for vaccine-preventable STDs;
• identification of asymptomatically infected persons and persons with symptoms 
associated with STDs;
• effective diagnosis, treatment, counseling, and follow up of infected persons; and
• evaluation, treatment, and counseling of sex partners of persons who are infected 
with an STD.
STD/HIV Risk Assessment
Primary prevention of STDs includes performing an assessment of behavioral risk (i.e., 
assessing the sexual behaviors that may place persons at risk for infection) as well as 
biologic risk (i.e., testing for risk markers for HIV acquisition or transmission). As part of 
the clinical encounter, health-care providers should routinely obtain sexual histories from 
their patients and address risk reduction as indicated in this report. Guidance for obtaining a 
sexual history is available on the CDC Division of STD Prevention resource page (http://
www.cdc.gov/std/treatment/resources.htm) and in the curriculum provided by CDC’s 
STD/HIV Prevention Training Centers (http://nnptc.org/clinical-ptcs). Effective interviewing 
and counseling skills characterized by respect, compassion, and a nonjudgmental attitude 
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toward all patients are essential to obtaining a thorough sexual history and delivering 
effective prevention messages. Effective techniques for facilitating rapport with patients 
include the use of 1) open-ended questions (e.g., “Tell me about any new sex partners you’ve 
had since your last visit,” and “What has your experience with using condoms been like?”); 
2) understandable, nonjudgmental language (“Are your sex partners men, women, or both?” 
“Have you ever had a sore or scab on your penis?”); and 3) normalizing language (“Some of 
my patients have difficulty using a condom with every sex act. How is it for you?”). The 
“Five P’s” approach to obtaining a sexual history is one strategy for eliciting information 
concerning five key areas of interest (Box 1). For additional information about gaining 
cultural competency when working with certain populations (e.g., gay, bisexual, or other 
men who have sex with men [MSM], women who have sex with women [WSW], or 
transgender men and women) see MSM, WSW and Transgender Men and Women.
In addition to obtaining a behavioral risk assessment, a comprehensive STD/HIV risk 
assessment should include STD screening, because STDs are biologic markers of risk, 
particularly for HIV acquisition and transmission among some MSM. STD screening is an 
essential and underutilized component of an STD/HIV risk assessment in most clinical 
settings. Persons seeking treatment or evaluation for a particular STD should be screened for 
HIV and other STDs as indicated by community prevalence and individual risk factors (see 
prevention section and sections on chlamydia, gonorrhea, and syphilis). Persons should be 
informed about all the STDs for which they are being tested and notified about tests for 
common STDs (e.g., genital herpes and human papillomavirus [HPV]) that are available but 
not being performed. Efforts should be made to ensure that all persons receive care 
regardless of individual circumstances (e.g., ability to pay, citizenship or immigration status, 
language spoken, or specific sex practices).
STD/HIV Prevention Counseling
After obtaining a sexual history from their patients, all providers should encourage risk 
reduction by providing prevention counseling. Prevention counseling is most effective if 
provided in a nonjudgmental and empathetic manner appropriate to the patient’s culture, 
language, gender, sexual orientation, age, and developmental level. Prevention counseling 
for STD/HIV should be offered to all sexually active adolescents and to all adults who have 
received an STD diagnosis, have had an STD in the past year, or have multiple sexual 
partners.
USPSTF recommends high-intensity behavioral counseling for all sexually active 
adolescents and for adults at increased risk for STDs and HIV (6,7). Such interactive 
counseling, which can be resource intensive, is directed at a person’s risk, the situations in 
which risk occurs, and the use of personalized goal-setting strategies. One such approach, 
known as client-centered STD/HIV prevention counseling, involves tailoring a discussion of 
risk reduction to the individual situation. While one large study in STD clinics (Project 
RESPECT) demonstrated that this approach was associated with lower acquisition of 
curable STDs (e.g., trichomoniasis, chlamydia, gonorrhea, and syphilis) (8), another study 
conducted 10 years later in the same settings but different contexts (Project AWARE) did not 
replicate this result (9). Briefer provider-delivered prevention messages have been shown to 
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be feasible and to decrease subsequent STDs in HIV primary-care settings (10). Other 
approaches use motivational interviewing to move clients toward achievable risk-reduction 
goals. Client-centered counseling and motivational interviewing can be used effectively by 
clinicians and staff trained in these approaches. CDC provides additional information on 
these and other effective behavioral interventions at http://effectiveinterventions.org. 
Training in client-centered counseling is available through the CDC STD/HIV National 
Network of Prevention Training Centers (http://nnptc.org).
In addition to one-on-one STD/HIV prevention counseling, videos and large-group 
presentations can provide explicit information concerning STDs and reducing disease 
transmission (e.g., how to use condoms correctly and the importance of routine screening). 
Group-based strategies have been effective in reducing the occurrence of STDs among 
persons at risk, including those attending STD clinics (11).
Because the incidence of some STDs, notably syphilis, is higher in persons with HIV 
infection, the use of client-centered STD counseling for persons with HIV infection 
continues to be strongly encouraged by public health agencies and other health 
organizations. A recent federal guideline recommends that clinical and nonclinical providers 
assess an individual’s behavioral and biologic risks for acquiring or transmitting STD and 
HIV, including having sex without condoms, recent STDs, and partners recently treated for 
STDs. This guideline also recommends that clinical and nonclinical providers offer or make 
referral for 1) regular screening for several STDs, 2) onsite STD treatment when indicated, 
and 3) risk-reduction interventions tailored to the individual’s risks (12). Brief risk-reduction 
counseling delivered by medical providers during HIV primary-care visits coupled with 
routine STD screening has been shown to reduce STD incidence in persons with HIV 
infection (10). Several other specific methods have been designed for the HIV care setting 
(http://effectiveinterventions.org) (13–15).
Prevention Methods
Pre-exposure Vaccination—Pre-exposure vaccination is one of the most effective 
methods for preventing transmission of human papillomavirus (HPV), HAV, and HBV. HPV 
vaccination is recommended routinely for boys and girls aged 11 or 12 years and can be 
administered beginning at 9 years of age. Either bivalent, quadrivalent, or 9-valent HPV 
vaccine is recommended for females, whereas quadrivalent vaccine or 9-valent vaccine is 
recommended for males (16) http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/
hpv.html. Vaccination is recommended through age 26 years for all females and through age 
21 years for all males that have not received any or all of the vaccine doses. For persons with 
HIV infection and for MSM, vaccination is recommended through age 26 years (16). Further 
details regarding HPV vaccination are available in another section of this document (see 
HPV Vaccine), at http://www.cdc.gov/std/hpv, and at http://www.cdc.gov/vaccines/hcp/acip-
recs/vacc-specific/hpv.html.
Hepatitis B vaccination is recommended for all unvaccinated, uninfected persons being 
evaluated or treated for an STD (3,4). In addition, hepatitis A and B vaccines are 
recommended for MSM, injection-drug users (IDUs), persons with chronic liver disease 
(CLD), and persons with HIV infection who have not yet been infected with one or both 
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types of hepatitis virus (3,4,17). Details regarding hepatitis A and B vaccination are 
available at http://www.cdc.gov/hepatitis.
Abstinence and Reduction of Number of Sex Partners—The most reliable way to 
avoid transmission of STDs is to abstain from oral, vaginal, and anal sex or to be in a long-
term, mutually monogamous relationship with a partner known to be uninfected. For persons 
who are being treated for an STD other than HIV (or whose partners are undergoing 
treatment), counseling that encourages abstinence from sexual intercourse until completion 
of the entire course of medication is crucial. A recent trial conducted among women on the 
effectiveness of counseling messages demonstrated that women whose sexual partners have 
used condoms may benefit from a hierarchical message that includes condoms, whereas 
women without such experience might benefit more from an abstinence-only message (18). 
A more comprehensive discussion of abstinence and other sexual practices than can help 
persons reduce their risk for STDs is available in Contraceptive Technology, 20th Edition 
(19).
Male Condoms—When used consistently and correctly, male latex condoms are highly 
effective in preventing the sexual transmission of HIV infection. In heterosexual HIV 
serodiscordant relationships (i.e., those involving one infected and one uninfected partner) in 
which condoms were consistently used, HIV-negative partners were 80% less likely to 
become infected with HIV compared with persons in similar relationships in which condoms 
were not used (20,21). Moreover, studies demonstrate that consistent condom use reduces 
the risk for other STDs, including chlamydia, gonorrhea, and trichomoniasis (22–24). By 
limiting lower genital tract infections, condoms also might reduce the risk of developing 
pelvic inflammatory disease (PID) in women (25). In addition, consistent and correct use of 
latex condoms reduces the risk for HPV infection and HPV-associated diseases, genital 
herpes, hepatitis B, syphilis, and chancroid when the infected area or site of potential 
exposure is covered (26–32).
Condoms are regulated as medical devices and are subject to random sampling and testing 
by the U.S. Food and Drug Administration (FDA). Each latex condom manufactured in the 
United States is tested electronically for holes before packaging. Rate of condom breakage 
during sexual intercourse and withdrawal is approximately two broken condoms per 100 
condoms used in the United States. Rates of breakage and slippage may be slightly higher 
during anal intercourse (33,34). The failure of condoms to protect against STD or 
unintended pregnancy usually results from inconsistent or incorrect use rather than condom 
breakage (35). Users should check the expiration or manufacture date on the box or 
individual package. Latex condoms should not be used beyond their expiration date or more 
than 5 years after the manufacturing date. Male condoms made of materials other than latex 
are available in the United States and can be classified in two general categories: 1) 
polyurethane and other synthetic and 2) natural membrane.
Polyurethane male condoms provide comparable protection against STDs/HIV and 
pregnancy to that of latex condoms (19,24). These can be substituted for latex condoms by 
persons with latex allergy, are generally more resistant to deterioration, and are compatible 
with use of both oil-based and water-based lubricants. The effectiveness of other synthetic 
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male condoms to prevent sexually transmitted infections has not been extensively studied, 
and FDA-labeling restricts their recommended use to latex-sensitive or allergic persons. 
Natural membrane condoms (frequently called “natural skin” condoms or [incorrectly] 
“lambskin” condoms) are made from lamb cecum and can have pores up to 1,500 nm in 
diameter. Although these pores do not allow the passage of sperm, they are more than 10 
times the diameter of HIV and more than 25 times that of HBV. Moreover, laboratory 
studies demonstrate that sexual transmission of viruses, including hepatitis B, herpes 
simplex, and HIV, can occur with natural membrane condoms (19). While natural membrane 
condoms are recommended for pregnancy prevention, they are not recommended for 
prevention of STDs and HIV.
Providers should advise that condoms must be used consistently and correctly to be effective 
in preventing STDs and HIV infection; providing instructions about the correct use of 
condoms can be useful. Communicating the following recommendations can help ensure 
that patients use male condoms correctly:
• Use a new condom with each sex act (i.e., oral, vaginal, and anal).
• Carefully handle the condom to avoid damaging it with fingernails, teeth, or 
other sharp objects.
• Put the condom on after the penis is erect and before any genital, oral, or anal 
contact with the partner.
• Use only water-based lubricants (e.g., K-Y Jelly, Astroglide, AquaLube, and 
glycerin) with latex condoms. Oil-based lubricants (e.g., petroleum jelly, 
shortening, mineral oil, massage oils, body lotions, and cooking oil) can weaken 
latex and should not be used; however, oil-based lubricants can generally be used 
with synthetic condoms.
• Ensure adequate lubrication during vaginal and anal sex, which might require the 
use of exogenous water-based lubricants.
• To prevent the condom from slipping off, hold the condom firmly against the 
base of the penis during withdrawal, and withdraw while the penis is still erect.
Additional information about male condoms is available at http://www.cdc.gov/
condomeffectiveness/index.html.
Female Condoms—Several condoms for females are globally available, including the 
FC2 Female Condom, Reddy condom, Cupid female condom, and Woman’s condom (36). 
Use of female condoms can provide protection from acquisition and transmission of STDs, 
although data are limited (36). Although female condoms are more costly compared with 
male condoms, they offer the advantage of being a female-controlled STD/HIV prevention 
method, and the newer versions may be acceptable to both men and women. Although the 
female condom also has been used during receptive anal intercourse, efficacy associated 
with this practice remains unknown (37). Additional information about the female condom 
is available at http://www.ashasexualhealth.org/sexual-health/all-about-condoms/female-
condoms.
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Cervical Diaphragms—In observational studies, diaphragm use has been demonstrated to 
protect against cervical gonorrhea, chlamydia, and trichomoniasis (38). However, a trial 
examining the effect of a diaphragm plus lubricant on HIV acquisition among women in 
Africa showed no additional protective effect when compared with the use of male condoms 
alone. Likewise, no difference by study arm in the rate of acquisition of chlamydia, 
gonorrhea, or herpes occurred (39,40). Diaphragms should not be relied on as the sole 
source of protection against HIV or other STDs.
Topical Microbicides and Spermicides—Nonspecific topical microbicides are 
ineffective for preventing HIV (41–45). Spermicides containing N-9 might disrupt genital or 
rectal epithelium and have been associated with an increased risk for HIV infection. 
Condoms with N-9 are no more effective than condoms without N-9; therefore, N-9 alone or 
in a condom is not recommended for STD or HIV prevention (41). N-9 use has also been 
associated with an increased risk for bacterial urinary tract infections in women (46,47). No 
proven topical antiretroviral agents exist for the prevention of HIV, though trials are 
underway to evaluate several candidates for vaginal and rectal microbicides using tenofovir 
and other antiretroviral drugs.
Nonbarrier Contraception, Surgical Sterilization, and Hysterectomy—
Contraceptive methods that are not mechanical barriers offer no protection against HIV or 
other STDs. Sexually active women who use hormonal contraception (i.e., oral 
contraceptives, patch, ring, implants, injectables, or intrauterine hormonal methods), have 
nonhormonal intrauterine devices (IUDs), have been surgically sterilized, or have had 
hysterectomies should be counseled to use condoms to reduce the risk for STDs, including 
HIV infection. Women who take oral contraceptives and are prescribed certain 
antimicrobials should be counseled about potential interactions (19).
Whether hormonal contraception raises a woman’s risk for acquiring HIV or another STD is 
unclear. A systematic review of epidemiologic evidence found that most studies showed no 
association between use of oral contraceptives and HIV acquisition among women. Studies 
examining the association between progestin-only injectables and HIV acquisition have had 
mixed results; some studies show a higher risk of acquisition among women using depo-
medroxyprogesterone acetate (DMPA), while other studies do not (48). The World Health 
Organization (WHO) and CDC reviewed the evidence on hormonal contraception and HIV 
acquisition and concluded that data are insufficient to recommend that women modify their 
hormonal contraceptive practices, but that women using progestin-only injectables should be 
strongly advised to also use condoms as an HIV prevention strategy (49,50).
Male Circumcision—Male circumcision reduces the risk for HIV and some STDs in 
heterosexual men. Three randomized, controlled trials performed in regions of sub-Saharan 
Africa where generalized HIV epidemics involving predominantly heterosexual transmission 
were occurring demonstrated that male circumcision reduced the risk for HIV acquisition 
among men by 50%–60% (51–53). In these trials, circumcision was also protective against 
other STDs, including high-risk genital HPV infection and genital herpes (54–56). Follow 
up studies have demonstrated sustained benefit of circumcision for HIV prevention (57) and 
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that the effect is not mediated solely through a reduction in herpes simplex virus type 2 
(HSV-2) infection or genital ulcer disease (58).
WHO and the Joint United Nations Programme on HIV/AIDS (UNAIDS) have 
recommended that male circumcision efforts be scaled up as an effective intervention for the 
prevention of heterosexually acquired HIV infection (59). These organizations also 
recommend that countries with hyperendemic and generalized HIV epidemics and low 
prevalence of male circumcision expand access to safe male circumcision services within the 
context of ensuring universal access to comprehensive HIV prevention, treatment, care, and 
support. In the United States, the American Academy of Pediatrics (AAP) recommends that 
newborn male circumcision be available to families that desire it, as the benefits of the 
procedure, including prevention of penile cancers, urinary tract infections, genital ulcer 
disease, and HIV outweigh the risks (60). ACOG has also endorsed the AAP’s policy 
statement (60). In light of these benefits, the American Urological Association states that 
male circumcision should be considered an option for risk reduction, among other strategies 
(61).
No definitive data exist to determine whether male circumcision reduces HIV acquisition in 
MSM, although one randomized trial is ongoing in China (62). A review found a modest 
protective effect among men who were the insertive partner for anal intercourse, but the 
evidence was rated as poor. Further higher quality studies are needed to confirm any 
potential benefit of male circumcision for this population (62).
Emergency Contraception—Unprotected intercourse exposes women to risks for STDs 
and unplanned pregnancy. Providers managing such women should offer counseling about 
the option of emergency contraception (EC) if pregnancy is not desired. The options for EC 
in the United States include the copper IUD and emergency contraceptive pills (ECPs) (63). 
ECPs are available in the following formulations: ulipristal acetate in a single dose (30 mg), 
levonorgestrel in a single dose (1.5 mg) or as a split dose (0.75 mg each taken 12 hours 
apart), or combined estrogen and progestin (Yuzpe regimen). Some ECPs can be obtained 
over the counter; ECPs can also be provided through advance prescription or supply from 
providers (64,65). Emergency insertion of a copper IUD up to 5 days after sex can reduce 
pregnancy risk by more than 99% (66). ECPs are most efficacious when initiated as soon as 
possible after unprotected sex but have some efficacy up to 5 days later. ECPs are ineffective 
(but not harmful) if the woman is already pregnant (67). A 2012 Cochrane review 
summarized the efficacy, safety, and convenience of various methods of emergency 
contraception (67). More information about EC is available in the 20th edition of 
Contraceptive Technology (19) or http://www.arhp.org/topics/emergency-contraception.
Postexposure Prophylaxis for HIV and STD—Guidelines for the use of postexposure 
prophylaxis (PEP) aimed at preventing HIV infection and other STDs as a result of sexual 
exposure are discussed in another section of this report (see Sexual Assault and STDs). 
Genital hygiene methods (e.g., vaginal washing and douching) after sexual exposure are 
ineffective in protecting against HIV and STDs and might increase the risk for bacterial 
vaginosis (BV), some STDs, and HIV infection (68).
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Antiretroviral Treatment of Persons with HIV Infection to Prevent HIV Infection 
in Partners—The randomized controlled trial HPTN 052 demonstrated that in HIV 
serodiscordant, heterosexual couples, HIV antiretroviral therapy in the infected partner 
decreases the risk for transmission to the uninfected partner by 96% (69). Therefore, 
antiretroviral therapy not only is beneficial to the health of persons with HIV infection, but 
also reduces the risk for continued transmission. For these reasons, treatment should be 
offered to all persons with HIV infection. Detailed guidance for prescribing antiretroviral 
regimens can be found in the U.S. Department of Health and Human Services’ HIV 
treatment guidelines at http://aidsinfo.nih.gov/guidelines (70).
HSV Treatment of Persons with HIV and HSV Infections to Prevent HIV 
Infection in Uninfected Partners—Providing HSV treatment to persons co-infected 
with HIV and HSV has not been demonstrated to be beneficial in reducing HIV acquisition 
in uninfected partners. A large randomized, controlled trial evaluated 3,408 serodiscordant 
heterosexual couples enrolled at 14 Africa sites in which the partner with HIV infection was 
also seropositive for HSV-2. The co-infected partner was randomized to receive either 
placebo or acyclovir 400-mg twice per day, and the primary outcome was HIV transmission 
to the uninfected partner. Use of acyclovir had no effect on HIV transmission (71). These 
findings are consistent with those from a previous trial that found no benefit of acyclovir in 
preventing HIV-1 acquisition in persons who were seropositive for HSV-2 (72).
Preexposure Prophylaxis for HIV—Certain large, randomized, placebo-controlled trials 
examining daily oral antiretroviral preexposure prophylaxis (PrEP) with a fixed-dose 
combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) have 
demonstrated safety (73) and a substantial reduction in the rate of HIV acquisition for MSM 
(74), HIV-discordant heterosexual couples (75), and heterosexual men and women recruited 
as individuals (76). In addition, one clinical trial involving IDUs (77) and one involving 
heterosexual HIV-discordant couples (75) demonstrated substantial efficacy and safety of 
daily oral PrEP with TDF alone when combined with repeated condom provision, sexual 
risk-reduction counseling, and the diagnosis and treatment of STDs. High adherence to oral 
PrEP with TDF alone or in a fixed-dose combination with FTC was strongly associated with 
protection from infection. Data suggest that when administered orally, levels of TDF are 
lower in vaginal tissue than rectal tissue, potentially explaining why high levels of adherence 
were needed to yield benefits among women in these trials (78). Despite initial concerns 
about PrEP fostering antiretroviral resistance among persons who become infected, standard 
tests employed in these studies detected emergence of resistance only in persons 
inadvertently started on PrEP during acute HIV infection, not in persons who were initially 
uninfected but later became infected while taking PrEP medication (79).
The U.S. Public Health Service (USPHS) has issued recommendations on the basis of these 
trial results and the FDA approval of an indication for the use of TDF/FTC for PrEP. USPHS 
recommends that clinicians evaluate HIV-negative men and women who are sexually active 
or injecting illicit drugs and consider PrEP as a prevention option for persons whose sexual 
or injection behaviors and epidemiologic context place them at substantial risk for acquiring 
HIV infection. Comprehensive guidance for the use of daily PrEP to reduce the risk for 
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acquiring HIV infection can be found at http://www.cdc.gov/hiv/prevention/research/prep/
index.html.
HIV Seroadaptation Strategies—Seroadaptive strategies for HIV prevention have 
largely originated within communities of MSM. They are predicated on knowledge of self 
and partner HIV-infection status. One specific seroadaptive practice is serosorting, which 
includes limiting anal sex without a condom to partners with the same HIV status as their 
own, or choosing to selectively use condoms only with HIV serodiscordant partners. 
Another practice among serodiscordant couples is seropositioning, in which the person with 
HIV infection is the receptive partner for anal intercourse. Observational studies have 
consistently found that serosorting confers greater risk of HIV infection than consistent 
condom use, but is lower risk compared with anal intercourse without a condom and without 
serosorting (80–82). Serosorting practices have been associated with increased risk of STDs 
including chlamydia and gonorrhea (83,84).
Serosorting is not recommended for the following reasons: 1) too many MSM who have 
HIV do not know they are infected because they have not been tested for HIV recently, 2) 
men’s assumptions about the HIV status of their partners might be wrong, and 3) some men 
with HIV infection might not disclose or may misrepresent their HIV status. All of these 
factors increase the risk that serosorting could lead to HIV infection. Additional information 
is available at http://www.cdc.gov/msmhealth/serosorting.htm or http://
www.who.int/hiv/pub/guidelines/msm_guidelines2011/en.
Retesting After Treatment to Detect Repeat Infections—Retesting several months 
after diagnosis of chlamydia, gonorrhea, or trichomoniasis can detect repeat infection and 
potentially can be used to enhance population-based prevention (85,86). Any person who 
tests positive for chlamydia or gonorrhea, along with women who test positive for 
trichomonas, should be rescreened 3 months after treatment. Any person who receives a 
syphilis diagnosis should undergo follow-up serologic syphilis testing per current 
recommendations (see Syphilis). Further details on retesting can be found in the specific 
sections on chlamydia, gonorrhea, syphilis, and trichomonas within this report.
Partner Services
The term “partner services” refers to a continuum of clinical evaluation, counseling, 
diagnostic testing, and treatment designed to increase the number of infected persons 
brought to treatment and to disrupt transmission networks. This continuum includes efforts 
undertaken by health departments, medical providers, and patients themselves. The term 
“public health partner services” refers to efforts by public health departments to identify the 
sex- and needle-sharing partners of infected persons to assure their medical evaluation and 
treatment.
Clinicians can provide partner services by counseling infected persons and providing them 
with written information and medication to give to their partners (if recommended and 
allowable by state law), directly evaluating and treating sex partners, and cooperating with 
state and local health departments. Clinicians’ efforts to ensure the treatment of a patient’s 
sex partners can reduce the risk for reinfection and potentially diminish transmission of 
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STDs (87). Therefore, clinicians should encourage all persons with STDs to notify their sex 
partners and urge them to seek medical evaluation and treatment. Timespent counseling 
patients on the importance of notifying partners is associated with improved notification 
outcomes (88). When possible, clinicians should advise persons to bring their primary sex 
partner along with them when returning for treatment and should concurrently treat both 
persons. Although this approach can be effective for a main partner (89,90), it might not be 
feasible approach for additional sex partners. Some evidence suggests that providing patients 
with written information to share with sex partners can increase rates of partner treatment 
(87).
The types and comprehensiveness of public health partner services and the specific STDs for 
which they are offered vary by public health agency and the geographic burden of STDs. In 
most areas of the United States, health departments routinely attempt to provide partner 
services to all persons with early syphilis (primary, secondary, and early latent syphilis) and 
persons with a new diagnosis of HIV infection. It is also recommended that health 
departments provide partner services for persons who might have cephalosporin-resistant 
gonorrhea. In contrast, relatively few U.S. health departments routinely provide partner 
services to persons with gonorrhea, chlamydial infection, trichomonas, or other STDs (91). 
Clinicians should familiarize themselves with public health practices in their area, but in 
most instances, providers should understand that responsibility for ensuring the treatment of 
partners of persons with STDs other than syphilis and HIV rests with the diagnosing 
provider and the patient.
Many health departments now use the internet to notify the sex partners of persons with 
STDs (92), especially MSM and in cases where no other identifying information is available 
(http://www.ncsddc.org/Internet_Guidelines). Clinical providers are unlikely to participate 
directly in internet partner notification. Internet sites allowing patients to send anonymous e-
mail or text messages advising partners of their exposure to an STD are operational in some 
areas; anonymous notification via the internet is considered better than no notification at all 
and might be an option in some instances. However, because the extent to which these sites 
affect partner notification and treatment is uncertain, patients should be encouraged either to 
notify their partners in person or by telephone, personal e-mail, or text message; 
alternatively, patients can authorize a medical provider or public health professional to do so.
Expedited Partner Therapy—Expedited Partner Therapy (EPT), also termed patient-
delivered partner therapy (PDPT), is the clinical practice of treating the sex partners of 
persons who receive chlamydia or gonorrhea diagnoses by providing medications or 
prescriptions to the patient. Patients then provide partners with these therapies without the 
health-care provider having examined the partner (see http://www.cdc.gov/std/ept). Unless 
prohibited by law or other regulations, medical providers should routinely offer EPT to 
heterosexual patients with chlamydia or gonorrhea infection when the provider cannot 
confidently ensure that all of a patient’s sex partners from the prior 60 days will be treated. 
If the patient has not had sex in the 60 days before diagnosis, providers should attempt to 
treat a patient’s most recent sex partner. EPT is legal in most states. However, providers 
should visit http://www.cdc.gov/std/ept to obtain updated information for their state. 
Providing patients with appropriately packaged medication is the preferred approach to 
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PDPT because data on the efficacy of PDPT using prescriptions is limited and many persons 
do not fill the prescriptions given to them by a sex partner. Medication or prescriptions 
provided for PDPT should be accompanied by treatment instructions, appropriate warnings 
about taking medications (if the partner is pregnant or has an allergy to the medication), 
general health counseling, and a statement advising that partners seek medical evaluation for 
any symptoms of STD, particularly PID.
The evidence supporting PDPT is based on three U.S. clinical trials involving heterosexual 
men and women with chlamydia or gonorrhea (93–95). All three trials reported that more 
partners were treated when patients were offered PDPT: two reported statistically significant 
declines in the rate of reinfection and one observed a lower risk of persistent or recurrent 
infection that was statistically nonsignificant. A fourth trial in the United Kingdom did not 
demonstrate a difference in the risk of reinfection or in the numbers of partners treated 
between persons offered PDPT and those advised to notify their sex partners (96).
U.S. trials and a meta-analysis of PDPT revealed that the magnitude of reduction in 
reinfection of index case-patients compared with patient referral differed according to the 
STD and the sex of the index case-patient (87,93–95). However, across trials, reductions in 
chlamydia prevalence at follow-up were approximately 20%; reductions in gonorrhea at 
follow-up were approximately 50%. Existing data suggest that PDPT also might have a role 
in partner management for trichomoniasis; however, no single partner management 
intervention has been shown to be more effective than any other in reducing trichomoniasis 
reinfection rates (97,98). No data support use of PDPT in the routine management of 
patients with syphilis. Data on the use of PDPT for gonorrhea or chlamydial infection 
among MSM are limited (99,100). Published studies suggest that >5% of MSM without a 
previous HIV diagnosis have a new diagnosis of HIV infection when evaluated as partners of 
patients with gonorrhea or chlamydial infection (101,102). As a result, PDPT should not be 
used routinely in MSM. All persons who receive bacterial STD diagnoses and their sex 
partners, particularly MSM, should be tested for HIV infection.
Reporting and Confidentiality
The accurate and timely reporting of STDs is integral to public health efforts to assess 
morbidity trends, allocate limited resources, and assist local health authorities in partner 
notification and treatment. STD/HIV and acquired immunodeficiency syndrome (AIDS) 
cases should be reported in accordance with state and local statutory requirements. Syphilis 
(including congenital syphilis), gonorrhea, chlamydia, chancroid, HIV infection, and AIDS 
are reportable diseases in every state. Because the requirements for reporting other STDs 
differ by state, clinicians should be familiar with the reporting requirements applicable 
within their jurisdictions.
Reporting can be provider- or laboratory-based or both. Clinicians who are unsure of state 
and local reporting requirements should seek advice from state or local health department 
STD programs. STDs and HIV reports are kept strictly confidential. In most jurisdictions, 
such reports are protected by statute or regulation. Before conducting a follow-up of a 
positive STD-test result, public health professionals should consult the patient’s health-care 
provider if possible to verify the diagnosis and determine the treatments being received.
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Special Populations
Pregnant Women
Intrauterine or perinatally transmitted STDs can have severely debilitating effects on 
pregnant women, their partners, and their fetuses. All pregnant women and their sex partners 
should be asked about STDs, counseled about the possibility of perinatal infections, and 
provided access to screening and treatment, if needed.
Recommendations to screen pregnant women for STDs are based on disease severity and 
sequelae, prevalence in the population, costs, medico-legal considerations (e.g., state laws), 
and other factors. The screening recommendations in this report are generally broader (i.e., 
more pregnant women will be screened for more STDs than would by following other 
screening recommendations) and are consistent with other CDC guidelines.
Recommended Screening Tests
• All pregnant women in the United States should be screened for HIV infection at 
the first prenatal visit, even if they have been previously tested (103,104). 
Screening should be conducted after the woman is notified of the need to be 
screened for HIV as part of the routine panel of prenatal tests, unless she declines 
(i.e., opt-out screening). For women who decline HIV testing, providers should 
address their objections, and when appropriate, continue to encourage testing. 
Women who decline testing because they have had a previous negative HIV test 
should be informed of the importance of retesting during each pregnancy. Testing 
pregnant women and treating those who are infected are vital not only to 
maintain the health of the woman, but to reduce perinatal transmission of HIV 
through available antiretroviral and obstetrical interventions. Retesting in the 
third trimester (preferably before 36 weeks’ gestation) is recommended for 
women at high risk for acquiring HIV infection (e.g., women who use illicit 
drugs, have STDs during pregnancy, have multiple sex partners during 
pregnancy, live in areas with high HIV prevalence, or have partners with HIV 
infection). Rapid HIV screening should be performed on any woman in labor 
who has not been screened for HIV during pregnancy unless she declines. If a 
rapid HIV test result is positive in these women, antiretroviral prophylaxis should 
be administered without waiting for the results of the confirmatory test (105).
• A serologic test for syphilis should be performed for all pregnant women at the 
first prenatal visit (106). When access to prenatal care is not optimal, rapid 
plasma reagin (RPR) card test screening (and treatment, if that test is reactive) 
should be performed at the time that a pregnancy is confirmed. Women who are 
at high risk for syphilis or live in areas of high syphilis morbidity should be 
screened again early in the third trimester (at approximately 28 weeks’ gestation) 
and at delivery. Some states require all women to be screened at delivery. 
Neonates should not be discharged from the hospital unless the syphilis serologic 
status of the mother has been determined at least one time during pregnancy and 
preferably again at delivery if at risk. Any woman who delivers a stillborn infant 
should be tested for syphilis.
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• All pregnant women should be routinely tested for hepatitis B surface antigen 
(HBsAg) at the first prenatal visit even if they have been previously vaccinated or 
tested (107). Women who were not screened prenatally those who engage in 
behaviors that put them at high risk for infection (e.g., having had more than one 
sex partner in the previous 6 months, evaluation or treatment for an STD, recent 
or current injection-drug use, and an HBsAg-positive sex partner) and those with 
clinical hepatitis should be retested at the time of admission to the hospital for 
delivery. Pregnant women at risk for HBV infection also should be vaccinated. 
To avoid misinterpreting a transient positive HBsAg result during the 21 days 
after vaccination, HBsAg testing should be performed before vaccine 
administration. All laboratories that conduct HBsAg tests should test initially 
reactive specimens with a licensed neutralizing confirmatory test. When pregnant 
women are tested for HBsAg at the time of admission for delivery, shortened 
testing protocols can be used, and initially reactive results should prompt 
expedited administration of immunoprophylaxis to neonates (107). Pregnant 
women who are HBsAg positive should be reported to the local or state health 
department to ensure that they are entered into a case-management system and 
that timely and appropriate prophylaxis is provided to their infants. Information 
concerning the pregnant woman’s HBsAg status should be provided to the 
hospital in which delivery is planned and to the health-care provider who will 
care for the newborn. In addition, household and sex contacts of women who are 
HBsAg positive should be vaccinated. Women who are HBsAg positive should 
be provided with, or referred for, appropriate counseling and medical 
management.
• All pregnant women aged <25 years and older women at increased risk for 
infection (e.g., those who have a new sex partner, more than one sex partner, a 
sex partner with concurrent partners, or a sex partner who has a sexually 
transmitted infection) should be routinely screened for Chlamydia trachomatis at 
the first prenatal visit (108). Women aged <25 years and those at increased risk 
for chlamydia also should be retested during the third trimester to prevent 
maternal postnatal complications and chlamydial infection in the neonate. 
Pregnant women found to have chlamydial infection should have a test-of-cure to 
document chlamydial eradication (preferably by nucleic acid amplification 
testing [NAAT]) 3–4 weeks after treatment and then retested within 3 months. 
Screening during the first trimester might prevent the adverse effects of 
chlamydia during pregnancy, but evidence for such screening is lacking.
• All pregnant women aged <25 years and older women at increased risk for 
gonorrhea (e.g., those with a new sex partner, more than one sex partner, a sex 
partner with concurrent partners, or a sex partner who has a sexually transmitted 
infection) should be screened for N. gonorrhoeae at the first prenatal visit (108). 
Additional risk factors for gonorrhea include inconsistent condom use among 
persons not in mutually monogamous relationships, previous or coexisting 
sexually transmitted infection, and exchanging sex for money or drugs. 
Clinicians should consider the communities they serve and might choose to 
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consult local public health authorities for guidance on identifying groups that are 
at increased risk. Gonococcal infection, in particular, is concentrated in specific 
geographic locations and communities. Women found to have gonococcal 
infection should be treated immediately and retested within 3 months. Pregnant 
women who remain at high risk for gonococcal infection also should be retested 
during the third trimester to prevent maternal postnatal complications and 
gonococcal infection in the neonate.
• All pregnant women at risk for HCV infection should be screened for hepatitis C 
antibodies at the first prenatal visit. The most important risk factor for HCV 
infection is past or current injection drug use (109). Additional risk factors 
include having had a blood transfusion before July 1992, receipt of an 
unregulated tattoo, having been on long-term hemodialysis, intranasal drug use, 
and other percutaneous exposures. No established treatment regimen exists for 
pregnant women infected with HCV. However, all women with HCV infection 
should receive appropriate counseling and supportive care as needed (see 
Hepatitis C, Prevention). No vaccine is available to prevent HCV transmission.
• Pregnant women should undergo a Papanicolau (Pap) test at the same frequency 
as nonpregnant women, although recommendations for management of abnormal 
Pap tests in pregnancy differ (110).
Other Tests
• Evidence does not support routine screening for BV in asymptomatic pregnant 
women at high risk for preterm delivery (111). Symptomatic women should be 
evaluated and treated (see Bacterial Vaginosis).
• Evidence does not support routine screening for Trichomonas vaginalis in 
asymptomatic pregnant women. Women who report symptoms should be 
evaluated and treated appropriately (see Trichomonas).
• Evidence does not support routine HSV-2 serologic screening among 
asymptomatic pregnant women. However, type-specific serologic tests might be 
useful for identifying pregnant women at risk for HSV infection and guiding 
counseling regarding the risk for acquiring genital herpes during pregnancy. In 
the absence of lesions during the third trimester, routine serial cultures for HSV 
are not indicated for women in the third trimester who have a history of recurrent 
genital herpes.
For a more detailed discussion of STD screening and treatment among pregnant women, 
refer to the following references: Screening for HIV in Pregnant Women: Systematic Review 
to Update the 2005 U.S. Preventive Services Task Force Recommendation (103); Screening 
for HIV: U.S. Preventive Services Task Force Recommendation Statement (104); 
ACOG/AAP Guidelines for Perinatal Care (112); Rapid HIV Antibody Testing During 
Labor and Delivery for Women of Unknown HIV Status: A Practical Guide and Model 
Protocol (113); Viral Hepatitis in Pregnancy (114); Hepatitis B Virus: A Comprehensive 
Strategy for Eliminating Transmission in the United States — Recommendations of the 
Immunization Practices Advisory Committee (ACIP) (4); Screening for Chlamydia and 
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Gonorrhea: U.S. Preventive Services Task Force Recommendation Statement (108); 
Canadian guidelines on sexually transmitted infections (115); USPSTF recommendations for 
STI screening (116); and Screening for Bacterial Vaginosis in Pregnancy to Prevent Preterm 
Delivery: U.S. Preventive Services Task Force Recommendation Statement (111).
Adolescents
In the United States, prevalence rates of many sexually acquired infections are highest 
among adolescents and young adults (117,118). For example, the reported rates of 
chlamydia and gonorrhea are highest among females during their adolescent and young 
adult years, and many persons acquire HPV infection at this time.
Persons who initiate sex early in adolescence are at higher risk for STDs, along with 
adolescents residing in detention facilities, those who use injection drugs, adolescents 
attending STD clinics, and young men who have sex with men (YMSM). Factors 
contributing to this increased risk during adolescence include having multiple sexual 
partners concurrently, having sequential sexual partnerships of limited duration, failing to 
use barrier protection consistently and correctly, having increased biologic susceptibility to 
infection, and facing multiple obstacles to accessing health care (118).
All 50 states and the District of Columbia explicitly allow minors to consent for their own 
health services for STDs. No state requires parental consent for STD care, although some 
states restrict a minor’s ability to provide consent on the basis of age or type of service (i.e., 
prevention, diagnosis, or treatment only). No state requires that providers notify parents that 
an adolescent minor has received STD services, except in limited or unusual circumstances. 
However, many states authorize parental notification of a minor’s receipt of STD services, 
even where the minor can legally provide his or her own consent to the service (http://
www.guttmacher.org/statecenter/spibs/spib_OMCL.pdf; http://www.cahl.org/state-minor-
consent-laws-a-summary-third-edition). Protecting confidentiality for such care, particularly 
for adolescents enrolled in private health insurance plans, presents multiple problems. After 
a claim has been reported, many states mandate that health plans provide a written statement 
to the beneficiary indicating the service performed, the charges covered, what the insurer 
allows, and the amount for which the patient is responsible (i.e., explanation of benefit 
[EOB]) (119). In addition, federal laws obligate notices to beneficiaries when claims are 
denied, including alerting beneficiaries who need to pay for care until the allowable 
deductible is reached. For STD detection- and treatment-related care, an EOB or medical bill 
that is received by a parent might disclose services provided and list STD laboratory tests 
performed or treatment given.
Despite the high rates of infections documented in the adolescent population, providers 
frequently fail to inquire about sexual behaviors, assess STD risks, provide risk-reduction 
counseling, and ultimately, screen for asymptomatic infections during clinical encounters. 
Discussions concerning sexual behavior should be appropriate for the patient’s 
developmental level and should be aimed at identifying risk behaviors (e.g., multiple 
partners; unprotected oral, anal, or vaginal sex; and drug-use behaviors). Careful, 
nonjudgmental, and thorough counseling is particularly vital for adolescents who might not 
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feel comfortable acknowledging their engagement in behaviors that place them at high risk 
for STDs.
Screening Recommendations—Routine laboratory screening for common STDs is 
indicated for sexually active adolescents. The following screening recommendations 
summarize published federal agency and medical professional organizations’ clinical 
guidelines for sexually active adolescents.
• Routine screening for C. trachomatis on an annual basis is recommended for all 
sexually active females aged <25 years (108). Evidence is insufficient to 
recommend routine screening for C. trachomatis in sexually active young men 
based on efficacy and cost-effectiveness. However, screening of sexually active 
young males should be considered in clinical settings serving populations of 
young males with a high prevalence of chlamydia (e.g., adolescent clinics, 
correctional facilities, and STD clinics) and should be offered to YMSM (see 
Special Populations, MSM) (120,121).
• Routine screening for N. gonorrhoeae on an annual basis is recommended for all 
sexually active females <25 years of age (108). Gonococcal infection is 
concentrated in specific geographic locations and communities. Clinicians 
should consider the communities they serve and might choose to consult local 
public health authorities for guidance on identifying groups that are at increased 
risk. Screening should be offered to YMSM (see MSM section).
• HIV screening should be discussed and offered to all adolescents. Frequency of 
repeat screenings of those who are at risk for HIV infection should be based on 
level of risk (122,123). Persons who test positive for HIV should receive 
prevention counseling and referral to care before leaving the testing site.
• The routine screening of adolescents who are asymptomatic for certain STDs 
(e.g., syphilis, trichomoniasis, BV, HSV, HPV, HAV, and HBV) is not generally 
recommended. However, YMSM and pregnant adolescent females should be 
screened for syphilis.
• Guidelines from USPSTF, ACOG, and ACS recommend that cervical cancer 
screening begin at age 21 years (124–126). This recommendation is based on the 
low incidence of cervical cancer and limited utility of screening for cervical 
cancer in adolescents (127).
Primary Prevention Recommendations—Primary prevention and anticipatory 
guidance to recognize symptoms and behaviors associated with STDs are strategies that can 
be incorporated into any or all types of healthcare visits for adolescents and young adults. 
The following recommendations for primary prevention of STDs (i.e., vaccination and 
counseling) are based on published federal agency and medical professional organizations’ 
clinical guidelines for sexually active adolescents and young adults.
• The HPV vaccine, bivalent, quadrivalent, or 9-valent, is recommended routinely 
for females aged 11 and 12 years and can be administered beginning at 9 years of 
age (16) http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html. 
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Vaccination is also recommended for females aged 13–26 years who have not yet 
received all doses or completed the vaccine series. The quadrivalent or 9-valent 
HPV vaccine is recommended routinely for males aged 11 and 12 years and also 
can be administered beginning at 9 years of age (16). Vaccination with 
quadrivalent or the 9-valent HPV vaccine is recommended for males aged 13–21 
years who have not yet received all doses or completed the vaccine series, 
although males aged 22–26 years also can be vaccinated (16). For persons with 
HIV infection and for MSM, vaccination is recommended through age 26. HPV 
vaccination has not been associated with a change in perceptions about risks 
posed by sexual behavior (128).
• The HBV vaccination series is recommended for all adolescents and young 
adults who have not previously received the hepatitis B vaccine (3,4).
• The HAV vaccination series should be offered to adolescents and young adults 
who have not previously received the HAV vaccine series.
• Information regarding HIV infection, testing, transmission, and implications of 
infection should be regarded as an essential component of the anticipatory 
guidance provided to all adolescents and young adults as part of health care 
(122).
• Health-care providers who care for adolescents and young adults should integrate 
sexuality education into clinical practice. Providers should counsel adolescents 
about the sexual behaviors that are associated with risk for acquiring STDs and 
educate patients regarding evidence-based prevention strategies, all of which 
include a discussion about abstinence and other risk-reduction behaviors (e.g., 
consistent and correct condom use and reduction in the number of sex partners). 
Interactive counseling approaches, such as high-intensity behavioral counseling 
(HIBC) and motivational interviewing, are effective STD/HIV prevention 
strategies. USPSTF recommends high-intensity behavioral counseling for all 
sexually active adolescents (7) to prevent sexually transmitted infections.* 
Educational materials (e.g., handouts, pamphlets, and videos) can reinforce 
office-based educational efforts.
Children
Management of children who have STDs requires close cooperation between clinicians, 
laboratorians, and child-protection authorities. Official investigations, when indicated, 
should be initiated promptly. Certain diseases (e.g., gonorrhea, syphilis, and chlamydia), if 
acquired after the neonatal period, strongly suggest sexual contact. For other diseases (e.g., 
HPV infections and vaginitis), the association with sexual contact is not as clear (see Sexual 
Assault and STDs).
*STI is the term used by USPSTF to describe the syndromes caused by various pathogens that can be acquired and transmitted 
through sexual activity.
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Persons in Correctional Facilities
Multiple studies have demonstrated that persons entering correctional facilities have high 
rates of STDs (including HIV) and viral hepatitis (http://www.cdc.gov/hepatitis/Settings/
corrections.htm), especially those aged ≤35 years (118). Incarcerated persons are more likely 
to have low socioeconomic status, live in urban areas, and be ethnic and racial minorities. 
Risk behaviors for contracting STDs (e.g., having unprotected sex; having multiple sexual 
partners; using drugs and alcohol; and engaging in commercial, survival, or coerced sex) are 
common among incarcerated populations. Before incarceration, many have had limited 
access to medical care.
Although no comprehensive national guidelines regarding STD care and management have 
been developed for correctional populations, growing evidence demonstrates the utility of 
expanded STD screening and treatment services in correctional settings. For example, in 
jurisdictions with comprehensive, targeted jail screening, more chlamydial infections among 
females (and males if screened) are detected and subsequently treated in the correctional 
setting than any other single reporting source (118,129) and might represent the majority of 
reported cases in certain jurisdictions (130).
Both men and women ≤35 years of age in juvenile and adult detention facilities have been 
reported to have higher rates of chlamydia (131) and gonorrhea (118) than their 
nonincarcerated counterparts in the community, and across many studies, rates have been 
consistently higher among women than men. Syphilis seroprevalence rates, which can 
indicate previous or current infection, are considerably higher among adult men and women 
than in adolescents, consistent with the overall national syphilis trends (132). Detection and 
treatment of early syphilis in correctional facilities might impact rates of transmission (133).
In short-term facilities, including jails and juvenile detention facilities that commonly house 
entrants for <1 year, up to half of entrants are released back in the community within 48 
hours. As a result, treatment completion rates for those screened for STDs and who receive 
STD diagnoses in short-term facilities might not be optimal. However, because of the 
mobility of incarcerated populations in and out of the community, the impact of screening in 
correctional facilities on the prevalence of infections among detainees and subsequent 
transmission in the community after release might be considerable (134). Moreover, 
treatment completion rates of ≥95% can be achieved by offering screening at or shortly after 
intake, facilitating earlier receipt of test results; follow-up of untreated persons can be 
conducted through public health outreach (130).
Universal screening for chlamydia and gonorrhea in women ≤35 years entering juvenile and 
adult correctional facilities has been a long-standing recommendation. However, no such 
recommendation existed for men until 2006, when CDC convened a consultation on male 
chlamydia screening (121) that resulted in recommendations to screen men <30 years for 
chlamydia at intake into jails.
Whereas several studies have shown a high prevalence of trichomonas among incarcerated 
persons, none have demonstrated the impact of trichomonas screening in correctional 
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facilities (135–137). Women who report vaginal discharge should be evaluated and treated 
appropriately.
Chlamydia and Gonorrhea Screening—Women ≤35 and men <30 years in 
correctional facilities should be screened for chlamydia and gonorrhea. Chlamydia and 
gonorrhea screening should be conducted at intake.
Syphilis Screening—Universal screening should be conducted on the basis of the local 
area and institutional prevalence of early (primary, secondary, and early latent) infectious 
syphilis. Correctional facilities should stay apprised of syphilis prevalence as it changes over 
time.
Men Who Have Sex with Men
The term “men who have sex with men” (MSM) describes a heterogeneous group of men 
who have varied behaviors, identities, and health-care needs (138). Some MSM are at high 
risk for HIV infection and other viral and bacterial STDs because MSM may practice anal 
sex, and the rectal mucosa is uniquely susceptible to certain STD pathogens. In addition, 
multiple sex partners, substance use, and sexual network dynamics of MSM increase risk for 
HIV and STDs in this population. The frequency of unsafe sexual practices and the reported 
rates of bacterial STDs and incident HIV infection declined substantially in MSM from the 
1980s through the mid-1990s. However, since that time, increased rates of early syphilis 
(primary, secondary, or early latent), gonorrhea, and chlamydial infection and higher rates of 
sexual risk behaviors have been documented among MSM in the United States and virtually 
all industrialized countries.
Approximately two thirds of the cases of primary and secondary syphilis diagnoses in the 
United States are in MSM, particularly those in ethnic minority groups (118,139,140). 
Increased syphilis screening in MSM demonstrated a doubling of early syphilis detection; 
however, 71% of the syphilis diagnoses occurred when the patient sought care for symptoms 
(141). Acute HIV infection has been associated with a recent or concurrent STD, including 
syphilis, among men at a municipal STD clinic (142) and in the multisite iPrex study (143), 
and several studies have demonstrated that early syphilis is associated with HIV infection 
among MSM (144,145). Factors associated with increases in syphilis among MSM have 
included substance abuse (e.g., methamphetamine), having multiple anonymous partners, 
and seeking sex partners through the internet (146,147). One study found that 5.9% of MSM 
had repeat primary or secondary syphilis infection within 2 years of an initial infection; 
factors associated with repeat syphilis infection were HIV infection, black race, and having 
≥10 recent sexual partners (148). Because of this risk for repeat infection, these data suggest 
that prevention efforts should include follow up serologic testing.
Gonococcal infection in MSM has been associated with similar risk factors, including 
having multiple anonymous partners and abuse of substances, particularly crystal 
methamphetamine (149). Rectal gonococcal rates are increasing among MSM with HIV 
infection, underscoring the importance of obtaining an accurate, current sexual history and 
asking about correlates of increased risk (e.g., anonymous sex and substance use) (150). 
Insertive oral sex has been associated with urethral gonorrhea acquisition (151,152); the 
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prevalence of pharyngeal gonorrhea and pharyngeal chlamydia has been demonstrated to be 
7.3% and 2.3%, respectively (153). In a multicity study, rectal gonorrhea and rectal 
chlamydia prevalence rates among MSM were 5.4% and 8.9%, respectively (154). Rectal 
gonorrhea and chlamydia infections, especially those that are recurrent, have been associated 
with increased risk for HIV seroconversion among MSM (155,156). MSM with new HIV 
infection diagnoses are more likely than HIV-uninfected MSM to receive a diagnosis of 
asymptomatic gonorrhea (25.9% versus 10.9%, p<0.001) and chlamydia (18.5% vs 7.8%, 
p<0.001) (157). Thus, rectal gonorrhea and chlamydia screening in MSM might be a cost-
effective intervention in certain urban settings (158).
MSM remain at disproportionate risk for HIV acquisition and transmission in the United 
States, particularly those who are black or Hispanic. Factors that increase the risk for HIV 
infection in MSM include either receptive or insertive anal sex without a condom, having 
another STD, having sex with anonymous partners without a condom, and using 
methamphetamines or drugs that enhance sexual performance (159).
Substantial numbers of MSM remain unaware of their serostatus (up to 44% in one recent 
survey of young men in minority populations) (160). Unfortunately, many men are not asked 
about STD-related risks, including the gender of sex partners. Even if gender of sex partners 
is ascertained, many MSM, including those with HIV infection, are neither asked about risky 
sexual behaviors nor provided with routine STD testing (especially at anatomic sites of 
exposure for gonorrhea or chlamydia), often because of the discomfort associated with these 
discussions (161–163). Clinicians should routinely ask sexually active MSM about 
symptoms consistent with common STDs, including urethral discharge, dysuria, genital and 
perianal ulcers, regional lymphadenopathy, skin rash, and anorectal symptoms consistent 
with proctitis (e.g., discharge and pain on defecation or during anal intercourse) and then 
perform appropriate diagnostic testing. In addition, providers should offer evidence-based 
counseling on safer sex using interventions that have been demonstrated to decrease STD 
incidence in clinical-care settings (10).
Clinicians should be familiar with local resources available to assist MSM with syphilis and 
HIV partner services as well as HIV linkage and retention in care. In addition, interventions 
promoting behavior change also might be appropriate. In recent years, medical educational 
materials have been developed in print (164) and through electronic media (http://
www.lgbthealtheducation.org) to increase primary-care provider knowledge and cultural 
competency regarding the diagnosis and management of STDs and other clinical conditions 
in the lesbian, gay, bisexual, and transgender populations. Electronic media is also an 
important tool for disseminating and collecting information to and from MSM. Because 
many MSM meet partners online and seek health information from websites, increased use 
of the internet for STD prevention might be warranted. MSM are amenable to receiving HIV 
and STD risk-reduction messages online (165) and willing to respond to requests for partner 
identification from public health authorities through the internet (166).
The following screening tests should be performed at least annually for sexually active 
MSM, including those with HIV infection.
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• HIV serology if HIV status is unknown or negative and the patient himself or his 
sex partner(s) has had more than one sex partner since most recent HIV test.
• Syphilis serology to establish whether persons with reactive tests have untreated 
syphilis, have partially treated syphilis, are manifesting a slow serologic response 
to appropriate prior therapy, or are serofast.
• A test for urethral infection† with N. gonorrhoeae and C. trachomatis in men 
who have had insertive intercourse§ during the preceding year (testing of the 
urine using NAAT† is the preferred approach).
• A test for rectal infection† with N. gonorrhoeae and C. trachomatis in men who 
have had receptive anal intercourse§ during the preceding year (NAAT of a rectal 
specimen is the preferred approach).
• A test for pharyngeal infection† with N. gonorrhoeae in men who have had 
receptive oral intercourse§ during the preceding year (NAAT of a pharyngeal 
specimen is the preferred approach). Testing for C. trachomatis pharyngeal 
infection is not recommended.
MSM with HIV infection are also at risk for STDs. Data from a study of 557 adults with 
HIV infection receiving primary care in four U.S. cities demonstrate that 13% had STD at 
study enrollment, and 7% had incident STD at 6 months; among MSM with HIV infection, 
STD incidence was 20% (10). Excluding trichomoniasis, 94% of incident STDs were 
diagnosed in MSM. All MSM with HIV infection entering care should be screened for 
gonorrhea and chlamydia at appropriate anatomic sites of exposure, as well as for syphilis 
(17). The frequency of follow-up testing might be dictated by subsequent behavior; 
screening is recommended annually, at a minimum, to include syphilis serologic testing and 
chlamydia and gonorrhea screening at exposed anatomic sites (138). STD screening rates in 
HIV clinics have been suboptimal. In one study involving eight U.S. cities, although syphilis 
testing was provided to most MSM with HIV infection, <10% were screened for extra-
genitourinary gonorrhea or chlamydia, and <20% provided the urine or urethral specimens 
needed for testing (162). More frequent STD screening (i.e., for syphilis, gonorrhea, and 
chlamydia) at 3–6-month intervals is indicated for MSM, including those with HIV infection 
if risk behaviors persist or if they or their sexual partners have multiple partners. Evaluation 
for HSV-2 infection with type-specific serologic tests also can be considered if infection 
status is unknown in persons with previously undiagnosed genital tract infection.
HPV infection and HPV-associated conditions (e.g., anogenital warts and anal squamous 
intraepithelial lesions) are highly prevalent among MSM. The quadrivalent vaccine is 
recommended routinely for MSM through age 26 years (16,167,168); the efficacy of this 
vaccine in preventing HPV associated diseases in men aged >26 years is unknown.
†Regardless of condom use during exposure.§Commerically available NAATs have not been cleared by FDA for these indications, but they can be used by laboratories that have 
met all regulatory requirements for an off-label procedure. Source: CDC. Recommendations for the laboratory-based detection of 
Chlamydia trachomatis and Neisseria gonorrhoeae — 2014. MMWR Recomm Rep 2014;63(No RR-2):1–19.
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Data are insufficient to recommend routine anal-cancer screening with anal cytology in 
persons with HIV infection or HIV-negative MSM. More evidence is needed concerning the 
natural history of anal intraepithelial neoplasia, the best screening methods and target 
populations, safety of and response to treatments, and other programmatic considerations 
before screening can be routinely recommended. However, some clinical centers perform 
anal cytology to screen for anal cancer among high-risk populations (e.g., persons with HIV 
infection and MSM), followed by high-resolution anoscopy for those with abnormal 
cytologic results (e.g., ASC-US).
All MSM should be tested for HBsAg to detect chronic HBV infection. Prompt 
identification of chronic infection with HBV is essential to ensure necessary care and 
services to prevent transmission to others (169). Screening among past or current drug users 
should include HCV and HBV testing. Vaccination against hepatitis A and B is 
recommended for all MSM in whom previous infection or vaccination cannot be 
documented (2,3). Preimmunization serologic testing might be considered to reduce the cost 
of vaccinating MSM who are already immune to these infections, but this testing should not 
delay vaccination. Vaccinating persons who are immune to HAV or HBV infection because 
of previous infection or vaccination does not increase the risk for vaccine-related adverse 
events (see Hepatitis A and Hepatitis B).
Sexual transmission of HCV can occur, especially among MSM with HIV infection (see 
Emerging Issues, Hepatitis C). Serologic screening for HCV is recommended at initial 
evaluation of persons with newly diagnosed HIV infection. Because of accumulating 
evidence of acute HCV infection acquisition among persons with HIV infection (especially 
MSM with HIV infection [170–175]) and because regular screening for HCV infection is 
cost effective (176,177), MSM with HIV infection should be regularly screened for HCV. 
Screening should be performed at least yearly and more frequently depending on specific 
circumstances (e.g., local HCV prevalence and incidence, high-risk sexual behavior, and 
concomitant ulcerative STDs or STD-related proctitis). Screening should be performed 
using HCV antibody assays followed by HCV RNA testing for those with a positive 
antibody result (178).
Women Who Have Sex with Women
Women who have sex with women (WSW) are a diverse group with variations in sexual 
identity, sexual behaviors, sexual practices, and risk behaviors. Recent studies indicate that 
some WSW, particularly adolescents and young women as well as women with both male 
and female partners, might be at increased risk for STDs and HIV based on reported risk 
behaviors (179–183). Certain studies have highlighted the wide diversity of sexual practices 
and examined use of protective/risk reduction strategies among populations of WSW (184–
186). Use of barrier protection with female partners (gloves during digital-genital sex, 
condoms with sex toys, and latex or plastic barriers [also known as dental dams for oral-
genital sex]) was infrequent in all studies. Despite this, few comprehensive and reliable 
resources of sexual health information for WSW are available (187).
Few data are available on the risk for STDs conferred by sex between women, but 
transmission risk probably varies by the specific STD and sexual practice (e.g., oral-genital 
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sex; vaginal or anal sex using hands, fingers, or penetrative sex items; and oral-anal sex) 
(188,189). Practices involving digital-vaginal or digital-anal contact, particularly with shared 
penetrative sex items, present a possible means for transmission of infected cervicovaginal 
or anal secretions. This possibility is most directly supported by reports of shared 
trichomonas infections (190,191) and by concordant drug resistance genotype testing and 
phylogenetic linkage analysis identifying HIV transmitted sexually between women 
(192,193). Most self-identified WSW (53%–97%) have had sex with men in the past and 
might continue this practice, with 5%–28% of WSW reporting male partners within the past 
year (189,194–196).
HPV, which can be transmitted through skin-to-skin contact, is common among WSW, and 
sexual transmission of HPV likely occurs between female sex partners (197–199). HPV 
DNA has been detected through polymerase chain reaction (PCR)-based methods from the 
cervix, vagina, and vulva in 13%–30% of WSW (197,198). Among WSW who reported 
never having had a male sexual partner, 26% had antibodies to HPV-16, and 42% had 
antibodies to HPV-6 (197). High- and low-grade squamous intraepithelial lesions (SIL) have 
been detected on Pap tests in WSW who reported no previous sex with men 
(197,198,200,201). WSW are at risk for acquiring HPV from both their female partners and 
from current or prior male partners, and thus are at risk for cervical cancer. Therefore, 
routine cervical cancer screening should be offered to all women, regardless of sexual 
orientation or sexual practices, and women should be offered HPV vaccine as per current 
guidelines (16).
Genital transmission of HSV-2 between female sex partners is inefficient, but can occur. A 
U.S. population-based survey among women aged 18–59 years demonstrated an HSV-2 
seroprevalence of 30% among women reporting same-sex partners in the past year, 36% 
among women reporting samesex partners in their lifetime, and 24% among women 
reporting no lifetime same-sex behavior (195). HSV-2 seroprevalence among women self-
identifying as “homosexual or lesbian” was 8%, similar to a prior clinic-based study of 
WSW (195,196). The relatively frequent practice of orogenital sex among WSW might 
place them at higher risk for genital infection with HSV-1, a hypothesis supported by the 
recognized association between HSV-1 seropositivity and previous number of female 
partners among WSW. Thus, sexual transmission of HSV-1 and HSV-2 can occur between 
female sex partners. This information should be communicated to women as part of a larger 
sexual health counseling and evaluation effort.
Less is known regarding transmission of bacterial STDs between female partners. 
Transmission of syphilis between female sex partners, probably through oral sex, has been 
reported. Although the rate of transmission of C. trachomatis between women is unknown, 
infection also might be acquired from past or current male partners. More recent data 
suggests that C. trachomatis infection among WSW might be more common than previously 
believed (179,202). Reports of same-sex behavior in women should not deter providers from 
offering and providing screening for STDs, including chlamydia, according to current 
guidelines.
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BV is common among women in general and even more so among women with female 
partners (203,204). Sexual behaviors that facilitate the transfer of vaginal fluid and bacteria 
between partners may be involved in the pathogenesis of BV. A study including 
monogamous couples demonstrated that female sex partners frequently share identical 
genital Lactobacillus strains (205). Within a community-based cohort of WSW, extravaginal 
(i.e., oral and rectal) reservoirs of BV-associated bacteria were a risk factor for incident BV 
(206). Several new studies have examined the impact of specific sexual practices on the 
vaginal microflora (207–209) and on recurrent (210) or incident (211,212) BV among WSW 
and non-WSW. These studies have continued to support, though have not proven, the 
hypothesis that sexual behaviors, specific BV-associated bacteria, and possibly exchange of 
vaginal or extravaginal microbiota (e.g., oral bacterial communities) between partners might 
be involved in the pathogenesis of BV in WSW.
Although BV is common in WSW, routine screening for BV is not recommended. Results of 
a randomized trial using a behavioral intervention to reduce persistent BV among WSW 
through reduced sharing of vaginal fluid on hands or sex toys has been published (213). 
Although women randomized to the intervention were 50% less likely to report receptive 
digitalvaginal contact without gloves than controls and reported sharing sex toys 
infrequently, these women had no reduction in persistent BV at 1 month post-treatment and 
no reduction in incident episodes of recurrent BV. To date, no reported trials have examined 
the potential benefits of treating female partners of women with BV; thus, no 
recommendation can be made regarding partner therapy in WSW. Increasing awareness of 
signs and symptoms of BV in women and encouraging healthy sexual practices (e.g., 
avoiding shared sex toys, cleaning shared sex toys, and barrier use) might benefit women 
and their partners. WSW are at risk for acquiring bacterial, viral, and protozoal STDs from 
current and prior partners, both male and female. WSW should not be presumed to be at low 
or no risk for STDs based on sexual orientation. Report of same sex behavior in women 
should not deter providers from considering and performing screening for STDs and cervical 
cancer according to current guidelines. Effective screening requires that care providers and 
their female patients engage in a comprehensive and open discussion of sexual and 
behavioral risks that extends beyond sexual identity.
Transgender Men and Women
Persons who are transgender identify with a sex that differs from that they were assigned at 
birth. Transgender women (“trans-women” or “transgender male to female”) identify as 
women but were born with male anatomy. Similarly, transgender men (also referred to as 
“trans-men” or “transgender female to male”) identify as men but were born with female 
anatomy. However, transgender persons might use different and often fluid terminology to 
refer to themselves through their life course. Gender identity is independent from sexual 
orientation. Persons who are transgender might have sex with men, women, or both and 
consider themselves to be heterosexual, gay, lesbian, or bisexual. Prevalence studies of 
transgender persons in the overall population have been limited and often based on small 
convenience samples.
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Transgender Women—A systematic review of studies of HIV among transgender 
women suggests that the prevalence of HIV in the United States is 27.7% among all 
transgender women and 56.3% among black transgender women (214). Data also suggests 
high rates of HIV among transgender women globally (215). Bacterial STD prevalence 
varies among transgender women, but is based largely on convenience samples. Providers 
caring for transgender women should have knowledge of their patients’ current anatomy and 
patterns of sexual behavior before counseling them about STD and HIV prevention (216). 
Most transgender women have not undergone genital affirmation surgery and may retain a 
functional penis (217–219); in this instance, they might engage in insertive oral, vaginal, or 
anal sex with men and women.
Transgender Men—The few studies of HIV prevalence and incidence in transgender men 
suggest that although some transgender men engage in risky behaviors, they have a lower 
prevalence of HIV than transgender women (220). Providers should consider the anatomic 
diversity among transgender men, because many still have a vagina and cervix and are at 
risk for bacterial STDs, cervical HPV, and cervical cancer (221).
Recommendations—Clinicians should assess STD- and HIV-related risks for their 
transgender patients based on current anatomy and sexual behaviors. Because of the 
diversity of transgender persons regarding surgical affirming procedures, hormone use, and 
their patterns of sexual behavior, providers must remain aware of symptoms consistent with 
common STDs and screen for asymptomatic STDs on the basis of behavioral history and 
sexual practices.
Emerging Issues
Hepatitis C
HCV infection is the most common chronic bloodborne infection in the United States, with 
an estimated 2.7 million persons living with chronic infection (222). HCV is not efficiently 
transmitted through sex (170,223). Studies of HCV transmission between heterosexual or 
homosexual couples have yielded mixed results, but generally have found either no or very 
minimally increased rates of HCV infection in partners of persons with HCV infection 
compared with those whose partners are not HCV-infected (223–230). However, data 
indicate that sexual transmission of HCV can occur, especially among persons with HIV 
infection. Increasing incidence of acute HCV infection among MSM with HIV infection has 
been reported in New York City (231,232) and Boston (175,177), along with multiple 
European cities (233–235). These men usually engage in high-risk and traumatic sexual 
practices and might have concurrent genital ulcerative disease or STD-related proctitis 
(233,235). Other common practices associated with new cases of HCV infection include 
group sex and use of cocaine and other nonintravenous drugs during sex. Certain studies 
have revealed that risk increases commensurate with increasing numbers of sex partners 
among heterosexual persons with HIV infection (225,226,236–238) and MSM (239–242), 
especially if their partners are also coinfected with HIV (234,235,239–243).
Persons newly infected with HCV typically are either asymptomatic or have a mild clinical 
illness. HCV RNA can be detected in blood within 1–3 weeks after exposure. The average 
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time from exposure to antibody to HCV (anti-HCV) seroconversion is 8–9 weeks, and anti-
HCV can be detected in >97% of persons by 6 months after exposure. Chronic HCV 
infection develops in 70%–85% of HCV-infected persons; 60%–70% of chronically infected 
persons develop evidence of active liver disease. Most infected persons remain unaware of 
their infection because they are not clinically ill. However, infected persons serve as a source 
of transmission to others and are at risk for CLD and other HCV-related chronic diseases 
decades after infection.
HCV is primarily transmitted parenterally, usually through shared drug-injection needles and 
paraphernalia. HCV also can be transmitted through exposures in health-care settings as a 
consequence of inadequate infection-control practices (244). Transmission following receipt 
of blood, tissues, and organs from donors with HCV infection has occurred only rarely since 
1992, when routine screening of these donated products was mandated in the United States. 
Tattoos applied in regulated settings have not been associated with HCV transmission, 
although those obtained in unregulated settings have been linked to such transmission (224). 
Occupational and perinatal exposures also can result in transmission of HCV, but such 
transmission is uncommon.
Acute hepatitis C is a reportable condition in 49 states, and matching viral hepatitis and HIV 
surveillance registries can facilitate early detection of social networks of HCV transmission 
among MSM with HIV infection. Suspected clusters of acute HCV infection should be 
reported to the appropriate public health authorities.
HCV screening is recommended by CDC and USPSTF for all persons born during 1945–
1965 and others based on their risk for infection or on a recognized exposure, including past 
or current injection drug use, receiving a blood transfusion before 1992, long-term 
hemodialysis, being born to a mother with HCV infection, intranasal drug use, receipt of an 
unregulated tattoo, and other percutaneous exposures (109,224,245).
Diagnosis—Testing for HCV infection should include use of an FDA-cleared test for 
antibody to HCV (i.e., immunoassay, EIA, or enhanced chemiluminescence immunoassay 
and, if recommended, a supplemental antibody test) followed by NAAT to detect HCV RNA 
for those with a positive antibody result (178). Persons with HIV infection with low CD4-
positive cell count might require further testing by NAAT because of the potential for a 
false-negative antibody assay.
Persons determined to be anti-HCV positive should be evaluated (by referral or consultation, 
if appropriate) for the presence of acute infection; presence, severity, or development of 
CLD; and eligibility for treatment. Nucleic acid testing, including reverse transcriptase 
polymerase chain reaction (RT-PCR) to detect HCV RNA, is necessary to confirm the 
diagnosis of current HCV infection, and testing of liver function (alanine aminotransferase 
level) provides biochemical evidence of CLD.
Treatment—Providers should consult with specialists knowledgeable about management 
of hepatitis C infection. Further, they can consult existing guidelines to learn about the latest 
advances in the management of hepatitis C (http://www.hcvguidelines.org).
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Management of Sex Partners—Because incident HCV has not been demonstrated to 
occur in heterosexual couples followed over time (223,227–229), condom use might not be 
necessary in such circumstances. Persons with HCV infection with one long-term, steady 
sex partner do not need to change their sexual practices. However, they should discuss the 
low but present risk for transmission with their partner and discuss the need for testing 
(170,245). Heterosexuals and MSM with HCV infection and more than one partner, 
especially those with concurrent HIV infection, should protect their partners against HCV 
and HIV acquisition by using male latex condoms (231,234,235). Partners of persons with 
HCV and HIV infection should be tested for HCV and HIV, if not known to be infected.
Other Management Considerations—All persons with HCV for whom HIV and HBV 
infection status is unknown should be tested for these infections. Those who have HIV or 
HBV should be referred for or provided with appropriate care and treatment.
Prevention—Reducing the burden of HCV infection and disease in the United States 
requires implementation of both primary and secondary prevention activities. Primary 
prevention reduces or eliminates HCV transmission, whereas secondary prevention activities 
are aimed at reducing CLD and other chronic diseases in persons with HCV infection by 
first identifying them and then providing medical management and antiviral therapy, if 
appropriate. No vaccine for hepatitis C is available, and prophylaxis with immune globulin 
is not effective in preventing HCV infection after exposure.
Persons with HCV infection should be provided information regarding how to protect their 
liver from further harm (i.e., hepatotoxic agents); for instance, persons with HCV infection 
should be advised to avoid drinking alcohol and taking any new medicines (including over-
the-counter and herbal medications) without checking with their clinician. In addition, a 
determination for the need of hepatitis A and B vaccination should be made; persons who 
are not immune should be vaccinated.
To reduce the risk for transmission to others, persons with HCV infection should be advised 
1) not to donate blood, body organs, other tissue, or semen; 2) not to share any personal 
items that might have blood on them (e.g., toothbrushes and razors); and 3) to cover cuts and 
sores on the skin to keep the virus from spreading by blood or secretions. Women with HCV 
infection do not need to avoid pregnancy or breastfeeding.
Persons who use or inject drugs should be counseled about the importance of stopping drug-
use behaviors and provided with assistance to enter and complete substance-abuse treatment 
(including relapse prevention). Persons who continue to inject drugs despite counseling 
should be encouraged to take the following additional steps to reduce personal and public 
health risks:
• never reuse or share syringes, water, or drug preparation equipment;
• only use syringes obtained from a reliable source (e.g., pharmacies);
• use a new, sterile syringe to prepare and inject drugs;
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• if possible, use sterile water to prepare drugs; otherwise, use clean water from a 
reliable source (e.g., fresh tap water);
• use a new or disinfected container (i.e., cooker) and a new filter (i.e., cotton) to 
prepare drugs;
• clean the injection site before injection with a new alcohol swab; and
• safely dispose of syringes after one use.
Postexposure Follow-Up—No postexposure prophylaxis has been demonstrated to be 
effective against HCV. HCV testing is recommended for health-care workers after 
percutaneous or permucosal exposures to HCV-positive blood. Children born to women with 
HCV infection also should be tested for HCV. Prompt identification of acute infection is 
important, because outcomes are improved when treatment is initiated early in the course of 
illness.
Special Considerations
Pregnancy: Routine screening for HCV infection is not recommended for all pregnant 
women. Pregnant women with a known risk factor for HCV infection should be offered 
screening. Although the rate for transmission is highly variable, up to six of every 100 
infants born to HCV-infected women become infected; this infection occurs predominantly 
during or near delivery, and no treatment or delivery method—such as caesarian section—
has been demonstrated to decrease this risk (246). However, the risk is increased by the 
presence of maternal HCV viremia at delivery and is two- to threefold greater if the woman 
is coinfected with HIV. HCV has not been shown to be transmitted through breast milk, 
although mothers with HCV infection should consider abstaining from breastfeeding if their 
nipples are cracked or bleeding. Infants born to mothers with HCV infection should be 
tested for HCV infection; because maternal antibody is present for the first 18 months of life 
and before the infant mounts an immunologic response, nucleic acid testing is recommended 
(http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6218a5.htm?s_cid=mm6218a5_w).
HIV Infection: All persons with HIV infection should undergo serologic screening for HCV 
at initial evaluation (17,247). Providers should be aware of the likelihood that MSM with 
HIV infection will acquire HCV after initial screening. Because of accumulating evidence of 
acute HCV infection acquisition in persons with HIV infection, especially MSM, and cost-
effectiveness of regular screening (176,177), periodic HCV screening should be considered 
(170–175). For persons with HIV infection, HCV screening with HCV antibody assays can 
be considered at least yearly in those at high risk for infection and more frequently 
depending on specific circumstances (e.g., community HCV prevalence and incidence, high-
risk sexual behavior, and concomitant ulcerative STDs and STD-related proctitis). Indirect 
testing (e.g., ALT) is not recommended for detecting incident HCV infections because such 
testing, especially if performed once a year, can miss many persons who have reverted after 
acute HCV infection to a normal ALT level at the time of testing (175,177). Conversely, 
ALT can be elevated by antiretroviral and other medications, alcohol, and toxins. If ALT 
levels are being monitored, persons with HIV infection who experience new and 
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unexplained increases in ALT should be tested for acute HCV infection and evaluated for 
possible medication toxicity or excessive alcohol use.
Continued unprotected sexual contact between partners with HIV infection can facilitate 
spread of HCV, as the virus can be recovered from the semen of men with HIV (248). 
Specific prevention practices (e.g., barrier precautions that limit contact with body fluids 
during sexual contact with other MSM) should be discussed.
Because a minimal percentage of persons with HIV infection fail to develop HCV 
antibodies, HCV RNA testing should be performed in persons with unexplained liver disease 
who are anti-HCV negative. The course of liver disease is more rapid in HIV/HCV 
coinfected persons, and the risk for cirrhosis is nearly twice that of persons with HCV 
infection alone. Coinfected persons receiving HIV antiviral regimens are now being treated 
for HCV after their CD4+ cell counts increase, optimizing their immune response.
Mycoplasma genitalium
M. genitalium was first identified in the early 1980s (249) and has become recognized as a 
cause of male urethritis, responsible for approximately 15%–20% of nongonococcal 
urethritis (NGU) cases, 20%–25% of nonchlamydial NGU, and approximately 30% of 
persistent or recurrent urethritis (250). In most settings, it is more common than N. 
gonorrhoeae but less common than C. trachomatis. While M. genitalium is often the sole 
pathogen detected, coinfection with C. trachomatis is not uncommon in selected areas (251–
253).
Although strong and consistent evidence has linked M. genitalium to urethritis in men, it 
remains unknown whether this infection can cause male infertility or other male anogenital 
tract disease syndromes. The organism has been detected in men with epididymitis in a 
limited number of cases, but this has not been extensively investigated. Similarly, M. 
genitalium has been found in the rectum, but detection is infrequently accompanied by rectal 
symptoms, and its presence does not appear to cause a syndrome of clinical proctitis.
The pathogenic role of M. genitalium is less definitive in women than it is in men. M. 
genitalium can be found in the vagina, cervix, and endometrium and, like chlamydial and 
gonococcal infections, M. genitalium infections in women are commonly asymptomatic. M. 
genitalium can be detected in 10%–30% of women with clinical cervicitis, and most (253–
259) studies have found that this organism is more common among women with cervicitis 
than those without this syndrome (251,260,261).
M. genitalium is found in the cervix and/or endometrium of women with PID more often 
than in women without PID (262–271), and endosalpingitis develops in nonhuman primates 
after inoculation with M. genitalium, suggesting that this organism can cause PID. M. 
genitalium has been detected in 2%–22% of PID cases (median: 10%) depending on the 
setting, but the frequency with which M. genitalium-infected women experience PID has 
been under studied. Although one study in Sweden reported a substantial increase in risk for 
postabortal PID among women with M. genitalium (262), the proportion of M. genitalium-
positive women who subsequently experienced PID in two other studies was relatively low 
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(<5%) (272,273), and evidence from serologic studies assessing the association of PID with 
antibody to M. genitalium is inconsistent. Overall, evidence suggests that M. genitalium can 
cause PID, but that this occurs less frequently than it does with C. trachomatis (271,273).
A few seroepidemologic studies have found that women with tubal factor infertility are more 
likely to have antibodies to M. genitalium than fertile women, suggesting that this organism 
might cause female infertility. However, more research is needed. On the basis of certain 
reports, M. genitalium was uncommonly identified in women who experience adverse 
pregnancy outcomes, but was associated with increased risk for preterm delivery in one U.S. 
and another Peruvian study (274,275). Data are scarce regarding M. genitalium and ectopic 
pregnancy.
Diagnostic Considerations—M. genitalium is a slow-growing organism. Culture can 
take up to 6 months, and only a few laboratories in the world are able to recover clinical 
isolates. Therefore, NAAT is the preferred method for M. genitalium detection. In research 
settings, M. genitalium is diagnosed by NAAT testing of urine, urethral, vaginal, and 
cervical swabs and through endometrial biopsies, typically using in-house PCR or assays 
intended for research use only. NAAT tests (polymerase chain reaction or transcription 
mediated amplification) for M. genitalium are available in some large medical centers and 
commercial laboratories, but there is no diagnostic test for M. genitalium that is cleared by 
the FDA for use in the United States. In the absence of validated tests, M. genitalium should 
be suspected in cases of persistent or recurrent urethritis and may be considered in persistent 
or recurrent cases of cervicitis and PID.
Treatment—M. genitalium lacks a cell wall, and thus antibiotics targeting cell-wall 
biosynthesis (e.g., beta-lactams including penicillins and cephalosporins) are ineffective 
against this organism. Given the diagnostic challenges, treatment of most M. genitalium 
infections will occur in the context of syndromic management for urethritis, cervicitis, and 
PID.
Urethritis and Cervicitis: The 7-day doxycycline regimen recommended for treatment of 
urethritis is largely ineffective against M. genitalium with a median cure rate of 
approximately 31% (276–278). The 1-g single dose of azithromycin was significantly more 
effective against M. genitalium than doxycycline in two randomized urethritis treatment 
trials (276,277) and is preferred over doxycycline. However, resistance to azithromycin 
appears to be rapidly emerging. The median cure rate for both men and women is 
approximately 85%, but was only 40% in the most recent trial (278). Persons with treatment 
failures after the 1-g azithromycin regimen frequently have macrolide-resistant strains, 
suggesting that single-dose azithromycin therapy might select for resistance. A longer 
course of azithromycin (an initial 500-mg dose followed by 250 mg daily for 4 days) might 
be marginally superior to the single dose regimen (279–281). However, in some settings, 
approximately 50% of all M. genitalium infections are caused by organisms that are already 
resistant to azithromycin (282), and persons who do not respond to the 1-g azithromycin 
regimen generally do not benefit from retreatment with the extended dose regimen. 
Moxifloxacin (400 mg daily × 7, 10 or 14 days) has been successfully used to treat M. 
genitalium in men and women with previous treatment failures, with cure rates of 100% in 
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initial reports (280,283). However, moxifloxacin has been used in only a few cases, and the 
drug has not been tested in clinical trials. Although generally considered effective, studies in 
Japan, Australia, and the United States have reported moxifloxacin treatment failures after 
the 7 day regimen (284–287).
PID: Recommended PID treatment regimens are based on antibiotics that are not effective 
against M. genitalium. Therefore, clinicians might consider M. genitalium in cases that do 
not respond to therapy within 7–10 days. Where validated M. genitalium testing is available, 
clinicians might test women with PID for M. genitalium. When M. genitalium is detected, a 
regimen of moxifloxacin 400 mg/day for 14 days has been effective in eradicating the 
organism (288). Nevertheless, no data have been published that assess the benefits of testing 
women with PID for M. genitalium, and the importance of directing treatment against this 
organism is currently unknown.
Follow-up—In settings where validated M. genitalium testing is available, persons with 
persistent urethritis, cervicitis, or PID accompanied by persistent detection of M. genitalium 
might be treated with moxifloxacin. However, routine tests-of-cure in asymptomatic persons 
are not recommended.
Management of Sex Partners—Sex partners should be managed according to guidelines 
for patients with nongonococcal urethritis (NGU), cervicitis, and PID. In settings with 
access to validated M. genitalium tests, partner testing and treatment of identified infections 
might be considered.
Special Considerations
HIV Infection: Persons who have an M. genitalium infection and HIV infection should 
receive the same treatment regimen as those who are HIV negative. Treatment of most M. 
genitalium infections will occur in the context of syndromic management for urethritis, 
cervicitis, and PID (See Mycoplasma genitalium, Treatment).
HIV Infection: Detection, Counseling, and Referral
HIV infection typically begins with a brief acute retroviral syndrome, transitions to a multi-
year chronic illness that progressively depletes CD4 T-lymphocytes critical for maintenance 
of effective immune function, and ends with symptomatic, life-threatening 
immunodeficiency. This late stage of infection, known as acquired immunodeficiency 
syndrome (AIDS), develops over months to years with an estimated median time of 
approximately 11 years (289). In the absence of treatment, virtually all persons with AIDS 
will die from AIDS-related causes; however with antiretroviral therapy, persons provided 
early effective treatment can expect to live a near normal lifespan (290–292). Early 
diagnosis of HIV infection and linkage to care are essential not only for the patients’ own 
health but also to reduce the risk for transmitting HIV to others. As of March 2012, U.S. 
guidelines recommend all persons with HIV infection diagnoses be offered effective 
antiretroviral therapy (70).
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As of 2011, approximately 16% of the estimated 1.2 million persons with HIV infection in 
the United States are unaware of their infection (http://www.cdc.gov/hiv/pdf/
2011_Monitoring_HIV_Indicators_HSSR_FINAL.pdf). Knowledge of HIV-infection status 
has important clinical implications, because HIV infection alters the immune system and 
thereby affects the diagnosis, evaluation, treatment, and follow-up of some other STDs. 
Diagnosing HIV infection during the acute phase of disease is particularly important (see 
Acute HIV Infection). Persons with acute HIV infection are highly infectious, because HIV 
concentrations are extremely high in plasma and genital secretions following initial infection 
(293–296). However, tests for HIV antibodies are often negative during this phase of 
infection, causing persons to mistakenly believe they are uninfected and unknowingly 
continue to engage in behaviors associated with HIV transmission. Of persons with acute 
HIV infection, 50%–90% are symptomatic, many of whom seek medical care (297,298). 
Because persons with no HIV-associated symptoms might present for assessment or 
treatment of a concomitantly acquired STD, providers serving persons at risk for STDs are 
in a position to diagnose HIV infection in persons during the acute phase of infection.
Despite the availability of effective antiretroviral therapy, many cases of HIV infection 
continue to be diagnosed at advanced stages, as evidenced by low CD4 cell counts. 
Nationally, the proportion of patients who receive AIDS diagnoses at or within 12 months of 
their HIV diagnosis in 2010 was 32% (299). Since 2006, CDC has recommended efforts to 
increase HIV testing by streamlining the consent process and expanding opt-out testing to all 
health-care settings, including those serving persons at risk for STDs (122). HIV testing 
facilitates early diagnosis, which reduces the spread of disease, extends life expectancy, and 
reduces costs of care. However, rates of testing remain low: CDC estimates that in 2008, 
only 45% of adults aged 18–64 years had ever been tested (300), and that during 2006–2009 
approximately 41% of persons with newly diagnosed HIV infection had never been 
previously tested (301).
Comprehensive HIV treatment services are usually not available in facilities focusing 
primarily on STD treatment (e.g., STD clinics). In such settings, patients with a new 
diagnosis of HIV infection or those with an existing diagnosis of HIV infection who are not 
engaged in regular on-going care should be linked promptly to a health-care provider or 
facility experienced in caring for HIV-infected patients (70). Providers working in STD 
clinics should be knowledgeable about the treatment options available in their communities, 
educate HIV-infected persons about their illness, and link these patients to HIV-related care 
and support services. Provision of care also should include behavioral and psychosocial 
services, especially for alcohol and drug addiction and for mental health problems.
A detailed discussion of the complex issues required for the management of HIV infection is 
beyond the scope of this report; however this information is available elsewhere (17,70,247). 
These HIV care and management resources are updated frequently, and the most current 
versions are available online (see URLs accompanying each reference). These resources 
provide additional information about the diagnosis, medical management, and counseling of 
persons with HIV infection, referral for support services, and management of sex and 
injection-drug partners in STD-treatment facilities. In addition, subsequent sections of this 
report briefly discuss HIV infection during pregnancy and among infants and children.
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Detection of HIV Infection: Screening
All persons who seek evaluation and treatment for STDs should be screened for HIV 
infection. Screening should be routine, regardless of whether the patient reports any specific 
behavioral risks for HIV infection. Persons at high risk for HIV infection with early syphilis, 
gonorrhea, or chlamydia should be screened at the time of the STD diagnosis, even if an 
HIV test was recently performed. Some STDs, especially rectal gonorrhea and syphilis, are a 
risk marker for HIV acquisition (142,145,156).
CDC recommends HIV screening for patients aged 13–64 years in all health-care settings 
(122). Persons should be notified that testing will be performed, but retain the option to 
decline or defer testing (an opt-out approach) (302). Consent for HIV screening should be 
incorporated into the general informed consent for medical care in the same manner as other 
screening or diagnostic tests. A separate consent form for HIV testing is not recommended.
Providing prevention counseling in conjunction with HIV diagnostic testing or as part of 
HIV screening programs should not be required in health-care settings. However, some 
persons might be more likely to think about HIV and consider their risk-related behavior 
when undergoing an HIV test. HIV testing presents providers with an opportunity to conduct 
HIV/STD prevention counseling and communicate risk-reduction messages.
Diagnosing HIV Infection
HIV infection can be diagnosed by serologic tests that detect antibodies against HIV-1 and 
HIV-2 and by virologic tests that detect HIV antigens or ribonucleic acid (RNA). Testing 
begins with a sensitive screening test, usually an antigen/antibody combination or antibody 
immunoassay (IA). Available serologic tests are both highly sensitive and specific and can 
detect all known subtypes of HIV-1. Most can also detect HIV-2 and uncommon variants of 
HIV-1 (e.g., group O and group N). Rapid HIV tests enable clinicians to make a preliminary 
diagnosis of HIV infection within 30 minutes. However, most rapid antibody assays become 
reactive later than conventional laboratory-based antibody or combination antigen/antibody 
serologic assays, and thus can produce negative results in recently infected persons.
The recommended diagnostic algorithm for HIV infection consists of a laboratory-based 
immunoassay, which if repeatedly reactive is followed by a supplemental test (e.g., an 
HIV-1/HIV-2 antibody differentiation assay, Western blot, or indirect immunofluorescence 
assay). However, available HIV laboratory antigen/antibody immunoassays detect HIV 
infection earlier than these supplemental tests. Therefore, during very early stages of HIV 
infection, discordant HIV test results (reactive immunoassay results with negative 
supplemental test results) have been erroneously interpreted as negative (303). This problem 
is minimized by use of a combination HIV-1/HIV-2 antigen-antibody (Ag/Ab) immunoassay 
which if reactive is followed by an HIV-1/HIV-2 antibody differentiation assay (304). This 
algorithm confers an additional advantage, as it can detect HIV-2 antibodies after the initial 
immunoassay. Although HIV-2 is uncommon in the United States, accurate identification is 
important because monitoring and therapy for HIV-2 differs from that for HIV-1 (305). RNA 
testing is performed on all specimens with reactive immunoassay but negative supplemental 
antibody test results to determine whether the discordance represents acute HIV infection.
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The following are specific recommendations that apply to testing for HIV infection.
• HIV screening is recommended for all persons who seek evaluation or treatment 
for STDs. This testing should be performed at the time of STD diagnosis (e.g., 
early syphilis, gonorrhea, and chlamydia) in populations at high risk for HIV 
infection.
• HIV testing must be voluntary and free from coercion. Patients must not be 
tested without their knowledge.
• Opt-out HIV screening (notifying the patient that an HIV test will be performed, 
unless the patient declines) is recommended in all health-care settings.
• Specific signed consent for HIV testing should not be required. General informed 
consent for medical care is considered sufficient to encompass informed consent 
for HIV testing.
• Use of Ag/Ab combination tests is encouraged unless persons are unlikely to 
receive their HIV test results.
• Preliminary positive screening tests for HIV infection must be followed by 
additional testing to definitively establish the diagnosis.
• Providers should be alert to the possibility of acute HIV infection and perform an 
antigen/antibody immunoassay or HIV RNA in conjunction with an antibody 
test. Persons suspected of recently acquired HIV infection should be referred 
immediately to an HIV clinical-care provider.
Acute HIV Infection—Health-care providers should be knowledgeable about the 
symptoms and signs of acute retroviral syndrome, which develops in 50%–90% of persons 
within the first few weeks after they become infected with HIV (298). Acute retroviral 
syndrome is characterized by nonspecific symptoms, including fever, malaise, 
lymphadenopathy and skin rash. Suspicion of acute retroviral syndrome should prompt 
urgent assessment with an antigen/antibody immunoassay or HIV RNA in conjunction with 
an antibody test. If the immunoassay is negative or indeterminate, then testing for HIV RNA 
should follow. Clinicians should not assume that a laboratory report of a negative HIV 
antibody test result indicates that the necessary RNA screening for acute HIV infection has 
been conducted. Further, HIV home-testing kits only detect HIV antibodies and therefore 
will not detect acute HIV infection.
Persons with acute HIV infection are highly infectious because the concentration of virus in 
plasma and genital secretions is extremely elevated during this stage of infection (294,306). 
Antiretroviral therapy during acute HIV infection is recommended, because it substantially 
reduces infectiousness to others, improves laboratory markers of disease, may decrease 
severity of acute disease, lowers viral set-point, reduces the size of the viral reservoir, 
decreases rate of viral mutation by suppressing replication, and preserves immune function 
(70). Persons who receive an acute HIV infection diagnosis should be referred immediately 
to an HIV clinical-care provider, provided prevention counseling (e.g., advised to reduce 
number of partners and to use condoms correctly and consistently), and screened for STDs. 
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Information should be provided on the availability of postexposure prophylaxis for sexual 
and needle-sharing partners not known to have HIV infection if the most recent contact was 
within the 72 hours preceding HIV diagnosis (http://www.cdc.gov/hiv).
After Establishing a New HIV Diagnosis—Persons with newly diagnosed HIV 
infection should be informed about 1) the importance of promptly initiating medical care for 
their own health and to reduce further transmission of HIV, 2) the effectiveness of HIV 
treatments, and 3) what to expect as they enter medical care for HIV infection (70). They 
should be linked promptly to a health-care provider or facility experienced in caring for 
patients with HIV. Persons with symptoms or signs that suggest advanced HIV infection 
(e.g., fever, weight loss, diarrhea, cough, shortness of breath, and oral candidiasis) should be 
immediately evaluated or referred for evaluation. Persons experiencing psychologic distress 
should be referred accordingly (see Counseling for Persons with HIV Infection and Referral 
to Support Services). Detailed and regularly updated recommendation for the initial 
management of persons with HIV infection can be found elsewhere (17,70,247).
Counseling for Persons with HIV Infection and Referral to Support Services
Providers should expect persons with HIV infection to be distressed when first informed of a 
positive test result. Such persons face multiple major adaptive challenges, including coping 
with the reactions of others to a stigmatizing illness, developing and adopting strategies for 
maintaining physical and emotional health, initiating changes in behavior to prevent HIV 
transmission to others, and reducing the risk for acquiring additional STDs. Many persons 
will require assistance with making reproductive choices, gaining access to health services, 
and coping with changes in personal relationships. Therefore, behavioral and psychosocial 
services are an integral part of health care for persons with HIV infection.
Persons testing positive for HIV infection have unique needs. Some require referral for 
specific behavioral interventions (e.g., a substance abuse program), mental health disorders 
(e.g., depression), and emotional distress, while others require assistance with securing and 
maintaining employment and housing. Women should be counseled or appropriately referred 
regarding reproductive choices and contraceptive options, and persons with multiple 
psychosocial problems might be candidates for comprehensive risk-reduction counseling 
and other support services.
The following are specific recommendations for HIV counseling and linkage to services that 
should be offered to patients before they leave the testing site.
• Persons who test positive for HIV should be counseled, either on-site or through 
referral, concerning the behavioral, psychosocial, and medical implications of 
HIV infection.
• Health-care providers should assess the need for immediate medical care and 
psychosocial support.
• Providers should link persons with newly diagnosed HIV infection to services 
provided by health-care personnel experienced in the management of HIV 
infection. Additional services that might be needed include substance abuse 
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counseling and treatment, treatment for mental health disorders or emotional 
distress, reproductive counseling, risk-reduction counseling, and case 
management. Providers should follow up to ensure that patients have received 
services for any identified needs.
• Persons with HIV infection should be educated about the importance of ongoing 
medical care and what to expect from these services.
Several successful, innovative interventions to assist persons with HIV infection reduce the 
possibility of transmission to others have been developed for diverse at-risk populations, and 
these can be locally replicated or adapted (12,15,307–310). Involvement of nongovernment 
and community-based organizations might complement such efforts in the clinical setting.
Management of Sex Partners and Injection-Drug Partners
Clinicians providing services to persons with HIV infection should determine whether any 
partners should be notified concerning possible exposure to HIV (122,311). In the context of 
HIV management, “partner” includes sex partners and persons with whom syringes or other 
injection equipment is shared. Partner notification is an important component of disease 
management, because early diagnosis and treatment of HIV infection reduces risk for HIV 
transmission, decreases individual morbidity and mortality risk, and provides the 
opportunity to modify risk behaviors. Partner notification for HIV infection should be 
confidential. Specific guidance regarding spousal notification varies by jurisdiction. Detailed 
recommendations concerning identification, notification, diagnosis, and treatment of 
exposed partners are available in CDC’s Recommendations for Partner Services Programs 
for HIV Infection, Syphilis, Gonorrhea, and Chlamydial Infections (See Partner Services) 
(311).
The following are specific recommendations for implementing partner-notification 
procedures:
• Health-care providers should inform persons with HIV infection about partner 
services including processes, benefits, and risks.
• Persons with HIV infection should be encouraged to notify their partners and to 
refer them for counseling and testing.
• Health-care providers should assist in the partner-notification process, either 
directly or by referral to health department partner-notification programs, which 
might attempt to contact them.
• If persons with HIV infection are unwilling to notify their partners or cannot 
ensure their partners will seek counseling, HIV care staff or health department 
personnel should use confidential partner notification procedures. Health 
department staff are trained to employ public health investigation strategies to 
confidentially locate persons who are hard to reach, whereas most clinical 
providers do not have the time or expertise to conduct this type of partner 
notification.
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• Partners who have been reached and are not known to have HIV infection should 
be offered postexposure prophylaxis with combination antiretrovirals if they 
were exposed to genital secretions or blood of a partner with HIV infection 
though sex or injection-drug use within the preceding 72 hours (312).
STD Testing During HIV Care
At the initial HIV care visit, providers should test all sexually active persons with HIV 
infection for curable STDs (e.g., syphilis, gonorrhea, and chlamydia) and perform testing at 
least annually during the course of HIV care (12). Specific testing includes syphilis serology 
and NAAT for N. gonorrhoeae and C. trachomatis at the anatomic site of exposure, as the 
preferred approach. Women with HIV infection should also be screened for trichomonas at 
the initial visit and annually thereafter. Women should be screened for cervical cancer 
precursor lesions by cervical Pap tests per existing guidelines (247).
More frequent screening for curable STDs might be appropriate depending on individual 
risk behaviors and the local epidemiology of STDs. Many STDs are asymptomatic, and their 
diagnosis might indicate risk behavior that should prompt referral for partner services and 
prevention counseling (10). Pathogen-specific sections of this document provide more 
detailed information on screening, testing, and treatment.
Special Considerations
Pregnancy—All pregnant women should be tested for HIV infection during the first 
prenatal visit. A second test during the third trimester, preferably at <36 weeks’ gestation, 
should be considered for all pregnant women and is recommended for those known to be at 
high risk for acquiring HIV, those who receive health care in jurisdictions with elevated 
incidence of HIV or AIDS among women, and women seen in clinical settings in which 
prenatal screening identifies at least one pregnant women with HIV infection per 1,000 
women screened (122). Diagnostic algorithms for HIV infection in pregnant women are not 
different than those for nonpregnant women (See Diagnosis, HIV Infection). Pregnant 
women should be informed about being tested for HIV as part of the panel of prenatal tests 
(103,122); for women who decline, providers should address concerns that pose obstacles to 
testing and encourage testing at subsequent prenatal visits. Women who decline testing 
because they have had a previous negative HIV test result should be informed about the 
importance of retesting during each pregnancy. Women with no prenatal care should be 
tested for HIV at the time of delivery.
Testing pregnant women is important not only because knowledge of infection status can 
help maintain the health of the woman, but because it enables receipt of interventions (i.e., 
antiretroviral and obstetrical) that can substantially reduce the risk for perinatal transmission 
of HIV. After a pregnant woman has been identified as having HIV infection, she should be 
educated about the benefits of antiretroviral treatment for her health and for reducing the risk 
for transmission to her infant. In the absence of antiretroviral treatment, a mother’s risk of 
transmitting HIV to her neonate is approximately 30% but can be reduced to <2% through 
antiretroviral treatment, obstetrical interventions (i.e., elective cesarean section at 38 weeks 
of pregnancy), and breastfeeding avoidance (105). Pregnant women who have HIV infection 
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should be linked to an HIV care provider and given appropriate antenatal and postpartum 
treatment and advice. Detailed and regularly updated recommendations for the initial 
management of persons with HIV infection and pregnancy are available in existing guidance 
at http://aidsinfo.nih.gov/guidelines.
HIV Infection Among Neonates, Infants, and Children—Diagnosis of HIV infection 
in a pregnant woman indicates the need to evaluate and manage the HIV-exposed neonate 
and consider whether the woman’s other children might be infected. Detailed 
recommendations regarding diagnosis and management of HIV in neonates and children of 
mothers with HIV infection are beyond the scope of this report and can be found at http://
aidsinfo.nih.gov/guidelines. Exposed neonates and children with HIV infection should be 
referred to physicians with such expertise.
Diseases Characterized by Genital, Anal, or Perianal Ulcers
In the United States, most young, sexually active patients who have genital, anal, or perianal 
ulcers have either genital herpes or syphilis. The frequency of each condition differs by 
geographic area and population; however, genital herpes is the most prevalent of these 
diseases. More than one etiologic agent (e.g., herpes and syphilis) can be present in a 
genital, anal, or perianal ulcer. Less common infectious causes of genital, anal, or perianal 
ulcers include chancroid and donovanosis. Genital herpes, syphilis, and chancroid have been 
associated with an increased risk for HIV acquisition and transmission. Genital, anal, or 
perianal lesions can also be associated with infectious as well as noninfectious conditions 
that are not sexually transmitted (e.g., yeast, trauma, carcinoma, aphthae, fixed drug 
eruption, and psoriasis).
A diagnosis based only on medical history and physical examination frequently is 
inaccurate. Therefore, all persons who have genital, anal, or perianal ulcers should be 
evaluated; in settings where chancroid is prevalent, a test for Haemophilus ducreyi also 
should be performed. Specific evaluation of genital, anal, or perianal ulcers includes 1) 
syphilis serology, darkfield examination, or PCR testing if available; 2) culture or PCR 
testing for genital herpes; and 3) serologic testing for type-specific HSV antibody.
No FDA-cleared PCR test to diagnose syphilis is available in the United States, but two 
FDA-cleared PCR tests are available for the diagnosis of HSV-1 and HSV-2 in genital 
specimens. Some clinical laboratories have developed their own syphilis and HSV PCR tests 
and have conducted Clinical Laboratory Improvement Amendment (CLIA) verification 
studies in genital specimens. Type-specific serology for HSV-2 might be helpful in 
identifying persons with genital herpes (see Genital Herpes, Type-Specific Serologic Tests). 
In addition, biopsy of ulcers can help identify the cause of ulcers that are unusual or that do 
not respond to initial therapy. HIV testing should be performed on all persons with genital, 
anal, or perianal ulcers not known to have HIV infection (see Diagnostic Considerations, 
sections on Syphilis, Chancroid, and Genital Herpes Simplex Virus).
Because early treatment decreases the possibility of transmission, public health standards 
require health-care providers to presumptively treat any patient with a suspected case of 
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infectious syphilis at the initial visit, even before test results are available. Presumptive 
treatment of a patient with a suspected first episode of genital herpes also is recommended, 
because successful treatment depends on prompt initiation of therapy. The clinician should 
choose the presumptive treatment on the basis of clinical presentation (i.e., HSV lesions 
begin as vesicles and primary syphilis as a papule) and epidemiologic circumstances (e.g., 
high incidence of disease among populations and communities and travel history). For 
example, syphilis is so common in MSM that any man who has sex with men presenting 
with a genital ulcer should be presumptively treated for syphilis at the initial visit after 
syphilis and HSV tests are performed. After a complete diagnostic evaluation, at least 25% 
of patients who have genital ulcers have no laboratory-confirmed diagnosis (313).
Chancroid
The prevalence of chancroid has declined in the United States (118). When infection does 
occur, it is usually associated with sporadic outbreaks. Worldwide, chancroid appears to 
have declined as well, although infection might still occur in some regions of Africa and the 
Caribbean. Like genital herpes and syphilis, chancroid is a risk factor in the transmission and 
acquisition of HIV infection (314).
Diagnostic Considerations—A definitive diagnosis of chancroid requires the 
identification of H. ducreyi on special culture media that is not widely available from 
commercial sources; even when these media are used, sensitivity is <80% (315). No FDA-
cleared PCR test for H. ducreyi is available in the United States, but such testing can be 
performed by clinical laboratories that have developed their own PCR test and have 
conducted CLIA verification studies in genital specimens.
The combination of a painful genital ulcer and tender suppurative inguinal adenopathy 
suggests the diagnosis of chancroid (316). For both clinical and surveillance purposes, a 
probable diagnosis of chancroid can be made if all of the following criteria are met: 1) the 
patient has one or more painful genital ulcers; 2) the clinical presentation, appearance of 
genital ulcers and, if present, regional lymphadenopathy are typical for chancroid; 3) the 
patient has no evidence of T. pallidum infection by darkfield examination of ulcer exudate or 
by a serologic test for syphilis performed at least 7 days after onset of ulcers; and 4) an HSV 
PCR test or HSV culture performed on the ulcer exudate is negative.
Treatment—Successful treatment for chancroid cures the infection, resolves the clinical 
symptoms, and prevents transmission to others. In advanced cases, scarring can result 
despite successful therapy.
Recommended Regimens
Azithromycin 1 g orally in a single dose
 OR
Ceftriaxone 250 mg IM in a single dose
 OR
Ciprofloxacin 500 mg orally twice a day for 3 days
 OR
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Erythromycin base 500 mg orally three times a day for 7 days
Azithromycin and ceftriaxone offer the advantage of singledose therapy. Worldwide, several 
isolates with intermediate resistance to either ciprofloxacin or erythromycin have been 
reported. However, because cultures are not routinely performed, data are limited regarding 
the current prevalence of antimicrobial resistance.
Other Management Considerations—Men who are uncircumcised and patients with 
HIV infection do not respond as well to treatment as persons who are circumcised or HIV-
negative. Patients should be tested for HIV infection at the time chancroid is diagnosed. If 
the initial test results were negative, a serologic test for syphilis and HIV infection should be 
performed 3 months after the diagnosis of chancroid.
Follow-Up—Patients should be re-examined 3–7 days after initiation of therapy. If 
treatment is successful, ulcers usually improve symptomatically within 3 days and 
objectively within 7 days after therapy. If no clinical improvement is evident, the clinician 
must consider whether 1) the diagnosis is correct, 2) the patient is coinfected with another 
STD, 3) the patient is infected with HIV, 4) the treatment was not used as instructed, or 5) 
the H. ducreyi strain causing the infection is resistant to the prescribed antimicrobial. The 
time required for complete healing depends on the size of the ulcer; large ulcers might 
require >2 weeks. In addition, healing is slower for some uncircumcised men who have 
ulcers under the foreskin. Clinical resolution of fluctuant lymphadenopathy is slower than 
that of ulcers and might require needle aspiration or incision and drainage, despite otherwise 
successful therapy. Although needle aspiration of buboes is a simpler procedure, incision 
and drainage might be preferred because of reduced need for subsequent drainage 
procedures.
Management of Sex Partners—Regardless of whether symptoms of the disease are 
present, sex partners of patients who have chancroid should be examined and treated if they 
had sexual contact with the patient during the 10 days preceding the patient’s onset of 
symptoms.
Special Considerations
Pregnancy: Data suggest ciprofloxacin presents a low risk to the fetus during pregnancy, 
with a potential for toxicity during breastfeeding (317). Alternate drugs should be used 
during pregnancy and lactation. No adverse effects of chancroid on pregnancy outcome have 
been reported.
HIV Infection: Persons with HIV infection who have chancroid should be monitored 
closely because they are more likely to experience treatment failure and to have ulcers that 
heal slowly. Persons with HIV infection might require repeated or longer courses of therapy, 
and treatment failures can occur with any regimen. Data are limited concerning the 
therapeutic efficacy of the recommended single-dose azithromycin and ceftriaxone regimens 
in persons with HIV infection.
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Genital HSV Infections
Genital herpes is a chronic, life-long viral infection. Tw o types of HSV can cause genital 
herpes: HSV-1 and HSV-2. Most cases of recurrent genital herpes are caused by HSV-2, and 
approximately 50 million persons in the United States are infected with this type of genital 
herpes (318). However, an increasing proportion of anogenital herpetic infections have been 
attributed to HSV-1 infection, which is especially prominent among young women and 
MSM (319–321).
Most persons infected with HSV-2 have not had the condition diagnosed. Many such persons 
have mild or unrecognized infections but shed virus intermittently in the anogenital area. As 
a result, most genital herpes infections are transmitted by persons unaware that they have the 
infection or who are asymptomatic when transmission occurs. Management of genital HSV 
should address the chronic nature of the disease rather than focusing solely on treatment of 
acute episodes of genital lesions.
Diagnostic Considerations—The clinical diagnosis of genital herpes can be difficult, 
because the painful multiple vesicular or ulcerative lesions typically associated with HSV 
are absent in many infected persons. Recurrences and subclinical shedding are much more 
frequent for genital HSV-2 infection than for genital HSV-1 infection (322,323). A patient’s 
prognosis and the type of counseling needed depend on the type of genital herpes (HSV-1 or 
HSV-2) causing the infection; therefore, the clinical diagnosis of genital herpes should be 
confirmed by type-specific laboratory testing (321,324). Both type-specific virologic and 
type-specific serologic tests for HSV should be available in clinical settings that provide care 
to persons with or at risk for STDs. Persons with genital herpes should be tested for HIV 
infection.
Virologic Tests—Cell culture and PCR are the preferred HSV tests for persons who seek 
medical treatment for genital ulcers or other mucocutaneous lesions. The sensitivity of viral 
culture is low, especially for recurrent lesions, and declines rapidly as lesions begin to heal. 
Nucleic acid amplification methods, including PCR assays for HSV DNA, are more 
sensitive and are increasingly available (325–327). PCR is the test of choice for diagnosing 
HSV infections affecting the central nervous system and systemic infections (e.g., 
meningitis, encephalitis, and neonatal herpes). Viral culture isolates and PCR amplicons 
should be typed to determine which type of HSV is causing the infection. Failure to detect 
HSV by culture or PCR, especially in the absence of active lesions, does not indicate an 
absence of HSV infection because viral shedding is intermittent. Cytologic detection of 
cellular changes associated with HSV infection is an insensitive and nonspecific method of 
diagnosing genital lesions (i.e., Tzanck preparation) and therefore should not be relied on. 
Although a direct immunofluorescence (IF) assay using fluorescein-labeled monoclonal 
antibodies is also available to detect HSV antigen from genital specimens, this assay lacks 
sensitivity (328).
Type-Specific Serologic Tests—Both type-specific and type-common antibodies to 
HSV develop during the first several weeks after infection and persist indefinitely. Accurate 
type-specific HSV serologic assays are based on the HSV-specific glycoprotein G2 (HSV-2) 
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and glycoprotein G1 (HSV-1). Providers should only request type-specific glycoprotein G 
(gG)-based serologic assays when serology is performed for their patients (329–331).
Both laboratory-based assays and point-of-care tests that provide results for HSV-2 
antibodies from capillary blood or serum during a clinic visit are available. The sensitivities 
of these glycoprotein G type-specific tests for the detection of HSV-2 antibody vary from 
80%–98%; false-negative results might be more frequent at early stages of infection 
(330,332,333). The most commonly used test, HerpeSelect HSV-2 Elisa might be falsely 
positive at low index values (1.1–3.5) (334–336). Such low values should be confirmed with 
another test, such as Biokit or the Western blot (337). The HerpeSelect HSV-2 Immunoblot 
should not be used for confirmation, because it uses the same antigen as the HSV-2 Elisa. 
Repeat testing is indicated if recent acquisition of genital herpes is suspected. The 
HerpeSelect HSV-1 Elisa is insensitive for detection of HSV-1 antibody. IgM testing for 
HSV 1 or HSV-2 is not useful, because IgM tests are not type-specific and might be positive 
during recurrent genital or oral episodes of herpes (337).
Because nearly all HSV-2 infections are sexually acquired, the presence of type-specific 
HSV-2 antibody implies anogenital infection. In this instance, education and counseling 
appropriate for persons with genital HSV infections should be provided. The presence of 
HSV-1 antibody alone is more difficult to interpret. Many persons with HSV-1 antibody 
have oral HSV infection acquired during childhood, which might be asymptomatic. 
However, acquisition of genital HSV-1 is increasing, and genital HSV-1 also can be 
asymptomatic (318–321,338). Lack of symptoms in a person who is HSV-1 seropositive 
does not distinguish anogenital from orolabial or cutaneous infection, and regardless of site 
of infection, these persons remain at risk for acquiring HSV-2.
Type-specific HSV serologic assays might be useful in the following scenarios: 1) recurrent 
genital symptoms or atypical symptoms with negative HSV PCR or culture; 2) clinical 
diagnosis of genital herpes without laboratory confirmation; and 3) a patient whose partner 
has genital herpes. HSV serologic testing should be considered for persons presenting for an 
STD evaluation (especially for those persons with multiple sex partners), persons with HIV 
infection, and MSM at increased risk for HIV acquisition. Screening for HSV-1 and HSV-2 
in the general population is not indicated.
Management of Genital Herpes—Antiviral chemotherapy offers clinical benefits to 
most symptomatic patients and is the mainstay of management. Counseling regarding the 
natural history of genital herpes, sexual and perinatal transmission, and methods to reduce 
transmission is integral to clinical management.
Systemic antiviral drugs can partially control the signs and symptoms of genital herpes when 
used to treat first clinical and recurrent episodes or when used as daily suppressive therapy. 
However, these drugs neither eradicate latent virus nor affect the risk, frequency, or severity 
of recurrences after the drug is discontinued. Randomized trials have indicated that three 
antiviral medications provide clinical benefit for genital herpes: acyclovir, valacyclovir, and 
famciclovir (339–347). Valacyclovir is the valine ester of acyclovir and has enhanced 
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absorption after oral administration. Famciclovir also has high oral bioavailability. Topical 
therapy with antiviral drugs offers minimal clinical benefit and is discouraged.
First Clinical Episode of Genital Herpes—Newly acquired genital herpes can cause a 
prolonged clinical illness with severe genital ulcerations and neurologic involvement. Even 
persons with first-episode herpes who have mild clinical manifestations initially can develop 
severe or prolonged symptoms. Therefore, all patients with first episodes of genital herpes 
should receive antiviral therapy.
Recommended Regimens*
Acyclovir 400 mg orally three times a day for 7–10 days
 OR
Acyclovir 200 mg orally five times a day for 7–10 days
 OR
Valacyclovir 1 g orally twice a day for 7–10 days
 OR
Famciclovir 250 mg orally three times a day for 7–10 days
*Treatment can be extended if healing is incomplete after 10 days of therapy.
Established HSV-2 Infection—Almost all persons with symptomatic first-episode 
genital HSV-2 infection subsequently experience recurrent episodes of genital lesions; 
recurrences are less frequent after initial genital HSV-1 infection. Intermittent asymptomatic 
shedding occurs in persons with genital HSV-2 infection, even in those with longstanding or 
clinically silent infection. Antiviral therapy for recurrent genital herpes can be administered 
either as suppressive therapy to reduce the frequency of recurrences or episodically to 
ameliorate or shorten the duration of lesions. Some persons, including those with mild or 
infrequent recurrent outbreaks, benefit from antiviral therapy; therefore, options for 
treatment should be discussed. Many persons prefer suppressive therapy, which has the 
additional advantage of decreasing the risk for genital HSV-2 transmission to susceptible 
partners (348,349).
Suppressive Therapy for Recurrent Genital Herpes: Suppressive therapy reduces the 
frequency of genital herpes recurrences by 70%–80% in patients who have frequent 
recurrences (345–348); many persons receiving such therapy report having experienced no 
symptomatic outbreaks. Treatment also is effective in patients with less frequent recurrences. 
Safety and efficacy have been documented among patients receiving daily therapy with 
acyclovir for as long as 6 years and with valacyclovir or famciclovir for 1 year (350,351). 
Quality of life is improved in many patients with frequent recurrences who receive 
suppressive therapy rather than episodic treatment (352).
The frequency of genital herpes recurrences diminishes over time in many persons, 
potentially resulting in psychological adjustment to the disease. Therefore, periodically 
during suppressive treatment (e.g., once a year), providers should discuss the need to 
continue therapy. However, neither treatment discontinuation nor laboratory monitoring in a 
healthy person is necessary.
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Treatment with valacyclovir 500 mg daily decreases the rate of HSV-2 transmission in 
discordant, heterosexual couples in which the source partner has a history of genital HSV-2 
infection (349). Such couples should be encouraged to consider suppressive antiviral therapy 
as part of a strategy to prevent transmission, in addition to consistent condom use and 
avoidance of sexual activity during recurrences. Suppressive antiviral therapy also is likely 
to reduce transmission when used by persons who have multiple partners (including MSM) 
and by those who are HSV-2 seropositive without a history of genital herpes.
Recommended Regimens
Acyclovir 400 mg orally twice a day
 OR
Valacyclovir 500 mg orally once a day*
 OR
Valacyclovir 1 g orally once a day
 OR
Famiciclovir 250 mg orally twice a day
*Valacyclovir 500 mg once a day might be less effective than other valacyclovir or acyclovir dosing regimens in persons 
who have very frequent recurrences (i.e., ≥10 episodes per year).
Acyclovir, famciclovir, and valacyclovir appear equally effective for episodic treatment of 
genital herpes (342–346), but famciclovir appears somewhat less effective for suppression of 
viral shedding (353). Ease of administration and cost also are important considerations for 
prolonged treatment.
Episodic Therapy for Recurrent Genital Herpes: Effective episodic treatment of recurrent 
herpes requires initiation of therapy within 1 day of lesion onset or during the prodrome that 
precedes some outbreaks. The patient should be provided with a supply of drug or a 
prescription for the medication with instructions to initiate treatment immediately when 
symptoms begin.
Recommended Regimens
Acyclovir 400 mg orally three times a day for 5 days
 OR
Acyclovir 800 mg orally twice a day for 5 days
 OR
Acyclovir 800 mg orally three times a day for 2 days
 OR
Valacyclovir 500 mg orally twice a day for 3 days
 OR
Valacyclovir 1 g orally once a day for 5 days
 OR
Famciclovir 125 mg orally twice daily for 5 days
 OR
Famciclovir 1 gram orally twice daily for 1 day
 OR
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Famciclovir 500 mg once, followed by 250 mg twice daily for 2 days
Severe Disease—Intravenous (IV) acyclovir therapy should be provided for patients who 
have severe HSV disease or complications that necessitate hospitalization (e.g., disseminated 
infection, pneumonitis, or hepatitis) or CNS complications (e.g., meningoencephalitis). The 
recommended regimen is acyclovir 5–10 mg/kg IV every 8 hours for 2–7 days or until 
clinical improvement is observed, followed by oral antiviral therapy to complete at least 10 
days of total therapy. HSV encephalitis requires 21 days of intravenous therapy. Impaired 
renal function warrants an adjustment in acyclovir dosage.
Counseling—Counseling of infected persons and their sex partners is critical to the 
management of genital herpes. The goals of counseling include helping patients cope with 
the infection and preventing sexual and perinatal transmission. Although initial counseling 
can be provided at the first visit, many patients benefit from learning about the chronic 
aspects of the disease after the acute illness subsides. Multiple resources, including websites 
(http://www.ashasexualhealth.org) and printed materials, are available to assist patients, their 
partners, and clinicians who become involved in counseling (354,355).
Although the psychological effect of a serologic diagnosis of HSV-2 infection in a person 
with asymptomatic or unrecognized genital herpes appears minimal and transient (356,357), 
some HSV-infected persons might express anxiety concerning genital herpes that does not 
reflect the actual clinical severity of their disease; the psychological effect of HSV infection 
can be substantial. Common concerns regarding genital herpes include the severity of initial 
clinical manifestations, recurrent episodes, sexual relationships and transmission to sex 
partners, and ability to bear healthy children. The misconception that HSV causes cancer 
should be dispelled.
The following topics should be discussed when counseling persons with genital HSV 
infection:
• the natural history of the disease, with emphasis on the potential for recurrent 
episodes, asymptomatic viral shedding, and the attendant risks of sexual 
transmission;
• the effectiveness of suppressive therapy for persons experiencing a first episode 
of genital herpes in preventing symptomatic recurrent episodes;
• use of episodic therapy to shorten the duration of recurrent episodes;
• importance of informing current sex partners about genital herpes and informing 
future partners before initiating a sexual relationship;
• potential for sexual transmission of HSV to occur during asymptomatic periods 
(asymptomatic viral shedding is more frequent in genital HSV-2 infection than 
genital HSV-1 infection and is most frequent during the first 12 months after 
acquiring HSV-2);
• importance of abstaining from sexual activity with uninfected partners when 
lesions or prodromal symptoms are present;
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• effectiveness of daily use of valacyclovir in reducing risk for transmission of 
HSV-2, and the lack of effectiveness of episodic or suppressive therapy in 
persons with HIV and HSV infection in reducing risk for transmission to 
partners who might be at risk for HSV-2 acquisition;
• effectiveness of male latex condoms, which when used consistently and correctly 
can reduce (but not eliminate) the risk for genital herpes transmission 
(27,358,359);
• HSV infection in the absence of symptoms (type-specific serologic testing of the 
asymptomatic partners of persons with genital herpes is recommended to 
determine whether such partners are already HSV seropositive or whether risk 
for acquiring HSV exists);
• risk for neonatal HSV infection; and
• increased risk for HIV acquisition among HSV-2 seropositive persons who are 
exposed to HIV (suppressive antiviral therapy does not reduce the increased risk 
for HIV acquisition associated with HSV-2 infection) (75,347).
Asymptomatic persons who receive a diagnosis of HSV-2 infection by type-specific 
serologic testing should receive the same counseling messages as persons with symptomatic 
infection. In addition, such persons should be educated about the clinical manifestations of 
genital herpes.
Pregnant women and women of childbearing age who have genital herpes should inform the 
providers who care for them during pregnancy and those who will care for their newborn 
infant about their infection. More detailed counseling messages are described in Special 
Considerations, Genital Herpes in Pregnancy.
Management of Sex Partners—The sex partners of persons who have genital herpes 
can benefit from evaluation and counseling. Symptomatic sex partners should be evaluated 
and treated in the same manner as patients who have genital herpes. Asymptomatic sex 
partners of patients who have genital herpes should be questioned concerning histories of 
genital lesions and offered type-specific serologic testing for HSV infection.
Special Considerations
Allergy, Intolerance, and Adverse Reactions: Allergic and other adverse reactions to oral 
acyclovir, valacyclovir, and famciclovir are rare. Desensitization to acyclovir has been 
described (360).
HIV Infection: Immunocompromised patients can have prolonged or severe episodes of 
genital, perianal, or oral herpes. Lesions caused by HSV are common among persons with 
HIV infection and might be severe, painful, and atypical. HSV shedding is increased in 
persons with HIV infection. Whereas antiretroviral therapy reduces the severity and 
frequency of symptomatic genital herpes, frequent subclinical shedding still occurs 
(361,362). Clinical manifestations of genital herpes might worsen during immune 
reconstitution early after initiation of antiretroviral therapy.
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Suppressive or episodic therapy with oral antiviral agents is effective in decreasing the 
clinical manifestations of HSV among persons with HIV infection (363–365). HSV type-
specific serologic testing can be offered to persons with HIV infection during their initial 
evaluation if infection status is unknown, and suppressive antiviral therapy can be 
considered in those who have HSV-2 infection. Suppressive anti-HSV therapy in persons 
with HIV infection does not reduce the risk for either HIV transmission or HSV-2 
transmission to susceptible sex partners (71,366).
Recommended Regimens for Daily Suppressive Therapy in Persons with HIV
Acyclovir 400–800 mg orally twice to three times a day
 OR
Valacyclovir 500 mg orally twice a day
 OR
Famciclovir 500 mg orally twice a day
Recommended Regimens for Episodic Infection in Persons with HIV
Acyclovir 400 mg orally three times a day for 5–10 days
 OR
Valacyclovir 1 g orally twice a day for 5–10 days
 OR
Famciclovir 500 mg orally twice a day for 5–10 days
For severe HSV disease, initiating therapy with acyclovir 5–10 mg/kg IV every 8 hours 
might be necessary.
Antiviral-resistant HSV: If lesions persist or recur in a patient receiving antiviral treatment, 
HSV resistance should be suspected and a viral isolate obtained for sensitivity testing (367). 
Such persons should be managed in consultation with an infectious-disease specialist, and 
alternate therapy should be administered. All acyclovir-resistant strains are also resistant to 
valacyclovir, and most are resistant to famciclovir. Foscarnet (40–80 mg/kg IV every 8 hours 
until clinical resolution is attained) is often effective for treatment of acyclovir-resistant 
genital herpes (368,369). Intravenous cidofovir 5 mg/kg once weekly might also be 
effective. Imiquimod is a topical alternative (370), as is topical cidofovir gel 1%; however, 
cidofovir must be compounded at a pharmacy (371). These topical preparations should be 
applied to the lesions once daily for 5 consecutive days.
Clinical management of antiviral resistance remains challenging among persons with HIV 
infection, necessitating other preventative approaches. However, experience with another 
group of immunocompromised persons (hematopoietic stem-cell recipients) demonstrated 
that persons receiving daily suppressive antiviral therapy were less likely to develop 
acyclovir-resistant HSV compared with those who received episodic therapy for outbreaks 
(372).
Genital Herpes in Pregnancy—Most mothers of newborns who acquire neonatal herpes 
lack histories of clinically evident genital herpes (373,374). The risk for transmission to the 
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neonate from an infected mother is high (30%–50%) among women who acquire genital 
herpes near the time of delivery and low (<1%) among women with prenatal histories of 
recurrent herpes or who acquire genital HSV during the first half of pregnancy (375,376).
Prevention of neonatal herpes depends both on preventing acquisition of genital HSV 
infection during late pregnancy and avoiding exposure of the neonate to herpetic lesions and 
viral shedding during delivery. Because the risk for herpes is highest in newborn infants of 
women who acquire genital HSV during late pregnancy, these women should be managed in 
consultation with maternal-fetal medicine and infectious-disease specialists.
Women without known genital herpes should be counseled to abstain from vaginal 
intercourse during the third trimester with partners known or suspected of having genital 
herpes. In addition, pregnant women without known orolabial herpes should be advised to 
abstain from receptive oral sex during the third trimester with partners known or suspected 
to have orolabial herpes. Type-specific serologic tests may be useful for identifying pregnant 
women at risk for HSV infection and guiding counseling regarding the risk for acquiring 
genital herpes during pregnancy. For example, such testing could be offered to women with 
no history of genital herpes whose sex partner has HSV infection. However, the 
effectiveness of antiviral therapy to decrease the risk for HSV transmission to pregnant 
women by infected partners has not been studied. Routine HSV-2 serologic screening of 
pregnant women is not recommended.
All pregnant women should be asked whether they have a history of genital herpes. At the 
onset of labor, all women should be questioned carefully about symptoms of genital herpes, 
including prodromal symptoms, and all women should be examined carefully for herpetic 
lesions. Women without symptoms or signs of genital herpes or its prodrome can deliver 
vaginally. Although cesarean delivery does not completely eliminate the risk for HSV 
transmission to the neonate, women with recurrent genital herpetic lesions at the onset of 
labor should deliver by cesarean delivery to reduce the risk for neonatal HSV infection.
Many infants are exposed to acyclovir each year, and no adverse effects in the fetus or 
newborn attributable to the use of this drug during pregnancy have been reported. Acyclovir 
can be safely used to treat women in all stages of pregnancy, along with those who are 
breastfeeding (317,377). Although data regarding prenatal exposure to valacyclovir and 
famciclovir are limited, data from animal trials suggest these drugs also pose a low risk in 
pregnant women. Acyclovir can be administered orally to pregnant women with first-episode 
genital herpes or recurrent herpes and should be administered IV to pregnant women with 
severe HSV infection. Suppressive acyclovir treatment late in pregnancy reduces the 
frequency of cesarean delivery among women who have recurrent genital herpes by 
diminishing the frequency of recurrences at term (378–380). However, such treatment may 
not protect against transmission to neonates in all cases (381). No data support use of 
antiviral therapy among HSV-seropositive women without a history of genital herpes.
Recommended regimen for suppressive therapy of pregnant women with recurrent genital herpes*
Acyclovir 400 mg orally three times a day
 OR
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Valacyclovir 500 mg orally twice a day
*Treatment recommended starting at 36 weeks of gestation. (Source: American College of Obstetricians and 
Gynecologists. Clinical management guidelines for obstetrician-gynecologists. Management of herpes in pregnancy. 
ACOG Practice Bulletin No. 82. Obstet Gynecol 2007;109:1489–98.)
Neonatal Herpes—Newborn infants exposed to HSV during birth, as documented by 
maternal virologic testing of maternal lesions at delivery or presumed by observation of 
maternal lesions, should be followed carefully in consultation with a pediatric infectious-
disease specialist. Guidance is available on management of neonates who are delivered 
vaginally in the presence of maternal genital HSV lesions (382).
Surveillance cultures or PCR of mucosal surfaces of the neonate to detect HSV infection 
might be considered before the development of clinical signs of neonatal herpes to guide 
initiation of treatment. In addition, administration of acyclovir might be considered for 
neonates born to women who acquired HSV near term because the risk for neonatal herpes 
is high for these infants. All infants who have neonatal herpes should be promptly evaluated 
and treated with systemic acyclovir. The recommended regimen for infants treated for 
known or suspected neonatal herpes is acyclovir 20 mg/kg IV every 8 hours for 14 days if 
disease is limited to the skin and mucous membranes, or for 21 days for disseminated 
disease and that involving the central nervous system.
Granuloma Inguinale (Donovanosis)
Granuloma inguinale is a genital ulcerative disease caused by the intracellular gram-negative 
bacterium Klebsiella granulomatis (formerly known as Calymmatobacterium granulomatis). 
The disease occurs rarely in the United States, although it is endemic in some tropical and 
developing areas, including India; Papua, New Guinea; the Caribbean; central Australia; and 
southern Africa (383–385). Clinically, the disease is commonly characterized as painless, 
slowly progressive ulcerative lesions on the genitals or perineum without regional 
lymphadenopathy; subcutaneous granulomas (pseudobuboes) also might occur. The lesions 
are highly vascular (i.e., beefy red appearance) and bleed. Extragenital infection can occur 
with extension of infection to the pelvis, or it can disseminate to intra-abdominal organs, 
bones, or the mouth. The lesions also can develop secondary bacterial infection and can 
coexist with other sexually transmitted pathogens.
Diagnostic Considerations—The causative organism of granuloma inguinale is difficult 
to culture, and diagnosis requires visualization of dark-staining Donovan bodies on tissue 
crush preparation or biopsy. No FDA-cleared molecular tests for the detection of K. 
granulomatis DNA exist, but such an assay might be useful when undertaken by laboratories 
that have conducted a CLIA verification study.
Treatment—Several antimicrobial regimens have been effective, but only a limited number 
of controlled trials have been published (383). Treatment has been shown to halt progression 
of lesions, and healing typically proceeds inward from the ulcer margins; prolonged therapy 
is usually required to permit granulation and re-epithelialization of the ulcers. Relapse can 
occur 6–18 months after apparently effective therapy.
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Recommended Regimen
Azithromycin 1 g orally once per week or 500 mg daily for at least 3 weeks and until all lesions have completely 
healed
Alternative Regimens
Doxycycline 100 mg orally twice a day for at least 3 weeks and until all lesions have completely healed
 OR
Ciprofloxacin 750 mg orally twice a day for at least 3 weeks and until all lesions have completely healed
 OR
Erythromycin base 500 mg orally four times a day for at least 3 weeks and until all lesions have completely healed
 OR
Trimethoprim-sulfamethoxazole one double-strength (160 mg/800 mg) tablet orally twice a day for at least 3 weeks 
and until all lesions have completely healed
The addition of another antibiotic to these regimens can be considered if improvement is not 
evident within the first few days of therapy. Addition of an aminoglycoside to these 
regimens is an option (gentamicin 1 mg/kg IV every 8 hours).
Other Management Considerations—Persons should be followed clinically until signs 
and symptoms have resolved. All persons who receive a diagnosis of granuloma inguinale 
should be tested for HIV.
Follow-up—Patients should be followed clinically until signs and symptoms resolve.
Management of Sex Partners—Persons who have had sexual contact with a patient who 
has granuloma inguinale within the 60 days before onset of the patient’s symptoms should 
be examined and offered therapy. However, the value of empiric therapy in the absence of 
clinical signs and symptoms has not been established.
Special Considerations
Pregnancy: Doxycycline should be avoided in the second and third trimester of pregnancy 
because of the risk for discoloration of teeth and bones, but is compatible with breastfeeding 
(317). Data suggest that ciprofloxacin presents a low risk to the fetus during pregnancy 
(317). Sulfonamides are associated with rare but serious kernicterus in those with G6PD 
deficiency and should be avoided in third trimester and during breastfeeding (317). For these 
reasons, pregnant and lactating women should be treated with a macrolide regimen 
(erythromycin or azithromycin). The addition of an aminoglycoside (gentamicin 1 mg/kg IV 
every 8 hours) can be considered if improvement is not evident within the first few days of 
therapy.
HIV Infection: Persons with both granuloma inguinale and HIV infection should receive 
the same regimens as those who do not have HIV infection. The addition of an 
aminoglycoside (gentamicin 1 mg/kg IV every 8 hours) can be considered if improvement is 
not evident within the first few days of therapy.
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Lymphogranuloma Venereum
Lymphogranuloma venereum (LGV) is caused by C. trachomatis serovars L1, L2, or L3 
(386,387). The most common clinical manifestation of LGV among heterosexuals is tender 
inguinal and/or femoral lymphadenopathy that is typically unilateral. A self-limited genital 
ulcer or papule sometimes occurs at the site of inoculation. However, by the time patients 
seek care, the lesions have often disappeared. Rectal exposure in women or MSM can result 
in proctocolitis mimicking inflammatory bowel disease, and clinical findings may include 
mucoid and/or hemorrhagic rectal discharge, anal pain, constipation, fever, and/or tenesmus 
(388,389). Outbreaks of LGV protocolitis have been reported among MSM (390–392). LGV 
can be an invasive, systemic infection, and if it is not treated early, LGV proctocolitis can 
lead to chronic colorectal fistulas and strictures; reactive arthropathy has also been reported. 
However, reports indicate that rectal LGV can be asymptomatic (393). Persons with genital 
and colorectal LGV lesions can also develop secondary bacterial infection or can be 
coinfected with other sexually and nonsexually transmitted pathogens.
Diagnostic Considerations—Diagnosis is based on clinical suspicion, epidemiologic 
information, and the exclusion of other etiologies for proctocolitis, inguinal 
lymphadenopathy, or genital or rectal ulcers. Genital lesions, rectal specimens, and lymph 
node specimens (i.e., lesion swab or bubo aspirate) can be tested for C. trachomatis by 
culture, direct immunofluorescence, or nucleic acid detection (394). NAATs for C. 
trachomatis perform well on rectal specimens, but are not FDA-cleared for this purpose. 
Many laboratories have performed the CLIA validation studies needed to provide results 
from rectal specimens for clinical management. MSM presenting with protocolitis should be 
tested for chlamydia; NAAT performed on rectal specimens is the preferred approach to 
testing.
Additional molecular procedures (e.g., PCR-based genotyping) can be used to differentiate 
LGV from non-LGV C. trachomatis in rectal specimens. However, they are not widely 
available, and results are not available in a timeframe that would influence clinical 
management.
Chlamydia serology (complement fixation titers ≥1:64 or microimmunofluorescence titers 
>1:256) might support the diagnosis of LGV in the appropriate clinical context. Comparative 
data between types of serologic tests are lacking, and the diagnostic utility of these older 
serologic methods has not been established. Serologic test interpretation for LGV is not 
standardized, tests have not been validated for clinical proctitis presentations, and C. 
trachomatis serovar-specific serologic tests are not widely available.
Treatment—At the time of the initial visit (before diagnostic tests for chlamydia are 
available), persons with a clinical syndrome consistent with LGV, including proctocolitis or 
genital ulcer disease with lymphadenopathy, should be presumptively treated for LGV. As 
required by state law, these cases should be reported to the health department.
Treatment cures infection and prevents ongoing tissue damage, although tissue reaction to 
the infection can result in scarring. Buboes might require aspiration through intact skin or 
incision and drainage to prevent the formation of inguinal/femoral ulcerations.
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Recommended Regimen
Doxycycline 100 mg orally twice a day for 21 days
Alternative Regimen
Erythromycin base 500 mg orally four times a day for 21 days
Although clinical data are lacking, azithromycin 1 g orally once weekly for 3 weeks is 
probably effective based on its chlamydial antimicrobial activity. Fluoroquinolone-based 
treatments also might be effective, but the optimal duration of treatment has not been 
evaluated.
Other Management Considerations—Patients should be followed clinically until signs 
and symptoms have resolved. Persons who receive an LGV diagnosis should be tested for 
other STDs, especially HIV, gonorrhea, and syphilis. Those who test positive for another 
infection should be referred for or provided with appropriate care and treatment.
Follow-up—Patients should be followed clinically until signs and symptoms resolve.
Management of Sex Partners—Persons who have had sexual contact with a patient who 
has LGV within the 60 days before onset of the patient’s symptoms should be examined and 
tested for urethral, cervical, or rectal chlamydial infection depending on anatomic site of 
exposure. They should be presumptively treated with a chlamydia regimen (azithromycin 1 g 
orally single dose or doxycycline 100 mg orally twice a day for 7 days).
Special Considerations
Pregnancy: Pregnant and lactating women should be treated with erythromycin. 
Doxycycline should be avoided in the second and third trimester of pregnancy because of 
risk for discoloration of teeth and bones, but is compatible with breastfeeding (317). 
Azithromycin might prove useful for treatment of LGV in pregnancy, but no published data 
are available regarding an effective dose and duration of treatment.
HIV Infection: Persons with both LGV and HIV infection should receive the same 
regimens as those who are HIV negative. Prolonged therapy might be required, and delay in 
resolution of symptoms might occur.
Syphilis
Syphilis is a systemic disease caused by Treponema pallidum. The disease has been divided 
into stages based on clinical findings, helping to guide treatment and follow-up. Persons 
who have syphilis might seek treatment for signs or symptoms of primary syphilis infection 
(i.e., ulcers or chancre at the infection site), secondary syphilis (i.e., manifestations that 
include, but are not limited to, skin rash, mucocutaneous lesions, and lymphadenopathy), or 
tertiary syphilis (i.e., cardiac, gummatous lesions, tabes dorsalis, and general paresis). Latent 
infections (i.e., those lacking clinical manifestations) are detected by serologic testing. 
Latent syphilis acquired within the preceding year is referred to as early latent syphilis; all 
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other cases of latent syphilis are late latent syphilis or syphilis of unknown duration. T. 
pallidum can infect the central nervous system and result in neurosyphilis, which can occur 
at any stage of syphilis. Early neurologic clinical manifestations (i.e., cranial nerve 
dysfunction, meningitis, stroke, acute altered mental status, and auditory or ophthalmic 
abnormalities) are usually present within the first few months or years of infection. Late 
neurologic manifestations (i.e., tabes dorsalis and general paresis) occur 10–30 years after 
infection.
Diagnostic Considerations
Darkfield examinations and tests to detect T. pallidum directly from lesion exudate or tissue 
are the definitive methods for diagnosing early syphilis (395). Although no T. pallidum 
detection tests are commercially available, some laboratories provide locally developed and 
validated PCR tests for the detection of T. pallidum DNA. A presumptive diagnosis of 
syphilis requires use of two tests: a nontreponemal test (i.e., Venereal Disease Research 
Laboratory [VDRL] or Rapid Plasma Reagin [RPR]) and a treponemal test (i.e., fluorescent 
treponemal antibody absorbed [FTA-ABS] tests, the T. pallidum passive particle 
agglutination [TP-PA] assay, various enzyme immunoassays [EIAs], chemiluminescence 
immunoassays, immunoblots, or rapid treponemal assays). Although many treponemal-
based tests are commercially available, only a few are approved for use in the United States. 
Use of only one type of serologic test is insufficient for diagnosis and can result in false-
negative results in persons tested during primary syphilis and false-positive results in 
persons without syphilis. False-positive nontreponemal test results can be associated with 
various medical conditions and factors unrelated to syphilis, including other infections (e.g., 
HIV), autoimmune conditions, immunizations, pregnancy, injection-drug use, and older age 
(395,396). Therefore, persons with a reactive nontreponemal test should always receive a 
treponemal test to confirm the diagnosis of syphilis.
Nontreponemal test antibody titers might correlate with disease activity and are used to 
follow treatment response. Results should be reported quantitatively. A fourfold change in 
titer, equivalent to a change of two dilutions (e.g., from 1:16 to 1:4 or from 1:8 to 1:32), is 
considered necessary to demonstrate a clinically significant difference between two 
nontreponemal test results obtained using the same serologic test. Sequential serologic tests 
in individual patients should be performed using the same testing method (VDRL or RPR), 
preferably by the same laboratory. The VDRL and RPR are equally valid assays, but 
quantitative results from the two tests cannot be compared directly because RPR titers 
frequently are slightly higher than VDRL titers. Nontreponemal test titers usually decline 
after treatment and might become nonreactive with time; however, in some persons, 
nontreponemal antibodies can persist for a long period of time, a response referred to as the 
“serofast reaction.” Most patients who have reactive treponemal tests will have reactive tests 
for the remainder of their lives, regardless of treatment or disease activity. However, 15%–
25% of patients treated during the primary stage revert to being serologically nonreactive 
after 2–3 years (397). Treponemal antibody titers do not predict treatment response and 
therefore should not be used for this purpose.
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Some clinical laboratories are screening samples using treponemal tests, typically by EIA or 
chemiluminescence immunoassays (398,399). This reverse screening algorithm for syphilis 
testing can identify persons previously treated for syphilis, those with untreated or 
incompletely treated syphilis, and persons with false-positive results that can occur with a 
low likelihood of infection. Persons with a positive treponemal screening test should have a 
standard nontreponemal test with titer performed reflexively by the laboratory to guide 
patient management decisions. If the nontreponemal test is negative, the laboratory should 
perform a different treponemal test (preferably one based on different antigens than the 
original test) to confirm the results of the initial test. If a second treponemal test is positive, 
persons with a history of previous treatment will require no further management unless 
sexual history suggests likelihood of re-exposure. In this instance, a repeat nontreponemal 
test in 2–4 weeks is recommended to evaluate for early infection. Those without a history of 
treatment for syphilis should be offered treatment. Unless history or results of a physical 
examination suggest a recent infection, previously untreated persons should be treated for 
late latent syphilis. If the second treponemal test is negative and the epidemiologic risk and 
clinical probability for syphilis are low, further evaluation or treatment is not indicated. Two 
studies demonstrate that high quantitative index values from treponemal EIA/CIA tests 
correlate with TPPA positivity; however, the range of optical density values varies among 
different treponemal immunoassays, and the clinical significance of these findings warrant 
further investigation (400,401).
For most persons with HIV infection, serologic tests are accurate and reliable for diagnosing 
syphilis and following a patient’s response to treatment. However, atypical nontreponemal 
serologic test results (i.e., unusually high, unusually low, or fluctuating titers) might occur 
regardless of HIV-infection status. When serologic tests do not correspond with clinical 
findings suggestive of early syphilis, presumptive treatment is recommended for persons 
with risk factors for syphilis, and use of other tests (e.g., biopsy and PCR) should be 
considered.
Further testing is warranted for persons with clinical signs of neurosyphilis (e.g., cranial 
nerve dysfunction, auditory or ophthalmic abnormalities, meningitis, stroke, acute or chronic 
altered mental status, and loss of vibration sense). Laboratory testing is helpful in supporting 
the diagnosis of neurosyphilis; however, no single test can be used to diagnose neurosyphilis 
in all instances. The diagnosis of neurosyphilis depends on a combination of cerebrospinal 
fluid (CSF) tests (CSF cell count or protein and a reactive CSF-VDRL) in the presence of 
reactive serologic test results and neurologic signs and symptoms. CSF laboratory 
abnormalities are common in persons with early syphilis and are of unknown significance in 
the absence of neurologic signs or symptoms (402). CSF-VDRL is highly specific but 
insensitive. In a person with neurologic signs or symptoms, a reactive CSF-VDRL (in the 
absence of blood contamination) is considered diagnostic of neurosyphilis. When CSF-
VDRL is negative despite the presence of clinical signs of neurosyphilis, reactive serologic 
test results, and abnormal CSF cell count and/or protein, neurosyphilis should be considered. 
In this instance, additional evaluation using FTA-ABS testing on CSF may be warranted. 
The CSF FTA-ABS test is less specific for neurosyphilis than the CSF-VDRL but is highly 
sensitive. Neurosyphilis is highly unlikely with a negative CSF FTA-ABS test, especially 
among persons with nonspecific neurologic signs and symptoms (403).
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Among persons with HIV infection, CSF leukocyte count usually is elevated (>5 white 
blood cell count [WBC]/mm3). Using a higher cutoff (>20 WBC/mm3) might improve the 
specificity of neurosyphilis diagnosis (404).
Treatment
Penicillin G, administered parenterally, is the preferred drug for treating persons in all stages 
of syphilis. The preparation used (i.e., benzathine, aqueous procaine, or aqueous crystalline), 
dosage, and length of treatment depend on the stage and clinical manifestations of the 
disease. Treatment for late latent syphilis and tertiary syphilis require a longer duration of 
therapy, because organisms theoretically might be dividing more slowly (the validity of this 
rationale has not been assessed). Longer treatment duration is required for persons with 
latent syphilis of unknown duration to ensure that those who did not acquire syphilis within 
the preceding year are adequately treated.
Selection of the appropriate penicillin preparation is important, because T. pallidum can 
reside in sequestered sites (e.g., the CNS and aqueous humor) that are poorly accessed by 
some forms of penicillin. Combinations of benzathine penicillin, procaine penicillin, and 
oral penicillin preparations are not considered appropriate for the treatment of syphilis. 
Reports have indicated that practitioners have inadvertently prescribed combination 
benzathine-procaine penicillin (Bicillin C-R) instead of the standard benzathine penicillin 
product (Bicillin L-A) widely used in the United States. Practitioners, pharmacists, and 
purchasing agents should be aware of the similar names of these two products to avoid using 
the inappropriate combination therapy agent for treating syphilis (405).
The effectiveness of penicillin for the treatment of syphilis was well established through 
clinical experience even before the value of randomized controlled clinical trials was 
recognized. Therefore, nearly all recommendations for the treatment of syphilis are based 
not only on clinical trials and observational studies, but many decades of clinical experience.
Special Considerations
Pregnancy—Parenteral penicillin G is the only therapy with documented efficacy for 
syphilis during pregnancy. Pregnant women with syphilis in any stage who report penicillin 
allergy should be desensitized and treated with penicillin (see Management of Persons Who 
Have a History of Penicillin Allergy).
Jarisch-Herxheimer Reaction—The Jarisch-Herxheimer reaction is an acute febrile 
reaction frequently accompanied by headache, myalgia, fever, and other symptoms that can 
occur within the first 24 hours after the initiation of any therapy for syphilis. Patients should 
be informed about this possible adverse reaction and how to manage it if it occurs. The 
Jarisch-Herxheimer reaction occurs most frequently among persons who have early syphilis, 
presumably because bacterial burdens are higher during these stages. Antipyretics can be 
used to manage symptoms, but they have not been proven to prevent this reaction. The 
Jarisch-Herxheimer reaction might induce early labor or cause fetal distress in pregnant 
women, but this should not prevent or delay therapy (see Syphilis During Pregnancy).
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Management of Sex Partners
Sexual transmission of T. pallidum is thought to occur only when mucocutaneous syphilitic 
lesions are present. Such manifestations are uncommon after the first year of infection. 
Persons exposed sexually to a person who has primary, secondary, or early latent syphilis 
should be evaluated clinically and serologically and treated according to the following 
recommendations:
• Persons who have had sexual contact with a person who receives a diagnosis of 
primary, secondary, or early latent syphilis within 90 days preceding the 
diagnosis should be treated presumptively for early syphilis, even if serologic test 
results are negative.
• Persons who have had sexual contact with a person who receives a diagnosis of 
primary, secondary, or early latent syphilis >90 days before the diagnosis should 
be treated presumptively for early syphilis if serologic test results are not 
immediately available and the opportunity for follow-up is uncertain. If serologic 
tests are negative, no treatment is needed. If serologic tests are positive, treatment 
should be based on clinical and serologic evaluation and stage of syphilis.
• In some areas or populations with high rates of syphilis, health departments 
recommend notification and presumptive treatment of sex partners of persons 
with late latent syphilis who have high nontreponemal serologic test titers (i.e., 
>1:32), because high titers might be indicative of early syphilis. These partners 
should be managed as if the index case had early syphilis.
• Long-term sex partners of persons who have late latent syphilis should be 
evaluated clinically and serologically for syphilis and treated on the basis of the 
evaluation’s findings.
• The following sex partners of persons with syphilis are considered at risk for 
infection and should be confidentially notified of the exposure and need for 
evaluation: partners who have had sexual contact within 1) 3 months plus the 
duration of symptoms for persons who receive a diagnosis of primary syphilis, 2) 
6 months plus duration of symptoms for those with secondary syphilis, and 3) 1 
year for persons with early latent syphilis.
Primary and Secondary Syphilis
Treatment—Parenteral penicillin G has been used effectively to achieve clinical resolution 
(i.e., the healing of lesions and prevention of sexual transmission) and to prevent late 
sequelae. However, no comparative trials have been conducted to guide the selection of an 
optimal penicillin regimen. Substantially fewer data are available for nonpenicillin regimens.
Recommended Regimen for Adults*
Benzathine penicillin G 2.4 million units IM in a single dose
*Recommendations for treating syphilis in persons with HIV infection and pregnant women are discussed elsewhere in 
this report (see Syphilis among Persons with HIV infection and Syphilis during Pregnancy).
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Available data demonstrate that use of additional doses of benzathine penicillin G, 
amoxicillin, or other antibiotics do not enhance efficacy when used to treat primary and 
secondary syphilis, regardless of HIV status (406,407).
Recommended Regimen for Infants and Children
Benzathine penicillin G 50,000 units/kg IM, up to the adult dose of 2.4 million units in a single dose
Infants and children aged ≥1 month who receive a diagnosis of syphilis should have birth 
and maternal medical records reviewed to assess whether they have congenital or acquired 
syphilis (see Congenital Syphilis). Infants and children aged ≥1 month with primary and 
secondary syphilis should be managed by a pediatric infectious-disease specialist and 
evaluated for sexual abuse (e.g., through consultation with child-protection services) (see 
Sexual Assault or Abuse of Children).
Other Management Considerations—All persons who have primary and secondary 
syphilis should be tested for HIV infection. In geographic areas in which the prevalence of 
HIV is high, persons who have primary or secondary syphilis should be retested for acute 
HIV in 3 months if the first HIV test result was negative.
Persons who have syphilis and symptoms or signs suggesting neurologic disease (e.g., 
cranial nerve dysfunction, meningitis, stroke, and hearing loss) or ophthalmic disease (e.g., 
uveitis, iritis, neuroretinitis, and optic neuritis) should have an evaluation that includes CSF 
analysis, ocular slit-lamp ophthalmologic examination, and otologic examination. Treatment 
should be guided by the results of this evaluation.
Invasion of CSF by T. pallidum accompanied by CSF laboratory abnormalities is common 
among adults who have primary or secondary syphilis (402). In the absence of clinical 
neurologic findings, no evidence supports variation from the recommended treatment 
regimen for primary and secondary syphilis. Symptomatic neurosyphilis develops in only a 
limited number of persons after treatment with the penicillin regimens recommended for 
primary and secondary syphilis. Therefore, unless clinical signs or symptoms of neurologic 
or ophthalmic involvement are present, routine CSF analysis is not recommended for 
persons who have primary or secondary syphilis.
Follow-Up—Clinical and serologic evaluation should be performed at 6 and 12 months 
after treatment; more frequent evaluation might be prudent if follow-up is uncertain or if 
repeat infection is a concern. Serologic response (i.e., titer) should be compared with the 
titer at the time of treatment. However, assessing serologic response to treatment can be 
difficult, and definitive criteria for cure or failure have not been well established. In addition, 
nontreponemal test titers might decline more slowly for persons previously treated for 
syphilis (408,409).
Persons who have signs or symptoms that persist or recur and those with at least a fourfold 
increase in nontreponemal test titer persisting for >2 weeks likely experienced treatment 
failure or were re-infected. These persons should be retreated and reevaluated for HIV 
infection. Because treatment failure usually cannot be reliably distinguished from reinfection 
Workowski and Bolan Page 59
MMWR Recomm Rep. Author manuscript; available in PMC 2018 April 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
with T. pallidum, a CSF analysis also should be performed; treatment should be guided by 
CSF findings.
Failure of nontreponemal test titers to decline fourfold within 6–12 months after therapy for 
primary or secondary syphilis might be indicative of treatment failure. However, clinical trial 
data have demonstrated that 15%–20% of persons with primary and secondary syphilis 
treated with the recommended therapy will not achieve the fourfold decline in 
nontreponemal titer used to define response at 1 year after treatment (406,409). Serologic 
response to treatment appears to be associated with several factors, including the person’s 
stage of syphilis (earlier stages are more likely to decline fourfold and become negative) and 
initial nontreponemal antibody titers (lower titers are less likely to decline fourfold than 
higher titers) (409). Optimal management of persons who have less than a fourfold decline 
in titers after treatment of syphilis is unclear. At a minimum, these persons should receive 
additional clinical and serologic follow-up and be evaluated for HIV infection. If additional 
follow-up cannot be ensured, retreatment is recommended. Because treatment failure might 
be the result of unrecognized CNS infection, CSF examination can be considered in such 
situations.
For retreatment, weekly injections of benzathine penicillin G 2.4 million units IM for 3 
weeks is recommended, unless CSF examination indicates that neurosyphilis is present (see 
Neurosyphilis). Serologic titers might not decline despite a negative CSF examination and a 
repeated course of therapy (410). In these circumstances, although the need for additional 
therapy or repeated CSF examinations is unclear, it is not generally recommended.
Management of Sex Partners
See Syphilis, Management of Sex Partners.
Special Considerations
Penicillin Allergy: Data to support use of alternatives to penicillin in the treatment of 
primary and secondary syphilis are limited. However, several therapies might be effective in 
nonpregnant, penicillin-allergic persons who have primary or secondary syphilis. Regimens 
of doxycycline 100 mg orally twice daily for 14 days (411,412) and tetracycline (500 mg 
four times daily for 14 days) have been used for many years. Compliance is likely to be 
better with doxycycline than tetracycline, because tetracycline can cause gastrointestinal side 
effects and requires more frequent dosing. Although limited clinical studies, along with 
biologic and pharmacologic evidence, suggest that ceftriaxone (1–2 g daily either IM or IV 
for 10–14 days) is effective for treating primary and secondary syphilis, the optimal dose 
and duration of ceftriaxone therapy have not been defined (413). Azithromycin as a single 2 
g oral dose has been effective for treating primary and secondary syphilis in some 
populations (414–416). However, T. pallidum chromosomal mutations associated with 
azithromycin and other macrolide resistance and treatment failures have been documented in 
multiple geographical areas in the United States (417–419). Accordingly, azithromycin 
should not be used as first-line treatment for syphilis and should be used with caution only 
when treatment with penicillin or doxycycline is not feasible. Azithromycin should not be 
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used in MSM, persons with HIV, or pregnant women. Careful clinical and serologic follow-
up of persons receiving any alternative therapies is essential.
Persons with a penicillin allergy whose compliance with therapy or follow-up cannot be 
ensured should be desensitized and treated with benzathine penicillin. Skin testing for 
penicillin allergy might be useful in some circumstances in which the reagents and expertise 
are available to perform the test adequately (see Management of Persons Who Have a 
History of Penicillin Allergy).
Pregnancy: Pregnant women with primary or secondary syphilis who are allergic to 
penicillin should be desensitized and treated with penicillin. For more information, see 
Management of Persons Who Have a History of Penicillin Allergy and Syphilis During 
Pregnancy.
HIV Infection: Persons with HIV infection who have primary or secondary syphilis should 
be treated as those without HIV infection. For more information on treatment and 
management, see Syphilis in Persons with HIV infection.
Latent Syphilis
Latent syphilis is defined as syphilis characterized by seroreactivity without other evidence 
of primary, secondary, or tertiary disease. Persons who have latent syphilis and who acquired 
syphilis during the preceding year are classified as having early latent syphilis, a subset of 
latent syphilis. Persons can receive a diagnosis of early latent syphilis if, during the year 
preceding the diagnosis, they had 1) a documented seroconversion or a sustained (>2 week) 
fourfold or greater increase in nontreponemal test titers; 2) unequivocal symptoms of 
primary or secondary syphilis; or 3) a sex partner documented to have primary, secondary, or 
early latent syphilis. In addition, for persons with reactive nontreponemal and treponemal 
tests whose only possible exposure occurred during the previous 12 months, early latent 
syphilis can be assumed. In the absence of these conditions, an asymptomatic person should 
be considered to have latent syphilis. Nontreponemal serologic titers usually are higher early 
in the course of syphilis infection. However, early latent syphilis cannot be reliably 
diagnosed solely on the basis of nontreponemal titers. All persons with latent syphilis should 
have careful examination of all accessible mucosal surfaces (i.e., the oral cavity, perianal 
area, perineum and vagina in women, and underneath the foreskin in uncircumcised men) to 
evaluate for mucosal lesions.
Treatment—Because latent syphilis is not transmitted sexually, the objective of treating 
persons in this stage of disease is to prevent complications and transmission from a pregnant 
woman to her fetus. Although clinical experience supports the effectiveness of penicillin in 
achieving this goal, limited evidence is available to guide choice of specific regimens or 
duration. Available data demonstrate that additional doses of benzathine penicillin G, 
amoxicillin, or other antibiotics in early latent syphilis do not enhance efficacy, regardless of 
HIV infection (406,407).
Recommended Regimens for Adults*
Workowski and Bolan Page 61
MMWR Recomm Rep. Author manuscript; available in PMC 2018 April 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Early Latent Syphilis
Benzathine penicillin G 2.4 million units IM in a single dose
Late Latent Syphilis or Latent Syphilis of Unknown Duration
Benzathine penicillin G 7.2 million units total, administered as 3 doses of 2.4 million units IM each at 1-week intervals
*Recommendations for treating syphilis in persons with HIV infection and pregnant women are discussed elsewhere in 
this report (see Syphilis in Persons with HIV infection and Syphilis during Pregnancy).
Recommended Regimens for Infants and Children
Early Latent Syphilis
Benzathine penicillin G 50,000 units/kg IM, up to the adult dose of 2.4 million units in a single dose
Late Latent Syphilis
Benzathine penicillin G 50,000 units/kg IM, up to the adult dose of 2.4 million units, administered as 3 doses at 1-
week intervals (total 150,000 units/kg up to the adult total dose of 7.2 million units)
Infants and children aged ≥1 month diagnosed with latent syphilis should be managed by a 
pediatric infectious-disease specialist and receive a CSF examination. In addition, birth and 
maternal medical records should be reviewed to assess whether these infants and children 
have congenital or acquired syphilis. For those with congenital syphilis, treatment should be 
undertaken as described in the congenital syphilis section in this document. Those with 
acquired latent syphilis should be evaluated for sexual abuse (e.g., through consultation with 
child protection services) (see Sexual Assault or Abuse of Children). These regimens are for 
penicillin nonallergic children who have acquired syphilis and who have normal CSF 
examination results.
Other Management Considerations—All persons who have latent syphilis should be 
tested for HIV infection. Persons who receive a diagnosis of latent syphilis and have 
neurologic signs and symptoms (e.g., cognitive dysfunction, motor or sensory deficits, 
ophthalmic or auditory symptoms, cranial nerve palsies, and symptoms or signs of 
meningitis or stroke) should be evaluated for neurosyphilis (see Neurosyphilis).
If a person misses a dose of penicillin in a course of weekly therapy for latent syphilis, the 
appropriate course of action is unclear. Clinical experience suggests that an interval of 10–14 
days between doses of benzathine penicillin for latent syphilis might be acceptable before 
restarting the sequence of injections (i.e., if dose 1 is given on day 0, dose 2 is administered 
between days 10 and 14). Pharmacologic considerations suggest that an interval of 7–9 days 
between doses, if feasible, might be more optimal (420–422). Missed doses are not 
acceptable for pregnant women receiving therapy for latent syphilis (423). Pregnant women 
who miss any dose of therapy must repeat the full course of therapy.
Follow-Up—Quantitative nontreponemal serologic tests should be repeated at 6, 12, and 24 
months. A CSF examination should be performed if 1) a sustained (>2 weeks) fourfold 
increase or greater in titer is observed, 2) an initially high titer (≥1:32) fails to decline at 
least fourfold within 12–24 months of therapy, or 3) signs or symptoms attributable to 
syphilis develop. In such circumstances, patients with CSF abnormalities should be treated 
for neurosyphilis. If the CSF examination is negative, retreatment for latent syphilis should 
be administered. Serologic titers might fail to decline despite a negative CSF examination 
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and a repeated course of therapy, especially if the initial nontreponemal titer is low (<1:8); in 
these circumstances, the need for additional therapy or repeated CSF examinations is unclear 
but is generally not recommended. Serologic and clinical monitoring should be offered along 
with a reevaluation for HIV infection.
Management of Sex Partners—See Syphilis, Management of Sex Partners.
Special Considerations
Penicillin Allergy: The effectiveness of alternatives to penicillin in the treatment of latent 
syphilis has not been well documented. Nonpregnant patients allergic to penicillin who have 
clearly defined early latent syphilis should respond to antibiotics recommended as 
alternatives to penicillin for the treatment of primary and secondary syphilis (see Primary 
and Secondary Syphilis, Treatment). The only acceptable alternatives for the treatment of 
latent syphilis are doxycycline (100 mg orally twice daily) or tetracycline (500 mg orally 
four times daily), each for 28 days. The efficacy of these alternative regimens in persons 
with HIV infection has not been well studied. These therapies should be used only in 
conjunction with close serologic and clinical follow-up, especially in persons with HIV 
infection. On the basis of biologic plausibility and pharmacologic properties, ceftriaxone 
might be effective for treating latent syphilis. However, the optimal dose and duration of 
ceftriaxone therapy have not been defined; treatment decisions should be discussed in 
consultation with a specialist. Persons with a penicillin allergy whose compliance with 
therapy or follow-up cannot be ensured should be desensitized and treated with benzathine 
penicillin. Skin testing for penicillin allergy might be useful in some circumstances in which 
the reagents and expertise are available to perform the test adequately (see Management of 
Persons Who Have a History of Penicillin Allergy).
Pregnancy: Pregnant women who are allergic to penicillin should be desensitized and 
treated with penicillin. For more information, see Management of Persons Who Have a 
History of Penicillin Allergy and Syphilis during Pregnancy.
HIV Infection: Persons with HIV infection with latent syphilis should be treated as persons 
who do not have HIV infection. For more information on treatment and management of 
latent syphilis, see Syphilis in Persons with HIV Infection.
Tertiary Syphilis
Tertiary syphilis refers to gummas and cardiovascular syphilis but not to neurosyphilis. 
Guidelines for all forms of neurosyphilis (e.g., early or late neurosyphilis) are discussed 
elsewhere in these recommendations (see Neurosyphilis). Persons who are not allergic to 
penicillin and have no evidence of neurosyphilis should be treated with the following 
regimen.
Recommended Regimen
Tertiary Syphilis with Normal CSF Examination
 Benzathine penicillin G 7.2 million units total, administered as 3 doses of 2.4 million units IM each at 1-week 
intervals
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Other Management Considerations—All persons who have tertiary syphilis should be 
tested for HIV infection and should receive a CSF examination before therapy is initiated. 
Persons with CSF abnormalities should be treated with a neurosyphilis regimen. Some 
providers treat all persons who have cardiovascular syphilis with a neurosyphilis regimen. 
These persons should be managed in consultation with an infectious-disease specialist. 
Limited information is available concerning clinical response and follow-up of persons who 
have tertiary syphilis.
Management of Sex Partners—See Syphilis, Management of Sex Partners.
Special Considerations
Penicillin Allergy: Providers should ask patients about known allergies to penicillin. Any 
person allergic to penicillin should be treated in consultation with an infectious-disease 
specialist.
Pregnancy: Pregnant women who are allergic to penicillin should be desensitized and 
treated with penicillin. For more information, see Management of Persons Who Have a 
History of Penicillin Allergy and Syphilis during Pregnancy.
HIV Infection: Persons with HIV infection who have tertiary syphilis should be treated as 
described for persons without HIV infection. For more information on the management of 
tertiary syphilis in persons with HIV infection, see Syphilis in Persons with HIV Infection.
Neurosyphilis
Treatment—CNS involvement can occur during any stage of syphilis, and CSF laboratory 
abnormalities are common in persons with early syphilis, even in the absence of clinical 
neurologic findings. No evidence exists to support variation from recommended treatment 
for syphilis at any stage for persons without clinical neurologic findings, with the exception 
of tertiary syphilis. If clinical evidence of neurologic involvement is observed (e.g., 
cognitive dysfunction, motor or sensory deficits, ophthalmic or auditory symptoms, cranial 
nerve palsies, and symptoms or signs of meningitis or stroke), a CSF examination should be 
performed.
Syphilitic uveitis or other ocular manifestations (e.g., neuroretinitis and optic neuritis) can 
be associated with neurosyphilis. A CSF examination should be performed in all instances 
of ocular syphilis, even in the absence of clinical neurologic findings. Ocular syphilis should 
be managed in collaboration with an ophthalmologist and according to the treatment and 
other recommendations for neurosyphilis, even if a CSF examination is normal. In instances 
of ocular syphilis and abnormal CSF test results, follow-up CSF examinations should be 
performed to assess treatment response.
Recommended Regimen
Neurosyphilis and Ocular Syphilis
 Aqueous crystalline penicillin G 18–24 million units per day, administered as 3–4 million units IV every 4 hours or 
continuous infusion, for 10–14 days
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If compliance with therapy can be ensured, the following alternative regimen might be 
considered.
Alternative Regimen
Procaine penicillin G 2.4 million units IM once daily
 PLUS
Probenecid 500 mg orally four times a day, both for 10–14 days
The durations of the recommended and alternative regimens for neurosyphilis are shorter 
than the duration of the regimen used for latent syphilis. Therefore, benzathine penicillin, 
2.4 million units IM once per week for up to 3 weeks, can be considered after completion of 
these neurosyphilis treatment regimens to provide a comparable total duration of therapy.
Other Management Considerations—The following are other considerations in the 
management of persons who have neurosyphilis:
• All persons who have neurosyphilis should be tested for HIV
• Although systemic steroids are used frequently as adjunctive therapy for otologic 
syphilis, such drugs have not been proven to be beneficial.
Follow-Up—If CSF pleocytosis was present initially, a CSF examination should be 
repeated every 6 months until the cell count is normal. Follow-up CSF examinations also 
can be used to evaluate changes in the CSF-VDRL or CSF protein after therapy; however, 
changes in these two parameters occur more slowly than cell counts, and persistent 
abnormalities might be less important (424,425). Leukocyte count is a sensitive measure of 
the effectiveness of therapy. If the cell count has not decreased after 6 months, or if the CSF 
cell count or protein is not normal after 2 years, retreatment should be considered. Limited 
data suggest that in immunocompetent persons and persons with HIV infection on highly 
active antiretroviral therapy, normalization of the serum RPR titer predicts normalization of 
CSF parameters following neurosyphilis treatment (425).
Management of Sex Partners—See Syphilis, Management of Sex Partners.
Special Considerations
Penicillin Allergy: Limited data suggest that ceftriaxone 2 g daily either IM or IV for 10–14 
days can be used as an alternative treatment for persons with neurosyphilis (426,427). Cross-
sensitivity between ceftriaxone and penicillin can occur, but the risk for penicillin cross-
reactivity between third-generation cephalosporins is negligible (428–431) (see Management 
of Persons Who Have a History of Penicillin Allergy). If concern exists regarding the safety 
of ceftriaxone for a patient with neurosyphilis, skin testing should be performed (if 
available) to confirm penicillin allergy and, if necessary, penicillin desensitization in 
consultation with a specialist is recommended. Other regimens have not been adequately 
evaluated for treatment of neurosyphilis.
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Pregnancy: Pregnant women who are allergic to penicillin should be desensitized and 
treated with penicillin. For more information, see Syphilis during Pregnancy.
HIV Infection: Persons with HIV infection who have neurosyphilis should be treated as 
described for persons without HIV infection. For more information on neurosyphilis, see 
Syphilis in Persons with HIV infection.
Persons with HIV Infection
Diagnostic Considerations—Interpretation of treponemal and nontreponemal serologic 
tests for persons with HIV infection is the same as for the HIV-uninfected patient. Although 
rare, unusual serologic responses have been observed among persons with HIV infection 
who have syphilis; although most reports have involved post-treatment serologic titers that 
were higher than expected (high serofast) or fluctuated, false-negative serologic test results 
and delayed appearance of seroreactivity have also been reported (432).
When clinical findings are suggestive of syphilis but serologic tests are nonreactive or their 
interpretation is unclear, alternative tests (e.g., biopsy of a lesion, darkfield examination, and 
PCR of lesion material) might be useful for diagnosis. Neurosyphilis should be considered 
in the differential diagnosis of neurologic signs and symptoms in persons with HIV 
infection.
Treatment—Persons with HIV infection who have early syphilis might be at increased risk 
for neurologic complications (433) and might have higher rates of serologic treatment failure 
with recommended regimens. The magnitude of these risks is not defined precisely, but is 
likely small. Although long-term (>1 year) comparative data are lacking, no treatment 
regimens for syphilis have been demonstrated to be more effective in preventing 
neurosyphilis in persons with HIV infection than the syphilis regimens recommended for 
persons without HIV infection (406). Careful follow-up after therapy is essential. The use of 
antiretroviral therapy as per current guidelines might improve clinical outcomes in persons 
with HIV infection and syphilis (425,434,435).
Primary and Secondary Syphilis among Persons with HIV Infection
Recommended Regimen
Benzathine penicillin G, 2.4 million units IM in a single dose
Available data demonstrate that additional doses of benzathine penicillin G, amoxicillin, or 
other antibiotics in primary and secondary syphilis do not result in enhanced efficacy 
(406,407).
Other Management Considerations: Most persons with HIV infection respond 
appropriately to the recommended benzathine penicillin treatment regimen for primary and 
secondary syphilis. CSF abnormalities (e.g., mononuclear pleocytosis and elevated protein 
levels) are common in persons with HIV infection, even in those without syphilis. The 
clinical and prognostic significance of such CSF laboratory abnormalities in persons with 
primary and secondary syphilis who lack neurologic symptoms is unknown. Certain studies 
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have demonstrated that among persons with HIV infection and syphilis, CSF abnormalities 
are associated with a CD4 count of ≤350 cells/mL and/or an RPR titer of ≥1:32 
(404,436,437); however, CSF examination has not been associated with improved clinical 
outcomes in the absence of neurologic signs and symptoms. All persons with HIV infection 
and syphilis should have a careful neurologic exam (425,434,435).
Follow-Up—Persons with HIV infection and primary or secondary syphilis should be 
evaluated clinically and serologically for treatment failure at 3, 6, 9, 12, and 24 months after 
therapy; those who meet the criteria for treatment failure (i.e., signs or symptoms that persist 
or recur or persons who have a sustained [>2 weeks] fourfold increase or greater in titer) 
should be managed in the same manner as HIV-negative patients (i.e., a CSF examination 
and retreatment guided by CSF findings). In addition, CSF examination and retreatment can 
be considered for persons whose nontreponemal test titers do not decrease fourfold within 
12–24 months of therapy. If CSF examination is normal, treatment with benzathine 
penicillin G administered as 2.4 million units IM each at weekly intervals for 3 weeks is 
recommended. Serologic titers might not decline despite a negative CSF examination and a 
repeated course of therapy (410). In these circumstances, the need for additional therapy or 
repeated CSF examinations is unclear, but is not generally recommended. Serologic and 
clinical monitoring should be provided.
Management of Sex Partners—See Syphilis, Management of Sex Partners.
Special Considerations
Penicillin Allergy: Persons with HIV infection who are penicillin-allergic and have primary 
or secondary syphilis should be managed according to the recommendations for penicillin-
allergic, HIV-negative persons. Persons with penicillin allergy whose compliance with 
therapy or follow-up cannot be ensured should be desensitized and treated with penicillin 
(see Management of Persons Who Have a History of Penicillin Allergy). The use of 
alternatives to penicillin has not been well studied in persons with HIV infection; 
azithromycin is not recommended in persons with HIV infection and primary and secondary 
syphilis. Alternative therapies should be used only in conjunction with close serologic and 
clinical follow-up.
Latent Syphilis among Persons with HIV Infection
Recommended Regimen for Early Latent Syphilis
Benzathine penicillin G, 2.4 million units IM in a single dose
Recommended Regimen for Late Latent Syphilis
Benzathine penicillin G, at weekly doses of 2.4 million units for 3 weeks
Other Management Considerations—All persons with HIV infection and syphilis 
should undergo a careful neurologic examination; those with neurologic symptoms or signs 
should undergo immediate CSF examination. In the absence of neurologic symptoms, CSF 
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examination has not been associated with improved clinical outcomes and therefore is not 
recommended.
Follow-Up—Patients should be evaluated clinically and serologically at 6, 12, 18, and 24 
months after therapy. If, at any time, clinical symptoms develop or a sustained (>2 weeks) 
fourfold or greater rise in nontreponemal titers occurs, a CSF examination should be 
performed and treatment administered accordingly. If the nontreponemal titer does not 
decline fourfold after 24 months, CSF examination can be considered and treatment 
administered accordingly, although initial low titers (<1:8) might not decline. Even after 
retreatment, serologic titers might fail to decline. In these circumstances, the need for 
repeated CSF examination or additional therapy is unclear but is generally not 
recommended. Serologic and clinical monitoring should be provided.
Management of Sex Partners—See Syphilis, Management of Sex Partners.
Special Considerations
Penicillin Allergy: The efficacy of alternative nonpenicillin regimens in persons with HIV 
infection has not been well studied, and these therapies should be used only in conjunction 
with close serologic and clinical follow-up. Patients with penicillin allergy whose 
compliance with therapy or follow-up cannot be ensured should be desensitized and treated 
with penicillin (See Management of Persons Who Have a History of Penicillin Allergy).
Neurosyphilis Among Persons with HIV Infection—All persons with HIV infection 
and syphilis should receive a careful neurologic examination. Persons with HIV infection 
and neurosyphilis should be treated according to the recommendations for HIV-negative 
persons with neurosyphilis (See Neurosyphilis).
Follow Up: Persons with HIV infection and neurosyphilis should be managed according to 
the recommendations for HIV-negative persons with neurosyphilis (see Neurosyphilis). 
Limited data suggest that changes in CSF parameters might occur more slowly in persons 
with HIV infection, especially those with more advanced immunosuppression (424,434).
Management of Sex Partners: See Syphilis, Management of Sex Partners.
Special Considerations
Penicillin Allergy: Persons with HIV infection who are penicillin-allergic and have 
neurosyphilis should be managed according to the recommendations for penicillin-allergic, 
HIV-negative patients with neurosyphilis (See Neurosyphilis). Several small observational 
studies conducted in persons with HIV infection with neurosyphilis suggest that ceftriaxone 
1–2 g IV daily for 10–14 days might be effective as an alternate agent (438–440). The 
possibility of cross-sensitivity between ceftriaxone and penicillin exists, but the risk of 
penicillin cross-reactivity between third-generation cephalosporins is negligible (428–431) 
(see Management of Persons Who Have a History of Penicillin Allergy). If concern exists 
regarding the safety of ceftriaxone for a person with HIV infection and neurosyphilis, skin 
testing should be performed (if available) to confirm penicillin allergy and, if necessary, 
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penicillin desensitization in consultation with a specialist is recommended. Other regimens 
have not been adequately evaluated for treatment of neurosyphilis.
Syphilis During Pregnancy
All women should be screened serologically for syphilis early in pregnancy (106). Most 
states mandate screening at the first prenatal visit for all women (441). In populations in 
which receipt of prenatal care is not optimal, RPR test screening and treatment (if the RPR 
test is reactive) should be performed at the time pregnancy is confirmed (442). Antepartum 
screening by nontreponemal antibody testing is typical, but treponemal antibody testing is 
being used in some settings. Pregnant women with reactive treponemal screening tests 
should have additional quantitative nontreponemal testing, because titers are essential for 
monitoring treatment response. For communities and populations in which the prevalence of 
syphilis is high and for women at high risk for infection, serologic testing should also be 
performed twice during the third trimester: once at 28–32 weeks’ gestation and again at 
delivery. Any woman who has a fetal death after 20 weeks’ gestation should be tested for 
syphilis. No mother or neonate should leave the hospital without maternal serologic status 
having been documented at least once during pregnancy, and if the mother is considered 
high risk, documented at delivery.
Diagnostic Considerations—Seropositive pregnant women should be considered 
infected unless an adequate treatment history is documented clearly in the medical records 
and sequential serologic antibody titers have declined appropriately for the stage of syphilis. 
In general, the risk for antepartum fetal infection or congenital syphilis at delivery is related 
to the stage of syphilis during pregnancy, with the highest risk occurring with the primary 
and secondary stage. Quantitative maternal nontreponemal titer, especially if >1:8, might be 
a marker of early infection and bacteremia. However, risk for fetal infection is still 
significant in pregnant women with late latent syphilis and low titers. Pregnant women with 
stable, serofast low antibody titers who have previously been treated for syphilis might not 
require additional treatment; however, rising or persistently high antibody titers might 
indicate reinfection or treatment failure, and treatment should be considered.
If a treponemal test (e.g., EIA or CIA) is used for antepartum syphilis screening, all positive 
EIA/CIA tests should be reflexed to a quantitative nontreponemal test (RPR or VDRL). If 
the nontreponemal test is negative, then the results are considered discrepant and a second 
treponemal test (TP-PA preferred) should be performed, preferably on the same specimen. If 
the second treponemal test is positive, current or past syphilis infection can be confirmed. 
For women with a history of adequately treated syphilis who do not have ongoing risk, no 
further treatment is necessary. Women without a history of treatment should be staged and 
treated accordingly with a recommended penicillin regimen. If the second treponemal test is 
negative, the positive EIA/CIA is more likely to represent a false-positive test result in low-
risk women with no history of treated syphilis (400). If the woman is at low risk for syphilis, 
lacks signs or symptoms of primary syphilis, has a partner with no clinical or serologic 
evidence of syphilis, and is likely to follow up, repeat serologic testing within 4 weeks can 
be considered to determine whether the EIA/CIA remains positive or if the RPR/VDRL or 
the TP-PA becomes positive. If both the RPR and TP-PA remain negative, no further 
Workowski and Bolan Page 69
MMWR Recomm Rep. Author manuscript; available in PMC 2018 April 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
treatment is necessary. If follow-up is not possible, women without a history of treated 
syphilis should be treated according to the stage of syphilis.
Treatment—Penicillin G is the only known effective antimicrobial for preventing maternal 
transmission to the fetus and treating fetal infection (443). Evidence is insufficient to 
determine optimal, recommended penicillin regimens (444).
Recommended Regimen
Pregnant women should be treated with the penicillin regimen appropriate for their stage of infection.
Other Management Considerations
• Some evidence suggests that additional therapy is beneficial for pregnant 
women. For women who have primary, secondary, or early latent syphilis, a 
second dose of benzathine penicillin 2.4 million units IM can be administered 1 
week after the initial dose (445–447).
• When syphilis is diagnosed during the second half of pregnancy, management 
should include a sonographic fetal evaluation for congenital syphilis. However, 
this evaluation should not delay therapy. Sonographic signs of fetal or placental 
syphilis (i.e., hepatomegaly, ascites, hydrops, fetal anemia, or a thickened 
placenta) indicate a greater risk for fetal treatment failure (448); cases 
accompanied by these signs should be managed in consultation with obstetric 
specialists. Evidence is insufficient to recommend specific regimens for these 
situations.
• Women treated for syphilis during the second half of pregnancy are at risk for 
premature labor and/or fetal distress if the treatment precipitates the Jarisch-
Herxheimer reaction (449). These women should be advised to seek obstetric 
attention after treatment if they notice any fever, contractions, or decrease in fetal 
movements. Stillbirth is a rare complication of treatment, but concern for this 
complication should not delay necessary treatment. No data are available to 
suggest that corticosteroid treatment alters the risk for treatment-related 
complications in pregnancy.
• Missed doses are not acceptable for pregnant women receiving therapy for late 
latent syphilis (423). Pregnant women who miss any dose of therapy must repeat 
the full course of therapy.
• All women who have syphilis should be offered testing for HIV infection.
Follow-Up—Coordinated prenatal care and treatment are vital. At a minimum, serologic 
titers should be repeated at 28–32 weeks’ gestation and at delivery. Serologic titers can be 
checked monthly in women at high risk for reinfection or in geographic areas in which the 
prevalence of syphilis is high. Providers should ensure that the clinical and antibody 
responses are appropriate for the patient’s stage of disease, although most women will 
deliver before their serologic response to treatment can be assessed definitively. Inadequate 
maternal treatment is likely if delivery occurs within 30 days of therapy, clinical signs of 
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infection are present at delivery, or the maternal antibody titer at delivery is fourfold higher 
than the pretreatment titer.
Management of Sex Partners—See Syphilis, Management of Sex Partners.
Special Considerations
Penicillin Allergy: No proven alternatives to penicillin are available for treatment of 
syphilis during pregnancy. Pregnant women who have a history of penicillin allergy should 
be desensitized and treated with penicillin. Skin testing or oral graded penicillin dose 
challenge might be helpful in identifying women at risk for acute allergic reactions (see 
Management of Persons Who Have a History of Penicillin Allergy).
Tetracycline and doxycycline are contraindicated in the second and third trimester of 
pregnancy (317) Erythromycin and azithromycin should not be used, because neither 
reliably cures maternal infection or treats an infected fetus (444). Data are insufficient to 
recommend ceftriaxone for treatment of maternal infection and prevention of congenital 
syphilis.
HIV Infection: Placental inflammation from congenital infection might increase the risk for 
perinatal transmission of HIV. All women with HIV infection should be evaluated for 
syphilis and receive a penicillin regimen appropriate for the stage of infection. Data are 
insufficient to recommend any alternative regimens for pregnant women with HIV infection 
(see Syphilis Among Persons with HIV infection).
Congenital Syphilis
Effective prevention and detection of congenital syphilis depends on the identification of 
syphilis in pregnant women and, therefore, on the routine serologic screening of pregnant 
women during the first prenatal visit. Additional testing at 28 weeks’ gestation and again at 
delivery is warranted for women who are at increased risk or live in communities with 
increased prevalence of syphilis infection (442,450). Moreover, as part of the management 
of pregnant women who have syphilis, information concerning ongoing risk behaviors and 
treatment of sex partners should be obtained to assess the risk for reinfection. Routine 
screening of newborn sera or umbilical cord blood is not recommended, as diagnosis at this 
time does not prevent symptomatic congenital syphilis in some newborns. No mother or 
newborn infant should leave the hospital without maternal serologic status having been 
documented at least once during pregnancy, and preferably again at delivery if at risk.
Evaluation and Treatment of Neonates (Infants Aged <30 Days)—The diagnosis 
of congenital syphilis can be difficult, as maternal nontreponemal and treponemal IgG 
antibodies can be transferred through the placenta to the fetus, complicating the 
interpretation of reactive serologic tests for syphilis in neonates. Therefore, treatment 
decisions frequently must be made on the basis of 1) identification of syphilis in the mother; 
2) adequacy of maternal treatment; 3) presence of clinical, laboratory, or radiographic 
evidence of syphilis in the neonate; and 4) comparison of maternal (at delivery) and neonatal 
nontreponemal serologic titers using the same test, preferably conducted by the same 
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laboratory. Any neonate at risk for congenital syphilis should receive a full evaluation and 
testing for HIV infection.
All neonates born to mothers who have reactive nontreponemal and treponemal test results 
should be evaluated with a quantitative nontreponemal serologic test (RPR or VDRL) 
performed on the neonate’s serum, because umbilical cord blood can become contaminated 
with maternal blood and yield a false-positive result, and Wharton’s jelly within the 
umbilical cord can yield a false-negative result. Conducting a treponemal test (i.e., TP-PA, 
FTA-ABS, EIA, or CIA) on neonatal serum is not recommended because it is difficult to 
interpret. No commercially available immunoglobulin (IgM) test can be recommended.
All neonates born to women who have reactive serologic tests for syphilis should be 
examined thoroughly for evidence of congenital syphilis (e.g., nonimmune hydrops, 
jaundice, hepatosplenomegaly, rhinitis, skin rash, and pseudoparalysis of an extremity). 
Pathologic examination of the placenta or umbilical cord using specific staining (e.g., silver) 
or a T. pallidum PCR test using a CLIA-validated test should be considered; DFA-TP 
reagents are not available. Darkfield microscopic examination or PCR testing of suspicious 
lesions or body fluids (e.g., bullous rash and nasal discharge) also should be performed. In 
addition to these tests, for stillborn infants, skeletal survey demonstrating typical osseous 
lesions might aid in the diagnosis of congenital syphilis.
The following scenarios describe the congenital syphilis evaluation and treatment of 
neonates born to women who have reactive serologic tests for syphilis during pregnancy. 
Maternal history of infection with T. pallidum and treatment for syphilis must be considered 
when evaluating and treating the neonate for congenital syphilis in most scenarios, except 
when congenital syphilis is proven or highly probable (See Scenario 1).
Scenario 1: Proven or highly probable congenital syphilis: Any neonate with:
1. an abnormal physical examination that is consistent with congenital syphilis;
OR
2. a serum quantitative nontreponemal serologic titer that is fourfold higher than the 
mother’s titer;¶
OR
3. a positive darkfield test or PCR of lesions or body fluid(s).
Recommended Evaluation
• CSF analysis for VDRL, cell count, and protein**
• Complete blood count (CBC) and differential and platelet count
¶The absence of a fourfold or greater titer for a neonate does not exclude congenital syphilis.
**CSF test results obtained during the neonatal period can be difficult to interpret; normal values differ by gestational age and are 
higher in preterm infants. Values as high as 25 white blood cells (WBCs)/mm3 and/or protein of 150 mg/dL might occur among 
normal neonates; lower values (i.e., 5 WBCs/mm3 and protein of 40 mg/dL) might be considered the upper limits of normal. Other 
causes of elevated values should be considered when an infant is being evaluated for congenital syphilis.
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• Other tests as clinically indicated (e.g., long-bone radiographs, chest radiograph, 
liver-function tests, neuroimaging, ophthalmologic examination, and auditory 
brain stem response).
Recommended Regimens
Aqueous crystalline penicillin G 100,000–150,000 units/kg/day, administered as 50,000 units/kg/dose IV every 12 
hours during the first 7 days of life and every 8 hours thereafter for a total of 10 days
 OR
Procaine penicillin G 50,000 units/kg/dose IM in a single daily dose for 10 days
If more than 1 day of therapy is missed, the entire course should be restarted. Data are 
insufficient regarding the use of other antimicrobial agents (e.g., ampicillin). When possible, 
a full 10-day course of penicillin is preferred, even if ampicillin was initially provided for 
possible sepsis. The use of agents other than penicillin requires close serologic follow-up to 
assess adequacy of therapy.
Scenario 2: Possible Congenital Syphilis: Any neonate who has a normal physical 
examination and a serum quantitative nontreponemal serologic titer equal to or less than 
fourfold the maternal titer and one of the following:
1. mother was not treated, inadequately treated, or has no documentation of having 
received treatment;
OR
2. mother was treated with erythromycin or a regimen other than those 
recommended in these guidelines (i.e., a nonpenicillin G regimen);††
OR
3. mother received recommended treatment <4 weeks before delivery.
Recommended Evaluation
• CSF analysis for VDRL, cell count, and protein**
• CBC, differential, and platelet count
• Long-bone radiographs
A complete evaluation is not necessary if 10 days of parenteral therapy is administered, 
although such evaluations might be useful. For instance, a lumbar puncture might document 
CSF abnormalities that would prompt close follow-up. Other tests (e.g., CBC, platelet count, 
and bone radiographs) can be performed to further support a diagnosis of congenital 
syphilis.
Recommended Regimens
Aqueous crystalline penicillin G 100,000–150,000 units/kg/day, administered as 50,000 units/kg/dose IV every 12 
hours during the first 7 days of life and every 8 hours thereafter for a total of 10 days
††A women treated with a regimen other than recommended in these guidelines should be considered untreated.
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 OR
Procaine penicillin G 50,000 units/kg/dose IM in a single daily dose for 10 days
 OR
Benzathine penicillin G 50,000 units/kg/dose IM in a single dose
Before using the single-dose benzathine penicillin G regimen, the complete evaluation (i.e., 
CSF examination, long-bone radiographs, and CBC with platelets) must be normal, and 
follow-up must be certain. If any part of the infant’s evaluation is abnormal or not 
performed, if the CSF analysis is uninterpretable because of contamination with blood, or if 
follow-up is uncertain, a 10-day course of penicillin G is required. If the neonate’s 
nontreponemal test is nonreactive and the provider determines that the mother’s risk of 
untreated syphilis is low, treatment of the neonate with a single IM dose of benzathine 
penicillin G 50,000 units/kg for possible incubating syphilis can be considered without an 
evaluation.
Neonates born to mothers with untreated early syphilis at the time of delivery are at 
increased risk for congenital syphilis, and the 10-day course of penicillin G may be 
considered even if the complete evaluation is normal and follow-up is certain.
Scenario 3: Congenital Syphilis less likely: Any neonate who has a normal physical 
examination and a serum quantitative nontreponemal serologic titer equal to or less than 
fourfold the maternal titer and both of the following are true:
1. mother was treated during pregnancy, treatment was appropriate for the stage of 
infection, and treatment was administered >4 weeks before delivery and
2. mother has no evidence of reinfection or relapse.
Recommended Evaluation: No evaluation is recommended.
Recommended Regimen
Benzathine penicillin G 50,000 units/kg/dose IM in a single dose*
*Another approach involves not treating the infant, but rather providing close serologic follow-up every 2–3 months for 
6 months for infants whose mother’s nontreponemal titers decreased at least fourfold after appropriate therapy for early 
syphilis or remained stable for low-titer, latent syphilis (e.g., VDRL <1:2; RPR <1:4).
Scenario 4: Congenital Syphilis unlikely: Any neonate who has a normal physical 
examination and a serum quantitative nontreponemal serologic titer equal to or less than 
fourfold the maternal titer and both of the following are true:
mother’s treatment was adequate before pregnancy and
mother’s nontreponemal serologic titer remained low and stable (i.e., serofast) before 
and during pregnancy and at delivery (VDRL <1:2; RPR <1:4).
Recommended Evaluation: No evaluation is recommended.
Recommended Regimen
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No treatment is required, but infants with reactive nontreponemal tests should be followed serologically to ensure the 
nontreponemal test returns to negative (see Follow-Up). Benzathine penicillin G 50,000 units/kg as a single IM injection 
might be considered, particularly if follow-up is uncertain and the neonate has a reactive nontreponemal test.
Follow-Up—All neonates with reactive nontreponemal tests should receive careful follow-
up examinations and serologic testing (i.e., a nontreponemal test) every 2–3 months until the 
test becomes nonreactive. In the neonate who was not treated because congenital syphilis 
was considered less likely or unlikely, nontreponemal antibody titers should decline by age 3 
months and be nonreactive by age 6 months, indicating that the reactive test result was 
caused by passive transfer of maternal IgG antibody. At 6 months, if the nontreponemal test 
is nonreactive, no further evaluation or treatment is needed; if the nontreponemal test is still 
reactive, the infant is likely to be infected and should be treated. Treated neonates that 
exhibit persistent nontreponemal test titers by 6–12 months should be re-evaluated through 
CSF examination and managed in consultation with an expert. Retreatment with a 10-day 
course of a penicillin G regimen may be indicated. Neonates with a negative nontreponemal 
test at birth and whose mothers were seroreactive at delivery should be retested at 3 months 
to rule out serologically negative incubating congenital syphilis at the time of birth. 
Treponemal tests should not be used to evaluate treatment response because the results are 
qualitative and passive transfer of maternal IgG treponemal antibody might persist for at 
least 15 months.
Neonates whose initial CSF evaluations are abnormal should undergo a repeat lumbar 
puncture approximately every 6 months until the results are normal. A reactive CSF 
Venereal Disease Research Laboratory (VDRL) test or abnormal CSF indices that persist 
and cannot be attributed to other ongoing illness requires retreatment for possible 
neurosyphilis and should be managed in consultation with an expert.
Special Considerations
Penicillin Allergy: Infants and children who require treatment for congenital syphilis but 
who have a history of penicillin allergy or develop an allergic reaction presumed secondary 
to penicillin should be desensitized and then treated with penicillin (see Management of 
Persons with a History of Penicillin Allergy). Skin testing remains unavailable for infants 
and children because the procedure has not been standardized for this age group. Data are 
insufficient regarding the use of other antimicrobial agents (e.g., ceftriaxone) for congenital 
syphilis in infants and children. If a nonpenicillin G agent is used, close clinical, serologic, 
and CSF follow-up is required in consultation with an expert.
Penicillin Shortage: During periods when the availability of aqueous crystalline penicillin 
G is compromised, the following is recommended (see http://www.cdc.gov/std/treatment/
drugnotices/penicilling.htm).
1. For neonates with clinical evidence of congenital syphilis (Scenario 1), check 
local sources for aqueous crystalline penicillin G (potassium or sodium). If IV 
penicillin G is limited, substitute some or all daily doses with procaine penicillin 
G (50,000 U/kg/dose IM a day in a single daily dose for 10 days).
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If aqueous or procaine penicillin G is not available, ceftriaxone (in doses 
appropriate for birthweight) can be considered with careful clinical and serologic 
follow-up and in consultation with an expert, as evidence is insufficient to 
support the use of ceftriaxone for the treatment of congenital syphilis. 
Management might include a repeat CSF examination at age 6 months if the 
initial examination was abnormal. Ceftriaxone must be used with caution in 
infants with jaundice.
2. For neonates without any clinical evidence of congenital syphilis (Scenario 2 and 
Scenario 3), use
a. procaine penicillin G, 50,000 U/kg/dose IM a day in a single dose for 
10 days
OR
b. benzathine penicillin G, 50,000 U/kg IM as a single dose.
If any part of the evaluation for congenital syphilis is abnormal or was not 
performed, CSF examination is not interpretable, or follow-up is uncertain, 
procaine penicillin G is recommended. A single dose of ceftriaxone is inadequate 
therapy.
3. For premature infants who have no clinical evidence of congenital syphilis 
(Scenario 2 and Scenario 3) and might not tolerate IM injections because of 
decreased muscle mass, IV ceftriaxone can be considered with careful clinical 
and serologic follow-up and in consultation with an expert. Ceftriaxone dosing 
must be adjusted according to birthweight.
HIV Infection: Evidence is insufficient to determine whether neonates who have congenital 
syphilis and HIV or whose mothers have HIV infection require different therapy or clinical 
management than is recommended for all neonates. All neonates with congenital syphilis 
and HIV infection should be managed similarly as neonates with congenital syphilis who do 
not have HIV infection.
Evaluation and Treatment of Infants and Children with Congenital Syphilis—
Infants and children aged ≥1 month who are identified as having reactive serologic tests for 
syphilis should be examined thoroughly and have maternal serology and records reviewed to 
assess whether they have congenital or acquired syphilis (see Primary and Secondary 
Syphilis and Latent Syphilis, Sexual Assault or Abuse of Children). Any infant or child at 
risk for congenital syphilis should receive a full evaluation and testing for HIV infection.
Recommended Evaluation
• CSF analysis for VDRL, cell count, and protein
• CBC, differential, and platelet count
• Other tests as clinically indicated (e.g., long-bone radiographs, chest radiograph, 
liver function tests, abdominal ultrasound, ophthalmologic examination, 
neuroimaging, and auditory brain-stem response)
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Recommended Regimen
Aqueous crystalline penicillin G 200,000–300,000 units/kg/day IV, administered as 50,000 units/kg every 4–6 hours 
for 10 days
If the infant or child has no clinical manifestations of congenital syphilis and the evaluation 
(including the CSF examination) is normal, treatment with up to 3 weekly doses of 
benzathine penicillin G, 50,000 U/kg IM can be considered. A single dose of benzathine 
penicillin G 50,000 units/kg IM up to the adult dose of 2.4 million units in a single dose can 
be considered after the 10-day course of IV aqueous penicillin to provide more comparable 
duration of treatment in those who have no clinical manifestations and normal CSF. All of 
the above treatment regimens also would be adequate for children who might have other 
treponemal infections.
Follow-Up: Careful follow-up examinations and serologic testing (i.e., a nontreponemal 
test) of infants and children treated for congenital syphilis after the neonatal period (30 days 
of age) should be performed every 3 months until the test becomes nonreactive or the titer 
has decreased fourfold. The serologic response after therapy might be slower for infants and 
children than neonates. If these titers increase at any point for more than 2 weeks or do not 
decrease fourfold after 12–18 months, the infant or child should be evaluated (e.g., through 
CSF examination), treated with a 10-day course of parenteral penicillin G, and managed in 
consultation with an expert. Treponemal tests should not be used to evaluate treatment 
response, because the results are qualitative and persist after treatment; further, passive 
transfer of maternal IgG treponemal antibody might persist for at least 15 months after 
delivery.
Infants or children whose initial CSF evaluations are abnormal should undergo a repeat 
lumbar puncture approximately every 6 months until the results are normal. After 2 years of 
follow-up, a reactive CSF VDRL test or abnormal CSF indices that persists and cannot be 
attributed to other ongoing illness requires retreatment for possible neurosyphilis and should 
be managed in consultation with an expert.
Special Considerations
Penicillin Allergy: Infants and children who require treatment for congenital syphilis but 
who have a history of penicillin allergy or develop an allergic reaction presumed secondary 
to penicillin should be desensitized and treated with penicillin (see Management of Persons 
with a History of Penicillin Allergy). Skin testing remains unavailable for infants and 
children because the procedure has not been standardized for this age group. Data are 
insufficient regarding the use of other antimicrobial agents (e.g., ceftriaxone) for congenital 
syphilis in infants and children. If a nonpenicillin G agent is used, close clinical, serologic, 
and CSF follow-up is required in consultation with an expert.
Penicillin Shortage: During periods when the availability of penicillin G is compromised, 
management options are similar to options for the neonate (see Evaluation and treatment of 
infants during the first month of life).
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1. For infants and children with clinical evidence of congenital syphilis, procaine 
penicillin G (50,000 U/kg/dose IM up to the adult dose of 2.4 million units a day 
in a single daily dose for 10 days) is recommended. A single dose of benzathine 
penicillin G 50,000 units/kg IM up to the adult dose of 2.4 million units in a 
single dose can be considered after the 10-day course of procaine penicillin. If 
procaine or benzathine penicillin G is not available, ceftriaxone (in doses 
appropriate for age and weight) can be considered with careful clinical and 
serologic follow-up. Infants and children receiving ceftriaxone should be 
managed in consultation with an expert, as evidence is insufcient to support the 
use of ceftriaxone for the treatment of congenital syphilis in infants or children. 
For infants aged ≥30 days, use 75 mg/kg IV/IM of ceftriaxone a day in a single 
daily dose for 10–14 days (dose adjustment might be necessary based on current 
weight). For children, the dose should be 100 mg/kg of ceftriaxone a day in a 
single daily dose.
2. For infants and children without any clinical evidence of infection (see Scenario 
2 and Scenario 3), use
a. procaine penicillin G, 50,000 U/kg/dose IM a day in a single dose for 
10 days or
b. benzathine penicillin G, 50,000 U/kg IM as a single dose.
If any part of the evaluation for congenital syphilis is abnormal or not performed, CSF 
examination is not interpretable, or follow-up is uncertain, procaine penicillin G is 
recommended.
HIV Infection: Evidence is insufficient to determine whether infants and children who have 
congenital syphilis and HIV or whose mothers have HIV infection require different therapy 
or clinical management than is recommended for all infants and children. All infants and 
children with congenital syphilis and HIV infection should be managed like infants and 
children without HIV infection.
Management of Persons Who Have a History of Penicillin Allergy
No proven alternatives to penicillin are available for treating neurosyphilis, congenital 
syphilis, or syphilis in pregnant women. Penicillin also is recommended, whenever possible, 
for persons with HIV infection. The prevalence of reported penicillin allergy in the United 
States is about 8%–10% (451–453) and might be higher in hospitalized persons (454). The 
prevalence of reported penicillin allergy in developing countries is unknown; however, 
limited data suggest that penicillin is one of the most frequently reported allergies in some 
developing countries (455,456). Of persons reporting penicillin allergy, 10%–15% have a 
positive skin test suggestive of a penicillin allergy; these persons are at risk for an 
immunoglobulin E (IgE)-mediated allergic response to penicillin such as urticaria, 
angioedema, or anaphylaxis (i.e., upper airway obstruction, bronchospasm, or hypotension) 
(428–430,457,458). Re-administration of penicillin to patients with a history of IgE-
mediated hypersensitivity reactions can cause severe, immediate reactions. Because 
anaphylactic reactions to penicillin can be fatal, every effort should be made to avoid 
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administering penicillin to penicillin-allergic persons, unless they undergo induction of drug 
tolerance (also referred to as “desensitization”) to temporarily eliminate IgE-mediated 
hypersensitivity. However, many persons with a reported history of penicillin allergy likely 
have had other types of adverse drug reactions or have lost their sensitivity to penicillin over 
time and can safely be treated with penicillin.
Penicillin skin testing with the major and minor determinants of penicillin can reliably 
identify persons at high risk for IgE-mediated reactions to penicillin (458,459). Although the 
testing reagents are easily generated, only the major determinant (benzylpenicilloyl poly-L-
lysine [Pre-Pen]) and penicillin G have been available commercially. These two tests 
identify an estimated 90%–99% of the allergic patients. However, because skin testing 
without the minor determinants would still fail to identify 1%–10% of allergic persons and 
because serious or fatal reactions can occur among these minor-determinant–positive 
persons, caution should be exercised when the full battery of skin-test reagents is not 
available (Box 2) (457–460). Manufacturers are working on a minor determinant mixture, 
but at the time of publication, no such product has been cleared by FDA for use in the 
United States. Penicillin skin testing has been used in a variety of settings to improve 
antibiotic use (453,461–463).
Some studies have reported cross-reactivity rates as high as 10% among persons with a 
history of penicillin allergy who take cephalosporins. However, more recent studies indicate 
a lower rate (<2.5%) of cross reactivity between these drugs (428–431,464). Risk is highest 
with first-generation cephalosporins and cephalosporins that have similar R-group side 
chains to specific penicillins (465,466). The risk for penicillin cross-reactivity between most 
second-generation (cefoxitin) and all third generation cephalosporins (cefixime and 
ceftriaxone) is negligible (428–431); cefoxitin, cefixime, and ceftriaxone do not have an R 
group side chain similar to penicillin G.
Recommendations
Persons with a history of severe non-IgE-mediated reactions (e.g., Stevens-Johnson 
syndrome, toxic epidermal necrolysis, interstitial nephritis, and hemolytic anemia) are not 
candidates for skin testing or challenge and should avoid penicillins indefinitely. If the full 
battery of skin-test reagents is available, including both major and minor determinants (see 
Penicillin Allergy Skin Testing), persons who report a history of penicillin reaction and who 
are skin-test negative can receive conventional penicillin therapy. Persons with positive skin 
test results should be desensitized before initiating treatment.
If the full battery of skin-test reagents, including the minor determinants, is not available, 
skin testing should be conducted using the major determinant (Pre-Pen) and penicillin G. 
Those persons who have positive test results should be desensitized. For persons with 
negative skin tests, a subsequent observed challenge to the penicillin of choice is 
recommended. In addition, for persons with a history of severe or recent suspected IgE-
mediated reactions to penicillin with negative skin testing, the penicillin of choice should be 
given by graded challenge. If the major determinant is not available for skin testing, all 
persons with a history suggesting IgE-mediated reactions to penicillin (e.g., anaphylaxis, 
angioedema, bronchospasm, or urticaria) should be desensitized in a hospital setting. In 
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persons with reactions not likely to be IgE-mediated, outpatient-monitored graded 
challenges can be considered.
Penicillin Allergy Skin Testing—Persons at high risk for anaphylaxis, including those 
who 1) have a history of penicillin-related anaphylaxis or other IgE-mediated reactions, 
asthma, or other diseases that would make anaphylaxis more dangerous or 2) are being 
treated with beta-adrenergic blocking agents should be tested with 100-fold dilutions of the 
full-strength skin-test reagents before being tested with full-strength reagents. In these 
situations, testing should be performed in a monitored setting in which treatment for an 
anaphylactic reaction is available. If possible, antihistamines (e.g., chlorpheniramine 
maleate, fexofenadine, diphenhydramine HCL, and hydroxyzine) should not have been taken 
within the 5 days before skin testing.
Procedures: Dilute the antigens in saline either 100-fold for preliminary testing (if the 
patient has had a IgE-mediated reaction to penicillin) or 10-fold (if the patient has had 
another type of immediate, generalized reaction to penicillin within the preceding year). Pre-
Pen is provided full-strength (6 × 10–5 meq penicilloyl) in a single dose ampoule. Penicillin 
G is diluted to 10,000 IU/ml in saline and aliquoted in sterile vials that remain stable for at 
least 6 months if frozen.
Epicutaneous (Prick) Tests: Duplicate drops of skin-test reagent are placed on the volar 
surface of the forearm. The underlying epidermis is pierced with a 26-gauge needle without 
drawing blood. An epicutaneous test is positive if the average wheal diameter after 15 
minutes is ≥4 mm larger than that of negative controls; otherwise, the test is negative. The 
histamine controls should be positive to ensure that results are not falsely negative because 
of the effect of antihistaminic drugs.
Intradermal Test: If epicutaneous tests are negative, duplicate 0.02-mL intradermal 
injections of negative control and antigen solutions are made into the volar surface of the 
forearm by using a 26-or 27-gauge needle on a syringe. The margins of the wheals induced 
by the injections should be marked with a ball point pen. An intradermal test is positive if 
the average wheal diameter 15 minutes after injection is >2 mm larger than the initial wheal 
size and also is >2 mm larger than the negative histamine controls. Otherwise, the tests are 
negative. If the duplicates are discordant, a second set of duplicate tests can be used to 
resolve the ambiguity.
Desensitization: Persons who have a positive skin test to one of the penicillin determinants 
can be desensitized (Table 1). This is a straightforward, relatively safe procedure that can be 
performed orally or intravenously. Modified protocols might be considered based on an 
individual’s symptoms, drug of choice, and route of administration (467–469). Although the 
two approaches have not been compared, oral desensitization is regarded as safer and easier 
to perform. Desensitization should occur in a hospital setting because serious IgE-mediated 
allergic reactions can occur; the procedure can usually be completed in approximately 4–12 
hours, after which time the first dose of penicillin is administered. After desensitization, 
penicillin should be maintained continuously for the duration of the course of therapy. Once 
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the course is completed, if penicillin is required in the future, the desensitization procedure 
should be repeated.
Diseases Characterized by Urethritis and Cervicitis
Urethritis
Urethritis, as characterized by urethral inflammation, can result from infectious and 
noninfectious conditions. Symptoms, if present, include dysuria; urethral pruritis; and 
mucoid, mucopurulent, or purulent discharge. Signs of urethral discharge on examination 
can also be present in persons without symptoms. Although N. gonorrhoeae and C. 
trachomatis are well established as clinically important infectious causes of urethritis, 
Mycoplasma genitalium has also been associated with urethritis and, less commonly, 
prostatitis (470–474). If point-of-care diagnostic tools (e.g., Gram, methylene blue [MB] or 
gentian violet [GV] stain microscopy, first void urine with microscopy, and leukocyte 
esterase) are not available, drug regimens effective against both gonorrhea and chlamydia 
should be administered. Further testing to determine the specific etiology is recommended to 
prevent complications, re-infection, and transmission because a specific diagnosis might 
improve treatment compliance, delivery of risk reduction interventions, and partner 
notification. Both chlamydia and gonorrhea are reportable to health departments. NAATs are 
preferred for the detection of C. trachomatis and N. gonorrhoeae, and urine is the preferred 
specimen in males (394). NAAT-based tests for the diagnosis of T. vaginalis in men have not 
been cleared by FDA; however, some laboratories have performed the CLIA-compliant 
validation studies (475) needed to provide such testing.
Etiology—Several organisms can cause infectious urethritis. The presence of Gram-
negative intracellular diplococci (GNID) or MB/GV purple intracellular diplococci on 
urethral smear is indicative of presumed gonorrhea infection, which is frequently 
accompanied by chlamydial infection. NGU, which is diagnosed when microscopy of 
urethral secretions indicates inflammation without GNID or MB/GV purple intracellular 
diplococci, is caused by C. trachomatis in 15%–40% of cases; however, prevalence varies by 
age group, with a lower burden of disease occurring among older men (476). Documentation 
of chlamydial infection as the etiology of NGU is essential because of the need for partner 
referral for evaluation and treatment to prevent complications of chlamydia, especially in 
female partners. Complications of C. trachomatis-associated NGU among males include 
epididymitis, prostatitis, and reactive arthritis.
M. genitalium, which can be sexually transmitted, is associated with symptoms of urethritis 
as well as urethral inflammation and accounts for 15%–25% of NGU cases in the United 
States (470–473). However, FDA-cleared diagnostic tests for M. genitalium are not 
available.
T. vaginalis can cause NGU in heterosexual men, but the prevalence varies substantially by 
region of the United States and within specific subpopulations. In some instances, NGU can 
be acquired by fellatio (i.e., oral penile contact), sometimes because of specific pathogens 
such as HSV, Epstein Barr Virus, and adenovirus (476); data supporting other Mycoplasma 
species and Ureaplasma as etiologic agents are inconsistent. Diagnostic and treatment 
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procedures for these organisms are reserved for situations in which these infections are 
suspected (e.g., contact with trichomoniasis, urethral lesions, or severe dysuria and meatitis, 
which might suggest genital herpes) or when NGU is not responsive to recommended 
therapy. Enteric bacteria have been identified as an uncommon cause of NGU and might be 
associated with insertive anal intercourse (476). The importance of NGU not caused by 
defined pathogens is uncertain; neither complications (e.g., urethral stricture and 
epididymitis) nor adverse outcomes in sex partners have been identified in these cases.
Diagnostic Considerations—Clinicians should attempt to obtain objective evidence of 
urethral inflammation. However, if point-of-care diagnostic tests (e.g., Gram, MB or GV, or 
Gram stain microscopy) are not available, all men should be tested by NAAT and treated 
with drug regimens effective against both gonorrhea and chlamydia.
In the setting of compatible symptoms, urethritis can be documented on the basis of any of 
the following signs or laboratory tests:
• Mucoid, mucopurulent, or purulent discharge on examination.
• Gram stain of urethral secretions demonstrating ≥2 WBC per oil immersion field 
(477). The Gram stain is a point-of-care diagnostic test for evaluating urethritis 
that is highly sensitive and specific for documenting both urethritis and the 
presence or absence of gonococcal infection. MB/GV stain of urethral secretions 
is an alternative point-of-care diagnostic test with performance characteristics 
similar to Gram stain; thus, the cutoff number for WBC per oil immersion field 
should be the same (478). Presumed gonococcal infection is established by 
documenting the presence of WBC containing GNID in Gram stain or 
intracellular purple diplococci in MB/GV smears; men should be presumptively 
treated and managed accordingly for gonorrhea (GC) infection (see Gonococcal 
Infections).
• Positive leukocyte esterase test on first-void urine or microscopic examination of 
sediment from a spun first-void urine demonstrating ≥10 WBC per high power 
field.
In settings where Gram stain or MB/GV smear is available, men who meet criteria for 
urethritis (microscopy of urethral secretions with ≥2 WBC per oil immersion field and no 
intracellular gram negative or purple diplococci) should receive NAAT testing for C. 
trachomatis and N. gonorrhoeae and can be managed as recommended (see Nongonococcal 
Urethritis). Men evaluated in settings in which Gram stain or MB/GV smear is not available 
(i.e., gonococcal infection cannot be ruled out at the point of care) who meet at least one 
criterion for urethritis (i.e., urethral discharge, positive LE test on first void urine, or 
microscopic exam of first void urine sediment with ≥10 WBC per hfp) should be tested by 
NAAT and treated with regimens effective against gonorrhea and chlamydia.
If symptoms are present but no evidence of urethral inflammation is present, NAAT testing 
for C. trachomatis and N. gonorrhoeae might identify infections (479). If the results 
demonstrate infection with these pathogens, the appropriate treatment should be given and 
sex partners referred for evaluation and treatment. If none of these clinical criteria are 
Workowski and Bolan Page 82
MMWR Recomm Rep. Author manuscript; available in PMC 2018 April 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
present, empiric treatment of symptomatic men is recommended only for those men at high 
risk for infection who are unlikely to return for a follow-up evaluation or test results. Such 
men should be treated with drug regimens effective against gonorrhea and chlamydia.
Nongonococcal Urethritis
Diagnostic Considerations—NGU is a nonspecific diagnosis that can have many 
infectious etiologies. NGU is confirmed in symptomatic men when staining of urethral 
secretions indicates inflammation without Gram negative or purple diplococci. All men who 
have confirmed NGU should be tested for chlamydia and gonorrhea even if point-of-care 
tests are negative for evidence of GC. NAATs for chlamydia and gonorrhea are 
recommended because of their high sensitivity and specificity; a specific diagnosis can 
potentially reduce complications, re-infection, and transmission (394). Testing for T. 
vaginalis should be considered in areas or populations of high prevalence.
Treatment—Presumptive treatment should be initiated at the time of NGU diagnosis. 
Azithromycin and doxycycline are highly effective for chlamydial urethritis. NGU 
associated with M. genitalium currently responds better to azithromycin than doxycycline, 
although azithromycin efficacy might be declining (See Mycoplasma genitalium).
Recommended Regimens
Azithromycin 1 g orally in a single dose
 OR
Doxycycline 100 mg orally twice a day for 7 days
Alternative Regimens
Erythromycin base 500 mg orally four times a day for 7 days
 OR
Erythromycin ethylsuccinate 800 mg orally four times a day for 7 days
 OR
Levofloxacin 500 mg orally once daily for 7 days
 OR
Ofloxacin 300 mg orally twice a day for 7 days
As a directly observed treatment, single-dose regimens might be associated with higher rates 
of compliance over other regimens. To maximize compliance with recommended therapies, 
medications should be dispensed onsite in the clinic, and regardless of the number of doses 
involved in the regimen, the first should be directly observed.
Other Management Considerations—To minimize transmission and reinfection, men 
treated for NGU should be instructed to abstain from sexual intercourse until they and their 
partner(s) have been adequately treated (i.e., for 7 days after single-dose therapy or until 
completion of a 7-day regimen and symptoms resolved). Men who receive a diagnosis of 
NGU should be tested for HIV and syphilis.
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Follow-Up—Men should be provided results of the testing obtained as part of the NGU 
evaluation, and those with a specific diagnosis of chlamydia, gonorrhea, or trichomonas 
should be offered partner services and instructed to return 3 months after treatment for 
repeat testing because of high rates of reinfection, regardless of whether their sex partners 
were treated (480,481) (see Chlamydia, Follow-Up and Gonorrhea, Follow-Up).
If symptoms persist or recur after completion of therapy, men should be instructed to return 
for re-evaluation. Symptoms alone, without documentation of signs or laboratory evidence 
of urethral inflammation, are not a sufficient basis for retreatment. Providers should be alert 
to the possible diagnosis of chronic prostatitis/chronic pelvic pain syndrome in men 
experiencing persistent perineal, penile, or pelvic pain or discomfort, voiding symptoms, 
pain during or after ejaculation, or new-onset premature ejaculation lasting for >3 months. 
Men with persistent pain should be referred to a urologist.
Management of Sex Partners—All sex partners of men with NGU within the preceding 
60 days should be referred for evaluation, testing, and presumptive treatment with a drug 
regimen effective against chlamydia. EPT is an alternative approach to treating female 
partners for CT in the absence of signs and symptoms of PID (95). If N. gonorrhea or T. 
vaginalis is documented, all partners should be evaluated and treated according to the 
management section for their respective pathogen. To avoid reinfection, sex partners should 
abstain from sexual intercourse until they and their partner(s) are adequately treated.
Persistent and Recurrent NGU—The objective diagnosis of persistent or recurrent 
NGU should be made before considering additional antimicrobial therapy. In men who have 
persistent symptoms after treatment without objective signs of urethral inflammation, the 
value of extending the duration of antimicrobials has not been demonstrated. Men who have 
persistent or recurrent NGU can be retreated with the initial regimen if they did not comply 
with the treatment regimen or were re-exposed to an untreated sex partner.
Recent studies have shown that the most common cause of persistent or recurrent NGU is 
M. genitalium, especially following doxycycline therapy (277,278). Azithromycin 1 g orally 
in a single dose should be administered to men initially treated with doxycycline. Certain 
observational studies have shown that moxifloxacin 400 mg orally once daily for 7 days is 
highly effective against M. genitalium. Therefore, men who fail a regimen of azithromycin 
should be retreated with moxifloxacin 400 mg orally once daily for 7 days. Higher doses of 
azithromycin have not been found to be effective for M. genitalium in cases of azithromycin 
failure (280).
T. vaginalis is also known to cause urethritis in men who have sex with women. Although no 
NAAT for T. vaginalis detection in men has been FDA-cleared in the United States, several 
large reference laboratories have performed the necessary CLIA validation of a urine-based 
T. vaginalis NAAT for men for clinical use. Trichomonas NAAT testing is more sensitive 
than culture (475). In areas where T. vaginalis is prevalent, men who have sex with women 
and have persistent or recurrent urethritis should be presumptively treated with 
metronidazole 2 g orally in a single dose or tinidazole 2 g orally in a single dose; their 
partners should be referred for evaluation and appropriate treatment. Persons with persistent 
Workowski and Bolan Page 84
MMWR Recomm Rep. Author manuscript; available in PMC 2018 April 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
or recurrent NGU after presumptive treatment for M. genitalium or T. vaginalis should be 
referred to a urologist.
Special Considerations
HIV Infection: NGU might facilitate HIV transmission. Persons with NGU and HIV should 
receive the same treatment regimen as those who are HIV negative.
Cervicitis
Two major diagnostic signs characterize cervicitis: 1) a purulent or mucopurulent 
endocervical exudate visible in the endocervical canal or on an endocervical swab specimen 
(commonly referred to as mucopurulent cervicitis) and 2) sustained endocervical bleeding 
easily induced by gentle passage of a cotton swab through the cervical os. Either or both 
signs might be present. Cervicitis frequently is asymptomatic, but some women complain of 
an abnormal vaginal discharge and intermenstrual vaginal bleeding (e.g., after sexual 
intercourse). A finding of leukorrhea (>10 WBC per high-power field on microscopic 
examination of vaginal fluid) has been associated with chlamydial and gonococcal infection 
of the cervix. In the absence of the major diagnostic signs of inflammatory vaginitis, 
leukorrhea might be a sensitive indicator of cervical inflammation with a high negative 
predictive value (i.e., cervicitis is unlikely in the absence of leucorrhea) (482,483). The 
criterion of using an increased number of WBCs on endocervical Gram stain in the 
diagnosis of cervicitis has not been standardized and therefore is not helpful. In addition, it 
has a low positive-predictive value (PPV) for infection with C. trachomatis and N. 
gonorrhoeae and is not available in most clinical settings. Finally, although the presence of 
gram negative intracellular diplococci on Gram stain of endocervical fluid may be specific 
for the diagnosis of gonococcal cervical infection when evaluated by an experienced 
laboratorian, it is not a sensitive indicator of infection.
Etiology—When an etiologic organism is isolated in the presence of cervicitis, it is 
typically C. trachomatis or N. gonorrhoeae. Cervicitis also can accompany trichomoniasis 
and genital herpes (especially primary HSV-2 infection). However, in most cases of 
cervicitis, no organism is isolated, especially in women at relatively low risk for recent 
acquisition of these STDs (e.g., women aged >30 years) (484). Limited data indicate that 
infection with M. genitalium or BV and frequent douching might cause cervicitis (257–
259,261,265,485–487). For reasons that are unclear, cervicitis can persist despite repeated 
courses of antimicrobial therapy. Because most persistent cases of cervicitis are not caused 
by recurrent or reinfection with C. trachomatis or N. gonorrhoeae, other factors (e.g., 
persistent abnormality of vaginal flora, douching [or exposure to other types of chemical 
irritants], or idiopathic inflammation in the zone of ectopy) might be involved.
Diagnostic Considerations—Because cervicitis might be a sign of upper-genital–tract 
infection (endometritis), women with a new episode of cervicitis should be assessed for 
signs of PID and should be tested for C. trachomatis and for N. gonorrhoeae with NAAT; 
such testing can be performed on either vaginal, cervical, or urine samples (394) (see 
Chlamydia and Gonorrhea Diagnostic Considerations). Women with cervicitis also should 
be evaluated for the presence of BV and trichomoniasis, and if these are detected, they 
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should be treated. Because the sensitivity of microscopy to detect T. vaginalis is relatively 
low (approximately 50%), symptomatic women with cervicitis and negative microscopy for 
trichomonads should receive further testing (i.e., culture, NAAT or other FDA approved 
diagnostic test) (see Trichomoniasis, Diagnosis). A finding of >10 WBC per high power 
field in vaginal fluid, in the absence of trichomoniasis, might indicate endocervical 
inflammation caused specifically by C. trachomatis or N. gonorrhoeae (488,489). Although 
HSV-2 infection has been associated with cervicitis, the utility of specific testing (i.e., PCR, 
culture or serologic testing) for HSV-2 is unknown. FDA-cleared diagnostic tests for M. 
genitalium are not available.
Treatment—Several factors should affect the decision to provide presumptive therapy for 
cervicitis. Presumptive treatment with antimicrobials for C. trachomatis and N. gonorrhoeae 
should be provided for women at increased risk (e.g., those aged <25 years and those with a 
new sex partner, a sex partner with concurrent partners, or a sex partner who has a sexually 
transmitted infection), especially if follow-up cannot be ensured or if testing with NAAT is 
not possible. Trichomoniasis and BV should also be treated if detected (see Bacterial 
Vaginosis and Trichomoniasis). For women at lower risk of STDs, deferring treatment until 
results of diagnostic tests are available is an option. If treatment is deferred and NAATs for 
C. trachomatis and N. gonorrhoeae are negative, a follow-up visit to see if the cervicitis has 
resolved can be considered.
Recommended Regimens for Presumptive Treatment*
Azithromycin 1 g orally in a single dose
 OR
Doxycycline 100 mg orally twice a day for 7 days
*Consider concurrent treatment for gonococcal infection if patient is at risk for gonorrhea or lives in a community where 
the prevalence of gonorrhea is high.
Other Considerations—To minimize transmission and reinfection, women treated for 
cervicitis should be instructed to abstain from sexual intercourse until they and their 
partner(s) have been adequately treated (i.e., for 7 days after single-dose therapy or until 
completion of a 7-day regimen) and symptoms have resolved. Women who receive a 
diagnosis of cervicitis should be tested for HIV and syphilis.
Follow-Up—Women receiving treatment should return to their provider for a follow-up 
visit, allowing the provider to determine whether cervicitis has resolved. For women who are 
not treated, a follow-up visit gives providers an opportunity to communicate results of tests 
obtained as part of the cervicitis evaluation. Additional follow-up should be conducted as 
recommended for the infections identified. Women with a specific diagnosis of chlamydia, 
gonorrhea, or trichomonas should be offered partner services and instructed to return in 3 
months after treatment for repeat testing because of high rates of reinfection, regardless of 
whether their sex partners were treated (480). If symptoms persist or recur, women should 
be instructed to return for re-evaluation.
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Management of Sex Partners—Management of sex partners of women treated for 
cervicitis should be appropriate for the specific STD identified or suspected. All sex partners 
in the past 60 days should be referred for evaluation, testing, and presumptive treatment if 
chlamydia, gonorrhea, or trichomoniasis was identified or suspected in the women with 
cervicitis. EPT or other effective partner referral strategies (see Partner Services) are 
alternative approaches to treating male partners of women who have chlamydia or 
gonococcal infection (93–95). To avoid reinfection, sex partners should abstain from sexual 
intercourse until they and their partner(s) are adequately treated.
Persistent or Recurrent Cervicitis—Women with persistent or recurrent cervicitis 
despite having been treated should be reevaluated for possible re-exposure or treatment 
failure to gonorrhea or chlamydia. If relapse and/or reinfection with a specific STD have 
been excluded, BV is not present, and sex partners have been evaluated and treated, 
management options for persistent cervicitis are undefined; in addition, the utility of 
repeated or prolonged administration of antibiotic therapy for persistent symptomatic 
cervicitis remains unknown. The etiology of persistent cervicitis including the potential role 
of M. genitalium (490) is unclear. M. genitalium might be considered for cases of clinically 
significant cervicitis that persist after azithromycin or doxycycline therapy in which re-
exposure to an infected partner or medical nonadherence is unlikely. In settings with 
validated assays, women with persistent cervicitis could be tested for M. genitalium with the 
decision to treat with moxifloxacin based on results of diagnostic testing (491). In treated 
women with persistent symptoms that are clearly attributable to cervicitis, referral to a 
gynecologic specialist can be considered.
Special Considerations
HIV Infection: Women with cervicitis and HIV infection should receive the same treatment 
regimen as those who are HIV negative. Cervicitis increases cervical HIV shedding. 
Treatment of cervicitis in women with HIV infection reduces HIV shedding from the cervix 
and might reduce HIV transmission to susceptible sex partners (492–496).
Pregnancy: Diagnosis and treatment of cervicitis in pregnant women does not differ from 
that in women that are not pregnant. For more information, see Cervicitis, sections on 
Diagnostic Considerations and Treatment.
Chlamydial Infections
Chlamydial Infections in Adolescents and Adults
Chlamydial infection is the most frequently reported infectious disease in the United States, 
and prevalence is highest in persons aged ≤24 years (118). Several sequelae can result from 
C. trachomatis infection in women, the most serious of which include PID, ectopic 
pregnancy, and infertility. Some women who receive a diagnosis of uncomplicated cervical 
infection already have subclinical upper-reproductive–tract infection.
Asymptomatic infection is common among both men and women. To detect chlamydial 
infections, health-care providers frequently rely on screening tests. Annual screening of all 
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sexually active women aged <25 years is recommended, as is screening of older women at 
increased risk for infection (e.g., those who have a new sex partner, more than one sex 
partner, a sex partner with concurrent partners, or a sex partner who has a sexually 
transmitted infection (108). Although CT incidence might be higher in some women aged 
≥25 years in some communities, overall the largest burden of infection is among women 
aged <25 years.
Chlamydia screening programs have been demonstrated to reduce the rates of PID in women 
(497,498). Although evidence is insufficient to recommend routine screening for C. 
trachomatis in sexually active young men because of several factors (e.g., feasibility, 
efficacy, and cost-effectiveness), the screening of sexually active young men should be 
considered in clinical settings with a high prevalence of chlamydia (e.g., adolescent clinics, 
correctional facilities, and STD clinics) or in populations with high burden of infection (e.g., 
MSM) (108,121). Among women, the primary focus of chlamydia screening efforts should 
be to detect chlamydia, prevent complications, and test and treat their partners, whereas 
targeted chlamydia screening in men should only be considered when resources permit, 
prevalence is high, and such screening does not hinder chlamydia screening efforts in 
women (499,500). More frequent screening for some women (e.g., adolescents) or certain 
men (e.g., MSM) might be indicated.
Diagnostic Considerations—C. trachomatis urogenital infection can be diagnosed in 
women by testing first-catch urine or collecting swab specimens from the endocervix or 
vagina. Diagnosis of C. trachomatis urethral infection in men can be made by testing a 
urethral swab or first-catch urine specimen. NAATs are the most sensitive tests for these 
specimens and therefore are recommended for detecting C. trachomatis infection (394). 
NAATs that are FDA-cleared for use with vaginal swab specimens can be collected by a 
provider or self-collected in a clinical setting. Self-collected vaginal swab specimens are 
equivalent in sensitivity and specificity to those collected by a clinician using NAATs 
(501,502), and women find this screening strategy highly acceptable (503,504). Optimal 
urogenital specimen types for chlamydia screening using NAAT include first catch-urine 
(men) and vaginal swabs (women) (394). Rectal and oropharyngeal C. trachomatis infection 
in persons engaging in receptive anal or oral intercourse can be diagnosed by testing at the 
anatomic site of exposure. NAATs are not FDA-cleared for use with rectal or oropharyngeal 
swab specimens. However, NAATs have been demonstrated to have improved sensitivity and 
specificity compared with culture for the detection of C. trachomatis at rectal sites (505–
507) and at oropharyngeal sites among men (505–508). Some laboratories have established 
CLIA-defined performance specifications when evaluating rectal and oropharyngeal swab 
specimens for C. trachomatis, thereby allowing results to be used for clinical management. 
Most persons with C. trachomatis detected at oropharyngeal sites do not have oropharyngeal 
symptoms. However, when gonorrhea testing is performed at the oropharyngeal site, 
chlamydia test results might be reported as well because some NAATs detect both bacteria 
from a single specimen. Data indicate that performance of NAATs on self-collected rectal 
swabs is comparable to clinician-collected rectal swabs, and this specimen collection 
strategy for rectal C. trachomatis screening is highly acceptable (509–511). Self-collected 
rectal swabs are a reasonable alternative to clinician-collected rectal swabs for C. 
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trachomatis screening by NAAT, especially when clinicians are not available or when self 
collection is preferred over clinician collection. Previous evidence suggests that the liquid-
based cytology specimens collected for Pap smears might be acceptable specimens for 
NAAT testing, although test sensitivity using these specimens might be lower than that 
associated with use of cervical or vaginal swab specimens (512); regardless, certain NAATs 
have been FDA-cleared for use on liquid-based cytology specimens.
Treatment—Treating persons infected with C. trachomatis prevents adverse reproductive 
health complications and continued sexual transmission, and treating their sex partners can 
prevent reinfection and infection of other partners. Treating pregnant women usually 
prevents transmission of C. trachomatis to neonates during birth. Chlamydia treatment 
should be provided promptly for all persons testing positive for infection; treatment delays 
have been associated with complications (e.g., PID) in a limited proportion of women (513).
Recommended Regimens
Azithromycin 1 g orally in a single dose
 OR
Doxycycline 100 mg orally twice a day for 7 days
Alternative Regimens
Erythromycin base 500 mg orally four times a day for 7 days
 OR
Erythromycin ethylsuccinate 800 mg orally four times a day for 7 days
 OR
Levofloxacin 500 mg orally once daily for 7 days
 OR
Ofloxacin 300 mg orally twice a day for 7 days
A meta-analysis of 12 randomized clinical trials of azithromycin versus doxycycline for the 
treatment of urogenital chlamydial infection demonstrated that the treatments were equally 
efficacious, with microbial cure rates of 97% and 98%, respectively (514). These studies 
were conducted primarily in populations with urethral and cervical infection in which 
follow-up was encouraged, adherence to a 7-day regimen was effective, and culture or EIA 
(rather than the more sensitive NAAT) was used for determining microbiological outcome. 
More recent retrospective studies have raised concern about the efficacy of azithromycin for 
rectal C. trachomatis infection (515,516), however, these studies have limitations, and 
prospective clinical trials comparing azithromycin versus doxycycline regimens for rectal C. 
trachomatis infection are needed.
Although the clinical significance of oropharyngeal C. trachomatis infection is unclear and 
routine oropharyngeal screening for CT is not recommended, available evidence suggests 
oropharyngeal C. trachomatis can be sexually transmitted to genital sites (152,517); 
therefore, detection of C. trachomatis from an oropharyngeal specimen should be treated 
with azithromycin or doxycycline. The efficacy of alternative antimicrobial regimens in 
resolving oropharyngeal chlamydia remains unknown.
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In a double-blinded randomized control trial, a doxycycline delayed-release 200 mg tablet 
administered daily for 7 days was as effective as generic doxycycline 100 mg twice daily for 
7 days for treatment of urogenital C. trachomatis infection in men and women and had a 
lower frequency of gastrointestinal side effects. However, this regimen is more costly than 
those that involve multiple daily doses (518). Delayed-release doxycycline (Doryx) 200 mg 
daily for 7 days might be an alternative regimen to the doxycycline 100 mg twice daily for 7 
days for treatment of urogenital C. trachomatis infection. Erythromycin might be less 
efficacious than either azithromycin or doxycycline, mainly because of the frequent 
occurrence of gastrointestinal side effects that can lead to nonadherence with treatment. 
Levofloxacin and ofloxacin are effective treatment alternatives, but they are more expensive 
and offer no advantage in the dosage regimen. Other quinolones either are not reliably 
effective against chlamydial infection or have not been evaluated adequately.
Other Management Considerations—To maximize adherence with recommended 
therapies, onsite, directly observed single-dose therapy with azithromycin should always be 
available for persons for whom adherence with multiday dosing is a concern. In addition, for 
multidose regimens, the first dose should be dispensed on site and directly observed. To 
minimize disease transmission to sex partners, persons treated for chlamydia should be 
instructed to abstain from sexual intercourse for 7 days after single-dose therapy or until 
completion of a 7-day regimen and resolution of symptoms if present. To minimize risk for 
reinfection, patients also should be instructed to abstain from sexual intercourse until all of 
their sex partners are treated. Persons who receive a diagnosis of chlamydia should be tested 
for HIV, GC, and syphilis.
Follow-Up—Test-of-cure to detect therapeutic failure (i.e., repeat testing 3–4 weeks after 
completing therapy) is not advised for persons treated with the recommended or alterative 
regimens, unless therapeutic adherence is in question, symptoms persist, or reinfection is 
suspected. Moreover, the use of chlamydial NAATs at <3 weeks after completion of therapy 
is not recommended because the continued presence of nonviable organisms (394,395,519) 
can lead to false-positive results.
A high prevalence of C. trachomatis infection has been observed in women and men who 
were treated for chlamydial infection during the preceding several months (480,481,520–
522). Most post-treatment infections do not result from treatment failure, but rather from 
reinfection caused by failure of sex partners to receive treatment or the initiation of sexual 
activity with a new infected partner, indicating a need for improved education and treatment 
of sex partners. Repeat infections confer an elevated risk for PID and other complications in 
women. Men and women who have been treated for chlamydia should be retested 
approximately 3 months after treatment, regardless of whether they believe that their sex 
partners were treated (480,481). If retesting at 3 months is not possible, clinicians should 
retest whenever persons next present for medical care in the 12-month period following 
initial treatment.
Management of Sex Partners—Sexual partners should be referred for evaluation, 
testing, and presumptive treatment if they had sexual contact with the partner during the 60 
days preceding the patient’s onset of symptoms or chlamydia diagnosis. Although the 
Workowski and Bolan Page 90
MMWR Recomm Rep. Author manuscript; available in PMC 2018 April 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
exposure intervals defined for the identification of at-risk sex partners are based on limited 
data, the most recent sex partner should be evaluated and treated, even if the time of the last 
sexual contact was >60 days before symptom onset or diagnosis.
Among heterosexual patients, if health department partner management strategies (e.g., 
disease intervention specialists) are impractical or not available for persons with chlamydia 
and a provider is concerned that sex partners are unable to promptly access evaluation and 
treatment services, EPT should be considered as permitted by law (see Partner Services). 
Compared with standard patient referral of partners, this approach to therapy, which involves 
delivering the medication itself or a prescription, has been associated with decreased rates of 
persistent or recurrent chlamydia (93–95). Providers should also provide patients with 
written educational materials to give to their partner(s) about chlamydia in general, to 
include notification that partner(s) have been exposed and information about the importance 
of treatment. These materials also should inform partners about potential therapy-related 
allergies and adverse effects, along with symptoms suggestive of complications (e.g., 
testicular pain in men and pelvic or abdominal pain in women). EPT is not routinely 
recommended for MSM with chlamydia because of a high risk for coexisting infections 
(especially undiagnosed HIV) among their partners, and because data are limited regarding 
the effectiveness of this approach in reducing persistent or recurrent chlamydia among 
MSM. Having partners accompany patients when they return for treatment is another 
strategy that has been used to ensure partner treatment (See Partner Services). To avoid 
reinfection, sex partners should be instructed to abstain from sexual intercourse until they 
and their sex partners have been adequately treated (i.e., for 7 days after a single-dose 
regimen or after completion of a 7-day regimen) and have resolved any symptoms.
Special Considerations
Pregnancy: Doxycycline is contraindicated in the second and third trimesters of pregnancy. 
Human data suggest ofloxacin and levofloxacin present a low risk to the fetus during 
pregnancy, with a potential for toxicity during breastfeeding; however, data from animal 
studies raise concerns about cartilage damage to neonates (317). Thus, alternative drugs 
should be used to treat chlamydia in pregnancy. Clinical experience and published studies 
suggest that azithromycin is safe and effective (523–525). Test-of-cure to document 
chlamydial eradication (preferably by NAAT) 3–4 weeks after completion of therapy is 
recommended because severe sequelae can occur in mothers and neonates if the infection 
persists. In addition, all pregnant women who have chlamydial infection diagnosed should 
be retested 3 months after treatment. Detection of C. trachomatis infection at repeat 
screening during the third semester is not uncommon in adolescent and young adult women, 
including in those without C. trachomatis detected at the time of initial prenatal screening 
(526,527). Women aged <25 years and those at increased risk for chlamydia (e.g., those who 
have a new sex partner, more than one sex partner, a sex partner with concurrent partners, or 
a sex partner who has a sexually transmitted infection) should be rescreened during the third 
trimester to prevent maternal postnatal complications and chlamydial infection in the infant 
(108).
Recommended Regimens
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Azithromycin 1 g orally in a single dose
Alternative Regimens
Amoxicillin 500 mg orally three times a day for 7 days
 OR
Erythromycin base 500 mg orally four times a day for 7 days
 OR
Erythromycin base 250 mg orally four times a day for 14 days
 OR
Erythromycin ethylsuccinate 800 mg orally four times a day for 7 days
 OR
Erythromycin ethylsuccinate 400 mg orally four times a day for 14 days
Because of concerns about chlamydia persistence following exposure to penicillin-class 
antibiotics that has been demonstrated in animal and in vitro studies, amoxicillin is now 
considered an alternative therapy for C. trachomatis in pregnant women (528,529). The 
frequent gastrointestinal side effects associated with erythromycin can result in 
nonadherence with these alternative regimens. The lower dose 14-day erythromycin 
regimens can be considered if gastrointestinal tolerance is a concern. Erythromycin estolate 
is contraindicated during pregnancy because of drug-related hepatotoxicity.
HIV Infection: Persons who have chlamydia and HIV infection should receive the same 
treatment regimen as those who do not have HIV infection. For more information, see 
Chlamydia, Treatment.
Chlamydial Infections Among Neonates
Prenatal screening and treatment of pregnant women is the best method for preventing 
chlamydial infection among neonates. C. trachomatis infection of neonates results from 
perinatal exposure to the mother’s infected cervix. Although the efficacy of neonatal ocular 
prophylaxis with erythromycin ophthalmic ointments to prevent chlamydia ophthalmia is not 
clear, ocular prophylaxis with these agents prevents gonococcal ophthalmia and therefore 
should be administered (see Ophthalmia Neonatorum Caused by N. gonnorrhoeae).
Initial C. trachomatis neonatal infection involves the mucous membranes of the eye, 
oropharynx, urogenital tract, and rectum, although infection might be asymptomatic in these 
locations. Instead, C. trachomatis infection in neonates is most frequently recognized by 
conjunctivitis that develops 5–12 days after birth. C. trachomatis also can cause a subacute, 
afebrile pneumonia with onset at ages 1–3 months. Although C. trachomatis has been the 
most frequent identifiable infectious cause of ophthalmia neonatorum, neonatal chlamydial 
infections (including ophthalmia and pneumonia) have occurred less frequently since the 
institution of widespread prenatal screening and treatment of pregnant women.
Ophthalmia Neonatorum Caused by C. trachomatis—A chlamydial etiology should 
be considered for all infants aged ≤30 days that have conjunctivitis, especially if the mother 
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has a history of chlamydia infection. These infants should receive evaluation and appropriate 
care and treatment.
Diagnostic Considerations: Sensitive and specific methods used to diagnose chlamydial 
ophthalmia in the neonate include both tissue culture and nonculture tests (e.g., direct 
fluorescence antibody [DFA] tests and NAAT). DFA is the only nonculture FDA-cleared test 
for the detection of chlamydia from conjunctival swabs; NAATs are not FDA-cleared for the 
detection of chlamydia from conjunctival swabs, and clinical laboratories must verify the 
procedure according to CLIA regulations. Specimens for culture isolation and nonculture 
tests should be obtained from the everted eyelid using a dacron-tipped swab or the swab 
specified by the manufacturer’s test kit; for culture and DFA, specimens must contain 
conjunctival cells, not exudate alone. Ocular specimens from neonates being evaluated for 
chlamydial conjunctivitis also should be tested for N. gonorrhoeae (see Ophthalmia 
Neonatorum Caused by N. gonnorrhoeae).
Treatment of Ophthalmia Neonatorum
Recommended Regimen
Erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into 4 doses daily for 14 days*
Alternative Regimen
Azithromycin suspension, 20 mg/kg/day orally, 1 dose daily for 3 days*
*An association between oral erythromycin and azithromycin and infantile hypertrophic pyloric stenosis (IHPS) has 
been reported in infants aged <6 weeks. Infants treated with either of these antimicrobials should be followed for signs 
and symptoms of IHPS.
Although data on the use of azithromycin for the treatment of neonatal chlamydia infection 
are limited, available data suggest a short course of therapy might be effective (530). Topical 
antibiotic therapy alone is inadequate for treatment for ophthalmia neonatorum caused by 
chlamydia and is unnecessary when systemic treatment is administered.
Follow-Up: Because the efficacy of erythromycin treatment for ophthalmia neonatorum is 
approximately 80%, a second course of therapy might be required (531). Data on the 
efficacy of azithromycin for ophthalmia neonatorum are limited. Therefore, follow-up of 
infants is recommended to determine whether initial treatment was effective. The possibility 
of concomitant chlamydial pneumonia should be considered (see Infant Pneumonia Caused 
by C. trachomatis).
Management of Mothers and Their Sex Partners: Mothers of infants who have 
ophthalmia caused by chlamydia and the sex partners of these women should be evaluated 
and presumptively treated for chlamydia. For more information, see Chlamydial Infection in 
Adolescents and Adults.
Infant Pneumonia Caused by C. trachomatis—Chlamydia pneumonia in infants 
typically occurs at 1–3 months and is a subacute pneumonia. Characteristic signs of 
chlamydial pneumonia in infants include 1) a repetitive staccato cough with tachypnea and 
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2) hyperinflation and bilateral diffuse infiltrates on a chest radiograph. In addition, 
peripheral eosinophilia (≥400 cells/mm3) occurs frequently. Because clinical presentations 
differ, all infants aged 1–3 months suspected of having pneumonia (especially those whose 
mothers have a history of chlamydial infection) should be tested for C. trachomatis and 
treated if infected.
Diagnostic Considerations: Specimens for chlamydial testing should be collected from the 
nasopharynx. Tissue culture is the definitive standard diagnostic test for chlamydial 
pneumonia. Nonculture tests (e.g., DFA and NAAT) can be used. DFA is the only nonculture 
FDA-cleared test for the detection of C. trachomatis from nasopharyngeal specimens, but 
DFA of nasopharyngeal specimens has a lower sensitivity and specificity than culture. 
NAATs are not FDA-cleared for the detection of chlamydia from nasopharyngeal specimens, 
and clinical laboratories must verify the procedure according to CLIA regulations (394). 
Tracheal aspirates and lung biopsy specimens, if collected, should be tested for C. 
trachomatis.
Treatment: Because test results for chlamydia often are not available at the time that initial 
treatment decisions must be made, treatment for C. trachomatis pneumonia must frequently 
be based on clinical and radiologic findings, age of the infant (i.e., 1–3 months), and risk of 
chlamydia in the mother (i.e., age <25, multiple partners, and history of chlamydial 
infection). The results of tests for chlamydial infection assist in the management of an 
infant’s illness.
Recommended Regimen
Erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into 4 doses daily for 14 days
Alternative Regimen
Azithromycin 20 mg/kg/day orally, 1 dose daily for 3 days
Follow-Up: Because the effectiveness of erythromycin in treating pneumonia caused by C. 
trachomatis is approximately 80%, a second course of therapy might be required (532). Data 
on the effectiveness of azithromycin in treating chlamydial pneumonia are limited. Follow-
up of infants is recommended to determine whether the pneumonia has resolved, although 
some infants with chlamydial pneumonia continue to have abnormal pulmonary function 
tests later in childhood.
Management of Mothers and Their Sex Partners: Mothers of infants who have 
chlamydia pneumonia and the sex partners of these women should be evaluated, tested, and 
presumptively treated for chlamydia. For more information, see Chlamydial Infection in 
Adolescents and Adults.
Neonates Born to Mothers Who Have Chlamydial Infection—Neonates born to 
mothers who have untreated chlamydia are at high risk for infection; however, prophylactic 
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antibiotic treatment is not indicated, as the efficacy of such treatment is unknown. Infants 
should be monitored to ensure appropriate treatment if symptoms develop.
Chlamydial Infections Among Infants and Children
Sexual abuse must be considered a cause of chlamydial infection in infants and children. 
However, perinatally transmitted C. trachomatis infection of the nasopharynx, urogenital 
tract, and rectum might persist for 2–3 years (see Sexual Assault or Abuse of Children).
Diagnostic Considerations—NAAT can be used for vaginal and urine specimens from 
girls (see Sexual Assault or Abuse of Children), although data are insufficient to recommend 
the use of NAAT in boys. Data also are lacking regarding use of NAAT for specimens from 
extragenital sites (rectum and pharynx) in boys and girls (394); other nonculture tests (e.g., 
DFA) are not recommended because of specificity concerns. Culture is still the preferred 
method for detection of urogenital C. trachomatis in boys and at extragenital sites in boys 
and girls.
Recommended Regimen for Infants and Children Who Weigh <45 kg
Erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into 4 doses daily for 14 days
Data are limited on the effectiveness and optimal dose of azithromycin for the treatment of chlamydial infection in 
infants and children who weigh <45 kg
Recommended Regimen for Children Who Weigh ≥45 kg but Who Are Aged <8 Years
Azithromycin 1 g orally in a single dose
Recommended Regimens for Children Aged ≥8 years
Azithromycin 1 g orally in a single dose
 OR
Doxycycline 100 mg orally twice a day for 7 days
Other Management Considerations—See Sexual Assault or Abuse of Children.
Follow-Up—A test-of-cure culture (repeat testing after completion of therapy) to detect 
therapeutic failure ensures treatment effectiveness. Therefore, a culture should be obtained at 
a follow-up visit approximately 2 weeks after treatment is completed.
Gonococcal Infections
Gonococcal Infections in Adolescents and Adults
In the United States, an estimated 820,000 new N. gonorrhoeae infections occur each year 
(533). Gonorrhea is the second most commonly reported communicable disease (118). 
Urethral infections caused by N. gonorrhoeae among men can produce symptoms that cause 
them to seek curative treatment soon enough to prevent sequelae, but often not soon enough 
to prevent transmission to others. Among women, gonococcal infections are commonly 
asymptomatic or might not produce recognizable symptoms until complications (e.g., PID) 
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have occurred. PID can result in tubal scarring that can lead to infertility and ectopic 
pregnancy.
Annual screening for N. gonorrhoeae infection is recommended for all sexually active 
women aged <25 years and for older women at increased risk for infection (e.g., those who 
have a new sex partner, more than one sex partner, a sex partner with concurrent partners, or 
a sex partner who has an STI) (108). Additional risk factors for gonorrhea include 
inconsistent condom use among persons who are not in mutually monogamous relationships, 
previous or coexisting sexually transmitted infections, and exchanging sex for money or 
drugs. Clinicians should consider the communities they serve and might opt to consult local 
public health authorities for guidance on identifying groups at increased risk. Gonococcal 
infection, in particular, is concentrated in specific geographic locations and communities. 
Subgroups of MSM are at high risk for gonorrhea infection and should be screened at sites 
of exposure (see MSM). Screening for gonorrhea in men and older women who are at low 
risk for infection is not recommended (108). A recent travel history with sexual contacts 
outside of the United States should be part of any gonorrhea evaluation.
Diagnostic Considerations—Specific microbiologic diagnosis of infection with N. 
gonorrhoeae should be performed in all persons at risk for or suspected to have gonorrhea; a 
specific diagnosis can potentially reduce complications, reinfections, and transmission. 
Culture and NAAT are available for the detection of genitourinary infection with N. 
gonorrhoeae (394); culture requires endocervical (women) or urethral (men) swab 
specimens. NAAT allows for the widest variety of FDA-cleared specimen types, including 
endocervical swabs, vaginal swabs, urethral swabs (men), and urine (from both men and 
women). However, product inserts for each NAAT manufacturer must be carefully consulted 
because collection methods and specimen types vary. Culture is available for detection of 
rectal, oropharyngeal, and conjunctival gonococcal infection, but NAAT is not FDA-cleared 
for use with these specimens. Some laboratories have met CLIA regulatory requirements and 
established performance specifications for using NAAT with rectal and oropharyngeal swab 
specimens that can inform clinical management. Certain NAATs that have been 
demonstrated to detect commensal Neisseria species might have comparable low specificity 
when testing oropharyngeal specimens for N. gonorrhoeae (394). The sensitivity of NAAT 
for the detection of N. gonorrhoeae in urogenital and nongenital anatomic sites is superior to 
culture, but varies by NAAT type (394,505–508). In cases of suspected or documented 
treatment failure, clinicians should perform both culture and antimicrobial susceptibility 
testing because nonculture tests cannot provide antimicrobial susceptibility results. Because 
N. gonorrhoeae has demanding nutritional and environmental growth requirements, optimal 
recovery rates are achieved when specimens are inoculated directly and when the growth 
medium is promptly incubated in an increased CO2 environment (394). Several non-nutritive 
swab transport systems are available that might maintain gonococcal viability for up to 48 
hours in ambient temperatures (534–536).
Because of its high specificity (>99%) and sensitivity (>95%), a Gram stain of urethral 
secretions that demonstrates polymorphonuclear leukocytes with intracellular Gramnegative 
diplococci can be considered diagnostic for infection with N. gonorrhoeae in symptomatic 
men. However, because of lower sensitivity, a negative Gram stain should not be considered 
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sufficient for ruling out infection in asymptomatic men. Detection of infection using Gram 
stain of endocervical, pharyngeal, and rectal specimens also is insufficient and is not 
recommended. MB/GV stain of urethral secretions is an alternative point-of-care diagnostic 
test with performance characteristics similar to Gram stain. Presumed gonococcal infection 
is established by documenting the presence of WBC containing intracellular purple 
diplococci in MB/GV smears.
Antimicrobial-Resistant N. gonorrhoeae—Gonorrhea treatment is complicated by the 
ability of N. gonorrhoeae to develop resistance to antimicrobials (537). In 1986, the 
Gonococcal Isolate Surveillance Project (GISP), a national sentinel surveillance system, was 
established to monitor trends in antimicrobial susceptibilities of urethral N. gonorrhoeae 
strains in the United States (538). The epidemiology of antimicrobial resistance guides 
decisions about gonococcal treatment recommendations and has evolved because of shifts in 
antimicrobial resistance patterns. In 2007, emergence of fluoroquinolone-resistant N. 
gonorrhoeae in the United States prompted CDC to cease recommending fluoroquinolones 
for treatment of gonorrhea, leaving cephalosporins as the only remaining class of 
antimicrobials available for treatment of gonorrhea in the United States (539). Reflecting 
concern about emerging gonococcal resistance, CDC’s 2010 STD treatment guidelines 
recommended dual therapy for gonorrhea with a cephalosporin plus either azithromycin or 
doxycycline, even if NAAT for C. trachomatis was negative at the time of treatment (1). 
However, during 2006–2011, the minimum concentrations of cefixime needed to inhibit in 
vitro growth of the N. gonorrhoeae strains circulating in the United States and many other 
countries increased, suggesting that the effectiveness of cefixime might be waning 
(118,540). In addition, treatment failures with cefixime or other oral cephalosporins have 
been reported in Asia (541– 544), Europe (545–549), South Africa (550), and Canada 
(551,552). Ceftriaxone treatment failures for pharyngeal infections have been reported in 
Australia (553,554), Japan (555), and Europe (556,557). As a result, CDC no longer 
recommends the routine use of cefixime as a first-line regimen for treatment of gonorrhea in 
the United States (540). In addition, U.S. gonococcal strains with elevated MICs to cefixime 
also are likely to be resistant to tetracyclines but susceptible to azithromycin (540). 
Consequently, only one regimen, dual treatment with ceftriaxone and azithromycin, is 
recommended for treatment of gonorrhea in the United States. CDC (http://
www.cdc.gov/std/gisp) and state health departments can provide the most current 
information on gonococcal susceptibility.
Criteria for resistance to cefixime and ceftriaxone have not been defined by the Clinical and 
Laboratory Standards Institute (CLSI). However, isolates with cefixime or ceftriaxone MICs 
≥0.5 μg/mL are considered to have decreased susceptibility (558). In the United States, the 
proportion of isolates in GISP demonstrating decreased susceptibility to ceftriaxone or 
cefixime has remained low; during 2013, no isolates with decreased susceptibility (MIC 
≥0.5 μg/mL) to ceftriaxone or cefixime were identified (118). Because increasing MICs 
might predict the emergence of resistance, GISP established lower cephalosporin MIC 
breakpoints than those set by CLSI to provide greater sensitivity in detecting declining 
gonococcal susceptibility for surveillance purposes. The percentage of isolates with cefixime 
MICs ≥0.25 μg/mL increased from 0.1% in 2006 to 1.4% in 2011 (118,540), and declined to 
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0.4% in 2013 (118). The percentage of isolates with ceftriaxone MICs ≥0.125 μg/mL 
increased from <0.1% in 2006 to 0.4% in 2011 and decreased to 0.05% in 2013. Isolates 
with high-level cefixime and ceftriaxone MICs (cefixime MICs 1.5–8 μg/mL and ceftriaxone 
MICs 1.5–4 μg/mL) have been identified in Japan (555), France (549), and Spain (559,560). 
Decreased susceptibility of N. gonorrhoeae to cephalosporins and other antimicrobials is 
expected to continue; state and local surveillance for antimicrobial resistance is crucial for 
guiding local therapy recommendations (537). Although approximately 3% of all U.S. men 
who have gonococcal infections are sampled through GISP, surveillance by clinicians also is 
critical. Clinicians who diagnose N. gonorrhoeae infection in a person with suspected 
cephalosporin treatment failure should perform culture and antimicrobial susceptibility 
testing (AST) of relevant clinical specimens, consult an infectious-disease specialist for 
guidance in clinical management, and report the case to CDC through state and local public 
health authorities. Isolates should be saved and sent to CDC through local and state public 
health laboratory mechanisms. Health departments should prioritize notification and culture 
evaluation for sexual partner(s) of persons with N. gonorrhoeae infection thought to be 
associated with cephalosporin treatment failure or persons whose isolates demonstrate 
decreased susceptibility to cephalosporin.
Dual Therapy for Gonococcal Infections—On the basis of experience with other 
microbes that have developed antimicrobial resistance rapidly, a theoretical basis exists for 
combination therapy using two antimicrobials with different mechanisms of action (e.g., a 
cephalosporin plus azithromycin) to improve treatment efficacy and potentially slow the 
emergence and spread of resistance to cephalosporins. Use of azithromycin as the second 
antimicrobial is preferred to doxycycline because of the convenience and compliance 
advantages of single-dose therapy and the substantially higher prevalence of gonococcal 
resistance to tetracycline than to azithromycin among GISP isolates, particularly in strains 
with elevated cefixime MICs (118,540). In addition, clinical trials have demonstrated the 
efficacy of azithromycin 1 g for the treatment of uncomplicated urogenital GC (561,562).
Limited data suggest that dual treatment with azithromycin might enhance treatment efficacy 
for pharyngeal infection when using oral cephalosporins (563,564). In addition, persons 
infected with N. gonorrhoeae frequently are coinfected with C. trachomatis; this finding has 
led to the longstanding recommendation that persons treated for gonococcal infection also 
be treated with a regimen that is effective against uncomplicated genital C. trachomatis 
infection, further supporting the use of dual therapy that includes azithromycin (565).
Uncomplicated Gonococcal Infections of the Cervix, Urethra, and Rectum
Recommended Regimen
Ceftriaxone 250 mg IM in a single dose
 PLUS
Azithromycin 1g orally in a single dose
As dual therapy, ceftriaxone and azithromycin should be administered together on the same 
day, preferably simultaneously and under direct observation. Ceftriaxone in a single 
injection of 250 mg provides sustained, high bactericidal levels in the blood. Extensive 
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clinical experience indicates that ceftriaxone is safe and effective for the treatment of 
uncomplicated gonorrhea at all anatomic sites, curing 99.2% of uncomplicated urogenital 
and anorectal and 98.9% of pharyngeal infections in clinical trials (566,567). No clinical 
data exist to support use of doses of ceftriaxone >250 mg.
Single-dose injectable cephalosporin regimens (other than ceftriaxone 250 mg IM) that are 
safe and generally effective against uncomplicated urogenital and anorectal gonococcal 
infections include ceftizoxime (500 mg IM), cefoxitin (2 g IM with probenecid 1 g orally), 
and cefotaxime (500 mg IM). None of these injectable cephalosporins offer any advantage 
over ceftriaxone for urogenital infection, and efficacy for pharyngeal infection is less certain 
(566,567). Several other antimicrobials are active against N. gonorrhoeae, but none have 
substantial advantages over the recommended regimen, and efficacy data (especially for 
pharyngeal infection) are limited.
Alternative Regimens
If ceftriaxone is not available:
Cefixime 400 mg orally in a single dose
 PLUS
Azithromycin 1 g orally in a single dose
A 400-mg oral dose of cefixime should only be considered as an alternative cephalosporin 
regimen because it does not provide as high, nor as sustained, bactericidal blood levels as a 
250-mg dose of ceftriaxone; further, it demonstrates limited efficacy for treatment of 
pharyngeal gonorrhea (92.3% cure; 95% confidence interval [CI] = 74.9%–99.1%); in older 
clinical studies, cefixime cured 97.5% of uncomplicated urogenital and anorectal gonococcal 
infections (95% CI = 95.4%–99.8%) (566,567). The increase in the prevalence of isolates 
obtained through GISP with elevated cefixime MICs might indicate early stages of 
development of clinically significant gonococcal resistance to cephalosporins. CDC 
anticipates that rising cefixime MICs soon will result in declining effectiveness of cefixime 
for the treatment of urogenital gonorrhea. Furthermore, as cefixime becomes less effective, 
continued used of cefixime might hasten the development of resistance to ceftriaxone, a safe, 
well-tolerated, injectable cephalosporin and the last antimicrobial known to be highly 
effective in a single dose for treatment of gonorrhea at all anatomic sites of infection. Other 
oral cephalosporins (e.g., cefpodoxime and cefuroxime) are not recommended because of 
inferior efficacy and less favorable pharmacodynamics (566,568).
Because of the prevalence of tetracycline resistance among GISP isolates, particularly those 
with elevated cefixime MICs (118), the use of azithromycin as the second antimicrobial is 
preferred. However, in the case of azithromycin allergy, doxycycline (100 mg orally twice a 
day for 7 days) can be used in place of azithromycin as an alternative second antimicrobial 
when used in combination with ceftriaxone or cefixime.
In a recent clinical trial, dual treatment of uncomplicated, urogenital gonorrhea with single 
doses of oral gemifloxacin 320 mg plus oral azithromycin 2 g was associated with cure rates 
of 99.5% (lower one-sided 95% CI bound = 97.6%), and dual treatment with single doses of 
intramuscular gentamicin 240 mg plus oral azithromycin 2 g cured 100% of cases (lower 
Workowski and Bolan Page 99
MMWR Recomm Rep. Author manuscript; available in PMC 2018 April 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
one-sided 95% CI bound = 98.5%) (569). This trial was not powered to provide reliable 
estimates of the efficacy of these regimens for treatment of rectal or pharyngeal infection, 
but both regimens cured the few extragenital infections among study participants. Either of 
these regimens might be considered as alternative treatment options in the presence of 
cephalosporin allergy. However, gastrointestinal adverse events might limit their use: 7.7% 
of patients treated with gemifloxacin plus azithromycin and 3.3% of patients treated with 
gentamicin plus azithromycin vomited within 1 hour of medication administration, 
necessitating retreatment with a ceftriaxone and azithromycin.
Spectinomycin, which is useful in persons who cannot tolerate cephalosporins, is expensive, 
has poor efficacy against pharyngeal infection (51.8%; 95% CI = 38.7%–64.9%) (566), and 
is not being produced in the United States (570). However, it has been effective in clinical 
trials, curing 98.2% of uncomplicated urogenital and anorectal gonococcal infections (566). 
When available, spectinomycin is an effective alternative for the treatment of urogenital and 
anorectal infection.
Monotherapy with azithromycin 2 g orally as a single dose has been demonstrated to be 
99.2% effective against uncomplicated urogenital gonorrhea (95% CI = 97.3%–99.9%) 
(567). However, monotherapy is no longer recommended because of concerns over the ease 
with which N. gonorrhoeae can develop resistance to macrolides, and because several 
studies have documented azithromycin treatment failures (546,571–574). Strains of N. 
gonorrhoeae circulating in the United States are not adequately susceptible to penicillins, 
tetracyclines, and older macrolides (e.g., erythromycin), and thus use of these antimicrobials 
cannot be recommended.
Uncomplicated Gonococcal Infections of the Pharynx—Most gonococcal 
infections of the pharynx are asymptomatic and can be relatively common in some 
populations (505,506,575,576). Gonococcal infections of the pharynx are more difficult to 
eradicate than are infections at urogenital and anorectal sites (551). Few antimicrobial 
regimens, including those involving oral cephalosporins, can reliably cure >90% of 
gonococcal pharyngeal infections (566,567). Providers should ask their patients with 
urogenital or rectal GC about oral sexual exposure; if reported, patients should be treated 
with a regimen with acceptable efficacy against pharyngeal gonorrhea infection.
Recommended Regimen
Ceftriaxone 250 mg IM in a single dose
 PLUS
Azithromycin 1 g orally in a single dose
Other Management Considerations—To maximize adherence with recommended 
therapies and reduce complications and transmission, medication for gonococcal infection 
should be provided on site and directly observed. If medications are not available when 
treatment is indicated, linkage to an STD treatment facility should be provided for same-day 
treatment. To minimize disease transmission, persons treated for gonorrhea should be 
instructed to abstain from sexual activity for 7 days after treatment and until all sex partners 
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are adequately treated (7 days after receiving treatment and resolution of symptoms, if 
present). All persons who receive a diagnosis of gonorrhea should be tested for other STDs, 
including chlamydia, syphilis, and HIV.
Follow-Up—A test-of-cure is not needed for persons who receive a diagnosis of 
uncomplicated urogenital or rectal gonorrhea who are treated with any of the recommended 
or alternative regimens; however, any person with pharyngeal gonorrhea who is treated with 
an alternative regimen should return 14 days after treatment for a test-of-cure using either 
culture or NAAT. If the NAAT is positive, effort should be made to perform a confirmatory 
culture before retreatment. All positive cultures for test-of-cure should undergo 
antimicrobial susceptibility testing.
Symptoms that persist after treatment should be evaluated by culture for N. gonorrhoeae 
(with or without simultaneous NAAT), and any gonococci isolated should be tested for 
antimicrobial susceptibility. Persistent urethritis, cervicitis, or proctitis also might be caused 
by other organisms (see Urethritis, Cervicitis, and Proctitis sections).
A high prevalence of N. gonorrhoeae infection has been observed among men and women 
previously treated for gonorrhea (86,480,481,577). Rather than signaling treatment failure, 
most of these infections result from reinfection caused by failure of sex partners to receive 
treatment or the initiation of sexual activity with a new infected partner, indicating a need for 
improved patient education and treatment of sex partners. Men or women who have been 
treated for gonorrhea should be retested 3 months after treatment regardless of whether they 
believe their sex partners were treated. If retesting at 3 months is not possible, clinicians 
should retest whenever persons next present for medical care within 12 months following 
initial treatment.
Management of Sex Partners—Recent sex partners (i.e., persons having sexual contact 
with the infected patient within the 60 days preceding onset of symptoms or gonorrhea 
diagnosis) should be referred for evaluation, testing, and presumptive dual treatment. If the 
patient’s last potential sexual exposure was >60 days before onset of symptoms or diagnosis, 
the most recent sex partner should be treated. To avoid reinfection, sex partners should be 
instructed to abstain from unprotected sexual intercourse for 7 days after they and their 
sexual partner(s) have completed treatment and after resolution of symptoms, if present.
For heterosexual men and women with gonorrhea for whom health department partner-
management strategies are impractical or unavailable and whose providers are concerned 
about partners’ access to prompt clinical evaluation and treatment, EPT with cefixime 400 
mg and azithromycin 1 g can be delivered to the partner by the patient, a disease 
investigation specialist, or a collaborating pharmacy as permitted by law (see Partner 
Services). With this approach, provision of medication must be accompanied by written 
materials (93,95) to educate partners about their exposure to gonorrhea, the importance of 
therapy, and when to seek clinical evaluation for adverse reactions or complications. 
Educational materials for female partners should include information about the importance 
of seeking medical evaluation for PID (especially if symptomatic); undertreatment of PID in 
female partners and missed opportunities to diagnose other STDs in women are of concern. 
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EPT should not be considered a routine partner management strategy in MSM with 
gonorrhea because of a high risk for coexisting infections (especially HIV infection) and 
because no data exist on efficacy in this population.
Special Considerations
Allergy, Intolerance, and Adverse Reactions: Allergic reactions to first-generation 
cephalosporins occur in <2.5% of persons with a history of penicillin allergy and are 
uncommon with third-generation cephalosporins (e.g., ceftriaxone and cefixime) 
(428,430,464). Use of ceftriaxone or cefixime is contraindicated in persons with a history of 
an IgE-mediated penicillin allergy (e.g., anaphylaxis, Stevens Johnson syndrome, and toxic 
epidermal necrolysis) (428,431). Data are limited regarding alternative regimens for treating 
gonorrhea among persons who have either a cephalosporin or IgE-mediated penicillin 
allergy. Potential therapeutic options are dual treatment with single doses of oral 
gemifloxacin 320 mg plus oral azithromycin 2 g or dual treatment with single doses of 
intramuscular gentamicin 240 mg plus oral azithromycin 2 g (569). Spectinomycin for 
treatment of urogenital and anorectal gonorrhea can be considered when available. Providers 
treating persons with cephalosporin or IgE-mediated penicillin allergy should consult an 
infectious-disease specialist.
Pregnancy: Pregnant women infected with N. gonorrhoeae should be treated with dual 
therapy consisting of ceftriaxone 250 mg in a single IM dose and azithromycin 1 g orally as 
a single dose. When cephalosporin allergy or other considerations preclude treatment with 
this regimen and spectinomycin is not available, consultation with an infectious-disease 
specialist is recommended.
HIV Infection: Persons who have gonorrhea and HIV infection should receive the same 
treatment regimen as those who are HIV negative. For more information, see appropriate 
treatment sections under Gonoccocal Infections.
Suspected Cephalosporin Treatment Failure: Cephalosporin treatment failure is the 
persistence of N. gonorrhoeae infection despite appropriate cephalosporin treatment and is 
indicative of infection with cephalosporin-resistant gonorrhea in persons whose partners 
were adequately treated and whose risk for reinfection is low. Suspected treatment failure 
has been reported among persons receiving oral and injectable cephalosporins (541–
557,578). Treatment failure should be considered in 1) persons whose symptoms do not 
resolve within 3–5 days after appropriate treatment and report no sexual contact during the 
post-treatment follow-up period and 2) persons with a positive test-of-cure (i.e., positive 
culture ≥72 hours or positive NAAT ≥7 days after receiving recommended treatment) when 
no sexual contact is reported during the post-treatment follow-up period (579). Treatment 
failure should also be considered in persons who have a positive culture on test-of-cure (if 
obtained) if there is evidence of decreased susceptibility to cephalosporins on antimicrobial 
susceptibility testing, regardless of whether sexual contact is reported during the post-
treatment follow-up period.
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Most suspected treatment failures in the United States are likely to be re-infections rather 
than actual treatment failures (86,480,481,577). However, in cases where reinfection is 
unlikely and treatment failure is suspected, before retreatment, relevant clinical specimens 
should be obtained for culture (preferably with simultaneous NAAT) and antimicrobial 
susceptibility testing if N. gonorrhoeae is isolated. Phenotypic antimicrobial susceptibility 
testing should be performed using disk diffusion, Etest (BioMérieux, Durham, NC), or agar 
dilution. Data are limited on the use of DNA amplification and sequencing for detection of 
genetic mutations associated with gonococcal antimicrobial resistance. All isolates of 
suspected treatment failures should be sent to CDC for antimicrobial susceptibility testing 
by agar dilution; local laboratories should store isolates for possible further testing if needed. 
Testing and/or storage of specimens or isolates should be facilitated by the state or local 
health department according to local public health protocol.
For persons with suspected cephalosporin treatment failure, the treating clinician should 
consult an infectious-disease specialist, an STD/HIV Prevention Training Center clinical 
expert (http://www.nnptc.org), the local or state health department STD program, or CDC 
(telephone: 404-639-8659) for advice on obtaining cultures, antimicrobial susceptibility 
testing, and treatment. Suspected treatment failure should be reported to CDC through the 
local or state health department within 24 hours of diagnosis.
Suspected treatment failures first should be retreated routinely with the recommended 
regimen (ceftriaxone 250 mg IM plus azithromycin 1 g orally), because reinfections are 
more likely than actual treatment failures. However, in situations with a higher likelihood of 
treatment failure than reinfection, relevant clinical specimens should be obtained for culture 
(preferably with simultaneous NAAT) and antimicrobial susceptibility testing performed 
before retreatment. Dual treatment with single doses of oral gemifloxacin 320 mg plus oral 
azithromycin 2 g or dual treatment with single doses of intramuscular gentamicin 240 mg 
plus oral azithromycin 2 g can be considered, particularly when isolates are found to have 
elevated cephalosporin MICs (569). Persons with suspected treatment failure after treatment 
with the alternative regimen (cefixime and azithromycin) should be treated with ceftriaxone 
250 mg as a single IM dose and azithromycin 2 g orally as a single dose. A test-of-cure at 
relevant clinical sites should be obtained 7–14 days after retreatment; culture is the 
recommended test, preferably with simultaneous NAAT and antimicrobial susceptibility 
testing of N. gonorrhoeae if isolated. Clinicians should ensure that the patient’s sex partners 
from the preceding 60 days are evaluated promptly with culture and presumptively treated 
using the same regimen used for the patient.
Gonococcal Conjunctivitis: In the only published study (conducted in 1989) of the 
treatment of gonococcal conjunctivitis among adults, all 12 study participants responded to a 
single 1 g IM injection of ceftriaxone (580). On the basis of experience with other microbes 
that have developed antimicrobial resistance rapidly, a theoretical basis exists for 
combination therapy using two antimicrobials with different mechanisms of action (e.g., a 
cephalosporin plus azithromycin) to improve treatment efficacy and potentially slow the 
emergence and spread of resistance to cephalosporins. Because gonococcal conjunctivitis is 
uncommon and data on treatment of gonococcal conjunctivitis in adults are limited, 
consultation with an infectious-disease specialist should be considered.
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Recommended Regimen
Ceftriaxone 1 g IM in a single dose
 PLUS
Azithromycin 1 g orally in a single dose
Consider one-time lavage of the infected eye with saline solution.
Management of Sex Partners: Patients should be instructed to refer their sex partners for 
evaluation and treatment. For more information, see Gonococcal Infections, Management of 
Sex Partners.
Disseminated Gonococcal Infection—Disseminated gonococcal infection (DGI) 
frequently results in petechial or pustular acral skin lesions, asymmetric polyarthralgia, 
tenosynovitis, or oligoarticular septic arthritis (581). The infection is complicated 
occasionally by perihepatitis and rarely by endocarditis or meningitis. Some strains of N. 
gonorrhoeae that cause DGI can cause minimal genital inflammation. If DGI is suspected, 
NAAT or culture specimens from urogenital and extragenital sites, as applicable, should be 
collected and processed in addition to specimens from disseminated sites of infection (e.g., 
skin, synovial fluid, blood, and the CNS). All N. gonorrhoeae isolates should be tested for 
antimicrobial susceptibility.
Hospitalization and consultation with an infectious-disease specialist are recommended for 
initial therapy, especially for persons who might not comply with treatment, have an 
uncertain diagnosis, or have purulent synovial effusions or other complications. Examination 
for clinical evidence of endocarditis and meningitis should be performed.
Treatment of Arthritis and Arthritis-Dermatitis Syndrome
Recommended Regimen
Ceftriaxone 1 g IM or IV every 24 hours
 PLUS
Azithromycin 1 g orally in a single dose
Alternative Regimens
Cefotaxime 1 g IV every 8 hours
 OR
Ceftizoxime 1 g IV every 8 hours
 PLUS
Azithromycin 1 g orally in a single dose
When treating for the arthritis-dermatitis syndrome, the provider can switch to an oral agent 
guided by antimicrobial susceptibility testing 24–48 hours after substantial clinical 
improvement, for a total treatment course of at least 7 days.
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Treatment of Gonococcal Meningitis and Endocarditis
Recommended Regimen
Ceftriaxone 1–2 g IV every 12–24 hours
 PLUS
Azithromycin 1 g orally in a single dose
No recent studies have been published on the treatment of DGI. The duration of treatment of 
DGI has not been systematically studied and should be determined in consultation with an 
infectious-disease specialist. Treatment for DGI should be guided by the results of 
antimicrobial susceptibility testing. Pending antimicrobial susceptibility results, treatment 
decisions should be made on the basis of clinical presentation. Therapy for meningitis 
should be continued with recommended parenteral therapy for 10–14 days. Parenteral 
antimicrobial therapy for endocarditis should be administered for at least 4 weeks.
Management of Sex Partners: Gonococcal infection frequently is asymptomatic in sex 
partners of persons who have DGI. Providers should instruct patients to refer partners with 
whom they have had sexual contact in the past 60 days for evaluation, testing, and 
presumptive treatment (see Gonococcal Infection, Management of Sex Partners).
Gonococcal Infections Among Neonates
Prenatal screening and treatment of pregnant women is the best method for preventing GC 
infection among neonates. Gonococcal infection among neonates results from perinatal 
exposure to the mother’s infected cervix. It is usually an acute illness that manifests 2–5 
days after birth. The prevalence of infection among infants depends on the prevalence of 
infection among pregnant women, whether pregnant women are screened and treated for 
gonorrhea, and whether newborns receive ophthalmia prophylaxis. The most severe 
manifestations of N. gonorrhoeae infection in newborns are ophthalmia neonatorum and 
sepsis, which can include arthritis and meningitis. Less severe manifestations include 
rhinitis, vaginitis, urethritis, and infection at sites of fetal monitoring.
Ophthalmia Neonatorum Prophylaxis—To prevent gonococcal ophthalmia 
neonatorum, a prophylactic agent should be instilled into both eyes of all newborn infants; 
this procedure is required by law in most states. Ocular prophylaxis is warranted because it 
can prevent sight-threatening gonococcal ophthalmia, has an excellent safety record, is easy 
to administer, and is inexpensive. The recommended prophylactic regimen prevents 
gonococcal ophthalmia; however, its efficacy for prevention of chlamydial ophthalmia is less 
clear, and it does not eliminate nasopharyngeal colonization by C. trachomatis.
Recommended Regimen
Erythromycin (0.5%) ophthalmic ointment in each eye in a single application at birth
This preparation should be instilled into both eyes of all neonates as soon as possible after 
delivery, regardless of whether they are delivered vaginally or by cesarean section. Ideally, 
ointment should be applied using single-use tubes or ampules rather than multiple-use tubes. 
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If prophylaxis is delayed (i.e., not administered in the delivery room), a monitoring system 
should be established to ensure that all infants receive prophylaxis.
Erythromycin is the only antibiotic ointment recommended for use in neonates. Silver nitrate 
and tetracycline ophthalmic ointment is no longer manufactured in the United States, 
bacitracin is not effective, and povidone iodine has not been studied adequately (582,583). 
Gentamicin ophthalmic ointment has been associated with severe ocular reactions in 
neonates and should not be used for ocular prophylaxis (584,585). If erythromycin ointment 
is not available, infants at risk for exposure to N. gonorrhoeae (especially those born to a 
mother at risk for gonococcal infection or with no prenatal care) can be administered 
ceftriaxone 25–50 mg/kg IV or IM, not to exceed 125 mg in a single dose (586).
N. gonorrhoeae causes ophthalmia neonatorum relatively infrequently in the United States 
(587). However, identifying and treating this infection is especially important, because 
ophthalmia neonatorum can result in perforation of the globe of the eye and blindness (588).
Diagnostic Considerations—Infants at increased risk for gonococcal ophthalmia 
include those who did not receive ophthalmia prophylaxis and whose mothers had no 
prenatal care or have a history of STDs or substance abuse. Gonococcal ophthalmia is 
strongly suspected when intracellular gram-negative diplococci are identified on Gram stain 
of conjunctival exudate, justifying presumptive treatment for gonorrhea after appropriate 
cultures and antimicrobial susceptibility testing for N. gonorrhoeae are performed. 
Presumptive treatment for N. gonorrhoeae might be indicated for newborns at increased risk 
for gonococcal ophthalmia who have increased WBCs (but not intracellular gram negative 
diplococci) in a Gram-stained smear of conjunctival exudate. Nongonococcal causes of 
neonatal ophthalmia include Moraxella catarrhalis and other Neisseria species, organisms 
that are indistinguishable from N. gonorrhoeae on Gram-stained smear but can be 
differentiated in the microbiology laboratory.
Treatment
Recommended Regimen
Ceftriaxone 25–50 mg/kg IV or IM in a single dose, not to exceed 125 mg
One dose of ceftriaxone is adequate therapy for gonococcal conjunctivitis. Ceftriaxone 
should be administered cautiously to hyperbilirubinemic infants, especially those born 
prematurely. No data exist on the use of dual therapy for the treatment of gonococcal 
ophthalmia. Topical antibiotic therapy alone is inadequate and unnecessary if systemic 
treatment is administered.
Other Management Considerations—Appropriate chlamydial testing should be done 
simultaneously from the inverted eyelid specimen (see Ophthalmia Neonatorum Caused by 
C. trachomatis). Infants who have gonococcal ophthalmia should be evaluated for signs of 
disseminated infection (e.g., sepsis, arthritis, and meningitis). Infants who have gonococcal 
ophthalmia should be managed in consultation with an infectious-disease specialist.
Workowski and Bolan Page 106
MMWR Recomm Rep. Author manuscript; available in PMC 2018 April 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Follow-up—Infants who have ophthalmia neonatorum should be managed in consultation 
with an infectious-disease specialist.
Management of Mothers and Their Sex Partners—Mothers of infants with 
ophthalmia neonatorum caused by N. gonorrhoeae should be evaluated, tested, and 
presumptively treated for gonorrhea, along with their sex partner(s). For more information, 
see Gonococcal Infections in Adolescents and Adults.
DGI and Gonococcal Scalp Abscesses in Neonates—DGI might present as sepsis, 
arthritis, or meningitis and is a rare complication of neonatal gonococcal infection. 
Localized gonococcal infection of the scalp can result from fetal monitoring through scalp 
electrodes. Detection of gonococcal infection in neonates who have sepsis, arthritis, 
meningitis, or scalp abscesses requires cultures of blood, CSF, and joint aspirate. Specimens 
obtained from the conjunctiva, vagina, oropharynx, and rectum are useful for identifying the 
primary site(s) of infection. Antimicrobial susceptibility testing of all isolates should be 
performed. Positive Gram-stained smears of exudate, CSF, or joint aspirate provide a 
presumptive basis for initiating treatment for N. gonorrhoeae.
Recommended Regimens
Ceftriaxone 25–50 mg/kg/day IV or IM in a single daily dose for 7 days, with a duration of 10–14 days if meningitis is 
documented
 OR
Cefotaxime 25 mg/kg IV or IM every 12 hours for 7 days, with a duration of 10–14 days if meningitis is documented
Ceftriaxone should be administered cautiously to hyperbilirubinemic infants, especially 
those born prematurely. No data exist on the use of dual therapy for the treatment of DGI or 
gonococcal scalp abscesses.
Other Management Considerations: Appropriate chlamydial testing should be done 
simultaneously in neonates with gonococcal infection. For more information, see Chlamydia 
Infection in Neonates. Infants who have DGI should be managed in consultation with an 
infectious-disease specialist.
Management of Mothers and Their Sex Partners: Mothers of infants who have DGI or 
scalp abscesses caused by N. gonorrhoeae should be evaluated, tested, and presumptively 
treated for gonorrhea, along with their sex partner(s). For more information, see Gonococcal 
Infections in Adolescents and Adults.
Neonates Born to Mothers Who Have Gonococcal Infection—Neonates born to 
mothers who have untreated gonorrhea are at high risk for infection. Neonates should be 
tested for gonorrhea at exposed sites and treated presumptively for gonorrhea as 
recommended in these guidelines. No data exist on the use of dual therapy to treat neonates 
born to mothers who have gonococcal infection.
Recommended Regimen in the Absence of Signs of Gonococcal Infection
Ceftriaxone 25–50 mg/kg IV or IM in a single dose, not to exceed 125 mg
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Other Management Considerations: Appropriate chlamydial testing should be done 
simultaneously in neonates with gonococcal infection. For more information, see Chlamydia 
Infection in Neonates. Follow-up examination is not required.
Management of Mothers and Their Sex Partners: Mothers who have gonorrhea and their 
sex partners should be evaluated, tested, and presumptively treated for gonorrhea. For more 
information, see Gonococcal Infections.
Gonococcal Infections Among Infants and Children
Sexual abuse is the most frequent cause of gonococcal infection in infants and children (see 
Sexual Assault or Abuse of Children). For preadolescent girls, vaginitis is the most common 
manifestation of this infection; gonococcal-associated PID after vaginal infection can be less 
common in preadolescents than adults. Among sexually abused children, anorectal and 
pharyngeal infections with N. gonorrhoeae are frequently asymptomatic.
Diagnostic Considerations—NAAT can be used to test vaginal and urine specimens 
from girls (see Sexual Assault or Abuse of Children), although data are insufficient to 
recommend the use of these tests in boys and from extragenital sites (rectum and pharynx) in 
boys and girls (394). Culture remains the preferred method for diagnosing boys and for 
detecting infection in specimens obtained from extragenital sites regardless of gender (394). 
Gram stains are inadequate for evaluating prepubertal children for gonorrhea and should not 
be used to diagnose or exclude gonorrhea. If evidence of disseminated gonococcal infection 
exists, gonorrhea culture and antimicrobial susceptibility testing should be obtained from 
relevant clinical sites (see DGI).
Recommended Regimen for Infants and Children Who Weigh ≤45 kg and Who Have Uncomplicated Gonococcal 
Vulvovaginitis, Cervicitis, Urethritis, Pharyngitis, or Proctitis
Ceftriaxone 25–50 mg/kg IV or IM in a single dose, not to exceed 125 mg IM
Recommended Regimen for Children Who Weigh >45 kg and Who Have Uncomplicated Gonococcal 
Vulvovaginitis, Cervicitis, Urethritis, Pharyngitis, or Proctitis
Treat with one of the regimens recommended for adults (see Gonococcal Infections)
Recommended Regimen for Children Who Weigh ≤45 kg and Who Have Bacteremia or Arthritis
Ceftriaxone 50 mg/kg (maximum dose: 1 g) IM or IV in a single dose daily for 7 days
Recommended Regimen for Children Who Weigh >45 kg and Who Have Bacteremia or Arthritis
Ceftriaxone 1 g IM or IV in a single dose daily every 24 hours for 7 days
No data exist regarding the use of dual therapy for treating children with gonococcal 
infection.
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Other Management Considerations—Follow-up cultures are unnecessary. Only 
parenteral cephalosporins (i.e., ceftriaxone) are recommended for use in children. All 
children found to have gonococcal infections should be tested for C. trachomatis, syphilis, 
and HIV. For a discussion of concerns regarding sexual assault, see Sexual Assault or Abuse 
of Children.
Diseases Characterized by Vaginal Discharge
Most women will have a vaginal infection, characterized by discharge, itching, or odor, 
during their lifetime. With the availability of complementary and alternative therapies and 
over-the-counter medications for candidiasis, many symptomatic women seek these products 
before or in addition to an evaluation by a medical provider.
Obtaining a medical history alone has been shown to be insufficient for accurate diagnosis 
of vaginitis and can lead to the inappropriate administration of medication. Therefore, a 
careful history, examination, and laboratory testing to determine the etiology of vaginal 
symptoms are warranted. Information on sexual behaviors and practices, gender of sex 
partners, menses, vaginal hygiene practices (e.g., douching), and self-treatment with 
medications should be elicited. The three diseases most frequently associated with vaginal 
discharge are BV (replacement of the vaginal flora by an overgrowth of anaerobic bacteria 
including Prevotella sp., Mobiluncus sp., G. vaginalis, Ureaplasma, Mycoplasma, and 
numerous fastidious or uncultivated anaerobes), T. vaginalis, and candidiasis. Cervicitis can 
also cause an abnormal discharge. Although vulvovaginal candidiasis (VVC) is usually not 
transmitted sexually, it is included in this section because it is frequently diagnosed in 
women who have vaginal symptoms or are being evaluated for STDs.
Various diagnostic methods are available to identify the etiology of an abnormal vaginal 
discharge. Clinical laboratory testing can identify the cause of vaginitis in most women and 
is discussed in detail in the sections of this report dedicated to each condition. In the 
clinician’s office, the cause of vaginal symptoms might be determined by pH, a potassium 
hydroxide (KOH) test, and microscopic examination of fresh samples of the discharge. The 
pH of the vaginal secretions can be determined by narrow-range pH paper; an elevated pH 
(i.e., ≥4.5) is common with BV or trichomoniasis. Because pH testing is not highly specific, 
discharge should be further examined microscopically by first diluting one sample in one or 
two drops of 0.9% normal saline solution on one slide and a second sample in 10% KOH 
solution (samples that emit an amine odor immediately upon application of KOH suggest 
BV or trichomoniasis). Coverslips are then placed on the slides, and they are examined 
under a microscope at low and high power.
The saline-solution specimen might show motile trichomonads or “clue cells” (i.e., epithelial 
cells with borders obscured by small bacteria), which are characteristic of BV. The KOH 
specimen typically is used to identify hyphae or blastospores seen with candidiasis. 
However, the absence of trichomonads in saline or fungal elements in KOH samples does 
not rule out these infections, because the sensitivity of microscopy is approximately 50% 
compared with NAAT (trichomoniasis) or culture (yeast) (475). The presence of WBCs 
without evidence of trichomonads or yeast may also suggest cervicitis (see Cervicitis).
Workowski and Bolan Page 109
MMWR Recomm Rep. Author manuscript; available in PMC 2018 April 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
In settings where pH paper, KOH, and microscopy are not available, alternative 
commercially available point-of-care tests or clinical laboratory testing can be used to 
diagnose vaginitis. The presence of objective signs of vulvar inflammation in the absence of 
vaginal pathogens after laboratory testing suggests the possibility of mechanical, chemical, 
allergic, or other noninfectious causes of vulvovaginal signs or symptoms. In patients with 
persistent symptoms and no clear etiology, referral to a specialist may be helpful.
Bacterial Vaginosis
BV is a polymicrobial clinical syndrome resulting from replacement of the normal hydrogen 
peroxide producing Lactobacillus sp. in the vagina with high concentrations of anaerobic 
bacteria (e.g., Prevotella sp. and Mobiluncus sp.), G. vaginalis, Ureaplasma, Mycoplasma, 
and numerous fastidious or uncultivated anaerobes. Some women experience transient 
vaginal microbial changes, whereas others experience them for longer intervals of time. 
Among women presenting for care, BV is the most prevalent cause of vaginal discharge or 
malodor; however, in a nationally representative survey, most women with BV were 
asymptomatic (203).
BV is associated with having multiple male or female partners, a new sex partner, douching, 
lack of condom use, and lack of vaginal lactobacilli; women who have never been sexually 
active are rarely affected (589). The cause of the microbial alteration that precipitates BV is 
not fully understood, and whether BV results from acquisition of a single sexually 
transmitted pathogen is not known. Nonetheless, women with BV are at increased risk for 
the acquisition of some STDs (e.g., HIV, N. gonorrhoeae, C. trachomatis, and HSV-2), 
complications after gynecologic surgery, complications of pregnancy, and recurrence of BV 
(590–593). BV also increases the risk for HIV transmission to male sex partners (594). 
Although BV-associated bacteria can be found in the male genitalia, treatment of male sex 
partners has not been beneficial in preventing the recurrence of BV (595).
Diagnostic Considerations—BV can be diagnosed by the use of clinical criteria (i.e., 
Amsel’s Diagnostic Criteria) (596) or Gram stain. A Gram stain (considered the gold 
standard laboratory method for diagnosing BV) is used to determine the relative 
concentration of lactobacilli (i.e., long Gram-positive rods), Gram-negative and Gram-
variable rods and cocci (i.e., G vaginalis, Prevotella, Porphyromonas, and 
peptostreptococci), and curved Gram-negative rods (i.e., Mobiluncus) characteristic of BV. 
Clinical criteria require three of the following symptoms or signs:
• homogeneous, thin, white discharge that smoothly coats the vaginal walls;
• clue cells (e.g., vaginal epithelial cells studded with adherent coccoobacilli) on 
microscopic examination;
• pH of vaginal fluid >4.5; or
• a fishy odor of vaginal discharge before or after addition of 10% KOH (i.e., the 
whiff test).
Detection of three of these criteria has been correlated with results by Gram stain (597). 
Other tests, including Affirm VP III (Becton Dickinson, Sparks, MD), a DNA hybridization 
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probe test for high concentrations of G vaginalis, and the OSOM BV Blue test (Sekisui 
Diagnostics, Framingham, MA), which detects vaginal fluid sialidase activity, have 
acceptable performance characteristics compared with Gram stain. Although a 
prolineaminopeptidase card test is available for the detection of elevated pH and 
trimethylamine, it has low sensitivity and specificity and therefore is not recommended. PCR 
has been used in research settings for the detection of a variety of organisms associated with 
BV, but evaluation of its clinical utility is still underway. Detection of specific organisms 
might be predictive of BV by PCR (598,599). Additional validation is needed before these 
tests can be recommended to diagnose BV. Culture of G vaginalis is not recommended as a 
diagnostic tool because it is not specific. Cervical Pap tests have no clinical utility for the 
diagnosis of BV because of their low sensitivity and specificity.
Treatment—Treatment is recommended for women with symptoms. The established 
benefits of therapy in nonpregnant women are to relieve vaginal symptoms and signs of 
infection. Other potential benefits to treatment include reduction in the risk for acquiring C. 
trachomatis, N. gonorrhoeae, T. vaginalis, HIV, and herpes simplex type 2 (592,593,600).
Recommended Regimens
Metronidazole 500 mg orally twice a day for 7 days
 OR
Metronidazole gel 0.75%, one full applicator (5 g) intravaginally, once a day for 5 days
 OR
Clindamycin cream 2%, one full applicator (5 g) intravaginally at bedtime for 7 days
Alcohol consumption should be avoided during treatment with nitroimidazoles. To reduce 
the possibility of a disulfiram-like reaction, abstinence from alcohol use should continue for 
24 hours after completion of metronidazole. Clindamycin cream is oil-based and might 
weaken latex condoms and diaphragms for 5 days after use (refer to clindamycin product 
labeling for additional information).
Women should be advised to refrain from sexual activity or use condoms consistently and 
correctly during the treatment regimen. Douching might increase the risk for relapse, and no 
data support the use of douching for treatment or relief of symptoms.
Alternative Regimens
Tinidazole 2 g orally once daily for 2 days
 OR
Tinidazole 1 g orally once daily for 5 days
 OR
Clindamycin 300 mg orally twice daily for 7 days
 OR
Clindamycin ovules 100 mg intravaginally once at bedtime for 3 days*
*Clindamycin ovules use an oleaginous base that might weaken latex or rubber products (e.g., condoms and vaginal 
contraceptive diaphragms). Use of such products within 72 hours following treatment with clindamycin ovules is not 
recommended.
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Alcohol consumption should be avoided during treatment with nitroimidazoles. To reduce 
the possibility of a disulfiram-like reaction, abstinence from alcohol use should continue for 
72 hours after completion of tinidazole.
Alternative regimens include several tinidazole regimens (601) or clindamycin (oral or 
intravaginal) (602). An additional regimen includes metronidazole (750-mg extended release 
tablets orally once daily for 7 days); however, data on the performance of this alternative 
regimen are limited.
Certain studies have evaluated the clinical and microbiologic efficacy of using intravaginal 
lactobacillus formulations to treat BV and restore normal flora (603–607). Overall, no 
studies support the addition of any available lactobacillus formulations or probiotic as an 
adjunctive or replacement therapy in women with BV. Further research efforts to determine 
the role of these regimens in BV treatment and prevention are ongoing.
Other Management Considerations—All women with BV should be tested for HIV 
and other STDs.
Follow-Up—Follow-up visits are unnecessary if symptoms resolve. Because persistent or 
recurrent BV is common, women should be advised to return for evaluation if symptoms 
recur. Detection of certain BV-associated organisms has been associated with antimicrobial 
resistance and might be predictive of risk for subsequent treatment failure (608–613). 
Limited data are available regarding optimal management strategies for women with 
persistent or recurrent BV. Using a different recommended treatment regimen can be 
considered in women who have a recurrence; however, retreatment with the same 
recommended regimen is an acceptable approach for treating persistent or recurrent BV after 
the first occurrence (614). For women with multiple recurrences after completion of a 
recommended regimen, 0.75% metronidazole gel twice weekly for 4–6 months has been 
shown to reduce recurrences, although this benefit might not persist when suppressive 
therapy is discontinued (615). Limited data suggest that an oral nitroimidazole 
(metronidazole or tinidazole 500 mg twice daily for 7 days) followed by intravaginal boric 
acid 600 mg daily for 21 days and then suppressive 0.75% metronidazole gel twice weekly 
for 4–6 months for those women in remission might be an option for women with recurrent 
BV (616). Monthly oral metronidazole 2 g administered with fluconazole 150 mg has also 
been evaluated as suppressive therapy; this regimen reduced the incidence of BV and 
promoted colonization with normal vaginal flora (617).
Management of Sex Partners—Data from clinical trials indicate that a woman’s 
response to therapy and the likelihood of relapse or recurrence are not affected by treatment 
of her sex partner(s) (595). Therefore, routine treatment of sex partners is not recommended.
Special Considerations
Allergy, Intolerance, or Adverse Reactions: Intravaginal clindamycin cream is preferred 
in case of allergy or intolerance to metronidazole or tinidazole. Intravaginal metronidazole 
gel can be considered for women who are not allergic to metronidazole but do not tolerate 
oral metronidazole. It is advised to avoid consuming alcohol during treatment with 
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nitroimidazoles. To reduce the possibility of a disulfiram-like reaction, abstinence from 
alcohol use should continue for 24 hours after completion of metronidazole or 72 hours after 
completion of tinidazole.
Pregnancy: Treatment is recommended for all symptomatic pregnant women. Studies have 
been undertaken to determine the efficacy of BV treatment among this population, including 
two trials demonstrating that metronidazole was efficacious during pregnancy using the 250-
mg regimen (618,619); however, metronidazole administered at 500 mg twice daily can be 
used. One trial involving a limited number of participants revealed treatment with oral 
metronidazole 500 mg twice daily to be equally effective as metronidazole gel, with cure 
rates of 70% using Amsel criteria to define cure (620). Another trial demonstrated a cure 
rate of 85% using Gram-stain criteria after treatment with oral clindamycin (621). Multiple 
studies and meta-analyses have failed to demonstrate an association between metronidazole 
use during pregnancy and teratogenic or mutagenic effects in newborns (622,623). Although 
older studies indicated a possible link between use of vaginal clindamycin during pregnancy 
and adverse outcomes for the newborn, newer data demonstrate that this treatment approach 
is safe for pregnant women (624). Because oral therapy has not been shown to be superior to 
topical therapy for treating symptomatic BV in effecting cure or preventing adverse 
outcomes of pregnancy, symptomatic pregnant women can be treated with either of the oral 
or vaginal regimens recommended for nonpregnant women. Although adverse pregnancy 
outcomes, including premature rupture of membranes, preterm labor, preterm birth, intra-
amniotic infection, and postpartum endometritis have been associated with symptomatic BV 
in some observational studies, treatment of BV in pregnant women can reduce the signs and 
symptoms of vaginal infection. A meta-analysis has concluded that no antibiotic regimen 
prevented preterm birth (early or late) in women with BV (symptomatic or asymptomatic). 
However, in one study, oral BV therapy reduced the risk for late miscarriage, and in two 
additional studies, such therapy decreased adverse outcomes in the neonate (625).
Treatment of asymptomatic BV among pregnant women who are at high risk for preterm 
delivery (i.e., those with a previous preterm birth) has been evaluated by several studies, 
which have yielded mixed results. Seven trials have evaluated treatment of pregnant women 
with asymptomatic BV at high risk for preterm delivery: one showed harm (626), two 
showed no benefit (627,628), and four demonstrated benefit (618,619,629,630).
Similarly, data are inconsistent regarding whether treatment of asymptomatic BV among 
pregnant women who are at low risk for preterm delivery reduces adverse outcomes of 
pregnancy. One trial demonstrated a 40% reduction in spontaneous preterm birth among 
women using oral clindamycin during weeks 13–22 of gestation (630). Several additional 
trials have shown that intravaginal clindamycin given at an average gestation of >20 weeks 
did not reduce likelihood of preterm birth (628,631–633). Therefore, evidence is insufficient 
to recommend routine screening for BV in asymptomatic pregnant women at high or low 
risk for preterm delivery for the prevention of preterm birth (111).
Although metronidazole crosses the placenta, no evidence of teratogenicity or mutagenic 
effects in infants has been found in multiple cross-sectional and cohort studies of pregnant 
women (634). Data suggest that metronidazole therapy poses low risk in pregnancy (317).
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Metronidazole is secreted in breast milk. With maternal oral therapy, breastfed infants 
receive metronidazole in doses that are less than those used to treat infections in infants, 
although the active metabolite adds to the total infant exposure. Plasma levels of the drug 
and metabolite are measurable, but remain less than maternal plasma levels (http://
toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT). Although several reported case series found 
no evidence of metronidazole-associated adverse effects in breastfed infants, some clinicians 
advise deferring breastfeeding for 12–24 hours following maternal treatment with a single 2 
g dose of metronidazole (635). Lower doses produce a lower concentration in breast milk 
and are considered compatible with breastfeeding (636,637). Data from studies of human 
subjects are limited regarding the use of tinidazole in pregnancy; however, animal data 
suggest that such therapy poses moderate risk. Thus tinidazole should be avoided during 
pregnancy (317).
HIV Infection: BV appears to recur with higher frequency in women who have HIV 
infection (638). Women with HIV who have BV should receive the same treatment regimen 
as those who do not have HIV infection.
Trichomoniasis
Trichomoniasis is the most prevalent nonviral sexually transmitted infection in the United 
States, affecting an estimated 3.7 million persons (533). Health disparities persist in the 
epidemiology of T. vaginalis infection in the United States: 13% of black women are 
affected compared with 1.8% of non-Hispanic white women (639). T. vaginalis infection 
affects >11% of women aged ≥40 years (640), and particularly high prevalence has been 
detected among STD clinic patients (641) (26% of symptomatic women and 6.5% 
asymptomatic women tested) and incarcerated persons (9%–32% of incarcerated women 
[135,136,640,642,643] and 2%–9% of incarcerated men) (136,137,644,645). The prevalence 
of trichomoniasis in MSM is low (646,647).
Some infected men have symptoms of urethritis, epididymitis, or prostatitis, and some 
infected women have vaginal discharge that might be diffuse, malodorous, or yellow-green 
with or without vulvar irritation. However, most infected persons (70%–85%) have minimal 
or no symptoms, and untreated infections might last for months to years (86,639,648,649). 
Although partners might be unaware of their infection, it is readily passed between sex 
partners during penile-vaginal sex (650). Among persons who are sexually active, the best 
way to prevent trichomoniasis is through consistent and correct use of condoms during all 
penile-vaginal sexual encounters (22). Partners of men who have been circumcised might 
have a somewhat reduced risk of T. vaginalis infection (56,651). Douching is not 
recommended because it might increase the risk for vaginal infections, including 
trichomoniasis (652).
T. vaginalis infection is associated with two- to threefold increased risk for HIV acquisition 
(653–656), preterm birth, and other adverse pregnancy outcomes among pregnant women. 
Among women with HIV infection, T. vaginalis infection is associated with increased risk 
for PID (657–659). Routine screening of asymptomatic women with HIV infection for T. 
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vaginalis is recommended because of the adverse events associated with asymptomatic 
trichomoniasis and HIV infection.
Diagnostic testing for T. vaginalis should be performed in women seeking care for vaginal 
discharge. Screening might be considered for persons receiving care in high-prevalence 
settings (e.g., STD clinics and correctional facilities) and for asymptomatic persons at high 
risk for infection (e.g., persons with multiple sex partners, exchanging sex for payment, 
illicit drug use, or a history of STD). However, data are lacking on whether screening and 
treatment for asymptomatic trichomoniasis in high prevalence settings or persons at high 
risk can reduce any adverse health events and health disparities or reduce community burden 
of infection. Decisions about screening might be informed by local epidemiology of T. 
vaginalis infection.
Whether the rectum can be a reservoir for T. vaginalis infection is unclear; data are needed 
to clarify whether this occasional finding might reflect recent depositing contamination in up 
to 5% of persons reporting recent receptive anal sex (660,661). Further, the efficacy, benefit, 
and cost-effectiveness of rectal screening are unknown; therefore, rectal testing for T. 
vaginalis is not recommended. Similarly, oral testing for T. vaginalis is not recommended 
because of a lack of evidence for oral infections. T. vaginalis infection is not a nationally 
notifiable condition in the United States (118,662).
Diagnostic Considerations—The use of highly sensitive and specific tests is 
recommended for detecting T. vaginalis. Among women, NAAT is highly sensitive, often 
detecting three to five times more T. vaginalis infections than wet-mount microscopy, a 
method with poor sensitivity (51%–65%) (663,664). The APTIMA T. vaginalis assay 
(Hologic Gen-Probe, San Diego, CA) is FDA-cleared for detection of T. vaginalis from 
vaginal, endocervical, or urine specimens from women. This assay detects RNA by 
transcription-mediated amplification with a clinical sensitivity of 95.3%–100% and 
specificity of 95.2%–100% (665,666). Among women, vaginal swab and urine have up to 
100% concordance (663). As analyte-specific reagents, this assay can be used with urine or 
urethral swabs from men if validated per CLIA regulations. The sale, distribution, and use of 
analyte-specific reagents are allowed under 21 C.F.R. 809.30 pertaining to in vitro 
diagnostic products for human use. For T. vaginalis diagnosis in men, the sensitivity of self-
collected penile-meatal swabs was higher than that of urine in one study (80% and 39%, 
respectively) (667). The BD Probe Tec TV Qx Amplified DNA Assay (Becton Dickinson, 
Franklin Lakes, New Jersey) is FDA-cleared for detection of T. vaginalis from endocervical, 
vaginal, or urine specimens from women. Although it might be feasible to perform these 
tests on the same specimen used for chlamydia and gonorrhea screening, the epidemiology 
of trichomoniasis is distinct and should not be overlooked in older adults.
Other FDA-cleared tests to detect T. vaginalis in vaginal secretions include the OSOM 
Trichomonas Rapid Test (Sekisui Diagnostics, Framingham, MA), an antigen-detection test 
using immunochromatographic capillary flow dipstick technology that can be performed at 
the point of care, and the Affirm VP III (Becton Dickinson, Sparks, MD), a DNA 
hybridization probe test that evaluates for T. vaginalis, G. vaginalis, and Candida albicans. 
The results of the OSOM Trichomonas Rapid Test are available in approximately 10 
Workowski and Bolan Page 115
MMWR Recomm Rep. Author manuscript; available in PMC 2018 April 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
minutes, with sensitivity 82%–95% and specificity 97%–100% (666,668). Self-testing might 
become an option, as a study of 209 young women aged 14–22 years found that >99% could 
correctly perform and interpret her own self-test using the OSOM assay, with a high 
correlation with clinician interpretation (96% agreement, κ = 0.87) (669). The results of the 
Affirm VP III are available within 45 minutes. Sensitivity and specificity are 63% and 
99.9%, respectively, compared with culture and TMA; sensitivity might be higher among 
women who are symptomatic (670,671). Neither the OSOM nor the Affirm VP III test is 
FDA-cleared for use with specimens obtained from men.
Culture was considered the gold standard method for diagnosing T. vaginalis infection 
before molecular detection methods became available. Culture has a sensitivity of 75%–96% 
and a specificity of up to 100% (475). In women, vaginal secretions are the preferred 
specimen type for culture, as urine culture is less sensitive (475,672,673). In men, culture 
specimens require a urethral swab, urine sediment, and/or semen. To improve yield, multiple 
specimens from men can be used to inoculate a single culture.
The most common method for T. vaginalis diagnosis might be microscopic evaluation of wet 
preparations of genital secretions because of convenience and relatively low cost. 
Unfortunately, the sensitivity of wet mount is low (51%–65%) in vaginal specimens 
(475,666) and lower in specimens from men (e.g., urethral specimens, urine sediment, and 
semen). Clinicians using wet mounts should attempt to evaluate slides immediately because 
sensitivity declines as evaluation is delayed, decreasing by up to 20% within 1 hour after 
collection (674,675). When highly sensitive (e.g., NAAT) testing on specimens is not 
feasible, a testing algorithm (e.g., wet mount first, followed by NAAT if negative) can 
improve diagnostic sensitivity in persons with an initial negative result by wet mount (475). 
Although T. vaginalis may be an incidental finding on a Pap test, neither conventional nor 
liquid-based Pap tests are considered diagnostic tests for trichomoniasis, because false 
negatives and false positives can occur.
Treatment—Treatment reduces symptoms and signs of T. vaginalis infection and might 
reduce transmission. Likelihood of adverse outcomes in women with HIV also is reduced 
with T. vaginalis therapy.
Recommended Regimen
Metronidazole 2 g orally in a single dose
 OR
Tinidazole 2 g orally in a single dose
Alternative Regimen
Metronidazole 500 mg orally twice a day for 7 days
Alcohol consumption should be avoided during treatment with nitroimidazoles. To reduce 
the possibility of a disulfiram-like reaction, abstinence from alcohol use should continue for 
24 hours after completion of metronidazole or 72 hours after completion of tinidazole.
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The nitroimidazoles are the only class of antimicrobial medications known to be effective 
against T. vaginalis infections. Of these drugs, metronidazole and tinidazole have been 
cleared by FDA for the oral or parenteral treatment of trichomoniasis. Tinidazole is 
generally more expensive, reaches higher levels in serum and the genitourinary tract, has a 
longer half-life than metronidazole (12.5 hours versus 7.3 hours), and has fewer 
gastrointestinal side effects (676–678). In randomized clinical trials, recommended 
metronidazole regimens have resulted in cure rates of approximately 84%–98% (679–681), 
and the recommended tinidazole regimen has resulted in cure rates of approximately 92%–
100% (680,682–685). Randomized controlled trials comparing single 2 g doses of 
metronidazole and tinidazole suggest that tinidazole is equivalent or superior to 
metronidazole in achieving parasitologic cure and resolution of symptoms (686).
Metronidazole gel does not reach therapeutic levels in the urethra and perivaginal glands. 
Because it is less efficacious than oral metronidazole, it is not recommended.
Other Management Considerations—Providers should advise persons infected with T. 
vaginalis to abstain from sex until they and their sex partners are treated (i.e., when therapy 
has been completed and any symptoms have resolved). Testing for other STDs including 
HIV should be performed in persons infected with T. vaginalis.
Follow-up—Because of the high rate of reinfection among women treated for 
trichomoniasis (17% within 3 months in one study) (86), retesting for T. vaginalis is 
recommended for all sexually active women within 3 months following initial treatment 
regardless of whether they believe their sex partners were treated (see Diagnostic 
Considerations). Testing by nucleic acid amplification can be conducted as soon as 2 weeks 
after treatment (687,688). Data are insufficient to support retesting men.
Management of Sex Partners—Concurrent treatment of all sex partners is critical for 
symptomatic relief, microbiologic cure, and prevention of transmission and reinfections. 
Current partners should be referred for presumptive therapy to avoid reinfection. Partners 
should be advised to abstain from intercourse until they and their sex partners have been 
adequately treated and any symptoms have resolved. EPT might have a role in partner 
management for trichomoniasis (97,98,689) and can be used in states where permissible by 
law; however, no one partner management intervention has been shown to be superior in 
reducing reinfection rates. Though no definitive data exist to guide treatment for partners of 
persons with persistent or recurrent trichomoniasis in whom nonadherance and reinfection 
are unlikely, partners benefit from undergoing evaluation and receiving the same regimen as 
the patient (see Persistent or Recurrent Trichomoniasis).
Persistent or Recurrent Trichomoniasis—Persistent or recurrent infection caused by 
antimicrobial-resistant T. vaginalis or other causes should be distinguished from the 
possibility of reinfection from an untreated sex partner. Although most recurrent T. vaginalis 
infections are thought to result from reinfection, some infections might be attributed to 
antimicrobial resistance. Metronidazole resistance occurs in 4%–10% of cases of vaginal 
trichomoniasis (690,691), and tinidazole resistance in 1% (691). In general, T. vaginalis 
isolates have lower minimum lethal concentrations to tinidazole than metronidazole (692). 
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Emerging nitroimidazole-resistant trichomoniasis is concerning, because few alternatives to 
standard therapy exist. Single-dose therapy should be avoided for treating recurrent 
trichomoniasis that is not likely a result of reinfection. If treatment failure has occurred with 
metronidazole 2 g single dose and reinfection is excluded, the patient (and their partner[s]) 
can be treated with metronidazole 500 mg orally twice daily for 7 days. If this regimen fails, 
clinicians should consider treatment with metronidazole or tinidazole at 2 g orally for 7 
days. If several 1-week regimens have failed in a person who is unlikely to have 
nonadherence or reinfection, testing of the organism for metronidazole and tinidazole 
susceptibility is recommended (693). CDC has experience with susceptibility testing for 
nitroimidazole-resistant T. vaginalis and treatment management of infected persons and can 
provide assistance (telephone: 404-718-4141; website: http://www.cdc.gov/std). Higher dose 
tinidazole at 2–3 g for 14 days, often in combination with intravaginal tinidazole, can be 
considered in cases of nitroimidazole-resistant infections; however, such cases should be 
managed in consultation with an expert.
Alternative regimens might be effective but have not been systematically evaluated; 
therefore, consultation with an infectious-disease specialist is recommended. The most 
anecdotal experience has been with intravaginal paromomycin in combination with high-
dose tinidazole (694–696); clinical improvement has been reported with other alternative 
regimens including intravaginal boric acid (697,698) and nitazoxanide (699). The following 
topically applied agents have shown minimal success (<50%) and are not recommended: 
intravaginal betadine (povidone-iodine), clotrimazole, acetic acid, furazolidone, gentian 
violet, nonoxynol-9, and potassium permanganate (700). No other topical microbicide has 
been shown to be effective against trichomoniasis (701).
Special Considerations
Allergy, Intolerance, and Adverse Reactions: Metronidazole and tinidazole are both 
nitroimidazoles. Patients with an IgE mediated-type allergy to a nitroimidazole can be 
managed by metronidazole desensitization according to a published regimen (702) and in 
consultation with a specialist.
Pregnancy: T. vaginalis infection in pregnant women is associated with adverse pregnancy 
outcomes, particularly premature rupture of membranes, preterm delivery, and delivery of a 
low birthweight infant (658,703–705). Although metronidazole treatment produces 
parasitologic cure, certain trials have shown no significant difference in perinatal morbidity 
following metronidazole treatment. One trial suggested the possibility of increased preterm 
delivery in women with T. vaginalis infection who received metronidazole treatment (706), 
yet study limitations prevented definitive conclusions regarding the risks of treatment. More 
recent, larger studies have shown no positive or negative association between metronidazole 
use during pregnancy and adverse outcomes of pregnancy (634,707–710). If treatment is 
considered, the recommended regimen in pregnant women is metronidazole 2 g orally in a 
single dose. Symptomatic pregnant women, regardless of pregnancy stage, should be tested 
and considered for treatment. Treatment of T. vaginalis infection can relieve symptoms of 
vaginal discharge in pregnant women and reduce sexual transmission to partners. Although 
perinatal transmission of trichomoniasis is uncommon, treatment also might prevent 
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respiratory or genital infection of the newborn (711,712). Clinicians should counsel 
symptomatic pregnant women with trichomoniasis regarding the potential risks for and 
benefits of treatment and about the importance of partner treatment and condom use in the 
prevention of sexual transmission.
The benefit of routine screening for T. vaginalis in asymptomatic pregnant women has not 
been established. However, screening at the first prenatal visit and prompt treatment, as 
appropriate, are recommended for pregnant women with HIV infection, because T. vaginalis 
infection is a risk factor for vertical transmission of HIV (713). Pregnant women with HIV 
who are treated for T. vaginalis infection should be retested 3 months after treatment.
Although metronidazole crosses the placenta, data suggest that it poses a low risk to 
pregnant women (317). No evidence of teratogenicity or mutagenic effects in infants has 
been found in multiple cross-sectional and cohort studies of pregnant women (708–
710,714). Women can be treated with 2 g metronidazole in a single dose at any stage of 
pregnancy.
Metronidazole is secreted in breast milk. With maternal oral therapy, breastfed infants 
receive metronidazole in doses that are lower than those used to treat infections in infants, 
although the active metabolite adds to the total infant exposure. Plasma levels of the drug 
and metabolite are measurable, but remain less than maternal plasma levels (http://
toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT). Although several reported case series found 
no evidence of adverse effects in infants exposed to metronidazole in breast milk, some 
clinicians advise deferring breastfeeding for 12–24 hours following maternal treatment with 
a single 2 g dose of metronidazole (635). Maternal treatment with metronidazole (400 mg 
three times daily for 7 days) produced a lower concentration in breast milk and was 
considered compatible with breastfeeding over longer periods of time (636,637).
Data from studies involving human subjects are limited regarding use of tinidazole in 
pregnancy; however, animal data suggest this drug poses moderate risk. Thus, tinidazole 
should be avoided in pregnant women, and breastfeeding should be deferred for 72 hours 
following a single 2-g dose of tinidazole (http://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm).
HIV Infection: Up to 53% of women with HIV infection also are infected with T. vaginalis 
(715,716). T. vaginalis infection in these women is significantly associated with PID (659), 
and treatment of trichomoniasis is associated with significant decreases in genital-tract HIV 
viral load and viral shedding (717,718). For these reasons, routine screening and prompt 
treatment are recommended for all women with HIV infection; screening should occur at 
entry to care and then at least annually thereafter. A randomized clinical trial involving 
women with HIV infection and T. vaginalis infection demonstrated that a single dose of 
metronidazole 2 g orally was less effective than 500 mg twice daily for 7 days (719). Thus, 
to improve cure rates, women with HIV infection who receive a diagnosis of T. vaginalis 
infection should be treated with metronidazole 500 mg orally twice daily for 7 days (rather 
than with a 2-g single dose of metronidazole). Factors that might interfere with standard 
single-dose treatment for trichomoniasis in these women include high rates of asymptomatic 
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BV co-infections, use of antiretroviral therapy, changes in vaginal ecology, and impaired 
immunity (656,720,721).
Treatment: Treatment reduces symptoms and signs of T. vaginalis infection and might 
reduce transmission. Likelihood of adverse outcomes in women with HIV is also reduced 
with T. vaginalis therapy.
Recommended Regimen for Women with HIV Infection
Metronidazole 500 mg orally twice daily for 7 days
In women with HIV infection who receive a diagnosis of T. vaginalis infection, retesting is 
recommended within 3 months following initial treatment; NAAT is encouraged because of 
higher sensitivity of these tests. Data are insufficient to recommend routine screening, 
alternative treatment regimens of longer duration, or retesting in men.
Vulvovaginal Candidiasis
VVC usually is caused by C. albicans but can occasionally be caused by other Candida sp. 
or yeasts. Typical symptoms of VVC include pruritus, vaginal soreness, dyspareunia, 
external dysuria, and abnormal vaginal discharge. None of these symptoms is specific for 
VVC. An estimated 75% of women will have at least one episode of VVC, and 40%–45% 
will have two or more episodes. On the basis of clinical presentation, microbiology, host 
factors, and response to therapy, VVC can be classified as either uncomplicated or 
complicated (Box 3). Approximately 10%–20% of women will have complicated VVC, 
requiring special diagnostic and therapeutic considerations.
Uncomplicated VVC
Diagnostic Considerations: A diagnosis of Candida vaginitis is suggested clinically by the 
presence of external dysuria and vulvar pruritus, pain, swelling, and redness. Signs include 
vulvar edema, fissures, excoriations, and thick curdy vaginal discharge. The diagnosis can be 
made in a woman who has signs and symptoms of vaginitis when either 1) a wet preparation 
(saline, 10% KOH) or Gram stain of vaginal discharge demonstrates budding yeasts, hyphae, 
or pseudohyphae or 2) a culture or other test yields a positive result for a yeast species. 
Candida vaginitis is associated with a normal vaginal pH (<4.5). Use of 10% KOH in wet 
preparations improves the visualization of yeast and mycelia by disrupting cellular material 
that might obscure the yeast or pseudohyphae. Examination of a wet mount with KOH 
preparation should be performed for all women with symptoms or signs of VVC, and 
women with a positive result should be treated. For those with negative wet mounts but 
existing signs or symptoms, vaginal cultures for Candida should be considered. If Candida 
cultures cannot be performed for these women, empiric treatment can be considered. 
Identifying Candida by culture in the absence of symptoms or signs is not an indication for 
treatment, because approximately 10%–20% of women harbor Candida sp. and other yeasts 
in the vagina. PCR testing for yeast is not FDA-cleared; culture for yeast remains the gold 
standard for diagnosis. VVC can occur concomitantly with STDs. Most healthy women with 
uncomplicated VVC have no identifiable precipitating factors.
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Treatment: Short-course topical formulations (i.e., single dose and regimens of 1–3 days) 
effectively treat uncomplicated VVC. The topically applied azole drugs are more effective 
than nystatin. Treatment with azoles results in relief of symptoms and negative cultures in 
80%–90% of patients who complete therapy.
Recommended Regimens
Over-the-Counter Intravaginal Agents:
 Clotrimazole 1% cream 5 g intravaginally daily for 7–14 days
  OR
 Clotrimazole 2% cream 5 g intravaginally daily for 3 days
  OR
 Miconazole 2% cream 5 g intravaginally daily for 7 days
  OR
 Miconazole 4% cream 5 g intravaginally daily for 3 days
  OR
 Miconazole 100 mg vaginal suppository, one suppository daily for 7 days
  OR
 Miconazole 200 mg vaginal suppository, one suppository for 3 days
  OR
 Miconazole 1,200 mg vaginal suppository, one suppository for 1 day
  OR
 Tioconazole 6.5% ointment 5 g intravaginally in a single application
Prescription Intravaginal Agents:
 Butoconazole 2% cream (single dose bioadhesive product), 5 g intravaginally in a single application
  OR
 Terconazole 0.4% cream 5 g intravaginally daily for 7 days
  OR
 Terconazole 0.8% cream 5 g intravaginally daily for 3 days
  OR
 Terconazole 80 mg vaginal suppository, one suppository daily for 3 days
Oral Agent:
 Fluconazole 150 mg orally in a single dose
The creams and suppositories in these regimens are oil-based and might weaken latex 
condoms and diaphragms. Refer to condom product labeling for further information. 
Intravaginal preparations of clotrimazole, miconazole, and tioconazole are available over-
the-counter (OTC). Even women who have previously received a diagnosis of VVC by a 
clinician are not necessarily more likely to be able to diagnose themselves; therefore, any 
woman whose symptoms persist after using an OTC preparation or who has a recurrence of 
symptoms within 2 months after treatment for VVC should be clinically evaluated and 
tested. Unnecessary or inappropriate use of OTC preparations is common and can lead to a 
delay in the treatment of other vulvovaginitis etiologies, which can in turn result in adverse 
outcomes.
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Follow-Up: Follow-up typically is not required. However, women in whom symptoms 
persist or recur after treatment of initial symptoms should be instructed to return for follow-
up visits.
Management of Sex Partners: Uncomplicated VVC is not usually acquired through sexual 
intercourse; thus, data do not support treatment of sex partners. A minority of male sex 
partners have balanitis, characterized by erythematous areas on the glans of the penis in 
conjunction with pruritus or irritation. These men benefit from treatment with topical 
antifungal agents to relieve symptoms.
Special Considerations
Allergy, Intolerance, and Adverse Reactions: Topical agents usually cause no systemic side 
effects, although local burning or irritation might occur. Oral azoles occasionally cause 
nausea, abdominal pain, and headache. Therapy with the oral azoles has been associated 
rarely with abnormal elevations of liver enzymes. Clinically important interactions can occur 
when oral azoles agents are administered with other drugs (722).
Complicated VVC
Diagnostic Considerations: Vaginal cultures should be obtained from women with 
complicated VVC to confirm clinical diagnosis and identify unusual species, including 
nonalbicans species. C. glabrata does not form pseudohyphae or hyphae and is not easily 
recognized on microscopy. Although C. albicans azole resistance is possibly becoming more 
common in vaginal isolates (723,724), susceptibility testing is usually not warranted for 
individual treatment guidance.
Recurrent Vulvovaginal Candidiasis: Recurrent Vulvovaginal Candidiasis (RVVC), 
usually defined as four or more episodes of symptomatic VVC within 1 year, affects a small 
percentage of women (<5%). The pathogenesis of RVVC is poorly understood, and most 
women with RVVC have no apparent predisposing or underlying conditions. C. glabrata and 
other nonalbicans Candida species are observed in 10%–20% of women with RVVC. 
Conventional antimycotic therapies are not as effective against these nonalbicans species as 
against C. albicans.
Treatment: Each individual episode of RVVC caused by C. albicans responds well to short 
duration oral or topical azole therapy. However, to maintain clinical and mycologic control, 
some specialists recommend a longer duration of initial therapy (e.g., 7–14 days of topical 
therapy or a 100-mg, 150-mg, or 200-mg oral dose of fluconazole every third day for a total 
of 3 doses [day 1, 4, and 7]) to attempt mycologic remission before initiating a maintenance 
antifungal regimen.
Oral fluconazole (i.e., 100-mg, 150-mg, or 200-mg dose) weekly for 6 months is the first 
line maintenance regimen. If this regimen is not feasible, topical treatments used 
intermittently can also be considered. Suppressive maintenance therapies are effective in 
reducing RVVC. However, 30%–50% of women will have recurrent disease after 
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maintenance therapy is discontinued. Symptomatic women who remain culture-positive 
despite maintenance therapy should be managed in consultation with a specialist.
Severe VVC: Severe vulvovaginitis (i.e., extensive vulvar erythema, edema, excoriation, and 
fissure formation) is associated with lower clinical response rates in patients treated with 
short courses of topical or oral therapy. Either 7–14 days of topical azole or 150 mg of 
fluconazole in two sequential oral doses (second dose 72 hours after initial dose) is 
recommended.
Nonalbicans VVC: Because at least 50% of women with positive cultures for nonalbicans 
Candida might be minimally symptomatic or have no symptoms and because successful 
treatment is often difficult, clinicians should make every effort to exclude other causes of 
vaginal symptoms in women with nonalbicans yeast (725). The optimal treatment of 
nonalbicans VVC remains unknown. Options include longer duration of therapy (7–14 days) 
with a nonfluconazole azole regimen (oral or topical) as first-line therapy. If recurrence 
occurs, 600 mg of boric acid in a gelatin capsule is recommended, administered vaginally 
once daily for 2 weeks. This regimen has clinical and mycologic eradication rates of 
approximately 70% (726). If symptoms recur, referral to a specialist is advised.
Management of Sex Partners: No data exist to support the treatment of sex partners of 
patients with complicated VVC. Therefore, no recommendation can be made.
Special Considerations
Compromised Host: Women with underlying immunodeficiency, those with poorly 
controlled diabetes or other immunocompromising conditions (e.g., HIV), and those 
receiving immunosuppression therapy (e.g., corticosteroid treatment) do not respond as well 
to short-term therapies. Efforts to correct modifiable conditions should be made, and more 
prolonged (i.e., 7–14 days) conventional treatment is necessary.
Pregnancy: VVC occurs frequently during pregnancy. Only topical azole therapies, applied 
for 7 days, are recommended for use among pregnant women.
HIV Infection: Vaginal Candida colonization rates among women with HIV infection are 
higher than among seronegative women with similar demographic and risk behavior 
characteristics, and the colonization rates correlate with increasing severity of 
immunosuppression. Symptomatic VVC is also more frequent in women with HIV infection 
and similarly correlates with severity of immunodeficiency. In addition, among women with 
HIV infection, systemic azole exposure is associated with the isolation of nonalbicans 
Candida species from the vagina.
On the basis of available data, therapy for uncomplicated and complicated VVC in women 
with HIV infection should not differ from that for seronegative women. Although long-term 
prophylactic therapy with fluconazole at a dose of 200 mg weekly has been effective in 
reducing C. albicans colonization and symptomatic VVC (727), this regimen is not 
recommended for women with HIV infection in the absence of complicated VVC (247). 
Although VVC is associated with increased HIV seroconversion in HIV-negative women 
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and increased HIV cervicovaginal levels in women with HIV infection, the effect of 
treatment for VVC on HIV acquisition and transmission remains unknown.
Pelvic Inflammatory Disease
Pelvic inflammatory disease (PID) comprises a spectrum of inflammatory disorders of the 
upper female genital tract, including any combination of endometritis, salpingitis, tubo-
ovarian abscess, and pelvic peritonitis (728). Sexually transmitted organisms, especially N. 
gonorrhoeae and C. trachomatis, are implicated in many cases. Recent studies suggest that 
the proportion of PID cases attributable to N. gonorrhoeae or C. trachomatis is declining; of 
women who received a diagnosis of acute PID, <50% test positive for either of these 
organisms (270,729,730). Microorganisms that comprise the vaginal flora (e.g., anaerobes, 
G. vaginalis, Haemophilus influenzae, enteric Gram-negative rods, and Streptococcus 
agalactiae) have been associated with PID (731). In addition, cytomegalovirus (CMV), M. 
hominis, U. urealyticum, and M. genitalium might be associated with some PID cases 
(264,265,267,732). Newer data suggest that M. genitalium might play a role in the 
pathogenesis of PID (270,487) and might be associated with milder symptoms (267), 
although one study failed to demonstrate a significant increase in PID following detection of 
M. genitalium in the lower genital tract (733). All women who receive a diagnosis of acute 
PID should be tested for HIV, as well as gonorrhea and chlamydia, using NAAT. The value 
of testing women with PID for M. genitalium is unknown, and there is no commercially 
available diagnostic test that has been cleared by FDA for use in the United States (see 
Mycoplasma genitalium).
Screening and treating sexually active women for chlamydia reduces their risk for PID 
(456,682). Although BV is associated with PID, whether the incidence of PID can be 
reduced by identifying and treating women with BV is unclear (731,734).
Diagnostic Considerations
Acute PID is difficult to diagnose because of the wide variation in symptoms and signs 
associated with this condition. Many women with PID have subtle or nonspecific symptoms 
or are asymptomatic. Delay in diagnosis and treatment probably contributes to inflammatory 
sequelae in the upper reproductive tract. Laparoscopy can be used to obtain a more accurate 
diagnosis of salpingitis and a more complete bacteriologic diagnosis. However, this 
diagnostic tool frequently is not readily available, and its use is not easily justifiable when 
symptoms are mild or vague. Moreover, laparoscopy will not detect endometritis and might 
not detect subtle inflammation of the fallopian tubes. Consequently, a diagnosis of PID 
usually is based on imprecise clinical findings (735,736).
Data indicate that a clinical diagnosis of symptomatic PID has a PPV for salpingitis of 65%–
90% compared with laparoscopy (737–739). The PPV of a clinical diagnosis of acute PID 
depends on the epidemiologic characteristics of the population, with higher PPVs among 
sexually active young women (particularly adolescents), women attending STD clinics, and 
those who live in communities with high rates of gonorrhea or chlamydia. Regardless of 
PPV, no single historical, physical, or laboratory finding is both sensitive and specific for the 
diagnosis of acute PID. Combinations of diagnostic findings that improve either sensitivity 
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(i.e., detect more women who have PID) or specificity (i.e., exclude more women who do 
not have PID) do so only at the expense of the other. For example, requiring two or more 
findings excludes more women who do not have PID and reduces the number of women 
with PID who are identified.
Many episodes of PID go unrecognized. Although some cases are asymptomatic, others are 
not diagnosed because the patient or the health-care provider fails to recognize the 
implications of mild or nonspecific symptoms or signs (e.g., abnormal bleeding, 
dyspareunia, and vaginal discharge). Even women with mild or asymptomatic PID might be 
at risk for infertility (740). Because of the difficulty of diagnosis and the potential for 
damage to the reproductive health of women, health-care providers should maintain a low 
threshold for the diagnosis of PID (729). The following recommendations for diagnosing 
PID are intended to help health-care providers recognize when PID should be suspected and 
when additional information should be obtained to increase diagnostic certainty. Diagnosis 
and management of other common causes of lower abdominal pain (e.g., ectopic pregnancy, 
acute appendicitis, ovarian cyst, and functional pain) are unlikely to be impaired by initiating 
antimicrobial therapy for PID.
Presumptive treatment for PID should be initiated in sexually active young women and other 
women at risk for STDs if they are experiencing pelvic or lower abdominal pain, if no cause 
for the illness other than PID can be identified, and if one or more of the following minimum 
clinical criteria are present on pelvic examination:
• cervical motion tenderness
or
• uterine tenderness
or
• adnexal tenderness.
The requirement that all three minimum criteria be present before the initiation of empiric 
treatment could result in insufficient sensitivity for the diagnosis of PID. After deciding 
whether to initiate empiric treatment, clinicians should also consider the risk profile for 
STDs.
More elaborate diagnostic evaluation frequently is needed because incorrect diagnosis and 
management of PID might cause unnecessary morbidity. For example, the presence of signs 
of lower-genital–tract inflammation (predominance of leukocytes in vaginal secretions, 
cervical exudates, or cervical friability), in addition to one of the three minimum criteria, 
increases the specificity of the diagnosis. One or more of the following additional criteria 
can be used to enhance the specificity of the minimum clinical criteria and support a 
diagnosis of PID:
• oral temperature >101°F (>38.3°C);
• abnormal cervical mucopurulent discharge or cervical friability;
• presence of abundant numbers of WBC on saline microscopy of vaginal fluid;
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• elevated erythrocyte sedimentation rate;
• elevated C-reactive protein; and
• laboratory documentation of cervical infection with N. gonorrhoeae or C. 
trachomatis.
Most women with PID have either mucopurulent cervical discharge or evidence of WBCs on 
a microscopic evaluation of a saline preparation of vaginal fluid (i.e., wet prep). If the 
cervical discharge appears normal and no WBCs are observed on the wet prep of vaginal 
fluid, the diagnosis of PID is unlikely, and alternative causes of pain should be considered. A 
wet prep of vaginal fluid also can detect the presence of concomitant infections (e.g., BV 
and trichomoniasis).
The most specific criteria for diagnosing PID include:
• endometrial biopsy with histopathologic evidence of endometritis;
• transvaginal sonography or magnetic resonance imaging techniques showing 
thickened, fluid-filled tubes with or without free pelvic fluid or tubo-ovarian 
complex, or Doppler studies suggesting pelvic infection (e.g., tubal hyperemia); 
or
• laparoscopic findings consistent with PID.
A diagnostic evaluation that includes some of these more extensive procedures might be 
warranted in some cases. Endometrial biopsy is warranted in women undergoing 
laparoscopy who do not have visual evidence of salpingitis, because endometritis is the only 
sign of PID for some women.
Treatment
PID treatment regimens must provide empiric, broad spectrum coverage of likely pathogens. 
Several parenteral and oral antimicrobial regimens have been effective in achieving clinical 
and microbiologic cure in randomized clinical trials with short-term follow-up (741,742). 
However, only a limited number of investigations have assessed and compared these 
regimens with regard to elimination of infection in the endometrium and fallopian tubes or 
determined the incidence of long-term complications (e.g., tubal infertility and ectopic 
pregnancy) after antimicrobial regimens (730,735,743). The optimal treatment regimen and 
long-term outcome of early treatment of women with subclinical PID are unknown. All 
regimens used to treat PID should also be effective against N. gonorrhoeae and C. 
trachomatis because negative endocervical screening for these organisms does not rule out 
upper-reproductive–tract infection. The need to eradicate anaerobes from women who have 
PID has not been determined definitively. Anaerobic bacteria have been isolated from the 
upper-reproductive tract of women who have PID, and data from in vitro studies have 
revealed that some anaerobes (e.g., Bacteroides fragilis) can cause tubal and epithelial 
destruction. BV is present in many women who have PID (731,734). Until treatment 
regimens that do not cover anaerobic microbes have been demonstrated to prevent long-term 
sequelae (e.g., infertility and ectopic pregnancy) as successfully as the regimens that are 
effective against these microbes, the use of regimens with anaerobic activity should be 
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considered. Treatment should be initiated as soon as the presumptive diagnosis has been 
made, because prevention of long-term sequelae is dependent on early administration of 
appropriate antibiotics. When selecting a treatment regimen, health-care providers should 
consider availability, cost, and patient acceptance (742). In women with PID of mild or 
moderate clinical severity, parenteral and oral regimens appear to have similar efficacy. The 
decision of whether hospitalization is necessary should be based on provider judgment and 
whether the woman meets any of the following suggested criteria:
• surgical emergencies (e.g., appendicitis) cannot be excluded;
• tubo-ovarian abscess;
• pregnancy;
• severe illness, nausea and vomiting, or high fever;
• unable to follow or tolerate an outpatient oral regimen;
or
• no clinical response to oral antimicrobial therapy.
No evidence is available to suggest that adolescents have improved outcomes from 
hospitalization for treatment of PID, and the clinical response to outpatient treatment is 
similar among younger and older women. The decision to hospitalize adolescents with acute 
PID should be based on the same criteria used for older women.
Parenteral Treatment—Several randomized trials have demonstrated the efficacy of 
parenteral regimens (734,741,742). Clinical experience should guide decisions regarding 
transition to oral therapy, which usually can be initiated within 24–48 hours of clinical 
improvement. In women with tubo-ovarian abscesses, at least 24 hours of inpatient 
observation is recommended.
Recommended Parenteral Regimens
Cefotetan 2 g IV every 12 hours
 PLUS
Doxycycline 100 mg orally or IV every 12 hours
 OR
Cefoxitin 2 g IV every 6 hours
 PLUS
Doxycycline 100 mg orally or IV every 12 hours
 OR
Clindamycin 900 mg IV every 8 hours
PLUS
Gentamicin loading dose IV or IM (2 mg/kg), followed by a maintenance dose (1.5 mg/kg) every 8 hours. Single daily 
dosing (3–5 mg/kg) can be substituted.
Because of the pain associated with intravenous infusion, doxycycline should be 
administered orally when possible. Oral and IV administration of doxycycline provide 
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similar bioavailability. Although use of a single daily dose of gentamicin has not been 
evaluated for the treatment of PID, it is efficacious in analogous situations.
When using the parenteral cefotetan or cefoxitin regimens, oral therapy with doxycycline 
100 mg twice daily can be used 24–48 hours after clinical improvement to complete the 14 
days of therapy for the clindamycin/gentamicin regimen, and oral therapy with clindamycin 
(450 mg orally four times daily) or doxycycline (100 mg twice daily) can be used to 
complete the 14 days of therapy. However, when tubo-ovarian abscess is present, 
clindamycin (450 mg orally four times daily) or metronidazole (500 mg twice daily) should 
be used to complete at least 14 days of therapy with doxycycline to provide more effective 
anaerobic coverage than doxycycline alone.
Limited data are available to support use of other parenteral second- or third-generation 
cephalosporins (e.g., ceftizoxime, cefotaxime, and ceftriaxone). In addition, these 
cephalosporins are less active than cefotetan or cefoxitin against anaerobic bacteria.
Alternative Parenteral Regimens: Ampicillin/sulbactam plus doxycycline has been 
investigated in at least one clinical trial and has broad-spectrum coverage (744). Ampicillin/
sulbactam plus doxycycline is effective against C. trachomatis, N. gonorrhoeae, and 
anaerobes in women with tubo-ovarian abscess. Another trial demonstrated high short-term 
clinical cure rates with azithromycin, either as monotherapy for 1 week (500 mg IV daily for 
1 or 2 doses followed by 250 mg orally for 5–6 days) or combined with a 12-day course of 
metronidazole (745). Limited data are available to support the use of other parenteral 
regimens.
Alternative Parenteral Regimen
Ampicillin/Sulbactam 3 g IV every 6 hours
 PLUS
Doxycycline 100 mg orally or IV every 12 hours
Intramuscular/Oral Treatment—Intramuscular/oral therapy can be considered for 
women with mild-to-moderately severe acute PID, because the clinical outcomes among 
women treated with these regimens are similar to those treated with intravenous therapy 
(729). Women who do not respond to IM/oral therapy within 72 hours should be reevaluated 
to confirm the diagnosis and should be administered intravenous therapy.
Recommended Intramuscular/Oral Regimens
Ceftriaxone 250 mg IM in a single dose
 PLUS
Doxycycline 100 mg orally twice a day for 14 days
 WITH* or WITHOUT
Metronidazole 500 mg orally twice a day for 14 days
 OR
Cefoxitin 2 g IM in a single dose and Probenecid, 1 g orally administered concurrently in a single dose
 PLUS
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Doxycycline 100 mg orally twice a day for 14 days
 WITH or WITHOUT
Metronidazole 500 mg orally twice a day for 14 days
 OR
Other parenteral third-generation cephalosporin (e.g., ceftizoxime or cefotaxime)
 PLUS
Doxycycline 100 mg orally twice a day for 14 days
 WITH* or WITHOUT
Metronidazole 500 mg orally twice a day for 14 days
*The recommended third-generation cephalsporins are limited in the coverage of anaerobes. Therefore, until it is known 
that extended anaerobic coverage is not important for treatment of acute PID, the addition of metronidazole to treatment 
regimens with third-generation cephalosporins should be considered (Source: Walker CK, Wiesenfeld HC. Antibiotic 
therapy for acute pelvic inflammatory disease: the 2006 CDC Sexually Transmitted Diseases Treatment Guidelines. Clin 
Infect Dis 2007;28[Supp 1]:S29–36).
These regimens provide coverage against frequent etiologic agents of PID, but the optimal 
choice of a cephalosporin is unclear. Cefoxitin, a second-generation cephalosporin, has 
better anaerobic coverage than ceftriaxone, and in combination with probenecid and 
doxycycline has been effective in short-term clinical response in women with PID. 
Ceftriaxone has better coverage against N. gonorrhoeae. The addition of metronidazole will 
also effectively treat BV, which is frequently associated with PID.
Alternative IM/Oral Regimens: Although information regarding other IM and oral 
regimens is limited, a few have undergone at least one clinical trial and have demonstrated 
broad-spectrum coverage. Azithromycin has demonstrated short-term clinical effectiveness 
in one randomized trial when used as monotherapy (500 mg IV daily for 1–2 doses, 
followed by 250 mg orally daily for 12–14 days) or in combination with metronidazole 
(745), and in another study, it was effective when used 1 g orally once a week for 2 weeks in 
combination with ceftriaxone 250 mg IM single dose (746). When considering these 
alternative regimens, the addition of metronidazole should be considered to provide 
anaerobic coverage. No data have been published regarding the use of oral cephalosporins 
for the treatment of PID. As a result of the emergence of quinolone-resistant N. 
gonorrhoeae, regimens that include a quinolone agent are no longer routinely recommended 
for the treatment of PID. If allergy precludes the use of cephalosporin therapy, if the 
community prevalence and individual risk for gonorrhea are low, and if follow-up is likely, 
use of fluoroquinolones for 14 days (levofloxacin 500 mg orally once daily, ofloxacin 400 
mg twice daily, or moxifloxacin 400 mg orally once daily) with metronidazole for 14 days 
(500 mg orally twice daily) can be considered (747–749). Diagnostic tests for gonorrhea 
must be obtained before instituting therapy, and persons should be managed as follows.
• If the culture for gonorrhea is positive, treatment should be based on results of 
antimicrobial susceptibility testing.
• If the isolate is determined to be quinolone-resistant N. gonorrhoeae (QRNG) or 
if antimicrobial susceptibility cannot be assessed (e.g., if only NAAT testing is 
available), consultation with an infectious-disease specialist is recommended.
Workowski and Bolan Page 129
MMWR Recomm Rep. Author manuscript; available in PMC 2018 April 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Other Management Considerations
To minimize disease transmission, women should be instructed to abstain from sexual 
intercourse until therapy is completed, symptoms have resolved, and sex partners have been 
adequately treated (See chlamydia and gonorrhea sections). All women who received a 
diagnosis of acute PID should be tested for HIV, as well as GC and chlamydia, using NAAT.
Follow-Up
Women should demonstrate clinical improvement (e.g., defervescence; reduction in direct or 
rebound abdominal tenderness; and reduction in uterine, adnexal, and cervical motion 
tenderness) within 3 days after initiation of therapy. If no clinical improvement has occurred 
within 72 hours after outpatient IM/oral therapy, hospitalization, assessment of the 
antimicrobial regimen, and additional diagnostics (including consideration of diagnostic 
laparoscopy for alternative diagnoses) are recommended. All women who have received a 
diagnosis of chlamydial or gonococcal PID should be retested 3 months after treatment, 
regardless of whether their sex partners were treated (480). If retesting at 3 months is not 
possible, these women should be retested whenever they next present for medical care in the 
12 months following treatment.
Management of Sex Partners—Men who have had sexual contact with a woman with 
PID during the 60 days preceding her onset of symptoms should be evaluated, tested, and 
presumptively treated for chlamydia and gonorrhea, regardless of the etiology of PID or 
pathogens isolated from the woman. If a woman’s last sexual intercourse was >60 days 
before onset of symptoms or diagnosis, the most recent sex partner should be treated. Male 
partners of women who have PID caused by C. trachomatis and/or N. gonorrhoeae 
frequently are asymptomatic. Arrangements should be made to link male partners to care. If 
linkage is delayed or unlikely, EPT and enhanced referral are alternative approaches to 
treating male partners of women who have chlamydia or gonococcal infections (see Partner 
Services) (93,94). Partners should be instructed to abstain from sexual intercourse until they 
and their sex partners have been adequately treated (i.e., until therapy is completed and 
symptoms have resolved, if originally present).
Special Considerations
Allergy, Intolerance, and Adverse Reactions—The cross reactivity between 
penicillins and cephalosporins is <2.5% in persons with a history of penicillin allergy (428–
431,464). The risk for penicillin cross-reactivity is highest with first-generation 
cephalosporins, but is negligible between most second-generation (cefoxitin) and all third-
generation (ceftriaxone) cephalosporins (428–431) (see Management of Persons who Have a 
History of Penicillin Allergy).
Pregnancy—Pregnant women suspected to have PID are at high risk for maternal 
morbidity and preterm delivery. These women should be hospitalized and treated with 
intravenous antibiotics.
HIV Infection—Differences in the clinical manifestations of PID between women with 
HIV infection and women without HIV infection have not been well delineated. In early 
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observational studies, women with HIV infection and PID were more likely to require 
surgical intervention. More comprehensive observational and controlled studies have 
demonstrated that women with HIV infection and PID have similar symptoms when 
compared with HIV-negative women with PID (266,750,751), except they are more likely to 
have a tubo-ovarian abscess; women with HIV infection responded equally well to 
recommended parenteral and IM/oral antibiotic regimens as women without HIV infection. 
The microbiologic findings for women with HIV infection and women without HIV 
infection were similar, except women with HIV infection had higher rates of concomitant M. 
hominis and streptococcal infections. These data are insufficient for determining whether 
women with HIV infection and PID require more aggressive management (e.g., 
hospitalization or intravenous antimicrobial regimens).
Intrauterine Contraceptive Devices—IUDs are one of the most effective contraceptive 
methods. Copper-containing and levonorgestrel-releasing IUDs are available in the United 
States. The risk for PID associated with IUD use is primarily confined to the first 3 weeks 
after insertion (752,753). If an IUD user receives a diagnosis of PID, the IUD does not need 
to be removed (63). However, the woman should receive treatment according to these 
recommendations and should have close clinical follow-up. If no clinical improvement 
occurs within 48–72 hours of initiating treatment, providers should consider removing the 
IUD. A systematic review of evidence found that treatment outcomes did not generally differ 
between women with PID who retained the IUD and those who had the IUD removed (754). 
These studies primarily included women using copper or other nonhormonal IUDs. No 
studies are available regarding treatment outcomes in women using levonorgestrel-releasing 
IUDs.
Epididymitis
Acute epididymitis is a clinical syndrome consisting of pain, swelling, and inflammation of 
the epididymis that lasts <6 weeks (755). Sometimes the testis is also involved— a condition 
referred to as epididymo-orchitis. A high index of suspicion for spermatic cord (testicular) 
torsion must be maintained in men who present with a sudden onset of symptoms associated 
with epididymitis, as this condition is a surgical emergency.
Among sexually active men aged <35 years, acute epididymitis is most frequently caused by 
C. trachomatis or N. gonorrhoeae. Acute epididymitis caused by sexually transmitted enteric 
organisms (e.g., Escherichia coli) also occurs among men who are the insertive partner 
during anal intercourse. Sexually transmitted acute epididymitis usually is accompanied by 
urethritis, which frequently is asymptomatic. Other nonsexually transmitted infectious 
causes of acute epididymitis (e.g., Fournier’s gangrene) are uncommon and should be 
managed in consultation with a urologist.
In men aged ≥35 years who do not report insertive anal intercourse, sexually transmitted 
acute epididymitis is less common. In this group, the epididymis usually becomes infected in 
the setting of bacteriuria secondary to bladder outlet obstruction (e.g., benign prostatic 
hyperplasia) (756). In older men, nonsexually transmitted acute epididymitis is also 
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associated with prostate biopsy, urinary tract instrumentation or surgery, systemic disease, 
and/or immunosuppression.
Chronic epididymitis is characterized by a ≥6 week history of symptoms of discomfort 
and/or pain in the scrotum, testicle, or epididymis. Chronic infectious epididymitis is most 
frequently seen in conditions associated with a granulomatous reaction; Mycobacterium 
tuberculosis (TB) is the most common granulomatous disease affecting the epididymis and 
should be suspected, especially in men with a known history of or recent exposure to TB. 
The differential diagnosis of chronic non-infectious epididymitis, sometimes termed 
“orchalgia/epididymalgia” is broad (i.e., trauma, cancer, autoimmune, and idiopathic 
conditions); men with this diagnosis should be referred to a urologist for clinical 
management (755,757).
Diagnostic Considerations
Men who have acute epididymitis typically have unilateral testicular pain and tenderness, 
hydrocele, and palpable swelling of the epididymis. Although inflammation and swelling 
usually begins in the tail of the epididymis, it can spread to involve the rest of the epididymis 
and testicle. The spermatic cord is usually tender and swollen. Spermatic cord (testicular) 
torsion, a surgical emergency, should be considered in all cases, but it occurs more 
frequently among adolescents and in men without evidence of inflammation or infection. In 
men with severe, unilateral pain with sudden onset, those whose test results do not support a 
diagnosis of urethritis or urinary-tract infection, or men in whom diagnosis of acute 
epididymitis is questionable, immediate referral to a urologist for evaluation of testicular 
torsion is important because testicular viability might be compromised.
Bilateral symptoms should raise suspicion of other causes of testicular pain. Radionuclide 
scanning of the scrotum is the most accurate method to diagnose epididymitis, but it is not 
routinely available. Ultrasound should be primarily used for ruling out torsion of the 
spermatic cord in cases of acute, unilateral, painful scrotum swelling. However, because 
partial spermatic cord torsion can mimic epididymitis on scrotal ultrasound, when torsion is 
not ruled out by ultrasound, differentiation between spermatic cord torsion and epididymitis 
must be made on the basis of clinical evaluation. Although ultrasound can demonstrate 
epididymal hyperemia and swelling associated with epididymitis, it provides minimal utility 
for men with a clinical presentation consistent with epididymitis, because a negative 
ultrasound does not alter clinical management. Ultrasound should be reserved for men with 
scrotal pain who cannot receive an accurate diagnosis by history, physical examination, and 
objective laboratory findings or if torsion of the spermatic cord is suspected.
All suspected cases of acute epididymitis should be evaluated for objective evidence of 
inflammation by one of the following point-of-care tests.
• Gram or methylene blue or gentian violet (MB/GV) stain of urethral secretions 
demonstrating ≥2 WBC per oil immersion field (478). These stains are preferred 
point-of-care diagnostic tests for evaluating urethritis because they are highly 
sensitive and specific for documenting both urethral inflammation and the 
presence or absence of gonococcal infection. Gonococcal infection is established 
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by documenting the presence of WBC-containing intracellular Gram-negative or 
purple diplococci on urethral Gram stain or MB/GV smear, respectively.
• Positive leukocyte esterase test on first-void urine.
• Microscopic examination of sediment from a spun first-void urine demonstrating 
≥10 WBC per high power field.
All suspected cases of acute epididymitis should be tested for C. trachomatis and for N. 
gonorrhoeae by NAAT. Urine is the preferred specimen for NAAT testing in men (394). 
Urine cultures for chlamydia and gonococcal epididymitis are insensitive and are not 
recommended. Urine bacterial culture might have a higher yield in men with sexually 
transmitted enteric infections and in older men with acute epididymitis caused by 
genitourinary bacteriuria.
Treatment
To prevent complications and transmission of sexually transmitted infections, presumptive 
therapy is indicated at the time of the visit before all laboratory test results are available. 
Selection of presumptive therapy is based on risk for chlamydia and gonorrhea and/or 
enteric organisms. The goals of treatment of acute epididymitis are 1) microbiologic cure of 
infection, 2) improvement of signs and symptoms, 3) prevention of transmission of 
chlamydia and gonorrhea to others, and 4) a decrease in potential chlamydia/gonorrhea 
epididymitis complications (e.g., infertility and chronic pain). Although most men with 
acute epididymitis can be treated on an outpatient basis, referral to a specialist and 
hospitalization should be considered when severe pain or fever suggests other diagnoses 
(e.g., torsion, testicular infarction, abscess, and necrotizing fasciitis) or when men are unable 
to comply with an antimicrobial regimen. Because high fever is uncommon and indicates a 
complicated infection, hospitalization for further evaluation is recommended.
Recommended Regimens
For acute epididymitis most likely caused by sexually transmitted chlamydia and gonorrhea
Ceftriaxone 250 mg IM in a single dose
 PLUS
Doxycycline 100 mg orally twice a day for 10 days
For acute epididymitis most likely caused by sexually-transmitted chlamydia and gonorrhea and enteric 
organisms (men who practice insertive anal sex)
Ceftriaxone 250 mg IM in a single dose
 PLUS
Levofloxacin 500 mg orally once a day for 10 days
 OR
Ofloxacin 300 mg orally twice a day for 10 days
For acute epididymitis most likely caused by enteric organisms
Levofloxacin 500 mg orally once daily for 10 days
 OR
Ofloxacin 300 mg orally twice a day for 10 days
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Therapy including levofloxacin or ofloxacin should be considered if the infection is most 
likely caused by enteric organisms and gonorrhea has been ruled out by gram, MB, or GV 
stain. This includes men who have undergone prostate biopsy, vasectomy, and other urinary-
tract instrumentation procedures. As an adjunct to therapy, bed rest, scrotal elevation, and 
nonsteroidal anti-inflammatory drugs are recommended until fever and local inflammation 
have subsided. Complete resolution of discomfort might not occur until a few weeks after 
completion of the antibiotic regimen.
Other Management Considerations
Men who have acute epididymitis confirmed or suspected to be caused by N. gonorrhoeae or 
C. trachomatis should be advised to abstain from sexual intercourse until they and their 
partners have been adequately treated and symptoms have resolved. All men with acute 
epididymitis should be tested for other STDs, including HIV.
Follow-Up
Men should be instructed to return to their health-care providers if their symptoms fail to 
improve within 72 hours of the initiation of treatment. Signs and symptoms of epididymitis 
that do not subside within 3 days require re-evaluation of the diagnosis and therapy. Men 
who experience swelling and tenderness that persist after completion of antimicrobial 
therapy should be evaluated for alternative diagnoses, including tumor, abscess, infarction, 
testicular cancer, tuberculosis, and fungal epididymitis.
Management of Sex Partners
Men who have acute sexually transmitted epididymitis confirmed or suspected to be caused 
by N. gonorrhoeae or C. trachomatis should be instructed to refer for evaluation, testing, and 
presumptive treatment all sex partners with whom they have had sexual contact within the 
60 days preceding onset of symptoms (see Chlamydial Infections and Gonorrheal 
Infections). If the last sexual intercourse was >60 days before onset of symptoms or 
diagnosis, the most recent sex partner should be treated. Arrangements should be made to 
link female partners to care. EPT and enhanced referral (see Partner Services) are effective 
strategies for treating female sex partners of men who have chlamydia or gonorrhea for 
whom linkage to care is anticipated to be delayed (93,94). Partners should be instructed to 
abstain from sexual intercourse until they and their sex partners are adequately treated and 
symptoms have resolved.
Special Considerations
Allergy, Intolerance, and Adverse Reactions—The cross reactivity between 
penicillins and cephalosporins is <2.5% in persons with a history of penicillin allergy (428–
431,464). The risk for penicillin cross-reactivity is highest with first-generation 
cephalosporins, but is negligible between most second-generation (cefoxitin) and all third-
generation (ceftriaxone) cephalosporins (428–431) (see Management of Persons with a 
History of Penicillin Allergy). Alternative regimens have not been studied; therefore, 
clinicians should consult infectious-disease specialists if such regimens are required.
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HIV Infection—Men with HIV infection who have uncomplicated acute epididymitis 
should receive the same treatment regimen as those who are HIV negative. Other etiologic 
agents have been implicated in acute epididymitis in men with HIV infection, including 
CMV, salmonella, toxoplasmosis, Ureaplasma urealyticum, Corynebacterium sp., 
Mycoplasma sp., and Mima polymorpha. Fungi and mycobacteria also are more likely to 
cause acute epididymitis in men with HIV infection than in those who are 
immunocompetent.
Human Papillomavirus Infection
Approximately 100 types of human papillomavirus infection (HPV) have been identified, at 
least 40 of which can infect the genital area (758). Most HPV infections are self-limited and 
are asymptomatic or unrecognized. Most sexually active persons become infected with HPV 
at least once in their lifetime (533,759). Oncogenic, high-risk HPV infection (e.g., HPV 
types 16 and 18) causes most cervical, penile, vulvar, vaginal, anal, and oropharyngeal 
cancers and precancers (760), whereas nononcogenic, low-risk HPV infection (e.g., HPV 
types 6 and 11) causes genital warts and recurrent respiratory papillomatosis. Persistent 
oncogenic HPV infection is the strongest risk factor for development of HPV-associated 
precancers and cancers. A substantial burden of cancers and anogenital warts are attributable 
to HPV in the United States: in 2009, an estimated 34,788 new HPV-associated cancers 
(761,762) and approximately 355,000 new cases of anogenital warts were associated with 
HPV infection (763).
Prevention
HPV Vaccines—There are several HPV vaccines licensed in the United States: a bivalent 
vaccine (Cervarix) that prevents infection with HPV types 16 and 18, a quadrivalent vaccine 
(Gardasil) that prevents infection with HPV types 6, 11, 16, and 18, and a 9-valent vaccine 
that prevents infection with HPV types 6, 11, 16, and 18, 31, 33, 45, 52, and 58. The bivalent 
and quadrivalent vaccines offer protection against HPV types 16 and 18, which account for 
66% of all cervical cancers, and the 9-valent vaccine protects against five additional types 
accounting for 15% of cervical cancers. The quadrivalent HPV vaccine also protects against 
types 6 and 11, which cause 90% of genital warts.
All HPV vaccines are administered as a 3-dose series of IM injections over a 6-month 
period, with the second and third doses given 1–2 and 6 months after the first dose, 
respectively. The same vaccine product should be used for the entire 3-dose series. For girls, 
either vaccine is recommended routinely at ages 11–12 years and can be administered 
beginning at 9 years of age (16); girls and women aged 13–26 years who have not started or 
completed the vaccine series should receive the vaccine. The quadrivalent or 9-valent HPV 
vaccine is recommended routinely for boys aged 11–12 years; boys can be vaccinated 
beginning at 9 years of age (http://www.cdc.gov/vaccines/hcp/acip-recs/index.html). Boys 
and men aged 13–21 years who have not started or completed the vaccine series should 
receive the vaccine (16) (http://www.cdc.gov/vaccines/hcp/acip-recs/index.html). For 
previously unvaccinated, immunocompromised persons (including persons with HIV 
infection) and MSM, vaccination is recommended through age 26 years (16). In the United 
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States, the vaccines are not licensed or recommended for use in men or women aged >26 
years (16). HPV vaccines are not recommended for use in pregnant women. HPV vaccines 
can be administered regardless of history of anogenital warts, abnormal Pap/HPV tests, or 
anogenital precancer. Women who have received HPV vaccine should continue routine 
cervical cancer screening if they are aged ≥21 years. HPV vaccine is available for eligible 
children and adolescents aged <19 years through the Vaccines for Children (VFC) program 
(information available by calling CDC INFO [800-232-4636]). For uninsured persons aged 
19–26 years, patient assistance programs are available from the vaccine manufacturers. 
Prelicensure and postlicensure safety evaluations have found the vaccine to be well tolerated 
(764) (http://www.cdc.gov/vaccinesafety/Vaccines/HPV/index.html). Impact-monitoring 
studies in the United States have demonstrated reductions of genital warts, as well as the 
HPV types contained within the quadrivalent vaccine (765,766). The current 
recommendations for HPV vaccination are available at http://www.cdc.gov/vaccines/hcp/
acip-recs/index.html.
Settings that provide STD services should either administer the vaccine to eligible clients 
who have not started or completed the vaccine series or refer these persons to another 
facility equipped to provide the vaccine. Clinicians providing services to children, 
adolescents, and young adults should be knowledgeable about HPV and HPV vaccine 
(http://www.cdc.gov/vaccines/who/teens/for-hcp/hpv-resources.html). HPV vaccination has 
not been associated with initiation of sexual activity or sexual risk behaviors or perceptions 
about sexually transmitted infections (128).
Abstaining from sexual activity is the most reliable method for preventing genital HPV 
infection. Persons can decrease their chances of infection by practicing consistent and 
correct condom use and limiting their number of sex partners. Although these interventions 
might not fully protect against HPV, they can decrease the chances of HPV acquisition and 
transmission.
Diagnostic Considerations
HPV tests are available to detect oncogenic types of HPV infection and are used in the 
context of cervical cancer screening and management or follow-up of abnormal cervical 
cytology or histology (see Cervical Cancer, Screening Recommendations). These tests 
should not be used for male partners of women with HPV or women aged <25 years, for 
diagnosis of genital warts, or as a general STD test.
The application of 3%–5% acetic acid, which might cause affected areas to turn white, has 
been used by some providers to detect genital mucosa infected with HPV. The routine use of 
this procedure to detect mucosal changes attributed to HPV infection is not recommended 
because the results do not influence clinical management.
Treatment
Treatment is directed to the macroscopic (e.g., genital warts) or pathologic precancerous 
lesions caused by HPV. Subclinical genital HPV infection typically clears spontaneously; 
therefore, specific antiviral therapy is not recommended to eradicate HPV infection. 
Precancerous lesions are detected through cervical cancer screening (see Cervical Cancer, 
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Screening Recommendations); HPV-related precancer should be managed based on existing 
guidance.
Counseling
Key Messages for Persons with HPV Infection
General
• Anogenital HPV infection is very common. It usually infects the anogenital area 
but can infect other areas including the mouth and throat. Most sexually active 
people get HPV at some time in their lives, although most never know it.
• Partners who have been together tend to share HPV, and it is not possible to 
determine which partner transmitted the original infection. Having HPV does not 
mean that a person or his/her partner is having sex outside the relationship.
• Most persons who acquire HPV clear the infection spontaneously and have no 
associated health problems. When the HPV infection does not clear, genital 
warts, precancers, and cancers of the cervix, anus, penis, vulva, vagina, head, and 
neck might develop.
• The types of HPV that cause genital warts are different from the types that can 
cause cancer.
• Many types of HPV are sexually transmitted through anogenital contact, mainly 
during vaginal and anal sex. HPV also might be transmitted during genital-to-
genital contact without penetration and oral sex. In rare cases, a pregnant woman 
can transmit HPV to an infant during delivery.
• Having HPV does not make it harder for a woman to get pregnant or carry a 
pregnancy to term. However, some of the precancers or cancers that HPV can 
cause, and the treatments needed to treat them, might lower a woman’s ability to 
get pregnant or have an uncomplicated delivery. Treatments are available for the 
conditions caused by HPV, but not for the virus itself.
• No HPV test can determine which HPV infection will clear and which will 
progress. However, in certain circumstances, HPV tests can determine whether a 
woman is at increased risk for cervical cancer. These tests are not for detecting 
other HPV-related problems, nor are they useful in women aged<25 years or men 
of any age.
Prevention of HPV
• Two HPV vaccines can prevent diseases and cancers caused by HPV. The 
Cervarix and Gardasil vaccines protect against most cases of cervical cancer; 
Gardasil also protects against most genital warts. HPV vaccines are 
recommended routinely for boys and girls aged 11–12 years; either vaccine is 
recommended for girls/women, whereas only one vaccine (Gardasil) is 
recommended for boys/men (http://www.cdc.gov/vaccines/vpd-vac/hpv). These 
vaccines are safe and effective.
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• Condoms used consistently and correctly can lower the chances of acquiring and 
transmitting HPV and developing HPV-related diseases (e.g., genital warts and 
cervical cancer). However, because HPV can infect areas not covered by a 
condom, condoms might not fully protect against HPV.
• Limiting number of sex partners can reduce the risk for HPV. However, even 
persons with only one lifetime sex partner can get HPV.
Abstaining from sexual activity is the most reliable method for preventing genital HPV 
infection.
Anogenital Warts
Of anogenital warts, 90% are caused by nononcogenic HPV types 6 or 11; these types can 
be commonly identified before or at the same time anogenital warts are detected (767). HPV 
types 16, 18, 31, 33, and 35 are also occasionally found in anogenital warts (usually as co-
infections with HPV 6 or 11) and can be associated with foci of high-grade squamous 
intraepithelial lesions (HSIL), particularly in persons who have HIV infection. In addition to 
anogenital warts, HPV types 6 and 11 have been associated with conjunctival, nasal, oral, 
and laryngeal warts.
Anogenital warts are usually asymptomatic, but depending on the size and anatomic 
location, they can be painful or pruritic. They are usually flat, papular, or pedunculated 
growths on the genital mucosa. Anogenital warts occur commonly at certain anatomic sites, 
including around the vaginal introitus, under the foreskin of the uncircumcised penis, and on 
the shaft of the circumcised penis. Warts can also occur at multiple sites in the anogenital 
epithelium or within the anogenital tract (e.g., cervix, vagina, urethra, perineum, perianal 
skin, anus, and scrotum). Intra-anal warts are observed predominantly in persons who have 
had receptive anal intercourse, but they also can occur in men and women who have not had 
a history of anal sexual contact.
Diagnostic Considerations
Diagnosis of anogenital warts is usually made by visual inspection. The diagnosis of 
anogenital warts can be confirmed by biopsy, which is indicated if lesions are atypical (e.g., 
pigmented, indurated, affixed to underlying tissue, bleeding, or ulcerated lesions). Biopsy 
might also be indicated in the following circumstances, particularly if the patient is 
immunocompromised (including those infected with HIV): 1) the diagnosis is uncertain; 2) 
the lesions do not respond to standard therapy; or 3) the disease worsens during therapy. 
HPV testing is not recommended for anogenital wart diagnosis, because test results are not 
confirmatory and do not guide genital wart management.
Treatment
The aim of treatment is removal of the wart and amelioration of symptoms, if present. The 
appearance of warts also can result in significant psychosocial distress, and removal can 
relieve cosmetic concerns. In most patients, treatment results in resolution of the wart(s). If 
left untreated, anogenital warts can resolve spontaneously, remain unchanged, or increase in 
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size or number. Because warts might spontaneously resolve within 1 year, an acceptable 
alternative for some persons is to forego treatment and wait for spontaneous resolution. 
Available therapies for anogenital warts might reduce, but probably do not eradicate, HPV 
infectivity. Whether the reduction in HPV viral DNA resulting from treatment reduces future 
transmission remains unknown.
Recommended Regimens—Treatment of anogenital warts should be guided by wart 
size, number, and anatomic site; patient preference; cost of treatment; convenience; adverse 
effects; and provider experience. No definitive evidence suggests that any one recommended 
treatment is superior to another, and no single treatment is ideal for all patients or all warts. 
The use of locally developed and monitored treatment algorithms has been associated with 
improved clinical outcomes and should be encouraged. Because all available treatments have 
shortcomings, some clinicians employ combination therapy (e.g., provider-administered 
cryotherapy with patient-applied topical therapy between visits to the provider). However, 
limited data exist regarding the efficacy or risk for complications associated with 
combination therapy. Treatment regimens are classified as either patient-applied or provider-
administered modalities. Patient-applied modalities are preferred by some persons because 
they can be administered in the privacy of their home. To ensure that patient-applied 
modalities are effective, instructions should be provided to patients while in the clinic, and 
all anogenital warts should be accessible and identified during the clinic visit. Follow-up 
visits after several weeks of therapy enable providers to answer any questions about the use 
of the medication and address any side effects experienced; follow-up visits also facilitate 
the assessment of the response to treatment.
Recommended Regimens for External Anogenital Warts (i.e., penis, groin, scrotum, vulva, perineum, external 
anus, and perianus*)
Patient-Applied:
Imiquimod 3.75% or 5% cream†
 OR
Podofilox 0.5% solution or gel
 OR
Sinecatechins 15% ointment†
Provider–Administered:
Cryotherapy with liquid nitrogen or cryoprobe
 OR
Surgical removal either by tangential scissor excision, tangential shave excision, curettage, laser, or electrosurgery
 OR
Trichloroacetic acid (TCA) or bichloroacetic acid (BCA) 80%–90% solution
*Many persons with external anal warts also have intra-anal warts. Thus, persons with external anal warts might benefit 
from an inspection of the anal canal by digital examination, standard anoscopy, or high-resolution anoscopy.
†Might weaken condoms and vaginal diaphragms.
Imiquimod is a patient-applied, topically active immune enhancer that stimulates production 
of interferon and other cytokines. Imiquimod 5% cream should be applied once at bedtime, 
three times a week for up to 16 weeks (768). Similarly, imiquimod 3.75% cream should be 
applied once at bedtime, but is applied every night (769). With either formulation, the 
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treatment area should be washed with soap and water 6–10 hours after the application. Local 
inflammatory reactions, including redness, irritation, induration, ulceration/erosions, and 
vesicles might occur with the use of imiquimod, and hypopigmentation has also been 
described (770). A small number of case reports demonstrate an association between 
treatment with imiquimod cream and worsened inflammatory or autoimmune skin diseases 
(e.g., psoriasis, vitiligo, and lichenoid dermatoses) (771–773). Data from studies of human 
subjects are limited regarding use of imiquimod in pregnancy, but animal data suggest that 
this therapy poses low risk (317).
Podofilox (podophyllotoxin) is a patient-applied antimitotic drug that causes wart necrosis. 
Podofilox solution (using a cotton swab) or podofilox gel (using a finger) should be applied 
to anogenital warts twice a day for 3 days, followed by 4 days of no therapy. This cycle can 
be repeated, as necessary, for up to four cycles. The total wart area treated should not exceed 
10 cm2, and the total volume of podofilox should be limited to 0.5 mL per day. If possible, 
the health-care provider should apply the initial treatment to demonstrate proper application 
technique and identify which warts should be treated. Mild to moderate pain or local 
irritation might develop after treatment. Podofilox is contraindicated in pregnancy (317).
Sinecatechins is a patient-applied, green-tea extract with an active product (catechins). 
Sinecatechins 15% ointment should be applied three times daily (0.5 cm strand of ointment 
to each wart) using a finger to ensure coverage with a thin layer of ointment until complete 
clearance of warts is achieved. This product should not be continued for longer than 16 
weeks (774–776). The medication should not be washed off after use. Genital, anal, and oral 
sexual contact should be avoided while the ointment is on the skin. The most common side 
effects of sinecatechins are erythema, pruritus/burning, pain, ulceration, edema, induration, 
and vesicular rash. The medication is not recommended for persons with HIV infection, 
other immunocompromised conditions, or with genital herpes because the safety and 
efficacy of therapy has not been evaluated. The safety of sinecatechins during pregnancy is 
unknown.
Cryotherapy is a provider-applied therapy that destroys warts by thermal-induced cytolysis. 
Health-care providers must be trained on the proper use of this therapy because over- and 
under-treatment can result in complications or low efficacy. Pain during and after application 
of the liquid nitrogen, followed by necrosis and sometimes blistering, is common. Local 
anesthesia (topical or injected) might facilitate therapy if warts are present in many areas or 
if the area of warts is large.
Surgical therapy has the advantage of eliminating most warts at a single visit, although 
recurrence can occur. Surgical removal requires substantial clinical training, additional 
equipment, and sometimes a longer office visit. After local anesthesia is applied, anogenital 
warts can be physically destroyed by electrocautery, in which case no additional hemostasis 
is required. Care must be taken to control the depth of electrocautery to prevent scarring. 
Alternatively, the warts can be removed either by tangential excision with a pair of fine 
scissors or a scalpel, by carbon dioxide (CO2) laser, or by curettage. Because most warts are 
exophytic, this procedure can be accomplished with a resulting wound that only extends into 
the upper dermis. Hemostasis can be achieved with an electrocautery unit or, in cases of very 
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minor bleeding, a chemical styptic (e.g., an aluminum chloride solution). Suturing is neither 
required nor indicated in most cases. In patients with large or extensive warts, surgical 
therapy, including CO2 laser, might be most beneficial; such therapy might also be useful for 
intraurethral warts, particularly for those persons who have not responded to other 
treatments. Treatment of anogenital and oral warts should be performed in an appropriately 
ventilated room using standard precautions (http://www.cdc.gov/hicpac/pdf/isolation/
Isolation2007.pdf#page=2) and local exhaust ventilation (e.g., a smoke evacuator) (777) 
(http://www.cdc.gov/niosh/docs/hazardcontrol/hc11.html).
Trichloroacetic acid (TCA) and bichloroacetic acid (BCA) are provider-applied caustic 
agents that destroy warts by chemical coagulation of proteins. Although these preparations 
are widely used, they have not been investigated thoroughly. TCA solution has a low 
viscosity comparable with that of water and can spread rapidly and damage adjacent tissues 
if applied excessively. A small amount should be applied only to the warts and allowed to 
dry (i.e., develop white frost on tissue) before the patient sits or stands. If pain is intense or 
an excess amount of acid is applied, the area can be covered with sodium bicarbonate (i.e., 
baking soda), washed with liquid soap preparations, or be powdered with talc to neutralize 
the acid or remove unreacted acid. TCA/BCA treatment can be repeated weekly if necessary.
Alternative Regimens for External Genital Warts—Less data are available regarding 
the efficacy of alternative regimens for treating anogenital warts, which include podophyllin 
resin, intralesional interferon, photodynamic therapy, and topical cidofovir. Further, 
alternative regimens might be associated with more side effects. Podopyllin resin is no 
longer a recommended regimen because of the number of safer regimens available, and 
severe systemic toxicity has been reported when podophyllin resin was applied to large areas 
of friable tissue and was not washed off within 4 hours (778–780). Podophyllin resin 10%–
25% in a compound tincture of benzoin might be considered for provider-administered 
treatment under conditions of strict adherence to recommendations. Podophyllin should be 
applied to each wart and then allowed to air-dry before the treated area comes into contact 
with clothing. Over-application or failure to air-dry can result in local irritation caused by 
spread of the compound to adjacent areas and possible systemic toxicity. The treatment can 
be repeated weekly, if necessary. To avoid the possibility of complications associated with 
systemic absorption and toxicity, 1) application should be limited to <0.5 mL of podophyllin 
or an area of <10 cm2 of warts per session; 2) the area to which treatment is administered 
should not contain any open lesions, wounds, or friable tissue; and 3) the preparation should 
be thoroughly washed off 1–4 hours after application. Podophyllin resin preparations differ 
in the concentration of active components and contaminants. Shelf-life and stability of 
podophyllin preparations are unknown. The safety of podophyllin during pregnancy has not 
been established.
Recommended Regimens for Urethral Meatus Warts
Cryotherapy with liquid nitrogen
 OR
Surgical removal
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Recommended Regimens for Vaginal Warts
Cryotherapy with liquid nitrogen. The use of a cryoprobe in the vagina is not recommended because of the risk for 
vaginal perforation and fistula formation.
 OR
Surgical removal
 OR
TCA or BCA 80%–90% solution
Recommended Regimens for Cervical Warts
Cryotherapy with liquid nitrogen
 OR
Surgical removal
 OR
TCA or BCA 80%–90% solution
Management of cervical warts should include consultation with a specialist.
For women who have exophytic cervical warts, a biopsy evaluation to exclude high-grade SIL must be performed before 
treatment is initiated.
Recommended Regimens for Intra-anal Warts
Cryotherapy with liquid nitrogen
 OR
Surgical removal
 OR
TCA or BCA 80%–90% solution
Management of intra-anal warts should include consultation with a specialist.
Follow-Up
Most anogenital warts respond within 3 months of therapy. Factors that might affect 
response to therapy include immunosuppression and treatment compliance. In general, warts 
located on moist surfaces or in intertriginous areas respond best to topical treatment. A new 
treatment modality should be selected when no substantial improvement is observed after a 
complete course of treatment or in the event of severe side effects; treatment response and 
therapy-associated side effects should be evaluated throughout the course of therapy. 
Complications occur rarely when treatment is administered properly. Persistent 
hypopigmentation or hyperpigmentation can occur with ablative modalities (e.g., 
cryotherapy and electrocautery) and have been described with immune modulating therapies 
(e.g., imiquimod cream). Depressed or hypertrophic scars are uncommon but can occur, 
especially if patients have insufficient time to heal between treatments. Rarely, treatment can 
result in chronic pain syndromes (e.g., vulvodynia and hyperesthesia of the treatment site) 
or, in the case of anal warts, painful defecation or fistulas.
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Counseling
Key Messages for Persons with Anogenital Warts
• If left untreated, genital warts may go away, stay the same, or increase in size or 
number. The types of HPV that cause genital warts are different from the types 
that can cause cancer.
• Women with genital warts do not need Pap tests more often than other women.
• Time of HPV acquisition cannot be definitively determined. Genital warts can 
develop months or years after getting HPV. HPV types that cause genital warts 
can be passed on to another person even in the absence of visible signs of warts. 
Sex partners tend to share HPV, even though signs of HPV (e.g., warts) might 
occur in only one partner or in neither partner.
• Although genital warts are common and benign, some persons might experience 
considerable psychosocial impact after receiving this diagnosis.
• Although genital warts can be treated, such treatment does not cure the virus 
itself. For this reason, it is common for genital warts to recur after treatment, 
especially in the first 3 months.
• Because genital warts can be sexually transmitted, patients with genital warts 
benefit from testing for other STDs. Sexual activity should be avoided with new 
partners until the warts are gone or removed. HPV might remain present and can 
still be transmitted to partners even after the warts are gone.
• Condoms might lower the chances of transmitting genital warts if used 
consistently and correctly; however, HPV can infect areas that are not covered by 
a condom and might not fully protect against HPV.
• A vaccine is available for males and females to prevent genital warts (Gardasil), 
but it will not treat existing HPV or genital warts. This vaccine can prevent most 
cases of genital warts in persons who have not yet been exposed to wart-causing 
types of HPV.
Management of Sex Partners
Persons should inform current partner(s) about having genital warts because the types of 
HPV that cause warts can be passed on to partners. Partners should receive counseling 
messages that partners might already have HPV despite no visible signs of warts, so HPV 
testing of sex partners of persons with genital warts is not recommended. Partner(s) might 
benefit from a physical examination to detect genital warts and tests for other STDs. No 
recommendations can be made regarding informing future sex partners about a diagnosis of 
genital warts because the duration of viral persistence after warts have resolved is unknown.
Special Considerations
Pregnancy—Podofilox (podophyllotoxin), podophyllin, and sinecatechins should not be 
used during pregnancy. Imiquimod appears to pose low risk but should be avoided until 
more data are available. Anogenital warts can proliferate and become friable during 
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pregnancy. Although removal of warts during pregnancy can be considered, resolution might 
be incomplete or poor until pregnancy is complete. Rarely, HPV types 6 and 11 can cause 
respiratory papillomatosis in infants and children, although the route of transmission (i.e., 
transplacental, perinatal, or postnatal) is not completely understood. Whether cesarean 
section prevents respiratory papillomatosis in infants and children also is unclear (781); 
therefore, cesarean delivery should not be performed solely to prevent transmission of HPV 
infection to the newborn. Cesarean delivery is indicated for women with anogenital warts if 
the pelvic outlet is obstructed or if vaginal delivery would result in excessive bleeding. 
Pregnant women with anogenital warts should be counseled concerning the low risk for 
warts on the larynx of their infants or children (recurrent respiratory papillomatosis).
HIV Infection and Other Causes of Immunosuppression—Persons with HIV 
infection or who are otherwise immunosuppressed are more likely to develop anogenital 
warts than those who do not have HIV infection (782). Moreover, such persons can have 
larger or more numerous lesions, might not respond to therapy as well as those who are 
immunocompetent, and might have more frequent recurrences after treatment (782–785). 
Despite these factors, data do not support altered approaches to treatment for persons with 
HIV infection. Squamous cell carcinomas arising in or resembling anogenital warts might 
occur more frequently among immunosuppressed persons, therefore requiring biopsy for 
confirmation of diagnosis for suspicious cases (786–788).
High-grade Squamous Intraepithelial Lesions (HSIL)—Biopsy of an atypical wart 
might reveal HSIL or cancer of the anogenital tract. In this instance, referral to a specialist 
for treatment is recommended.
HPV-Associated Cancers and Precancers
Persistent infection with oncogenic types of HPV has a causal role in nearly all cervical 
cancers and in many vulvar, vaginal, penile, anal, and oropharyngeal cancers (789). 
However, the only HPV-associated cancer for which routine screening is recommended is 
cervical cancer.
Cervical Cancer
Screening Recommendations—Recommendations for cervical cancer screening in the 
United States are based on systematic evidence reviews and are largely consistent across the 
major medical organizations, including ACS, ACOG, and USPSTF (124–126) (http://
www.cdc.gov/cancer/cervical/index.htm). Routine cervical screening should be performed 
starting at age 21 years and continue through age 65 years to prevent invasive cervical 
cancer. Testing can be performed using either conventional or liquid-based cytologic tests 
(i.e., Pap tests). For women aged ≥30 years, screening can include several FDA-approved 
oncogenic or high risk HPV (HR-HPV) tests. For cytopathologic and HR-HPV testing, 
clinics should use CLIA-certified laboratories using acceptable terminology (Bethesda 2001 
or LAST terminology) (790,791). Annual cervical cancer screening is no longer 
recommended for all women. Instead, Pap testing is recommended every 3 years from ages 
21–29 years. During age 30–65 years, women should either receive a Pap test every 3 years 
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or a Pap test plus HPV test (co-test) every 5 years; co-testing can be done by either 
collecting one swab for the Pap test and another for the HPV test or by using the remaining 
liquid cytology material for the HPV test. Because of the high negative predictive value of 
two tests, women who test negative for both HPV and Pap test should not be screened again 
for 5 years. Cervical screening programs should screen women who have received HPV 
vaccination in the same manner as unvaccinated women. All major medical organizations 
concur that no Pap testing is recommended before age 21 years.
Women should be given a copy of their test results (Pap and HPV, if applicable); those with 
normal results should also be provided with general recommendations regarding when to 
schedule follow-up visits and the importance of cervical cancer screening. Women with 
abnormal screening tests should be referred to providers who are experienced in managing 
these cases (see Follow-Up). Women should be reassured and counseled about abnormal 
cervical cancer screening test results and informed about any implications for sex partner(s). 
(See counseling messages for HPV infection and for women receiving cervical cancer 
screening.)
The following additional management considerations are associated with performing Pap 
tests:
• The Pap test should not be considered a screening test for STDs.
• All women should receive cervical cancer screening, regardless of sexual 
orientation (i.e., women who identify as lesbian, bisexual, or heterosexual).
• Ideally, women should be advised to have a Pap test 10–20 days after the first 
day of menses. However, this test can be performed during menstruation 
depending on menstrual flow and type of cytology used (liquid-based cytology 
can differentiate cells from blood and mucus; conventional Pap test might not).
• If specific infections other than HPV (e.g., chlamydia or gonorrhea) are 
identified at the visit, the woman might need to have a repeat Pap test after 
appropriate treatment for those infections. However, in most instances (even in 
the presence of some severe infections), Pap tests will be reported as satisfactory 
for evaluation, and reliable final reports can be produced without the need to 
repeat the Pap test after treatment is received.
• The presence of a mucopurulent discharge should not postpone Pap testing. The 
test can be performed after removal of the discharge with a saline-soaked cotton 
swab.
• In the presence of cervical friability (see Cervicitis), liquid-based cytology 
should be used; conventional pap testing might need to be deferred in the 
presence of heavy bleeding until cervicitis is treated.
• In the absence of other indications, women who have external genital warts do 
not need Pap tests more frequently than women who do not have warts.
• The sequence of Pap testing in relation to collection of other endocervical 
specimens does not influence Pap test results or their interpretation (792). In 
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general, vaginal specimens are preferred for chlamydia and gonorrhea screening 
in women, but in the setting of a pelvic exam, endocervical specimens for STD 
testing can be collected first.
• Women who have had a total hysterectomy do not require a routine Pap test 
unless the hysterectomy was performed because of cervical cancer or its 
precursor lesions. In women whose cervix remains intact after a hysterectomy, 
regularly scheduled Pap tests should be performed as indicated (793–795).
• Health-care facilities that train providers on Pap test collection and employ 
simple quality assurance measures are more likely to obtain satisfactory test 
results (as determined by the laboratory).
• The use of instruments designed to sample to the cervical transformation zone 
(e.g., cytobrushes) improves the accuracy of Pap tests (796).
• Liquid-based cytology is an acceptable alternative to conventional Pap tests, as it 
has similar test-performance characteristics.
• At an initial visit, providers should ask women about their most recent Pap test 
and results and history of evaluation and treatment (e.g., loop electrosurgical 
excision procedure and colposcopy) to assist with management; every effort 
should be made to obtain copies of recent results. The importance and frequency 
of Pap testing or co-testing (Pap and HPV testing) should be reinforced.
HPV Tests for Cervical Cancer Screening—Clinical tests for oncogenic types of HPV 
are used for 1) cervical cancer screening in conjunction with a Pap test, 2) triage of 
abnormal cervical cytology results, and 3) follow-up after treatment of cervical precancers. 
These tests are only approved for use with cervical specimens, not oral or anal specimens. 
The role of testing for non-oncogenic HPV types (e.g., 6 and 11) is unclear and is not 
recommended.
Current FDA-cleared HPV tests detect viral nucleic acid (DNA) or messenger RNA 
(mRNA). Several FDA-cleared tests for HPV are available for use in the United States, but 
use of non-oncogenic (e.g., types 6 and 11) tests is not recommended (110). The Hybrid 
Capture 2 High-Risk HPV DNA test (Qiagen, Gaithersburg, Maryland) and the Cervista 
HPV High-Risk DNA test (Hologics, Beford, Massachusetts) detect presence of 13–14 
oncogenic HPV types, whereas the Cervista HPV 16/18 DNA test only detects oncogenic 
HPV types 16 and 18. The Digene HC2 HPV DNA test (Qiagen, Gaithersburg, Maryland) 
detects 13 oncogenic or five non-oncogenic HPV types. The Cobas 4500 (Roche, Pleasanton 
California) test detects 14 oncogenic HPV DNA types and can detect individual types HPV 
16 and 18, while the APTIMA HR HPV (Gen Probe, San Diego CA) test detects 14 
oncogenic HPV types of HPV mRNA. Aptima HPV 16/18/45 test is also FDA-cleared to 
triage its pooled Aptima HR HPV test further, although there are no algorithms for HPV 
16/18/45 testing in any clinical guidelines. HPV assays should be FDA-cleared and used 
only for the appropriate indications (110).
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In the United States, HPV tests to detect oncogenic types of HPV infection are most 
commonly used to triage Pap test results indicating atypical squamous cells of undetermined 
significance (ASC-US) in women aged ≥25 years (110). HPV testing for oncogenic types 
are now being incorporated into cervical cancer screening recommendations with Pap tests 
(i.e., co-testing) to reduce follow-up visits in women aged ≥30 years (see Screening 
Recommendations). HPV testing can be performed on the same swab as used for the Pap test 
or a separate supplied swab; reflex testing of residual material of a liquid-based cytology 
specimen is another option. HPV testing for 16 and 18 is also used to triage discordant test 
results (i.e., in the case of a negative Pap test and positive HPV test). In the future, 
oncogenic (high-risk) HPV tests might be considered for primary cervical cancer screening, 
but no such recommendation has been made by any medical organization.
HPV testing (including oncogenic HPV and HPV 16/18 tests) should not be performed in 
the following situations:
• Deciding whether to vaccinate against HPV;
• Conducting STD screening in women or men at risk for STDs;
• Providing care to persons with genital warts or their partners;
• Conducting screening for cervical cancer as a stand-alone test (i.e., without a 
concurrent Pap test);
• Testing women aged <30 years as part of routine cervical cancer screening; or
• Testing oral or anal specimens.
Follow-Up—If the results of the Pap test are abnormal, follow-up care should be provided 
according to ASCCP 2012 Consensus Guidelines for Management of Abnormal Cervical 
Cytology (110). If clinic resources do not allow for follow-up of women with abnormal 
results, protocols for linkage to follow-up care and management should be in place. The 
following are highlights of the ASCCP guidelines.
• Women aged 21–24 years are managed more conservatively than other women 
because of potential harms of overtreatment and low risk for cancer. For women 
in this age group who have ASC-US or LSIL, cytology should be repeated in 12 
months.
• For women with ASC-US cytology, either cytology can be repeated in 12 months 
(for women of all ages) or reflex HPV testing can be performed (for women aged 
≥25 years).
• For women with ASC-US who are HPV negative, a repeat HPV and Pap test in 3 
years is recommended.
• For women who have normal cytology but lack endocervical cells, a repeat Pap 
is not required. For women who have unsatisfactory cytology, regardless of 
negative HPV result, a repeat cytology is required in 2–4 months.
• HPV 16/18 testing is one follow-up option for women who have discordant 
results (normal Pap test accompanied by a positive HPV test). If the HPV 16/18 
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test is positive, women should immediately receive colposcopy. If negative, these 
women should repeat the HPV co-test in 1 year.
• For women with LSIL or HSIL, management should be provided by a specialist 
according to existing guidelines (http://www.asccp.org).
Clinics in settings serving women who might not adhere to follow-up recommendations for 
whom linkage to care is unlikely should consider offering in-house colposcopy and biopsy 
services. ASCCP has an app available for purchase and download for management of 
abnormal cytologic and histologic results. Although this app takes current results into 
consideration, clinicians are required to have knowledge of past abnormal Pap or cervical 
procedures to provide management guidance (http://www.asccp.org/Bookstore/ASCCP-
Algorithms-Mobile-App).
Counseling—Women might believe the Pap test screens for conditions other than cervical 
cancer or might be confused by abnormal results (797–799). Health-care providers, a trusted 
source of information about HPV and abnormal Pap test results, are critical in educating 
women about high-risk HPV and can moderate the psychosocial impact of abnormal results 
(1,735,800,801). Women should be counseled on the risks, uncertainties, and benefits of 
screening (126,802). Education, counseling, and follow-up reminders by phone, text, or 
email might increase screening and adherence to follow-up (803). Multiple forms of 
communication (e.g., in-person counseling and printed or online information) might be more 
effective than one form alone (804). Print materials and online resources are available at 
http://www.cdc.gov/cancer/cervical/basic_info/screening.htm; http://www.cdc.gov/std/hpv/
common/; http://www.ashasexualhealth.org/stdsstis/hpv/hpv-cervical-cancer.
Abnormal Pap test and/or HPV test results can cause short-term anxiety, stress, fear, and 
confusion, decreasing women’s ability to absorb and retain information and possibly acting 
as a barrier to follow-up care (798,805–807). A positive HPV test might exacerbate these 
feelings and elicit concerns about partner(s); worry about disclosure; and feelings of guilt, 
anger, and stigmatization (800,806). Providers should frame oncogenic HPV positivity in a 
neutral, nonstigmatizing context and emphasize its common, asymptomatic, and transient 
nature. Providers also should emphasize that HPV is often shared between partners. 
Therefore, having HPV does not imply infidelity, nor should it raise concerns about a 
partner’s health (800).
Key Messages for Women Regarding Cervical Cancer Screening
• Cervical cancer can be prevented with regular screening tests, like the Pap test 
and the HPV DNA test (HPV test). All women should start getting regular Pap 
tests at age 21 years.
• The Pap test can find abnormal cells on a woman’s cervix, which could lead to 
cervical cancer over time, and an HPV test detects HPV infection of the cervix. 
The HPV test can be used at the same time as the Pap test (known as “co-
testing”) for women aged ≥30 years. The HPV test also can be used after an 
inconclusive Pap test among women aged ≥25 years; testing for this purpose is 
known as “reflex HPV testing.”
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• Positive Pap and HPV tests are markers of early signs of cervical cancer, which 
often does not cause symptoms until it is advanced. Appropriate follow-up is 
essential to ensure that cervical cancer does not develop. All women, even those 
who feel healthy, should receive screening for cervical cancer.
• HPV is a common infection and is often cleared from the body without any 
medical interventions. A positive HPV test does not mean that a person has 
cancer.
• HPV is often shared between partners and can lie dormant for many years; 
having HPV does not imply infidelity, nor should it necessarily raise concerns 
about a partner’s health (http://www.cdc.gov/cancer/hpv/basic_info/screening).
Management of Sex Partners—The benefit of disclosing a positive oncogenic HPV test 
to current and future sex partners is unclear. The following counseling messages can be 
communicated to sex partners:
• Sex partners do not need to be tested for HPV.
• Sex partners tend to share HPV, even though signs of HPV such as an abnormal 
Pap-test result might occur in only one partner. Sex partners of persons with 
HPV infection also likely have HPV.
• When used correctly and consistently, condoms might lower the risk for HPV 
infection and might decrease the time to clear in women with HPV infection. 
However, HPV can infect areas not covered by the condom and might not fully 
protect against HPV.
Additional messages for partners include the messages for persons with HPV (see 
Counseling Messages for Persons with HPV).
Special Considerations
Pregnancy: Pregnant women should be screened at the same intervals as nonpregnant 
women. However, pregnant women with abnormal screening tests should be referred to a 
specialist (808–810), because treatment recommendations differ for this population. A swab, 
Ayre’s spatula, or cytobrush can be used for obtaining Pap tests in pregnant women (811–
813).
HIV Infection: Several studies have documented an increased risk for cervical precancers 
and cancers in women with HIV infection (814,815). Women with HIV infection should be 
screened within 1 year of sexual activity or initial HIV diagnosis using conventional or 
liquid-based cytology (Pap test); testing should be repeated 6 months later. Management 
recommendations for women with HIV infection are detailed elsewhere (http://
aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-
guidelines/0) (247).
Adolescents: Prevalence of oncogenic HPV types are high among adolescents aged <21 
years (816), and oncogenic HPV and squamous intraepithelial lesions caused by HPV in 
adolescent girls are more likely to regress than those in older women. For these reasons, 
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cervical cancer screening and HPV testing are not recommended in adolescents. However, 
for adolescents with HIV infection, providers should screen 1 year after onset of sexual 
activity, regardless of age or mode of HIV infection (e.g., perinatally acquired or sexually 
acquired) (247); such screening is warranted because of the reported high rate of progression 
of abnormal cytology in adolescents with HIV infection.
Anal Cancer
Data are insufficient to recommend routine anal cancer screening with anal cytology in 
persons with HIV infection, MSM without HIV infection, and the general population. 
However, anal cytology might be useful for detecting anal cancer in persons who have 
masses on palpation, particularly persons with HIV infection and HIV-negative MSM with a 
history of receptive anal intercourse (247). More evidence is needed concerning the natural 
history of anal intraepithelial neoplasia, the best screening methods and target populations, 
the safety and response to treatments, and other programmatic considerations before 
screening can be routinely recommended. However, some clinical centers perform anal 
cytology to screen for anal cancer among high-risk populations (e.g., persons with HIV 
infection, MSM, and history of receptive anal intercourse), followed by high-resolution 
anoscopy (HRA) for those with abnormal cytologic results (e.g., ASC-US or worse). 
Oncogenic HPV tests are not clinically useful for anal cancer screening among MSM 
because of a high prevalence of anal HPV infection (817,818).
Viral Hepatitis
Hepatitis A
Hepatitis A, caused by infection with the hepatitis A virus (HAV), has an incubation period 
of approximately 28 days (range: 15–50 days) (819). HAV replicates in the liver and is shed 
in high concentrations in feces from 2–3 weeks before to 1 week after the onset of clinical 
illness. HAV infection produces a self-limited disease that does not result in chronic 
infection or CLD. However, up to 10% of patients experience a relapse of symptoms during 
the 6 months after acute illness. Acute liver failure from hepatitis A is rare (overall case-
fatality rate: 0.5%). The risk for symptomatic infection is directly related to age, with >70% 
of adults having symptoms compatible with acute viral hepatitis and most children having 
either asymptomatic or unrecognized infection. Antibody produced in response to HAV 
infection persists for life and confers protection against reinfection (820).
HAV infection is primarily transmitted by the fecal-oral route, by either person-to-person 
contact or through consumption of contaminated food or water (821). Transmission of HAV 
during sexual activity probably results from fecal-oral contact; however, efforts to promote 
good personal hygiene have not been successful in interrupting outbreaks of hepatitis A. 
Although viremia occurs early in infection and can persist for several weeks after onset of 
symptoms, bloodborne transmission of HAV is uncommon (822). Transmission by saliva has 
not been demonstrated.
In the United States, of the hepatitis A cases accompanied by risk information reported 
during 2010, a particular risk was identified in only 25% (823). Among adults with 
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identified risk factors, most cases occurred among sexual and household contacts; those with 
children attending a nursery, daycare, or preschool and persons working in such settings; 
MSM; IDUs (823); international travelers; and persons exposed to a common-source food or 
water outbreak.
Diagnostic Considerations—The diagnosis of hepatitis A cannot be made on a clinical 
basis alone, but rather requires serologic testing. The presence of IgM antibody to HAV is 
diagnostic of acute HAV infection. A positive test for total anti-HAV indicates immunity to 
HAV infection but does not differentiate current from previous HAV infection. Although 
usually not sensitive enough to detect the low level of protective antibody after vaccination, 
anti-HAV tests also might be positive after hepatitis A vaccination.
Treatment—Patients with acute hepatitis A usually require only supportive care, with no 
restrictions in diet or activity. Hospitalization might be necessary for patients who become 
dehydrated because of nausea and vomiting and is critical for patients with signs or 
symptoms of acute liver failure. Medications that might cause liver damage or are 
metabolized by the liver should be used with caution among persons with hepatitis A.
Prevention—Vaccination is the most effective means of preventing HAV transmission 
among persons at risk for infection (e.g., MSM, drug users, and persons with CLD). 
Hepatitis A vaccines are prepared from formalin-inactivated, cell-culture–derived HAV. Two 
monovalent vaccines (HAVRIX, GlaxoSmithKline; VAQTA, Merck and Co., Inc.) are 
cleared by FDA for persons aged ≥12 months (Table 2), and these vaccines are available to 
eligible children and adolescents aged <19 years through the VFC program (telephone: 
800-232-4636).
Administered IM in a 2-dose series at 0 and 6–18 months, hepatitis A vaccines induce 
protective antibody levels in virtually all adults: by 1 month after the first dose, 94%–100% 
of adults have protective antibody levels and after a second dose, 100% achieve protective 
levels (2). Kinetic models of antibody decline indicate that protective levels of antibody 
persist for at least 20 years. A study in persons who are Alaska Natives demonstrated that 
seropositivity for hepatitis A persists for at least 10 years after completing 2-dose 
vaccination at age 12–21 months (824). Sustained protection and the need for booster dosing 
will continue to be assessed (825,826). A combined hepatitis A and hepatitis B vaccine 
(Twinrix) has been developed and licensed for use as a 3-dose series in adults aged ≥18 
years at risk for hepatitis A and hepatitis B infections. When administered IM on a 0-, 1-, 
and 6-month schedule, the vaccine has equivalent immunogenicity to that of the monovalent 
vaccines.
Immune globulin (IG) administered IM can provide postexposure prophylaxis against HAV. 
IG is a sterile solution of concentrated immunoglobulins prepared from pooled human 
plasma processed by cold ethanol fractionation. In the United States, IG is produced only 
from plasma that has tested negative for hepatitis B surface antigen, antibodies to HIV and 
HCV, and HIV and HCV RNA. In addition, the process used to manufacture IG inactivates 
viruses (e.g., HBV, HCV, and HIV). When administered IM within 2 weeks after exposure to 
HAV, IG is >85% effective in preventing HAV infections (827).
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Pre-exposure Vaccination: The following persons seeking STD services should be offered 
hepatitis A vaccine: 1) all MSM; 2) drug users (injection and noninjection illicit drugs); and 
3) persons with CLD, including persons with chronic HBV and HCV infection who have 
evidence of CLD. If persons are at risk for both hepatitis A and hepatitis B, the combined 
vaccine can be considered.
Prevaccination Serologic Testing: Approximately one third of the U.S. population has 
serologic evidence of previous HAV infection, the prevalence of which increases with age 
(828). The potential cost-savings of prevaccination testing for susceptibility should be 
weighed against cost and the likelihood that testing will interfere with initiating vaccination; 
serologic testing should not be a barrier to vaccination of at-risk populations. In these cases, 
the first vaccine dose should be administered immediately after collection of the blood 
sample for serologic testing. Vaccination of a person who is already immune is not harmful. 
Persons who have a documented history of ≥2-dose hepatitis A vaccination do not need 
further vaccination or serologic testing.
Postvaccination Serologic Testing: Postvaccination serologic testing for immunity is not 
indicated because most persons respond to the vaccine. In addition, the commercially 
available serologic test is not sensitive enough to detect the low but protective levels of 
antibody produced by vaccination.
Postexposure Prophylaxis: Persons who recently have been exposed to HAV and who 
previously have not received hepatitis A vaccine should be administered a single dose of 
monovalent hepatitis A vaccine or IG (0.02 mL/kg) as soon as possible, ideally within 2 
weeks of exposure because the efficacy of vaccine or IG or vaccine when administered >2 
weeks after exposure has not been established (820). Information about the relative efficacy 
of vaccine compared with IG postexposure is limited, and no data are available for persons 
aged >40 years or those with underlying medical conditions. Therefore, decisions to use 
vaccine versus IG should be informed by patient characteristics associated with more severe 
manifestations of hepatitis A (including older age and CLD) and the magnitude of the risk 
for HAV transmission resulting from the exposure.
IG should be used for children aged <12 months, immunocompromised persons, persons 
who have had diagnosed CLD, and persons for whom vaccine is contraindicated. For 
persons aged >40 years, IG is preferred because of the absence of information regarding 
vaccine performance and the more severe manifestations of hepatitis A in this age group; 
vaccine can be used if IG cannot be obtained. For healthy persons aged 12 months to 40 
years, monovalent hepatitis A vaccine at the age-appropriate dose is preferred over IG 
because of the advantages associated with vaccination, including long-term protection and 
ease of administration.
If IG is administered to persons for whom hepatitis A vaccine also is recommended, a dose 
of vaccine should be provided simultaneously with IG, and the second vaccine dose should 
be administered according to the licensed schedule to complete the series. The combined 
vaccine can be considered in persons for whom both hepatitis A and hepatitis B vaccine is 
recommended.
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Special Considerations—Limited data indicate that hepatitis A vaccination of persons 
with CLD and of persons with advanced HIV infection results in lower efficacy and 
antibody concentrations (247). In persons with HIV infection, antibody response can be 
directly related to CD4+ levels.
Hepatitis B
Hepatitis B is caused by infection with the hepatitis B virus (HBV). The incubation period 
from time of exposure to onset of symptoms is 6 weeks to 6 months. The highest 
concentrations of HBV are found in blood, with lower concentrations found in other body 
fluids including wound exudates, semen, vaginal secretions, and saliva (829,830). HBV is 
more infectious and more stable in the environment than other bloodborne pathogens (e.g., 
HCV and HIV).
HBV infection can be self-limited or chronic. In adults, approximately half of newly 
acquired HBV infections are symptomatic, and approximately 1% of reported cases result in 
acute liver failure and death (831). Risk for chronic infection is inversely related to age at 
acquisition; approximately 90% of infected infants and 30% of infected children aged <5 
years become chronically infected compared with 2%–6% of persons who become infected 
as adults (832). Among persons with chronic HBV infection, the risk for premature death 
from cirrhosis or hepatocellular carcinoma (HCC) is 15%–25% (833).
HBV is efficiently transmitted by percutaneous or mucous membrane exposure to HBV-
infected blood or body fluids that contain HBV. The primary risk factors associated with 
infection among adolescents and adults are unprotected sex with an infected partner, 
multiple partners, MSM, history of other STDs, and injection-drug use. In addition, several 
studies have demonstrated other modes of HBV transmission, including premastication and 
lapses in health-care infection-control procedures, as less common sources of transmission 
(244,834–836).
CDC’s national strategy to eliminate transmission of HBV infection includes 1) prevention 
of perinatal infection through routine screening of all pregnant women for HBsAg and 
immunoprophylaxis of infants born to mothers with HBsAg or mothers whose HBsAg status 
is unknown, 2) routine infant vaccination, 3) vaccination of previously unvaccinated children 
and adolescents through age 18 years, and 4) vaccination of previously unvaccinated adults 
at increased risk for infection (3,4). High vaccination coverage rates with subsequent 
declines in acute hepatitis B incidence have been achieved among infants and adolescents 
(4,823,837). The aging of persons vaccinated as children and adolescents likely has led to 
improved vaccination coverage in adults aged <30 years (838) and corresponding lower rates 
of acute HBV infection in this group. In contrast, vaccination coverage among most high-
risk adult populations aged ≥30 years (e.g., persons with multiple sex partners, MSM, and 
IDUs) has remained low; these groups account for the highest rates of preventable acute 
infections (3,169,838–840). STD clinics and other settings providing STD services to high-
risk adults should administer hepatitis B vaccine to those who are unvaccinated, as adults 
seeking STD services are at risk for this infection.
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Diagnosis—Diagnosis of acute or chronic HBV infection requires serologic testing (Table 
3). Because HBsAg is present in both acute and chronic infection, the presence of IgM 
antibody to hepatitis B core antigen (IgM anti-HBc) is diagnostic of acute or recently 
acquired HBV infection. Antibody to HBsAg (anti-HBs) is produced after a resolved 
infection and is the only HBV antibody marker present after vaccination. The presence of 
HBsAg and total anti-HBc, with a negative test for IgM anti-HBc, indicates chronic HBV 
infection. The presence of anti-HBc alone might indicate acute, resolved, or chronic 
infection or a false-positive result.
Treatment—No specific therapy is available for persons with acute hepatitis B; treatment is 
supportive. Persons with chronic HBV infection should be referred for evaluation to a 
provider experienced in the management of chronic HBV infection. Therapeutic agents 
cleared by FDA for treatment of chronic hepatitis B can achieve sustained suppression of 
HBV replication and remission of liver disease (841).
Prevention—Two products have been approved for hepatitis B prevention: hepatitis B 
immune globulin (HBIG) for postexposure prophylaxis and hepatitis B vaccine (3,4). HBIG 
provides temporary (i.e., 3–6 months) protection from HBV infection and is typically used 
as PEP as an adjunct to hepatitis B vaccination (in previously unvaccinated persons) or in 
persons who have not responded to vaccination. HBIG is prepared from plasma known to 
contain high concentrations of anti-HBs. The recommended dose of HBIG is 0.06 mL/kg.
Hepatitis B vaccine contains HBsAg produced in yeast by recombinant DNA technology 
and provides protection from HBV infection when used for both pre-exposure vaccination 
and PEP. The two available monovalent hepatitis B vaccines for use in the United States are 
Recombivax HB (Merck and Co., Inc., Whitehouse Station, New Jersey) and Engerix-B 
(GlaxoSmithKline Biologicals, Pittsburgh, Pennsylvania). A combination hepatitis A and 
hepatitis B vaccine for use in persons ≥18 years, Twinrix (GlaxoSmithKline Biologicals, 
Pittsburgh, Pennsylvania), also is available.
When selecting a hepatitis B vaccination schedule, health-care providers should consider the 
need to achieve completion of the vaccine series. The recommended HBV dose and schedule 
varies by product and age of recipient (Table 4). Three different 3-dose schedules for 
adolescents and adults have been approved for both monovalent hepatitis B vaccines (i.e., 
Engerix-B and Recombivax HB); these vaccines can be administered at 0, 1, and 6 months; 
0, 1, and 4 months; and 0, 2, and 4 months. A 4-dose schedule of Engerix-B at 0, 1, 2, and 
12 months is licensed for all age groups. A 2-dose schedule of Recombivax HB adult 
formulation (10 μg) is licensed for adolescents aged 11–15 years, with a 4 month minimal 
interval between doses. When scheduled to receive the second dose, adolescents aged 16–19 
years should be switched to a 3-dose series, with doses two and three consisting of the 
pediatric formulation (5 μg) administered on an appropriate schedule. Twinrix is a 3-dose 
schedule administered at 0, 1, and 6 months to persons aged ≥18 years at risk for both HAV 
and HBV infections.
Hepatitis B vaccine should be administered IM in the deltoid muscle and can be 
administered simultaneously with other vaccines. If the vaccine series is interrupted after the 
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first or second dose of vaccine, the missed dose should be administered as soon as possible. 
The series does not need to be restarted after a missed dose. HBV vaccination is available 
for eligible children and adolescents aged <19 years through the VFC program (telephone: 
800-232-4636).
In adolescents and healthy adults aged <40 years, approximately 30%–55% achieve a 
protective antibody response (i.e., anti-HBs ≥10 mIU/mL) after the first vaccine dose, 75% 
after the second, and >90% after the third. Vaccine-induced immune memory has been 
demonstrated to persist for at least 20 years (837,842,843). Periodic testing to determine 
antibody levels after routine vaccination in immunocompetent persons is not necessary, and 
booster doses of vaccine are not currently recommended.
Hepatitis B vaccination is generally well tolerated by most recipients. Pain at the injection 
site and low-grade fever are reported by a minority of recipients. For children and 
adolescents, a causal association exists between receipt of hepatitis B vaccination and 
anaphylaxis: for each 1.1 million doses of vaccine administered, approximately one vaccinee 
will experience this type of reaction. No deaths have been reported in these patients 
(3,4,839). Vaccine is contraindicated in persons with a history of anaphylaxis after a 
previous dose of hepatitis B vaccine and in persons with a known anaphylactic reaction to 
any vaccine component. No other adverse events after administration of hepatitis B vaccine 
have been demonstrated.
Pre-exposure Vaccination: Hepatitis B vaccination is recommended for all unvaccinated 
children and adolescents, all unvaccinated adults at risk for HBV infection (especially IDU, 
MSM, and adults with multiple sex partners), and all adults seeking protection from HBV 
infection (3). For adults, acknowledgment of a specific risk factor is not a requirement for 
vaccination.
Hepatitis B vaccine should be routinely offered to all unvaccinated persons attending STD 
clinics and to all unvaccinated persons seeking evaluation or treatment for STDs in other 
settings, especially correctional facilities, facilities providing drug-abuse treatment and 
prevention services, federally qualified health centers, and settings serving MSM (e.g., HIV 
care and prevention settings). If hepatitis B vaccine is unavailable at a particular facility, 
persons should be linked to a setting where they can receive vaccine. Persons with a reliable 
vaccination history (i.e., a written, dated record of each dose of a complete series) or reliable 
history of hepatitis B infection (i.e., a written record of infection and serologic results 
showing evidence of past infection) do not require vaccination. In all settings, vaccination 
should be initiated at the initial visit, even if concerns about completion of the vaccine series 
exist.
Prevaccination Serologic Testing: Conducting prevaccination serologic testing for 
susceptibility just before the initial vaccine dose is administered might be considered to 
reduce the cost of completing the vaccination series in adult populations that have an 
expected high prevalence (20%–30%) of HBV infection (e.g., IDUs and MSM, especially 
those in older age groups). In addition, prevaccination testing for susceptibility is 
recommended for unvaccinated household, sexual, and needle-sharing contacts of HBsAg-
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positive persons (169). Serologic testing should not be a barrier to vaccination. The first 
vaccine dose should be administered immediately after collection of the blood sample for 
serologic testing. Vaccination of persons who are immune to HBV infection because of 
current or previous infection or vaccination is not harmful and does not increase the risk for 
adverse events.
Anti-HBc is the test of choice for prevaccination testing. Persons who are anti-HBc–positive 
should be tested for HBsAg. If persons are determined to be HBsAg negative, no further 
action is required. Persons with HBsAg should be referred to a specialist in the management 
of hepatitis B infection and receive further serologic evaluation, prevention counseling, and 
evaluation for antiviral treatment (see Management of HBsAg-Positive Persons).
Postvaccination Serologic Testing for Response: Postvaccination serologic testing for 
immunity is not necessary after routine vaccination of adolescents or adults. However, such 
testing is recommended for persons whose subsequent clinical management depends on 
knowledge of their immune status (e.g., health-care workers or public safety workers at high 
risk for continued percutaneous or mucosal exposure to blood or body fluids). In addition, 
postvaccination testing is recommended for 1) persons with HIV infection and other 
immunocompromised persons to determine the need for revaccination and 2) sex and 
needle-sharing partners of HBsAg-positive persons to determine the need for revaccination 
and other methods to protect themselves from HBV infection.
If indicated, anti-HBs testing should be performed 1–2 months after administration of the 
last dose of the vaccine series. Persons determined to have anti-HBs levels of <10 mIU/mL 
after the primary vaccine series should be revaccinated with a 3-dose series and tested again 
for anti-HBs 1–2 months after the third dose. Persons who do not respond to revaccination 
should be tested for HBsAg. If HBsAg positive, the person should receive appropriate 
management (see Management of HBsAg-Positive Persons); if HBsAg negative, the person 
should be considered susceptible to HBV infection and counseled concerning precautions to 
prevent HBV infection and the need for HBIG PEP for any known exposure (see 
Postexposure Prophylaxis).
Postexposure Prophylaxis: Both passive-active PEP (the simultaneous administration of 
HBIG [i.e., 0.06 mL/kg] and hepatitis B vaccine at separate sites) and active PEP (the 
administration of hepatitis B vaccination alone) have been demonstrated to be highly 
effective in preventing transmission after exposure to HBV (4). HBIG alone also has been 
demonstrated to be effective in preventing HBV transmission, but with the availability of 
hepatitis B vaccine, HBIG typically is used as an adjunct to vaccination.
Exposure to an HBsAg-Positive Source: Unvaccinated persons or persons known not to 
have responded to a complete hepatitis B vaccine series should receive both HBIG and 
hepatitis vaccine as soon as possible (preferably ≤24 hours) after a discrete, identifiable 
exposure to blood or body fluids that contain blood from a person with HBsAg (Table 5). 
Hepatitis B vaccine should be administered simultaneously with HBIG at a separate 
injection site, and the vaccine series should be completed by using the age-appropriate 
vaccine dose and schedule (Table 4). Exposed persons who are in the process of being 
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vaccinated but who have not completed the vaccine series should receive HBIG (i.e., 0.06 
mL/kg) and complete the vaccine series. Exposed persons who are known to have responded 
to vaccination are considered protected; therefore, they need no additional doses of vaccine 
or HBIG. Persons who have written documentation of a complete hepatitis B vaccine series 
who did not receive postvaccination testing should receive a single vaccine booster dose. 
These persons should be managed according to guidelines for management of persons with 
occupational exposure to blood or body fluids that contain HBV (844).
Exposure to a Source with Unknown HBsAg Status: Unvaccinated persons and persons 
with previous nonresponse to hepatitis B vaccination who have a discrete, identifiable 
exposure to blood or body fluids containing blood from a person with unknown HBsAg 
status should receive the hepatitis B vaccine series, with the first dose initiated as soon as 
possible after exposure (preferably <24 hours) and the series completed using the age-
appropriate dose and schedule. Exposed persons who are not fully vaccinated should 
complete the vaccine series. Generally, exposed persons with written documentation of a 
complete hepatitis B vaccine series who did not receive postvaccination testing require no 
further treatment.
Special Considerations
Pregnancy: Regardless of whether they have been previously tested or vaccinated, all 
pregnant women should be tested for HBsAg at the first prenatal visit and at delivery if at 
high risk for HBV infection (see Special Populations Pregnant Women). Pregnant women at 
risk for HBV infection should receive hepatitis B vaccination. All pregnant women with 
HBsAg should be reported to state and local perinatal hepatitis B prevention programs and 
referred to a specialist. Information on the management of pregnant women with HBsAg and 
their infants is available at http://www.cdc.gov/mmwr/PDF/rr/rr5416.pdf.
HIV Infection: HIV infection can impair the response to hepatitis B vaccination. Persons 
with HIV infection should be tested for anti-HBs 1–2 months after the third vaccine dose 
(see Postvaccination Serologic Testing). Modified dosing regimens, including a doubling of 
the standard antigen dose and administration of additional doses, might increase the 
response rate (247). Additional recommendations for management of persons with HBsAg 
and HIV infection are available (247).
Management of HBsAg-Positive Persons: Recommendations for management of all 
persons with HBsAg-include the following:
• All persons with HBsAg documented on laboratory results should be reported to 
the state or local health department.
• To verify the presence of chronic HBV infection, persons with HBsAg should be 
retested. The absence of IgM anti-HBc or the persistence of HBsAg for 6 months 
indicates chronic HBV infection.
• Persons with chronic HBV infection should be referred for evaluation to a 
specialist experienced in the management of chronic hepatitis B infection.
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• Household, sexual, and needle-sharing contacts of chronically infected persons 
should be evaluated. Unvaccinated sex partners and household and needle-
sharing contacts should be tested for susceptibility to HBV infection (see 
Prevaccination Antibody Screening) and receive the first dose of hepatitis B 
vaccine immediately after collection of the blood sample for serologic testing. 
Susceptible persons should complete the vaccine series by using an age-
appropriate vaccine dose and schedule.
• Sex partners of persons with HBsAg should be counseled to use latex condoms 
(32) to protect themselves from sexual exposure to infectious body fluids (e.g., 
semen and vaginal secretions), unless they have been demonstrated to be immune 
after vaccination (anti-HBs ≥10 mIU/mL) or previously infected (anti-HBc 
positive).
• To prevent or reduce the risk for transmission to others in addition to vaccination, 
persons with HBsAg also should be advised to:
– use methods (e.g., condoms) to protect nonimmune sex partners from 
acquiring HBV infection from sexual activity until the partner can be 
vaccinated and immunity documented;
– cover cuts and skin lesions to prevent spread by infectious secretions or 
blood;
– refrain from donating blood, plasma, body organs, other tissue, or 
semen; and
– refrain from sharing household articles (e.g., toothbrushes, razors, or 
personal injection equipment) that could become contaminated with 
blood and refrain from premastication of food.
• To protect the liver from further harm, persons with HBsAg should be advised to:
– avoid or limit alcohol consumption because of the effects of alcohol on 
the liver;
– refrain from starting any new medicines, including OTC and herbal 
medicines, without checking with their health-care provider; and
– obtain vaccination against hepatitis A.
When seeking medical or dental care, HBsAg-positive persons should be advised to inform 
their health-care providers of their HBsAg status so that they can be appropriately evaluated 
and managed. The following are key counseling messages for persons with HBsAg:
• HBV is not usually spread by hugging, coughing, food or water, sharing eating 
utensils or drinking glasses, or casual contact.
• Persons should not be excluded from work, school, play, child care, or other 
settings because they are infected with HBV.
• Involvement with a support group might help patients cope with chronic HBV 
infection.
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Proctitis, Proctocolitis, and Enteritis
Sexually transmitted gastrointestinal syndromes include proctitis, proctocolitis, and enteritis. 
Evaluation for these syndromes should include appropriate diagnostic procedures (e.g., 
anoscopy or sigmoidoscopy, stool examination, and culture).
Proctitis is inflammation of the rectum (i.e., the distal 10–12 cm) that can be associated with 
anorectal pain, tenesmus, or rectal discharge. N. gonorrhoeae, C. trachomatis (including 
LGV serovars), T. pallidum, and HSV are the most common sexually transmitted pathogens 
involved. In persons with HIV infection, herpes proctitis can be especially severe. Proctitis 
occurs predominantly among persons who participate in receptive anal intercourse.
Proctocolitis is associated with symptoms of proctitis, diarrhea or abdominal cramps, and 
inflammation of the colonic mucosa extending to 12 cm above the anus. Fecal leukocytes 
might be detected on stool examination, depending on the pathogen. Pathogenic organisms 
include Campylobacter sp., Shigella sp., Entamoeba histolytica, and LGV serovars of C. 
trachomatis. CMV or other opportunistic agents can be involved in immunosuppressed HIV-
infected patients. Proctocolitis can be acquired through receptive anal intercourse or by oral-
anal contact, depending on the pathogen.
Enteritis usually results in diarrhea and abdominal cramping without signs of proctitis or 
proctocolitis; it occurs among persons whose sexual practices include oral-anal contact. In 
otherwise healthy persons, Giardia lamblia is most frequently implicated. When outbreaks of 
gastrointestinal illness occur among social or sexual networks of MSM, clinicians should 
consider sexual transmission as a mode of spread and provide counseling accordingly. 
Among persons with HIV infection, enteritis can be caused by pathogens that may not be 
sexually transmitted, including CMV, Mycobacterium avium–intracellulare, Salmonella sp., 
Campylobacter sp., Shigella sp., Cryptosporidium, Microsporidium, and Isospora. Multiple 
stool examinations might be necessary to detect Giardia, and special stool preparations are 
required to diagnose cryptosporidiosis and microsporidiosis. In addition, enteritis can be 
directly caused by HIV infection. Diagnostic and treatment recommendations for all enteric 
infections are beyond the scope of these guidelines.
Diagnostic Considerations for Acute Proctitis
Persons who present with symptoms of acute proctitis should be examined by anoscopy. A 
Gram-stained smear of any anorectal exudate from anoscopic or anal examination should be 
examined for polymorphonuclear leukocytes. All persons should be evaluated for HSV (by 
PCR or culture), N. gonorrhoeae (NAAT or culture), C. trachomatis (NAAT), and T. 
pallidum (Darkfield if available and serologic testing) (see pathogen-specific sections). If the 
C. trachomatis test is positive on a rectal swab, a molecular test PCR for LGV should be 
performed, if available, to confirm an LGV diagnosis (see LGV) (394).
Treatment for Acute Proctitis
Acute proctitis of recent onset among persons who have recently practiced receptive anal 
intercourse is usually sexually acquired (845,846). Presumptive therapy should be initiated 
while awaiting results of laboratory tests for persons with anorectal exudate detected on 
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examination or polymorphonuclear leukocytes detected on a Gram-stained smear of 
anorectal exudate or secretions; such therapy also should be initiated when anoscopy or 
Gram stain is unavailable and the clinical presentation is consistent with acute proctitis in 
persons reporting receptive anal intercourse.
Recommended Regimen
Ceftriaxone 250 mg IM in a single dose
 PLUS
Doxycycline 100 mg orally twice a day for 7 days
Bloody discharge, perianal ulcers, or mucosal ulcers among MSM with acute proctitis and 
either a positive rectal chlamydia NAAT or HIV infection should be offered presumptive 
treatment for LGV with doxycycline 100 mg twice daily orally for a total of 3 weeks 
(847,848) (see LGV). If painful perianal ulcers are present or mucosal ulcers are detected on 
anoscopy, presumptive therapy should also include a regimen for genital herpes (see Genital 
HSV Infections).
Other Management Considerations
To minimize transmission and reinfection, men treated for acute proctitis should be 
instructed to abstain from sexual intercourse until they and their partner(s) have been 
adequately treated (i.e., until completion of a 7-day regimen and symptoms resolved). All 
persons with acute proctitis should be tested for HIV and syphilis.
Follow-Up
Follow-up should be based on specific etiology and severity of clinical symptoms. For 
proctitis associated with gonorrhea or chlamydia, retesting for the respective pathogen 
should be performed 3 months after treatment.
Management of Sex Partners
Partners who have had sexual contact with persons treated for GC, CT, or LGV within the 60 
days before the onset of the persons symptoms should be evaluated, tested, and 
presumptively treated for the respective pathogen. Partners of persons with sexually 
transmitted enteric infections should be evaluated for any diseases diagnosed in the person 
with acute proctitis. Sex partners should abstain from sexual intercourse until they and their 
partner with acute proctitis are adequately treated.
Allergy, Intolerance, and Adverse Reactions
Allergic reactions with third-generation cephalosporins (e.g., ceftriaxone) are uncommon in 
persons with a history of penicillin allergy (428,430,464). In those persons with a history of 
an IgE mediated penicillin allergy (e.g., those who have had anaphylaxis, Stevens Johnson 
syndrome, or toxic epidermal necrolysis), the use of ceftriaxone is contraindicated 
(428,431).
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HIV Infection
Persons with HIV infection and acute proctitis may present with bloody discharge, painful 
perianal ulcers, or mucosal ulcers. Presumptive treatment should include a regimen for 
genital herpes and LGV.
Ectoparasitic Infections
Pediculosis Pubis
Persons who have pediculosis pubis (i.e., pubic lice) usually seek medical attention because 
of pruritus or because they notice lice or nits on their pubic hair. Pediculosis pubis is usually 
transmitted by sexual contact (849).
Treatment
Recommended Regimens
Permethrin 1% cream rinse applied to affected areas and washed off after 10 minutes
 OR
Pyrethrins with piperonyl butoxide applied to the affected area and washed off after 10 minutes
Alternative Regimens
Malathion 0.5% lotion applied to affected areas and washed off after 8–12 hours
 OR
Ivermectin 250 µg/kg repeated in 2 weeks
Reported resistance to pediculcides (permethrin and pyrethrins) has been increasing and is 
widespread (850,851). Malathion can be used when treatment failure is believed to have 
occurred as a result of resistance. The odor and long duration of application associated with 
malathion therapy make it a less attractive alternative compared with the recommended 
pediculcides. Ivermectin has limited ovicidal activity (852). Ivermectin might not prevent 
recurrences from eggs at the time of treatment, and therefore treatment should be repeated in 
14 days (853,854). Ivermectin should be taken with food because bioavailability is 
increased, in turn increasing penetration of the drug into the epidermis. Adjustment of 
ivermectin dosage is not required for persons with renal impairment, but the safety of 
multiple doses in persons with severe liver disease is not known.
Lindane is recommended as an alternative therapy because it can cause toxicity, as indicated 
by seizure and aplastic anemia (855); it should only be used when other therapies cannot be 
tolerated or have failed. Lindane toxicity has not been reported when treatment was limited 
to the recommended 4-minute period. Lindane should not be used immediately after a bath 
or shower, and it should not be used by persons who have extensive dermatitis, women who 
are breastfeeding, or children aged <10 years (855).
Other Management Considerations—The recommended regimens should not be 
applied to the eyes. Pediculosis of the eyelashes should be treated by applying occlusive 
ophthalmic ointment or petroleum jelly to the eyelid margins twice a day for 10 days. 
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Bedding and clothing should be decontaminated (i.e., machine-washed and dried using the 
heat cycle or dry cleaned) or removed from body contact for at least 72 hours. Fumigation of 
living areas is not necessary. Persons with pediculosis pubis should be evaluated for other 
STDs, including HIV.
Follow-Up—Evaluation should be performed after 1 week if symptoms persist. Re-
treatment might be necessary if lice are found or if eggs are observed at the hair-skin 
junction. If no clinical response is achieved to one of the recommended regimens, 
retreatment with an alternative regimen is recommended.
Management of Sex Partners—Sex partners within the previous month should be 
treated. Sexual contact should be avoided until patients and partners have been treated, 
bedding and clothing decontaminated, and reevaluation performed to rule out persistent 
infection.
Special Considerations
Pregnancy: Existing data from human subjects suggest that pregnant and lactating women 
should be treated with either permethrin or pyrethrins with piperonyl butoxide. Because no 
teratogenicity or toxicity attributable to ivermectin has been observed in human pregnancy 
experience, ivermectin is classified as “human data suggest low risk” in pregnancy and 
probably compatible with breastfeeding (317). Use of lindane during pregnancy has been 
associated with neural tube defects and mental retardation, and it can accumulate in the 
placenta and in breast milk (855).
HIV Infection: Persons who have pediculosis pubis and also HIV infection should receive 
the same treatment regimen as those who are HIV negative. For more information, see 
Pediculosis pubis.
Scabies
The predominant symptom of scabies is pruritus. Sensitization to Sarcoptes scabiei occurs 
before pruritus begins. The first time a person is infested with S. scabiei, sensitization takes 
up to several weeks to develop. However, pruritus might occur within 24 hours after a 
subsequent reinfestation. Scabies in adults frequently is sexually acquired, although scabies 
in children usually is not (856,857).
Treatment
Recommended Regimens
Permethrin 5% cream applied to all areas of the body from the neck down and washed off after 8–14 hours*
 OR
Ivermectin 200ug/kg orally, repeated in 2 weeks†
*Infants and young children should be treated with permethrin.
†Infants and young children aged <10 years should not be treated with lindane.
Alternative Regimens
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Lindane (1%) 1 oz of lotion or 30 g of cream applied in a thin layer to all areas of the body from the neck down and 
thoroughly washed off after 8 hours
Permethrin is effective, safe, and less expensive than ivermectin (858). One study 
demonstrated increased mortality among elderly, debilitated persons who received 
ivermectin, but this observation has not been confirmed in subsequent reports (859). 
Ivermectin has limited ovicidal activity and may not prevent recurrences of eggs at the time 
of treatment; therefore, a second dose of ivermectin should be administered 14 days after the 
first dose. Ivermectin should be taken with food because bioavailability is increased, thereby 
increasing penetration of the drug into the epidermis. Adjustments to ivermectin dosing are 
not required in patients with renal impairment, but the safety of multiple doses in patients 
with severe liver disease is not known.
Lindane is an alternative regimen because it can cause toxicity (855); it should only be used 
if the patient cannot tolerate the recommended therapies or if these therapies have failed 
(860–862). Lindane should not be used immediately after a bath or shower, and it should not 
be used by persons who have extensive dermatitis or children aged <10 years. Seizures have 
occurred when lindane was applied after a bath or used by patients who had extensive 
dermatitis. Aplastic anemia after lindane use also has been reported. Lindane resistance has 
been reported in some areas of the world, including parts of the United States.
Other Management Considerations—Bedding and clothing should be decontaminated 
(i.e., either machine-washed, machine-dried using the hot cycle, or dry cleaned) or removed 
from body contact for at least 72 hours. Fumigation of living areas is unnecessary. Persons 
with scabies should be advised to keep fingernails closely trimmed to reduce injury from 
excessive scratching.
Crusted Scabies—Crusted scabies (i.e., Norwegian scabies) is an aggressive infestation 
that usually occurs in immunodeficient, debilitated, or malnourished persons, including 
persons receiving systemic or potent topical glucocorticoids, organ transplant recipients, 
persons with HIV infection or human T-lymphotrophic virus-1-infection, and persons with 
hematologic malignancies. Crusted scabies is transmitted more easily than scabies (863). No 
controlled therapeutic studies for crusted scabies have been conducted, and the appropriate 
treatment remains unclear. Substantial treatment failure might occur with a single-dose 
topical scabicide or with oral ivermectin treatment. Combination treatment is recommended 
with a topical scabicide, either 5% topical benzyl benzoate or 5% topical permethrin cream 
(full-body application to be repeated daily for 7 days then 2x weekly until discharge or 
cure), and treatment with oral ivermectin 200 ug/kg on days 1,2,8,9, and 15. Additional 
ivermectin treatment on days 22 and 29 might be required for severe cases (864). Lindane 
should be avoided because of the risks for neurotoxicity with heavy applications or denuded 
skin.
Follow-Up: The rash and pruritus of scabies might persist for up to 2 weeks after treatment. 
Symptoms or signs persisting for >2 weeks can be attributed to several factors. Treatment 
failure can occur as a result of resistance to medication or faulty application of topical 
scabicides. These medications do not easily penetrate into thick, scaly skin of persons with 
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crusted scabies, perpetuating the harboring of mites in these difficult-to-penetrate layers. In 
the absence of appropriate contact treatment and decontamination of bedding and clothing, 
persisting symptoms can be attributed to reinfection by family members or fomites. Finally, 
other household mites can cause symptoms to persist as a result of cross reactivity between 
antigens. Even when treatment is successful, reinfection is avoided, and cross reactivity does 
not occur, symptoms can persist or worsen as a result of allergic dermatitis.
Retreatment 2 weeks after the initial treatment regimen can be considered for those persons 
who are still symptomatic or when live mites are observed. Use of an alternative regimen is 
recommended for those persons who do not respond initially to the recommended treatment.
Management of Sex Partners and Household Contacts—Persons who have had 
sexual, close personal, or household contact with the patient within the month preceding 
scabies infestation should be examined. Those found to be infested should be provided 
treatment.
Management of Outbreaks in Communities, Nursing Homes, and Other 
Institutional Settings—Scabies epidemics frequently occur in nursing homes, hospitals, 
residential facilities, and other communities (865). Control of an epidemic can only be 
achieved by treating the entire population at risk. Ivermectin can be considered in these 
settings, especially if treatment with topical scabicides fails. Epidemics should be managed 
in consultation with a specialist.
Special Considerations
Infants, Young Children, and Pregnant or Lactating Women: Infants and young children 
should be treated with permethrin; the safety of ivermectin in children who weigh <15 kg 
has not been determined. Infants and young children aged<10 years should not be treated 
with lindane. Ivermectin likely poses a low risk to pregnant women and is likely compatible 
with breastfeeding (See Pediculosis pubis); however, because of limited data regarding its 
use in pregnant and lactating women, permethrin is the preferred treatment (317).
HIV Infection: Persons with HIV infection who have uncomplicated scabies should receive 
the same treatment regimens as those who are HIV negative. Persons with HIV infection and 
others who are immunosuppressed are at increased risk for crusted scabies. Such persons 
should be managed in consultation with a specialist.
Sexual Assault and Abuse and STDs
Adolescents and Adults
These guidelines are primarily limited to the identification, prophylaxis, and treatment of 
STDs and conditions among adolescent and adult female sexual assault survivors. However, 
some of the following guidelines might still apply to male sexual assault survivors. The 
documentation of findings, collection of nonmicrobiologic specimens for forensic purposes, 
and the management of potential pregnancy or physical and psychological trauma are 
beyond the scope of these guidelines.
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Examinations of survivors of sexual assault should be conducted by an experienced clinician 
in a way that minimizes further trauma to the survivor. The decision to obtain genital or 
other specimens for STD diagnosis should be made on an individual basis. Care systems for 
survivors should be designed to ensure continuity (including timely review of test results), 
support adherence, and monitor adverse reactions to any prescribed therapeutic or 
prophylactic regimens. Laws in all 50 states strictly limit the evidentiary use of a survivor’s 
previous sexual history, including evidence of previously acquired STDs, as part of an effort 
to undermine the credibility of the survivor’s testimony. Evidentiary privilege against 
revealing any aspect of the examination or treatment also is enforced in most states. 
Although it rarely occurs, STD diagnoses might later be accessed, and the survivor and 
clinician might opt to defer testing for this reason. While collection of specimens at initial 
examination for laboratory STD diagnosis gives the survivor and clinician the option to 
defer empiric prophylactic antimicrobial treatment, compliance with follow-up visits is 
typically poor (866,867). Among sexually active adults, the identification of an STD might 
represent an infection acquired before the assault, and therefore might be more important for 
the medical management of the patient than for legal purposes.
Trichomoniasis, BV, gonorrhea, and chlamydial infection are the most frequently diagnosed 
infections among women who have been sexually assaulted. Such conditions are prevalent in 
the population, and detection of these infections after an assault does not necessarily imply 
acquisition during the assault. However, a post-assault examination presents an important 
opportunity to identify or prevent STDs. Chlamydial and gonococcal infections in women 
are of particular concern because of the possibility of ascending infection. In addition, HBV 
infection can be prevented through postexposure vaccination (see Hepatitis B) (Table 5). 
Because female survivors also are at risk for acquiring HPV infection and the efficacy of the 
HPV vaccine is high (868,869), HPV vaccination is also recommended for females through 
age 26 years (16). Reproductive-aged female survivors should be evaluated for pregnancy.
Evaluating Adolescents and Adults for STDs
Initial Examination: Decisions to perform these tests should be made on an individual 
basis. An initial examination might include the following procedures:
• NAATs for C. trachomatis and N. gonorrhoeae at the sites of penetration or 
attempted penetration (394). These tests are preferred for the diagnostic 
evaluation of adolescent or adult sexual assault survivors.
• NAATs from a urine or vaginal specimen or point-of-care testing (i.e., DNA 
probes) from a vaginal specimen for T. vaginalis. Point-of-care testing and/or wet 
mount with measurement of vaginal pH and KOH application for the whiff test 
from vaginal secretions should be done for evidence of BV and candidiasis, 
especially if vaginal discharge, malodor, or itching is present.
• A serum sample for evaluation of HIV, hepatitis B, and syphilis infections.
Treatment—Compliance with follow-up visits is poor among survivors of sexual assault 
(866,867). As a result, the following routine presumptive treatment after a sexual assault is 
recommended:
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• An empiric antimicrobial regimen for chlamydia, gonorrhea, and trichomonas.
• Emergency contraception. This measure should be considered when the assault 
could result in pregnancy in the survivor.
• Postexposure hepatitis B vaccination (without HBIG) if the hepatitis status of the 
assailant is unknown and the survivor has not been previously vaccinated. If the 
assailant is known to be HBsAg-positive, unvaccinated survivors should receive 
both hepatitis B vaccine and HBIG. The vaccine and HBIG, if indicated, should 
be administered to sexual assault survivors at the time of the initial examination, 
and follow-up doses of vaccine should be administered 1–2 and 4–6 months after 
the first dose. Survivors who were previously vaccinated but did not receive 
postvaccination testing should receive a single vaccine booster dose (see hepatitis 
B).
• HPV vaccination is recommended for female survivors aged 9–26 years and 
male survivors aged 9–21 years. For MSM with who have not received HPV 
vaccine or who have been incompletely vaccinated, vaccine can be administered 
through age 26 years. The vaccine should be administered to sexual assault 
survivors at the time of the initial examination, and follow-up dose administered 
at 1–2 months and 6 months after the first dose.
• Recommendations for HIV PEP are individualized according to risk (see Risk 
for Acquiring HIV Infection and Postexposure HIV Risk Assessment for PEP).
Recommended Regimens
Ceftriaxone 250 mg IM in a single dose
 PLUS
Azithromycin 1 g orally in a single dose
 PLUS
Metronidazole 2 g orally in a single dose
 OR
Tinidazole 2 g orally in a single dose
If alcohol has been recently ingested or emergency contraception is provided, metronidazole 
or tinidazole can be taken by the sexual assault survivor at home rather than as directly 
observed therapy to minimize potential side effects and drug interactions. Clinicians should 
counsel persons regarding the possible benefits and toxicities associated with these treatment 
regimens; gastrointestinal side effects can occur with this combination. The efficacy of these 
regimens in preventing infections after sexual assault has not been evaluated. For those 
requiring alternative treatments, refer to the specific sections in this report relevant to the 
specific organism.
Other Management Considerations—At the initial examination and, if indicated, at 
follow-up examinations, patients should be counseled regarding symptoms of STDs and the 
need for immediate examination if symptoms occur. Further, they should be instructed to 
abstain from sexual intercourse until STD prophylactic treatment is completed.
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Follow-up—After the initial postassault examination, follow-up examinations provide an 
opportunity to 1) detect new infections acquired during or after the assault; 2) complete 
hepatitis B and HPV vaccinations, if indicated; 3) complete counseling and treatment for 
other STDs; and 4) monitor side effects and adherence to postexposure prophylactic 
medication, if prescribed.
If initial testing was done, follow-up evaluation should be conducted within 1 week to 
ensure that results of positive tests can be discussed promptly with the survivor, treatment is 
provided if not given at the initial visit, and any follow-up for the infection(s) can be 
arranged. If initial tests are negative and treatment was not provided, examination for STDs 
can be repeated within 1–2 weeks of the assault; repeat testing detects infectious organisms 
that might not have reached sufficient concentrations to produce positive test results at the 
time of initial examination. For survivors who are treated during the initial visit, regardless 
of whether testing was performed, post-treatment testing should be conducted only if the 
survivor reports having symptoms. A follow-up examination at 1–2 months should also be 
considered to reevaluate for development of anogenital warts, especially among sexual 
assault survivors who received a diagnosis of other STDs. If initial test results were negative 
and infection in the assailant cannot be ruled out, serologic tests for syphilis can be repeated 
at 4–6 weeks and 3 months; HIV testing can be repeated at 6 weeks and at 3 and 6 months 
using methods to identify acute HIV infection (see Sexual Assault and STDs, Risk for 
Acquiring HIV Infection).
Risk for Acquiring HIV Infection—HIV seroconversion has occurred in persons whose 
only known risk factor was sexual assault or sexual abuse, but the frequency of this 
occurrence likely is low (870,871). In consensual sex, the per-act risk for HIV transmission 
from vaginal intercourse is 0.1%–0.2%, and for receptive rectal intercourse, 0.5%–3% (872). 
The per-act risk for HIV transmission from oral sex is substantially lower. Specific 
circumstances of an assault (e.g., bleeding, which often accompanies trauma) might increase 
risk for HIV transmission in cases involving vaginal, anal, or oral penetration. Site of 
exposure to ejaculate, viral load in ejaculate, and the presence of an STD or genital lesions 
in the assailant or survivor also might increase risk for HIV.
Postexposure prophylaxis with a 28-day course of zidovudine was associated with an 81% 
reduction in risk for acquiring HIV in a study of health-care workers who had percutaneous 
exposures to HIV-infected blood (873). On the basis of these results and results from animal 
studies, PEP has been recommended for health-care workers who have occupational 
exposures to HIV (874). These findings have been extrapolated to nonoccupational injection 
and sexual HIV exposures, including sexual assault. The possibility of HIV exposure from 
the assault should be assessed at the initial examination; survivors determined to be at risk 
for HIV should be informed about the possible benefit of nonoccupational postexposure 
prophylaxis (nPEP) in preventing HIV infection. Initiation of nPEP as soon as possible after 
the exposure increases the likelihood of prophylactic benefit.
Several factors impact the medical recommendation for nPEP and affect the assault 
survivor’s acceptance of that recommendation, including 1) the likelihood of the assailant 
having HIV; 2) any exposure characteristics that might increase the risk for HIV 
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transmission; 3) the time elapsed after the event; and 4) the potential benefits and risks 
associated with the nPEP (312). Determination of the assailant’s HIV status at the time of 
the assault examination is usually not possible. Therefore, health-care providers should 
assess any available information concerning the 1) characteristics and HIV risk behaviors of 
the assailant(s) (e.g., being an MSM or using injection drugs), 2) local epidemiology of 
HIV/AIDS, and 3) exposure characteristics of the assault. When an assailant’s HIV status is 
unknown, determinations regarding risk for HIV transmission to the survivor should be 
based on 1) whether vaginal or anal penetration occurred; 2) whether ejaculation occurred 
on mucous membranes; 3) whether multiple assailants were involved; 4) whether mucosal 
lesions are present in the assailant or survivor; and 5) any other characteristics of the assault, 
survivor, or assailant that might increase risk for HIV transmission.
If nPEP is offered, the following information should be discussed with the survivor: 1) the 
necessity of early initiation of nPEP to optimize potential benefits (i.e., as soon as possible 
after and up to 72 hours after the assault; 2) the importance of close follow-up; 3) the benefit 
of adherence to recommended dosing; and 4) potential adverse effects of antiretrovirals. 
Providers should emphasize that severe adverse effects are rare from nPEP (875–877). 
Clinical management of the survivor should be implemented according to the HIV nPEP 
guidelines and in collaboration with specialists (312). However, distress after an assault also 
might prevent the survivor from accurately weighing exposure risks and benefits of nPEP 
and from making an informed decision regarding initiating therapy, even when such therapy 
is considered warranted by the health-care provider. In this instance, the survivor can be 
provided a 3–5-day supply of nPEP and scheduled for follow-up at a time that allows for 
provision of the remaining 23 days of medication (if nPEP has been initiated by the 
survivor) without interruption in dosing. A follow-up visit also creates opportunity for 
additional counseling as needed.
Recommendations for Postexposure HIV Risk Assessment of Adolescent and 
Adult Survivors Within 72 Hours of Sexual Assault
• Assess risk for HIV infection in the assailant, and test that person for HIV 
whenever possible.
• Use the algorithm to evaluate the survivor for the need for HIV nPEP (Figure) 
(312).
• Consult with a specialist in HIV treatment if nPEP is being considered.
• If the survivor appears to be at risk for acquiring HIV from the assault, discuss 
nPEP, including benefits and risks.
• If the survivor chooses to start nPEP (312), provide enough medication to last 
until the follow-up visit at 3–7 days after initial assessment and assess tolerance 
to medications.
• If nPEP is started, perform CBC and serum chemistry at baseline.
• Perform an HIV antibody test at original assessment; repeat at 6 weeks, 3 
months, and 6 months.
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Assistance with nPEP-related decisions can be obtained by calling the National Clinician’s 
Post Exposure Prophylaxis Hotline (PEP Line) (telephone: 888-448-4911).
Sexual Assault or Abuse of Children
These guidelines are limited to the identification and treatment of STDs in pre-pubertal 
children. Management of the psychosocial or legal aspects of the sexual assault or abuse of 
children is beyond the scope of these guidelines.
The identification of sexually transmissible agents in children beyond the neonatal period 
strongly suggests sexual abuse (878). The significance of the identification of a sexually 
transmitted organism in such children as evidence of possible child sexual abuse varies by 
pathogen. Postnatally acquired gonorrhea and syphilis; chlamydia infection; and 
nontransfusion, nonperinatally acquired HIV are indicative of sexual abuse. Chlamydia 
infection might be indicative of sexual abuse in children ≥3 years of age and among those 
aged <3 years when infection is not likely perinatally acquired. Sexual abuse should be 
suspected when genital herpes, T. vaginalis, or anogenital warts are diagnosed. The 
investigation of sexual abuse among children who have an infection that could have been 
transmitted sexually should be conducted in compliance with recommendations by clinicians 
who have experience and training in all elements of the evaluation of child abuse, neglect, 
and assault. The social significance of an infection that might have been acquired sexually 
varies by the specific organism, as does the threshold for reporting suspected child sexual 
abuse (Table 6). In cases in which any STD has been diagnosed in a child, efforts should be 
made in consultation with a specialist to evaluate the possibility of sexual abuse, including 
conducting a history and physical examination for evidence of abuse and diagnostic testing 
for other commonly occurring STDs (879,880).
The general rule that sexually transmissible infections beyond the neonatal period are 
evidence of sexual abuse has exceptions. For example, genital infection with T. vaginalis 
(881) or rectal or genital infection with C. trachomatis among young children might be the 
result of perinatally acquired infection and has, in some cases of chlamydia infection, 
persisted for as long as 2–3 years (882,883), though perinatal CT infection is now 
uncommon because of prenatal screening and treatment of pregnant women. Genital warts 
have been diagnosed in children who have been sexually abused (868), but also in children 
who have no other evidence of sexual abuse (884,885). BV has been diagnosed in children 
who have been abused, but its presence alone does not prove sexual abuse. Most HBV 
infections in children result from household exposure to persons who have chronic HBV 
infection rather than sexual abuse.
Reporting—All U.S. states and territories have laws that require the reporting of child 
abuse. Although the exact requirements differ by state, if a health-care provider has 
reasonable cause to suspect child abuse, a report must be made. Health-care providers 
should contact their state or local child-protection service agency regarding child-abuse 
reporting requirements in their states.
Evaluating Children for STDs—Evaluations of children for sexual assault or abuse 
should be conducted in a manner designed to minimize pain and trauma to the child. 
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Examinations and collection of vaginal specimens in prepubertal children can be very 
uncomfortable and should be performed by an experienced clinician to avoid psychological 
and physical trauma to the child. The decision to obtain genital or other specimens from a 
child to evaluate for STDs must be made on an individual basis; however, children who 
received a diagnosis of one STD should be screened for all STDs. Because STDs are not 
common in prepubertal children or infants evaluated for abuse, testing all sites for all 
organisms is not routinely recommended. Factors that should lead the physician to consider 
screening for STD include (878):
1. Child has experienced penetration or has evidence of recent or healed penetrative 
injury to the genitals, anus, or oropharynx.
2. Child has been abused by a stranger.
3. Child has been abused by a perpetrator known to be infected with an STD or at 
high risk for STDs (e.g., intravenous drug abusers, MSM, persons with multiple 
sexual partners, and those with a history of STDs).
4. Child has a sibling, other relative, or another person in the household with an 
STD.
5. Child lives in an area with a high rate of STD in the community.
6. Child has signs or symptoms of STDs (e.g., vaginal discharge or pain, genital 
itching or odor, urinary symptoms, and genital lesions or ulcers).
7. Child or parent requests STD testing.
If a child has symptoms, signs, or evidence of an infection that might be sexually 
transmitted, the child should be tested for common STDs before the initiation of any 
treatment that could interfere with the diagnosis of those other STDs. Because of the legal 
and psychosocial consequences of a false-positive diagnosis, only tests with high 
specificities should be used. The potential benefit to the child of a reliable STD diagnosis 
justifies deferring presumptive treatment until specimens for highly specific tests are 
obtained by providers with experience in the evaluation of sexually abused and assaulted 
children.
Evaluations should be scheduled on a case-by-case basis according to history of assault or 
abuse and in a manner that minimizes the possibility for psychological trauma and social 
stigma. If the initial exposure was recent, the infectious organisms acquired through the 
exposure might not have produced sufficient concentrations of organisms to result in positive 
test results or examination findings (886). Alternatively, positive test results following a 
recent exposure might represent the assailant’s secretions (but would nonetheless be an 
indication for treatment of the child). A second visit approximately 2 weeks after the most 
recent sexual exposure should be scheduled to include a repeat physical examination and 
collection of additional specimens to identify any infection that might not have been 
detected at the time of initial evaluation. A single evaluation might be sufficient if the child 
was abused for an extended period of time and if a substantial amount of time elapsed 
between the last suspected episode of abuse and the medical evaluation. Compliance with 
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follow-up appointments might be improved when law enforcement personnel or child 
protective services are involved.
Initial Examination: The following should be performed during the initial examination.
• Visual inspection of the genital, perianal, and oral areas for genital discharge, 
odor, bleeding, irritation, warts, and ulcerative lesions. The clinical 
manifestations of some STDs are different in children than in adults. For 
example, typical vesicular lesions might be absent even in the presence of HSV 
infection. Because HSV can be indicative of sexual abuse, specimens should be 
obtained from all vesicular or ulcerative genital or perianal lesions and then sent 
for viral culture or PCR.
• Culture for N. gonorrhoeae from specimens collected from the pharynx and anus 
in boys and girls, the vagina in girls, and the urethra in boys. Cervical specimens 
are not recommended for prepubertal girls. For boys with a urethral discharge, a 
meatal specimen discharge is an adequate substitute for an intraurethral swab 
specimen. Because of the legal implications of a diagnosis of N. gonorrhoeae 
infection in a child, if culture for the isolation of N. gonorrhoeae is done, only 
standard culture procedures should be performed. Gram stains are inadequate to 
evaluate prepubertal children for gonorrhea and should not be used to diagnose 
or exclude gonorrhea. Specimens from the vagina, urethra, pharynx, or rectum 
should be streaked onto selective media for isolation of N. gonorrhoeae, and all 
presumptive isolates of N. gonorrhoeae should be identified definitively by at 
least two tests that involve different approaches (e.g., biochemical, enzyme 
substrate, or serologic). Isolates should be preserved to enable additional or 
repeated testing. Data on use of NAAT for detection of N. gonorrhoeae in 
children are limited, and performance is test dependent (394). Consultation with 
an expert is necessary before using NAAT in this context, both to minimize the 
possibility of cross-reaction with nongonococcal Neisseria species and other 
commensals (e.g., N. meningitidis, N. sicca, N. lactamica, N. cinerea, and 
Moraxella catarrhalis) and to ensure appropriate interpretation of positive results. 
When testing vaginal secretions or urine from girls, NAAT can be used as an 
alternative to culture; however, culture remains the preferred method for testing 
urethral specimens or urine from boys and extragenital specimens (pharynx and 
rectum) from all children (394). All positive specimens should be retained for 
additional testing.
• Culture for C. trachomatis from specimens collected from the anus in both boys 
and girls and from the vagina in girls. The likelihood of recovering C. 
trachomatis from the urethra of prepubertal boys is too low to justify the trauma 
involved in obtaining an intraurethral specimen. However, a meatal specimen 
should be obtained if urethral discharge is present. Pharyngeal specimens for C. 
trachomatis are not recommended for children of either sex because the 
likelihood of recovering chlamydia is low, perinatally acquired infection might 
persist beyond infancy, and culture systems in some laboratories do not 
distinguish between C. trachomatis and C. pneumoniae. Only standard culture 
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systems for the isolation of C. trachomatis should be used. The isolation of C. 
trachomatis should be confirmed by microscopic identification of inclusions by 
staining with fluorescein-conjugated monoclonal antibody specific for C. 
trachomatis. Isolates should be preserved for additional testing. Nonculture tests 
for chlamydia (e.g., DFA) are not specific enough for use in cases of possible 
child abuse or assault. NAATs can be used for detection of C. trachomatis in 
vaginal specimens or urine from girls (394). No data are available regarding the 
use of NAAT from urine in boys or for extragenital specimens (e.g., those 
obtained from the rectum) in boys and girls. Culture remains the preferred 
method for extragenital sites. All specimens should be retained for additional 
testing.
• Culture for T. vaginalis infection and wet mount of a vaginal swab specimen for 
T. vaginalis infection. Testing for T. vaginalis should not be limited to girls with 
vaginal discharge if other indications for vaginal testing exist, as there is some 
evidence to indicate that asymptomatic sexually abused children might be 
infected with T. vaginalis and might benefit from treatment (887,888). Data on 
use of NAAT for detection of T. vaginalis in children are too limited to inform 
recommendations, but no evidence suggests that performance of NAAT for 
detection of T. vaginalis in children would differ from that in adults.
• Wet mount of a vaginal swab specimen for BV.
• Collection of serum samples to be evaluated, preserved for subsequent analysis, 
and used as a baseline for comparison with follow-up serologic tests. Sera can be 
tested for antibodies to T. pallidum, HIV, and HBV. Decisions regarding the 
infectious agents for which to perform serologic tests should be made on a case-
by-case basis.
Treatment—The risk of a child acquiring an STD as a result of sexual abuse or assault has 
not been well studied. Presumptive treatment for children who have been sexually assaulted 
or abused is not recommended because 1) the incidence of most STDs in children is low 
after abuse/assault, 2) prepubertal girls appear to be at lower risk for ascending infection 
than adolescent or adult women, and 3) regular follow-up of children usually can be ensured. 
However, some children or their parent(s) or guardian(s) might be concerned about the 
possibility of infection with an STD, even if the risk is perceived to be low by the health-
care provider. Such concerns might be an appropriate indication for presumptive treatment in 
some settings and might be considered after all relevant specimens for diagnostic tests have 
been collected.
Other Management Considerations—Because child sexual-assault survivors are at 
increased risk for future unsafe sexual practices that have been linked to higher risk of HPV 
acquisition (868,889) and are more likely to engage in these behaviors at an earlier age, 
ACIP recommends vaccination of children who are victims of sexual abuse or assault at age 
≥9 years who have not initiated or completed immunization (see HPV prevention section) 
(16). Although HPV vaccine will not protect against progression of infection already 
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acquired or promote clearance of the infection, the vaccine protects against vaccine types not 
yet acquired.
Follow-Up—If no infections were identified at the initial examination after the last 
suspected sexual exposure and if this exposure was recent, a follow-up evaluation 
approximately 2 weeks after the last exposure can be considered. Likewise, if no physical 
examination or diagnostic testing was done at the initial visit, then a complete examination 
can be scheduled approximately 2 weeks after the last exposure to identify any evidence of 
STDs.
In circumstances in which transmission of syphilis, HIV, hepatitis B, or HPV is a concern 
but baseline tests for syphilis, HIV, and HBV are negative and examinations for genital warts 
are negative, follow-up serologic testing and an examination approximately 6 weeks and 3 
months after the last suspected sexual exposure is recommended to allow time for antibodies 
to develop and signs of infection to appear. In addition, results of HBsAg testing must be 
interpreted carefully, because HBV can be transmitted nonsexually. Decisions regarding 
which tests should be performed must be made on an individual basis.
Risk for Acquiring HIV Infection—HIV infection has been reported in children for 
whom sexual abuse was the only known risk factor. Children might be at higher risk for HIV 
acquisition than adolescent and adult sexual assault or sexual abuse survivors because the 
sexual abuse of children is frequently associated with multiple episodes of assault and 
mucosal trauma might be more likely. Serologic testing for HIV infection should be 
considered for sexually abused children. The decision to test for HIV infection should 
involve the family, if possible, and be made on a case-by-case basis depending on the 
likelihood of infection among assailant(s) (890). Although data are insufficient concerning 
the efficacy of nPEP among children, treatment is well tolerated by infants and children with 
and without HIV infection, and children have a minimal risk for serious adverse reactions 
because of the short period recommended for prophylaxis (312,891). In considering whether 
to offer nPEP, health-care providers should consider whether the child can be treated soon 
after the sexual exposure (i.e., within 72 hours), the likelihood that the assailant is infected 
with HIV, and the likelihood of high compliance with the prophylactic regimen. The 
potential benefit of treating a sexually abused child should be weighed against the risk for 
adverse reactions. If nPEP is being considered, a provider specializing in evaluating or 
treating children with HIV infection should be consulted.
Recommendations for Postexposure HIV Risk Assessment of Children within 
72 Hours of Sexual Assault
• Review HIV/AIDS local epidemiology, assess risk for HIV infection in the 
assailant, and test for HIV infection.
• Evaluate circumstances of assault that might affect risk for HIV transmission.
• Consult with a specialist in treating children with HIV infection to select age-
appropriate dosing and regimens if nPEP is considered.
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• For children determined to be at risk for HIV transmission from the assault, 
discuss nPEP with the caregiver(s), including its toxicity, unknown efficacy, and 
possible benefits.
• If nPEP is begun, adequate doses of medication should be provided to last until 
the follow-up visit at 3–7 days after the initial assessment, at which time the 
child should be reevaluated and tolerance of medication assessed (105,312,892).
• If nPEP is started, perform CBC and serum chemistry at baseline.
• Perform HIV antibody testing during the original assessment and again at 6 
weeks, 3 months, and 6 months after the assault.
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Terms and Abbreviations Used in This Report
AIDS Acquired immunodeficiency syndrome
ALT Alanine aminotransferase
anti-HBc Antibody to hepatitis B core antigen
anti-HCV Hepatitis C antibodies
ASC-US Atypical squamous cells of undetermined significance
BCA Bichloroacetic acid
BV Bacterial vaginosis
CBC Complete blood count
CI Confidence interval
CIN Cervical intraepithelial neoplasia
CLD Chronic liver disease
CLIA Clinical Laboratory Improvement Amendments
CNS Central nervous system
CSF Cerebrospinal fluid
DFA Direct fluorescent antibody
DGI Disseminated gonococcal infection
dL Deciliter
DNA Deoxyribonucleic acid
EC Emergency contraception
EIA Enzyme immunoassay
ELISA Enzyme-linked immunosorbent assay
EPT Expedited partner therapy
FDA Food and Drug Administration
FTA-ABS Fluorescent treponemal antibody absorbed
gG Glycoprotein G
GNID Gram-negative intracellular diplococcic
HAART Highly active antiretroviral therapy
HAV Hepatitis A virus
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HBIG Hepatitis B immune globulin
HbsAg Hepatitis B surface antigen
HBV Hepatitis B virus
HCC hepatocellular carcinoma
HCV Hepatitis C virus
HIV Human immunodeficiency virus
IFA Immunofluorescence assay
IgE Immunoglobulin E
Ig Immune globulin
IgG Immunoglobulin G
IgM Immunoglobulin M
IM Intramuscularly
IUD Intrauterine device
IV Intravenous or intravenously
KOH Potassium hydroxide
LGV Lymphogranuloma venereum
MAC Mycobacterium avium complex
MIC Minimum inhibitory concentration
MSM Men who have sex with men
N-9 Nonoxynol-9
NAAT Nucleic acid amplification test
NGU Nongonococcal urethritis
nPEP Nonoccupational postexposure prophylaxis
Pap Papanicolaou
PCR Polymerase chain reaction
PEP Postexposure prophylaxis
PID Pelvic inflammatory disease
PO By mouth
PPV Positive predictive value
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QRNG Quinolone-resistant Neisseria gonorrhoeae
RNA Ribonucleic acid
RPR Rapid plasma regain
RT-PCR Reverse transcriptase polymerase chain reaction
RVVC Recurrent vulvovaginal candidiasis
SIL Squamous intraepithelial lesion
STD Sexually transmitted disease
TCA Trichloroacetic acid
TE Toxoplasmic encephalitis
TP-PA Treponema pallidum particle agglutation
VDRL Venereal Disease Research Laboratory
VVC Vulvovaginal candidiasis
WB Western blot
WBC White blood count
WSW Women who have sex with women
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BOX 1
The Five P’s: Partners, Practices, Prevention of Pregnancy, Protection from 
STDs, and Past History of STDs
1. Partners
• “Do you have sex with men, women, or both?”
• “In the past 2 months, how many partners have you had sex with?”
• “In the past 12 months, how many partners have you had sex with?”
• “Is it possible that any of your sex partners in the past 12 months had 
sex with someone else while they were still in a sexual relationship 
with you?”
2. Practices
• “To understand your risks for STDs, I need to understand the kind of 
sex you have had recently.”
• “Have you had vaginal sex, meaning ‘penis in vagina sex’?” If yes, 
“Do you use condoms: never, sometimes, or always?”
• “Have you had anal sex, meaning ‘penis in rectum/anus sex’?” If 
yes, “Do you use condoms: never, sometimes, or always?”
• “Have you had oral sex, meaning ‘mouth on penis/vagina’?”
• For condom answers:
• If “never”: “Why don’t you use condoms?”
• If “sometimes”: “In what situations (or with whom) do you use 
condoms?”
3. Prevention of pregnancy
• “What are you doing to prevent pregnancy?”
4. Protection from STDs
• “What do you do to protect yourself from STDs and HIV?”
5. Past history of STDs
• “Have you ever had an STD?”
• “Have any of your partners had an STD?”
Additional questions to identify HIV and viral hepatitis risk include:
• “Have you or any of your partners ever injected drugs?”
• “Have your or any of your partners exchanged money or drugs for sex?”
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• “Is there anything else about your sexual practices that I need to know 
about?”
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BOX 2
Skin-test reagents for identifying persons at risk for adverse reactions to 
penicillin
Major Determinant
• Benzylpenicilloyl poly-L-lysine (PrePen) (AllerQuest, Plainville Connecticut) 
(6 × 10–5M)
Minor Determinant Precursors*
• Benzylpenicillin G (10–2M, 3.3 mg/mL, 10,000 units/mL)
• Benzylpenicilloate (10–2M, 3.3 mg/mL)
• Benzylpenicilloate (or penicilloyl propylamine) (10–2M, 3.3 mg/mL)
Positive Control
• Commercial histamine for intradermal skin testing (1.0 mg/mL)
Negative Control
• Diluent (usually saline) or allergen diluent
Source: Adapted from Saxon A, Beall GN, Rohr AS, Adelman DC. Immediate 
hypersensitivity reactions to beta-lactam antibiotics. Ann Intern Med 1987;107:204–15.
*Aged penicillin is not an adequate source of minor determinants. Penicillin G should 
either be freshly prepared or come from a fresh-frozen source.
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BOX 3
Classification of vulvovaginal candidiasis
Uncomplicated VVC
• Sporadic or infrequent VVC
AND
• Mild-to-moderate VVC
AND
• Likely to be Candida albicans
AND
• Nonimmunocompromised women
Complicated VVC
• Recurrent VVC
OR
• Severe VVC
OR
• Nonalbicans candidiasis
OR
• Women with diabetes, immunocompromising conditions (e.g., HIV 
infection), debilitation, or immunosuppressive therapy (e.g., corticosteroids)
Abbreviation: HIV = human immunodeficiency virus; VVC = vulvovaginal candidiasis.
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FIGURE. Algorithm for evaluation and treatment of possible nonoccupational HIV exposures
Source: CDC. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or 
other nonoccupational exposure to HIV in the United States. MMWR Recomm Rep 
2005;54(No. RR-2).
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TABLE 1
Oral desensitization protocol for persons with a positive skin test*
Penicillin V suspension dose† Amount§ (units/mL) mL Units Cumulative dose (units)
  1 1,000 0.1 100 100
  2 1,000 0.2 200 300
  3 1,000 0.4 400 700
  4 1,000 0.8 800 1,500
  5 1,000 1.6 1,600 3,100
  6 1,000 3.2 3,200 6,300
  7 1,000 6.4 6,400 12,700
  8 10,000 1.2 12,000 24,700
  9 10,000 2.4 24,000 48,700
10 10,000 4.8 48,000 96,700
11 80,000 1.0 80,000 176,700
12 80,000 2.0 160,000 336,700
13 80,000 4.0 320,000 656,700
14 80,000 8.0 640,000 1,296,700
Source: Wendel GO, Jr, Stark BJ, Jamison RB, Melina RD, Sullivan TJ. Penicillin allergy and desensitization in serious infections during 
pregnancy. N Engl J Med 1985;312:1229–32.
*Observation period was 30 minutes before parenteral administration of penicillin.
†
Interval between doses, 15–30 minutes; elapsed time, 4–8 hours; cumulative dose, 1.3 million units.
§
The specific amount of drug was diluted in approximately 30 mL of water and then administered orally.
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TABLE 2
Recommended regimens: dose and schedule for hepatitis A vaccines
Vaccine Age (yrs) Dose Volume (mL) Two-dose schedule (months)*
HAVRIX† 1–18 720 (EL.U.) 0.5 0 (6–12)
>18 1,440 (EL.U.) 1.0 0 (6–12)
VAQTA§ 1–18 25 (U) 0.5 0 (6–18)
>18 50 (U) 1.0 0 (6–18)
Source: CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization 
Practices (ACIP). MMWR Recomm Rep 2006;55(No. RR-7).
Abbreviations: EL.U = Enzyme-linked immunosorbent assay (ELISA) units; U = units.
*0 months represents timing of the initial dose; subsequent numbers represent months after the initial dose.
†
Hepatitis A vaccine, inactivated, GlaxoSmithKline Biologicals; this vaccine is also licensed for a 3-dose series in children aged 2–18 years, with 
360 EL.U, 0.5 mL doses at 0, 1, and 6–12 months.
§
Hepatitis A vaccine, inactivated, Merck and Co., Inc.
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TABLE 3
Interpretation of serologic test results* for HBV infection
Serologic marker
InterpretationHBsAg Total anti-HBc IgM anti-HBc Anti-HBs
− − − − Never infected
+† − − − Early acute infection; transient (up to 18 days) after vaccination
+ + + − Acute infection
− + + − Acute resolving infection
− + − + Recovered from past infection and immune
+ + − − Chronic infection
− + − − False positive (i.e., susceptible); past infection; “low-level” chronic infection§; 
passive transfer to infant born to HBsAg-positive mother
− − − + Immune if concentration is >10 mIU/mL, passive transfer after HBIG 
administration
Abbreviations: anti-HBc = antibody to hepatitis B core antigen; anti-HBs = antibody to hepatitis B surface antigen; HBsAg = hepatitis B surface 
antigen; IgM = immunoglobulin M; mIU/mL = Milli-international units per milliliter.
*Symbol for negative test result, “−“; symbol for positive test result, “+.”
†
To ensure that an HBsAg-positive test result is not false-positive, samples with repeatedly reactive HBsAg results should be tested with an FDA-
cleared neutralizing confirmatory test.
§
Persons positive for only anti-HBc are unlikely to be infectious except under unusual circumstances involving direct percutaneous exposure to 
large quantities of blood (e.g., blood transfusion and organ transplantation).
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TABLE 5
Guidelines for postexposure prophylaxis* of persons with nonoccupational exposure† to blood or body fluids 
that contain blood, by exposure type and vaccination status
Source of exposure
Treatment
Unvaccinated person§ Previously vaccinated person¶
HBsAg-positive source
Percutaneous (e.g., bite or needlestick) or mucosal 
exposure to HBsAg-positive blood or body fluids
Administer hepatitis B vaccine series 
and HBIG
Administer hepatitis B vaccine booster 
dose
Sex or needle-sharing contact of an HBsAg-positive 
person
Administer hepatitis B vaccine series 
and HBIG
Administer hepatitis B vaccine booster 
dose
Victim of sexual assault/abuse by a perpetrator who is 
HBsAg positive
Administer hepatitis B vaccine series 
and HBIG
Administer hepatitis B vaccine booster 
dose
Source with unknown HBsAg status
Victim of sexual assault/abuse by a perpetrator with 
unknown HBsAg status
Administer hepatitis B vaccine series No treatment
Percutaneous (e.g., bite or needlestick) or mucosal 
exposure to potentially infectious blood or body fluids 
from a source with unknown HBsAg status
Administer hepatitis B vaccine series No treatment
Sex or needle-sharing contact of person with unknown 
HBsAg status
Administer hepatitis B vaccine series No treatment
Source: CDC. Postexposure prophylaxis to prevent hepatitis B virus infection. MMWR Recomm Rep 2006;55(No. RR-16).
Abbreviations: HBIG = hepatitis B immune globulin. HBsAg = hepatitis B surface antigen.
*When indicated, immunoprophylaxis should be initiated as soon as possible, preferably within 24 hours. Studies are limited on the maximum 
interval after exposure during which postexposure prophylaxis is effective, but the interval is unlikely to exceed 7 days for percutaneous exposures 
or 14 days for sexual exposures. The hepatitis B vaccine series should be completed.
†
These guidelines apply to nonoccupational exposures. Guidelines for management of occupational exposures have been published separately and 
also can be used for management of nonoccupational exposures, if feasible. Source: CDC. CDC guidance for evaluating health-care personnel for 
hepatitis B virus protection and for administering postexposure management. MMWR Recomm Rep 2013;62(No. RR-10).
§A person who is in the process of being vaccinated but who has not completed the vaccine series should complete the series and receive treatment 
as indicated.
¶A person who has written documentation of a complete hepatitis B vaccine series and who did not receive postvaccination testing.
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TABLE 6
Implications of commonly encountered sexually transmitted or sexually associated infections for diagnosis 
and reporting of sexual abuse among infants and prepubertal children
ST/SA confirmed Evidence for sexual abuse Suggested action
Gonorrhea* Diagnostic Report†
Syphilis* Diagnostic Report†
HIV§ Diagnostic Report†
Chlamydia trachomatis* Diagnostic Report†
Trichomonas vaginalis* Highly suspicious Report†
Genital herpes Highly suspicious (HSV-2 especially) Report†,¶
Condylomata acuminata (anogenital warts)* Suspicious Consider report†,¶,**
Bacterial vaginosis Inconclusive Medical follow-up
Source: Adapted from Kellogg N, American Academy of Pediatrics Committee on Child Abuse and Neglect. The evaluation of child abuse in 
children. Pediatrics 2005;116:506–12.
Abbreviations: HIV = human immunodeficiency virus; SA = sexually associated; ST = sexually transmitted.
*
If not likely to be perinatally acquired and rare vertical transmission is excluded.
†
Reports should be made to the agency in the community mandated to receive reports of suspected child abuse or neglect.
§
If not likely to be acquired perinatally or through transfusion.
¶Unless a clear history of autoinoculation exists.
**
Report if evidence exists to suspect abuse, including history, physical examination, or other identified infections.
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